Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
70 "Cardiovascular disease"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Guideline/Statement/Fact Sheet
Article image
Health Effects of Sugar-Sweetened and Artificially Sweetened Beverages: Umbrella Review and Evidence-Based Consensus Statement of the Korean Diabetes Association and the Korean Nutrition Society
Jong Han Choi, SuJin Song, Soo Kyoung Kim, Jae Won Cho, Jae Hyun Bae, Shinje Moon, Jeong Hyun Lim, YeonHee Lee, Ji-Yun Hwang, YoonJu Song, Sang Soo Kim
Diabetes Metab J. 2026;50(1):32-46.   Published online January 1, 2026
DOI: https://doi.org/10.4093/dmj.2025.0848
  • 1,688 View
  • 126 Download
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Excess intake of added sugars contributes to obesity, type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and premature mortality. Sugar-sweetened beverages (SSBs), the main source of added sugars, are consistently linked to adverse outcomes. Artificially sweetened beverages (ASBs) have been suggested as short-term substitutes, but evidence regarding benefits and harms remains inconclusive, and guidance is lacking.
Methods
This consensus statement draws on a structured evidence review combining two approaches: an updated meta-analysis of randomized controlled trials (RCTs) assessing short- to intermediate-term effects of replacing SSBs with ASBs on weight and metabolic outcomes; and an umbrella review of systematic reviews of cohort studies evaluating long-term associations of SSBs and ASBs with major outcomes, including mortality, CVD, and T2DM.
Results
In 14 RCTs (3–76 weeks), replacing SSBs with ASBs produced modest reductions in body weight (–0.73 kg) and body fat (–0.72%), with inconsistent effects on glycemic and cardiometabolic markers. Evidence from 20 systematic reviews of cohorts (up to 34 years follow-up) showed that higher intake of both SSBs and ASBs was associated with increased risks of T2DM, CVD, and mortality, with relative risks for ASBs similar to those for SSBs.
Conclusion
ASBs may serve as a short-term substitution for individuals with high SSB intake, particularly those at elevated metabolic risk. However, regular or long-term use is not recommended due to uncertain safety and potential reinforcement of sweet preference. Public health strategies should emphasize reducing both SSBs and ASBs, prioritizing water and unsweetened beverages as the ultimate goal.

Citations

Citations to this article as recorded by  
  • Do Not Replace Your Sugar, Simply Eat Less!
    Jeehyun Lee, Sunghwan Suh
    Diabetes & Metabolism Journal.2026; 50(1): 30.     CrossRef
Lifestyle and Behavioral Interventions
Article image
Association between the Life’s Essential 8 Health Behaviors Score and Mortality Risk in US Adults with Cardiovascular-Kidney-Metabolic Syndrome Stage 0–3
Junlin Zhang, Limei Yin, Yuping Liu, Xiang Xiao, Ping Shuai
Received April 26, 2025  Accepted June 16, 2025  Published online December 12, 2025  
DOI: https://doi.org/10.4093/dmj.2025.0366    [Epub ahead of print]
  • 1,263 View
  • 80 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The American Heart Association’s novel cardiovascular-kidney-metabolic (CKM) syndrome framework underscores the interconnected pathophysiology of metabolic dysfunction, chronic kidney disease, and cardiovascular disease (CVD). While the Life’s Essential 8 (LE8) has demonstrated strong associations with CVD risk in general populations, its prognostic relevance remains unexplored in individuals stratified by CKM syndrome stages.
Methods
This study analyzed longitudinal data from the nationally representative National Health and Nutrition Examination Survey (2005–2018). The eight components of the LE8 metric—diet quality, physical activity, nicotine exposure, sleep health, body mass index, blood lipid profiles, glycemic status, and blood pressure—were systematically evaluated and scored on a 0–100 scale. A Cox proportional hazards regression model was implemented to assess associations between LE8 scores and all-cause mortality risk. Mortality outcomes were prospectively tracked through December 31, 2019, using linked mortality records from the National Center for Health Statistics.
Results
Among 9,152 participants (mean age 45.08±0.29 years; 48.24% male), baseline CKM staging distributed as follows: stage 0 (12.08%, n=916), stage 1 (25.76%, n=2,162), stage 2 (60.02%, n=5,721), and stage 3 (2.14%, n=353). Unexpectedly, during a median follow-up of 7.92 years, the total LE8 score was not related with all-cause mortality in individuals with CKM stage 2–3 (P>0.05). However, fully adjusted analyses revealed a 22% and 13% decreased all-cause mortality risk per 10-points LE8 health behaviors score increment in CKM 0-1 (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.68 to 0.88) and CKM 2-3 (HR, 0.87; 95% CI, 0.81 to 0.93), respectively. Restricted cubic spline models confirmed a negative linear dose-response relationship between health behaviors score and all-cause mortality across all CKM stages 0–3.
Conclusion
This national cohort study establishes LE8 health behaviors score as a robust, linearly associated predictor of all-cause mortality in CKM syndrome populations, independent of disease stage severity. These findings advocate for integrating LE8 health behaviors score into routine metabolic-cardiovascular risk stratification protocols, particularly for early intervention in CKM stage 0–3 individuals.
Cardiovascular Risk/Epidemiology
Article image
High Waist-to-Height Ratio Increases the Risk of Cardiovascular Outcomes in Adults with Type 1 Diabetes Mellitus: A Nationwide Cohort Study
Kyeong-Jin Kim, Seohyun Kim, Rosa Oh, So Hyun Cho, Myunghwa Jang, You-Bin Lee, Gyuri Kim, Sang-Man Jin, Kyu Yeon Hur, Ji Yoon Kim, Jae Hyeon Kim
Received March 4, 2025  Accepted June 21, 2025  Published online September 4, 2025  
DOI: https://doi.org/10.4093/dmj.2025.0179    [Epub ahead of print]
  • 1,233 View
  • 79 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Central obesity contributes to an increased risk of cardiovascular disease (CVD) and mortality. The waist-to-height ratio (WHtR) is a practical marker of central obesity across sexes, ages, and ethnicities. However, its association with comprehensive cardiovascular (CV) outcomes in patients with type 1 diabetes mellitus (T1DM) remains unclear.
Methods
From a nationwide cohort database (2006–2020), 16,928 Korean adults with T1DM were included. Participants were categorized by their WHtR values using three criteria: a three-group classification (<0.5, 0.5 to <0.6, and ≥0.6) and two binary classifications (≥0.5 vs. <0.5; ≥0.6 vs. <0.6). The primary outcomes were composite CV events, including heart failure (HF), myocardial infarction (MI), ischemic stroke, and CVD-related deaths, with each component analyzed as a secondary outcome.
Results
During a median follow-up of 6.7 years (interquartile range, 5.2 to 8.8), 4,293 composite CV events occurred. Compared to the WHtR <0.5 group, the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for the composite CV outcome were 1.14 (1.05 to 1.24) in the WHtR 0.5 to <0.6 group and 1.62 (1.38 to 1.90) in the WHtR ≥0.6 group (P for trend <0.001). Increasing trends in aHRs were noted with rising WHtR values for each component of the composite outcome. Compared to the WHtR <0.6 group, the aHRs for the WHtR ≥0.6 group were as follows: HF, 1.49 (95% CI, 1.28 to 1.73); MI, 1.31 (95% CI, 1.02 to 1.68); ischemic stroke, 1.24 (95% CI, 1.02 to 1.51); and CVD-related death, 2.09 (95% CI, 1.49 to 2.92).
Conclusion
High WHtR is associated with an increased risk of CV events in adults with T1DM.
Cardiovascular Risk/Epidemiology
Article image
Associations of Cardiocerebrovascular Risks and Exercise according to Menopausal Status in Women with Type 2 Diabetes Mellitus: A Nationwide Cohort Study
Ji-Hee Ko, Sun Joon Moon, Kyung-Do Han, Hye-Mi Kwon, Se-Eun Park, Eun-Jung Rhee, Won-Young Lee
Diabetes Metab J. 2026;50(1):101-114.   Published online August 13, 2025
DOI: https://doi.org/10.4093/dmj.2024.0487
  • 1,661 View
  • 59 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Menopausal status can increase the risk of cardiocerebrovascular diseases (CCVDs) in women with type 2 diabetes mellitus (T2DM). Regular exercise is well-known to reduce this risk. This study explored the impact of exercise on CCVD and mortality in women with T2DM according to their menopausal status.
Methods
A total of 32,477 premenopausal and 53,690 postmenopausal Korean women with T2DM aged 40 to 60 years from a national health examination cohort (2009 to 2018) were included. We evaluated risks for stroke, myocardial infarction (MI), and mortality based on exercise intensity. Cox proportional hazard regression analyses were performed to obtain the adjusted hazard ratio (aHR) and 95% confidence interval.
Results
Exercise reduced stroke, MI, and mortality risks in women with T2DM, regardless of menopausal status. The highest effects of aHR compared to the sedentary group were 0.68 for stroke, 0.66 for MI, and 0.81 for mortality. Postmenopausal women experienced significant MI risk reductions at most exercise intensities, with the greatest reduction in the ≥1,500 metabolic equivalent of task score group unlike premenopausal women. However, stroke and mortality risk reductions in postmenopausal women were less pronounced compared to premenopausal women.
Conclusion
Exercise reduces CCVD risk in women with T2DM across menopausal status. Postmenopausal women with T2DM had more benefits from exercise on MI but fewer benefits on stroke and mortality than premenopausal women. In premenopausal women with T2DM, exercise was not associated with a lower MI risk.
Cardiovascular Risk/Epidemiology
Article image
Comparative Efficacy of Initial Statin and Ezetimibe Combination versus Statin Monotherapy on Cardiovascular Outcomes in Diabetes Mellitus: A Nationwide Cohort Study
Minji Sohn, Young-Hwan Park, Soo Lim
Diabetes Metab J. 2025;49(6):1318-1330.   Published online June 5, 2025
DOI: https://doi.org/10.4093/dmj.2024.0482
  • 8,779 View
  • 358 Download
  • 1 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study aimed to assess the efficacy of an initial combination therapy of statin and ezetimibe compared with statin monotherapy on major cardiovascular outcomes in individuals with diabetes.
Methods
In this population-based cohort study using National Health Insurance Service data (2010–2020), we included adults with diabetes who had not previously used any lipid-lowering medications. Those initiating statin monotherapy were matched 1:1 using propensity scores with patients starting combination therapy with a lower-potency statin and ezetimibe. This matching process resulted in 21,458 individuals in the primary prevention cohort and 10,094 in the secondary prevention cohort, respectively. The primary endpoint was a composite of myocardial infarction, stroke, and cardiovascular death. Hospitalizations for heart failure, angina, and all-cause mortality were analyzed. The impact of ezetimibe maintenance on the primary endpoint was analyzed, and other hospitalizations were categorized as adverse events.
Results
Compared with statin monotherapy, statin-ezetimibe combination significantly reduced the incidence of the primary endpoint (4.85 vs. 3.25 per 1,000 person-years: hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.56 to 0.81 in the primary cohort; and 19.5 vs. 15.7 per 1,000 person-years: HR, 0.80; 95% CI, 0.70 to 0.91 in the secondary cohort) and myocardial infarction (HR, 0.64; 95% CI, 0.46 to 0.82 in the primary cohort; and HR, 0.73; 95% CI, 0.60 to 0.89 in the secondary cohort). A longer maintenance period of ezetimibe was significantly related to better efficacy in the composite cardiovascular outcomes. High-intensity statin monotherapy was associated with an elevated risk of liver, muscle, and diabetes-related hospitalization in the primary prevention cohort.
Conclusion
Initial therapy with a statin-ezetimibe combination is associated with a reduced risk of cardiovascular events and fewer adverse events compared to statin monotherapy in individuals with diabetes, over a mean follow-up of 5.5 years (up to 9 years).

Citations

Citations to this article as recorded by  
  • Cardiovascular outcomes and adverse drug reactions associated with the use of ezetimibe in combination with a statin in diabetes mellitus patients with higher risk for myocardial infarction: a meta-analysis
    Yan Zhou, Ji Jin
    BMC Cardiovascular Disorders.2026;[Epub]     CrossRef
  • Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction
    Anna Nowak-Szwed, Ceren Eyileten, Zofia Wicik, Sara Ahmadova, Jeff Palatini, Jolanta Siller-Matula, Dirk von Lewinski, Harald Sourij, Marek Postula
    Cardiovascular Diabetology.2025;[Epub]     CrossRef
Review
Basic and Translational Research
Article image
Extracellular Vesicle-Mediated Network in the Pathogenesis of Obesity, Diabetes, Steatotic Liver Disease, and Cardiovascular Disease
Joonyub Lee, Won Gun Choi, Marie Rhee, Seung-Hwan Lee
Diabetes Metab J. 2025;49(3):348-367.   Published online May 1, 2025
DOI: https://doi.org/10.4093/dmj.2025.0184
  • 6,851 View
  • 223 Download
  • 6 Web of Science
  • 8 Crossref
AbstractAbstract PDFPubReader   ePub   
Extracellular vesicles (EVs) are lipid bilayer-enclosed particles carrying bioactive cargo, including nucleic acids, proteins, and lipids, facilitating intercellular and interorgan communication. In addition to traditional mediators such as hormones, metabolites, and cytokines, increasing evidence suggests that EVs are key modulators in various physiological and pathological processes, particularly influencing metabolic homeostasis and contributing to the progression of cardiometabolic diseases. This review provides an overview of the most recent insights into EV-mediated mechanisms involved in the pathogenesis of obesity, insulin resistance, diabetes mellitus, steatotic liver disease, atherosclerosis, and cardiovascular disease. EVs play a critical role in modulating insulin sensitivity, glucose homeostasis, systemic inflammation, and vascular health by transferring functional molecules to target cells. Understanding the EV-mediated network offers potential for identifying novel biomarkers and therapeutic targets, providing opportunities for EV-based interventions in cardiometabolic disease management. Although many challenges remain, this evolving field highlights the need for further research into EV biology and its translational applications in cardiovascular and metabolic health.

Citations

Citations to this article as recorded by  
  • Postbiotics in Functional Foods: Microbial Derivatives Shaping Health, Immunity and Next‐Generation Nutrition
    Alice Njolke Mafe, Javad Sharifi‐Rad, Daniela Calina, Ayobami Joshua Ogunyemi, Abiola O. Tubi
    Food Frontiers.2026;[Epub]     CrossRef
  • Decoding the Endocrine Code of Skeletal Muscle: Myokines, Exerkines, and Inter-Organ Crosstalk in Metabolic Health and Disease
    Young-Sool Hah, Jeongyun Hwang, Seung-Jun Lee, Seung-Jin Kwag
    Cells.2026; 15(4): 318.     CrossRef
  • Extracellular Vesicles: Biology, Intercellular Communication and Therapeutic Potential in Diabetes
    Swayam Prakash Srivastava, Lydia Herrmann, Eden Ozkan, Abhiram Kunamneni, Vinamra Swaroop, Geetika Nehra, Rohit Srivastava, Pratima Tripathi, Ken Inoki, Julie E. Goodwin
    Advanced Therapeutics.2026;[Epub]     CrossRef
  • Association between dyslipidemia and elevated liver enzymes: A cross-sectional study from the PERSIAN Guilan cohort study
    Milad Shahdkar, Mahdi Orang Goorabzarmakhi, Mahdi Shafizadeh, Farahnaz Joukar, Saman Maroufizadeh, Niloofar Faraji, Tahereh Zeinali, Fariborz Mansour-Ghanaei
    Endocrine and Metabolic Science.2025; 19: 100272.     CrossRef
  • Molecular Signatures of Obesity-Associated Infertility in Polycystic Ovary Syndrome: The Emerging Role of Exosomal microRNAs and Non-Coding RNAs
    Charalampos Voros, Georgios Papadimas, Despoina Mavrogianni, Aristotelis-Marios Koulakmanidis, Diamantis Athanasiou, Kyriakos Bananis, Antonia Athanasiou, Aikaterini Athanasiou, Ioannis Papapanagiotou, Dimitrios Vaitsis, Charalampos Tsimpoukelis, Maria An
    Genes.2025; 16(9): 1101.     CrossRef
  • Molecular mechanisms linking adipose tissue-derived small extracellular vesicles/exosomes to the development or amelioration of obesity, insulin resistance, and diabetes-related complications
    Linfeng Chen, Fatemeh Amraee, Sahar Sadegh-Nejadi, Mostafa Saberian, Seyed Arsalan Ghahari, Xiaolei Miao, Giuseppe Lisco, Reza Afrisham
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • Mitochondria-Enriched Extracellular Vesicles (EVs) for Cardiac Bioenergetics Restoration: A Scoping Review of Preclinical Mechanisms and Source-Specific Strategies
    Dhienda C. Shahannaz, Tadahisa Sugiura, Taizo Yoshida
    International Journal of Molecular Sciences.2025; 26(22): 11052.     CrossRef
  • A Comprehensive Insight Into the Roles of Exosomal circRNAs in Metabolic Syndrome
    Azadeh Taherpour, Safieh Ebrahimi, Farshad Mirzavi
    BioFactors.2025;[Epub]     CrossRef
Original Articles
Complications
Article image
Does 10-Year Atherosclerotic Cardiovascular Disease Risk Predict Incident Diabetic Nephropathy and Retinopathy in Patients with Type 2 Diabetes Mellitus? Results from Two Prospective Cohort Studies in Southern China
Jiaheng Chen, Yu Ting Li, Zimin Niu, Zhanpeng He, Yao Jie Xie, Jose Hernandez, Wenyong Huang, Harry H.X. Wang, on Behalf of the Guangzhou Diabetic Eye Study Group
Diabetes Metab J. 2025;49(2):298-310.   Published online February 4, 2025
DOI: https://doi.org/10.4093/dmj.2024.0239
  • 5,353 View
  • 171 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Diabetic macrovascular and microvascular complications often coexist and may share similar risk factors and pathological pathways. We aimed to investigate whether 10-year atherosclerotic cardiovascular disease (ASCVD) risk, which is commonly assessed in diabetes management, can predict incident diabetic nephropathy (DN) and retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM).
Methods
This prospective cohort study enrolled 2,891 patients with clinically diagnosed T2DM who were free of ASCVD, nephropathy, or retinopathy at baseline in the Guangzhou (2017–2022) and Shaoguan (2019–2021) Diabetic Eye Study in southern China. The 10-year ASCVD risk was calculated by the Prediction for ASCVD Risk in China (China-PAR) equations. Multivariable- adjusted Cox proportional hazard models were developed to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). The area under the receiver operating characteristic curve (AUC) was used to evaluate predictive capability.
Results
During follow-up, a total of 171 cases of DN and 532 cases of DR were documented. Each 1% increment in 10-year ASCVD risk was associated with increased risk of DN (pooled HR, 1.122; 95% CI, 1.094 to 1.150) but not DR (pooled HR, 0.996; 95% CI, 0.979 to 1.013). The model demonstrated acceptable performance in predicting new-onset DN (pooled AUC, 0.670; 95% CI, 0.628 to 0.715). These results were consistent across cohorts and subgroups, with the association appearing to be more pronounced in women.
Conclusion
Ten-year ASCVD risk predicts incident DN but not DR in our study population with T2DM. Regular monitoring of ASCVD risk in routine diabetes practice may add to the ability to enhance population-based prevention for both macrovascular and microvascular diseases, particularly among women.

Citations

Citations to this article as recorded by  
  • Investigation of the Potential Association Between Atherosclerotic Cardiovascular Disease Risk Score and Diabetic Retinopathy in Patients with Type 2 Diabetes: A Cross-Sectional Study
    Chrysa Agapitou, Theodoros N. Sergentanis, Effie G. Papageorgiou, Panagiotis Theodossiadis, Ignatios Ikonomidis, Vaia Lambadiari, Irini Chatziralli
    Biomedicines.2025; 13(3): 633.     CrossRef
Pharmacotherapy
Article image
Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP)
Nam Hoon Kim, Soo Lim, In-Kyung Jeong, Eun-Jung Rhee, Jun Sung Moon, Ohk-Hyun Ryu, Hyuk-Sang Kwon, Jong Chul Won, Sang Soo Kim, Sang Yong Kim, Bon Jeong Ku, Heung Yong Jin, Sin Gon Kim, Bong-Soo Cha, on Behalf of Investigators of ENVELOP Study
Diabetes Metab J. 2025;49(2):225-234.   Published online January 6, 2025
DOI: https://doi.org/10.4093/dmj.2024.0238
  • 6,968 View
  • 275 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The novel sodium-glucose cotransporter-2 (SGLT2) inhibitor enavogliflozin effectively lowers glycosylated hemoglobin levels and body weights without the increased risk of serious adverse events; however, the long-term clinical benefits of enavogliflozin in terms of cardiovascular and renal outcomes have not been investigated.
Methods
This study is an investigator-initiated, multicenter, randomized, pragmatic, open-label, active-controlled, non-inferiority trial. Eligible participants are adults (aged ≥19 years) with type 2 diabetes mellitus (T2DM) who have a history of, or are at risk of, cardiovascular disease. A total of 2,862 participants will be randomly assigned to receive either enavogliflozin or other SGLT2 inhibitors with proven cardiorenal benefits, such as dapagliflozin or empagliflozin. The primary endpoint is the time to the first occurrence of a composite of major adverse cardiovascular or renal events (Clinical Research Information Service registration number: KCT0009243).
Conclusion
This trial will determine whether enavogliflozin is non-inferior to dapagliflozin or empagliflozin in terms of cardiorenal outcomes in patients with T2DM and cardiovascular risk factors. This study will elucidate the role of enavogliflozin in preventing vascular complications in patients with T2DM.

Citations

Citations to this article as recorded by  
  • Reverse translational approach to clarify the strong potency of enavogliflozin, a novel sodium-glucose cotransporter 2 inhibitor
    Sun-Hwa Park, Hye-Young Ji, Ji-Soo Choi, Kyung Seok Oh, Jihoon Lee, Minyeong Pang, Im-Sook Song, Joon Seok Park
    The Journal of Pharmacology and Experimental Therapeutics.2025; 392(8): 103650.     CrossRef
Cardiovascular Risk/Epidemiology
Article image
Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
Jin Hwa Kim, Junyeop Lee, Kyungdo Han, Jae-Taek Kim, Hyuk-Sang Kwon, on Behalf of the Diabetic Vascular Disease Research Group of the Korean Diabetes Association
Diabetes Metab J. 2024;48(6):1084-1092.   Published online November 1, 2024
DOI: https://doi.org/10.4093/dmj.2024.0275
  • 7,683 View
  • 211 Download
  • 6 Web of Science
  • 8 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study aimed to provide updated insights into the incidence and management of cardiovascular disease (CVD) in Korean adults with diabetes.
Methods
Using data from the Korean National Health Insurance Service and Korea National Health and Nutrition Examination Survey, we analyzed the representative national estimates of CVD in adults with diabetes.
Results
The age- and sex-standardized incidence rate of ischemic heart disease (IHD), ischemic stroke, and peripheral artery disease (PAD) decreased from 2010 to 2019 in individuals with type 2 diabetes mellitus (T2DM). However, an increase in the incidence of heart failure (HF) was observed during the same period. Only 4.96% of adults with diabetes and CVD achieved optimal control of all three risk factors (glycemic levels, blood pressure, and lipid control). Additionally, high-intensity statin treatment rates were 8.84% and 9.15% in individuals with IHD and ischemic stroke, respectively. Treatment with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) or a glucagon-like peptide-1 receptor agonist (GLP-1RA) was relatively low in 2019, with only 11.87%, 7.10%, and 11.05% of individuals with IHD, ischemic stroke, and HF, respectively, receiving SGLT2i treatment. Furthermore, only 1.08%, 0.79%, and 1.06% of patients with IHD, ischemic stroke, and HF, respectively, were treated with GLP-1RA.
Conclusion
The incidence of most CVD (IHD, ischemic stroke, and PAD) decreased between 2010 and 2019, whereas the incidence of HF increased. The overall use of high-intensity statins, SGLT2i, and GLP-1RA remained low among individuals with T2DM and CVD.

Citations

Citations to this article as recorded by  
  • Big Data Research for Diabetes-Related Diseases Using the Korean National Health Information Database
    Kyung-Soo Kim, Bongseong Kim, Kyungdo Han
    Diabetes & Metabolism Journal.2025; 49(1): 13.     CrossRef
  • Heterogeneity in the development of diabetes-related complications: narrative review of the roles of ancestry and geographical determinants
    Andrea O. Y. Luk, Yingnan Fan, Baoqi Fan, Edith W. K. Chow, Tony C. K. O
    Diabetologia.2025; 68(11): 2386.     CrossRef
  • 2024 Cardio-cerebrovascular disease fact sheet in Korea
    Kyungdo Han, Jin-Hyung Jung, Sang-Suk Choi, Seung-Hyun Ko
    Cardiovascular Prevention and Pharmacotherapy.2025; 7(3): 85.     CrossRef
  • Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study
    Ji Yoon Kim, Nam Hoon Kim, Jiyoon Lee, Dong-Hoon Kim, Sin Gon Kim
    European Heart Journal - Cardiovascular Pharmacotherapy.2025; 11(7): 620.     CrossRef
  • SGLT2 Inhibitors and GLP-1 Receptor Agonists in PAD: A State-of-the-Art Review
    Alfredo Caturano, Damiano D’Ardes, Paola Giustina Simeone, Gianfranco Lessiani, Nicoletta Di Gregorio, Lorenzo Andreetto, Davide Grassi, Carla Serra, Francesca Santilli, Maria Teresa Guagnano, Fabio Piscaglia, Claudio Ferri, Francesco Cipollone, Andrea Bo
    Journal of Clinical Medicine.2025; 14(15): 5549.     CrossRef
  • Bridging the Gap between Evidence and Practice: Nationwide Retrospective Analysis of Lipid-Modifying Therapy Prescription Patterns in 5 Million Patients with Type 2 Diabetes Mellitus
    Ahmed Hassan, Menna A. Keshk, Mohamed Reyad, Nourhan Ahmed, Omar Nassar, Aisha Siraj, Salem Badr, Sherif Eltawansy, Anoop Misra, Muhammed Amir Essibayi, Ahmed Y. Azzam, Mahmoud Nassar, Diaa Hakim
    ASIDE Internal Medicine.2025; 2(2): 6.     CrossRef
  • Comparison of ischemic cardiovascular events between dapagliflozin and empagliflozin in combination with metformin: A nationwide population-based cohort study
    Hayeon Kim, Seung Won Lee, Yejee Lim, Nayoung Han, Suin Kang, Youngjoo Byun, Kyungim Kim, Marwan Salih Al-Nimer
    PLOS One.2025; 20(10): e0333604.     CrossRef
  • Association of lifestyle change after H. pylori eradication with cardiovascular disease: a nationwide Korean NHIS cohort study
    Jinju Choi, Kyungdo Han, Cheol Min Shin, Jin-Hyung Jung, Se Yun Kim, Seung-Gyun Im, Hyemin Jo, Ho-Kyoung Lee, Eun Hyo Jin, Seung Joo Kang, Joo Hyun Lim, Yoon Jin Choi, Dong Ho Lee
    BMJ Public Health.2025; 3(2): e002701.     CrossRef
Review
Pathophysiology
Article image
Protein Arginine Methyltransferases: Emerging Targets in Cardiovascular and Metabolic Disease
Yan Zhang, Shibo Wei, Eun-Ju Jin, Yunju Jo, Chang-Myung Oh, Gyu-Un Bae, Jong-Sun Kang, Dongryeol Ryu
Diabetes Metab J. 2024;48(4):487-502.   Published online July 24, 2024
DOI: https://doi.org/10.4093/dmj.2023.0362
  • 7,835 View
  • 284 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   ePub   
Cardiovascular diseases (CVDs) and metabolic disorders stand as formidable challenges that significantly impact the clinical outcomes and living quality for afflicted individuals. An intricate comprehension of the underlying mechanisms is paramount for the development of efficacious therapeutic strategies. Protein arginine methyltransferases (PRMTs), a class of enzymes responsible for the precise regulation of protein methylation, have ascended to pivotal roles and emerged as crucial regulators within the intrinsic pathophysiology of these diseases. Herein, we review recent advancements in research elucidating on the multifaceted involvements of PRMTs in cardiovascular system and metabolic diseases, contributing significantly to deepen our understanding of the pathogenesis and progression of these maladies. In addition, this review provides a comprehensive analysis to unveil the distinctive roles of PRMTs across diverse cell types implicated in cardiovascular and metabolic disorders, which holds great potential to reveal novel therapeutic interventions targeting PRMTs, thus presenting promising perspectives to effectively address the substantial global burden imposed by CVDs and metabolic disorders.

Citations

Citations to this article as recorded by  
  • Protein Arginine Methyltransferase 1: A Multi-Purpose Player in the Development of Cancer and Metabolic Disease
    Daphne de Korte, Menno Hoekstra
    Biomolecules.2025; 15(2): 185.     CrossRef
  • Arginine Methylation by PRMT1 Affects ADAMTS13 Secretion and Enzymatic Activity
    Szumam Liu, Min Ma, Jun Qu, Joshua Muia, Zhijian Wu, Quintijn Bonnez, Karen Vanhoorelbeke, Liang Zheng, Xinyang Zhao, X. Long Zheng
    Arteriosclerosis, Thrombosis, and Vascular Biology.2025; 45(4): 506.     CrossRef
  • Protein Arginine N‐Methyltransferase 4 Activation Contributes to Glucose‐Induced Skeletal Muscle Atrophy
    Pawan Kumar, Farah Gulzar, Nikita Chhikara, Arvind K. Maurya, Sushmita Singh, Ishbal Ahmad, Sanjeev Kanojiya, Akhilesh K. Tamrakar
    The FASEB Journal.2025;[Epub]     CrossRef
  • PRMT1 in Health and Disease: Emerging Perspectives From Molecular Mechanisms to Therapeutic Strategies
    Yanqun Luo, Ying Gao, Xiaoliang Deng, Lei Wang, Tao Wu
    MedComm.2025;[Epub]     CrossRef
Original Articles
Cardiovascular Risk/Epidemiology
Article image
Social Determinants of Health and Cardiovascular Risk among Adults with Diabetes: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study
Lisa Zhang, Evgeniya Reshetnyak, Joanna B. Ringel, Laura C. Pinheiro, April Carson, Doyle M. Cummings, Raegan W. Durant, Gargya Malla, Monika M. Safford
Diabetes Metab J. 2024;48(6):1073-1083.   Published online July 22, 2024
DOI: https://doi.org/10.4093/dmj.2023.0380
  • 5,871 View
  • 195 Download
  • 5 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Social determinants of health (SDOH) have been associated with diabetes risk; however, their association with cardiovascular disease (CVD) events in individuals with diabetes is poorly described. We hypothesized that a greater number of SDOH among individuals with diabetes would be associated with a higher risk of CVD events.
Methods
The REasons for Geographic and Racial Differences in Stroke (REGARDS) study is a national, biracial cohort of 30,239 individuals ≥45 years old recruited in 2003–2007. We included 6,322 participants with diabetes at baseline, defined as healthcare professional diagnosis, diabetes medication use, or blood glucose values. Seven SDOH that were individually associated with CVD events were included (P<0.20). The outcome was CVD events, a composite of expert-adjudicated myocardial infarction, stroke, or cardiovascular death. We estimated Cox proportional hazard models to examine associations between number of SDOH (0, 1, 2, ≥3) and CVD events.
Results
In an age and sex adjusted model, the presence of multiple SDOH significantly increased the risk of any CVD event (hazard ratio [HR], 1.48; 95% confidence interval [CI], 1.26 to 1.74 for two SDOH; HR, 1.68; 95% CI, 1.43 to 1.96 for ≥3 SDOH). This finding was attenuated but remained statistically significant in a fully adjusted model (HR, 1.19; 95% CI, 1.01 to 1.40 for two SDOH; HR, 1.27; 95% CI, 1.07 to 1.50 for ≥3 SDOH).
Conclusion
Having multiple SDOH was independently associated with an increased risk of CVD events, a finding driven by cardiovascular death. Identifying individuals with diabetes who have multiple SDOH may be helpful for detecting those at higher risk of experiencing or dying from CVD events.

Citations

Citations to this article as recorded by  
  • Tailoring interventions to close gaps in diabetes mellitus care
    Alicia Diaz-Thomas, Susanne Cabrera, Rocio I. Pereira, Pallavi Iyer
    Nature Reviews Endocrinology.2026;[Epub]     CrossRef
  • The impact of social determinants of health on diabetic gastroparesis: a retrospective analysis
    Ioana Soare, Nicoleta Andreea Tudose, Claudia Simona Stefan, Roxana Elena Mirică
    Frontiers in Public Health.2025;[Epub]     CrossRef
  • Hypertriglyceridemic waist phenotype in relation to diabetes mellitus and cardiovascular diseases in the Indonesian and Korean populations: evidence from two national surveys
    Fathimah S. Sigit, Sinyoung Cho, Farid Kurniawan, Hye-Ryeong Jeon, Ratu Ayu Dewi Sartika, Dicky L. Tahapary, Hyuktae Kwon
    Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
Metabolic Risk/Epidemiology
Article image
2023 Diabetic Kidney Disease Fact Sheet in Korea
Nam Hoon Kim, Mi-Hae Seo, Jin Hyung Jung, Kyung Do Han, Mi Kyung Kim, Nan Hee Kim, on Behalf of Diabetic Kidney Disease Research Group of the Korean Diabetes Association
Diabetes Metab J. 2024;48(3):463-472.   Published online March 19, 2024
DOI: https://doi.org/10.4093/dmj.2023.0310
  • 12,935 View
  • 629 Download
  • 17 Web of Science
  • 22 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
To investigate the prevalence, incidence, comorbidities, and management status of diabetic kidney disease (DKD) and diabetes-related end-stage kidney disease (ESKD) in South Korea.
Methods
We used the Korea National Health and Nutrition Examination Survey data (2019 to 2021, n=2,665) for the evaluation of prevalence, comorbidities, control rate of glycemia and comorbidities in DKD, and the Korean Health Insurance Service-customized database (2008 to 2019, n=3,950,857) for the evaluation of trends in the incidence and prevalence rate of diabetes-related ESKD, renin-angiotensin system (RAS) blockers and sodium glucose cotransporter 2 (SGLT2) inhibitors use for DKD, and the risk of atherosclerotic cardiovascular disease (ASCVD) and mortality according to DKD stages. DKD was defined as albuminuria or low estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 in patients with diabetes mellitus.
Results
The prevalence of DKD was 25.4% (albuminuria, 22.0%; low eGFR, 6.73%) in patients with diabetes mellitus aged ≥30 years. Patients with DKD had a higher rate of comorbidities, including hypertension, dyslipidemia, and central obesity; however, their control rates were lower than those without DKD. Prescription rate of SGLT2 inhibitors with reduced eGFR increased steadily, reaching 5.94% in 2019. Approximately 70% of DKD patients were treated with RAS blockers. The prevalence rate of diabetesrelated ESKD has been steadily increasing, with a higher rate in older adults. ASCVD and mortality were significantly associated with an in increase in DKD stage.
Conclusion
DKD is prevalent among Korean patients with diabetes and is an independent risk factor for cardiovascular morbidity and mortality, which requiring intensive management of diabetes and comorbidities. The prevalence of diabetes-related ESKD has been increasing, especially in the older adults, during past decade.

Citations

Citations to this article as recorded by  
  • THE STATE OF CARBOHYDRATE METABOLISM AND RENAL FUNCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME. LITERATURE REVIEW
    S.U. Kazaryan, R.B. Bazarbekova, A.K. Dosanova, R.A. Kasymalieva, Zh.A. Nurlykaimova, K.S. Absatarova, M.M. Yakubova
    Наука и здравоохранение.2026; (6(27)): 172.     CrossRef
  • Glycemia Risk Index is Associated With Risk of Albuminuria Among Individuals With Type 1 Diabetes
    Ji Yoon Kim, Jee Hee Yoo, Nam Hoon Kim, Jae Hyeon Kim
    Journal of Diabetes Science and Technology.2025;[Epub]     CrossRef
  • Big Data Research for Diabetes-Related Diseases Using the Korean National Health Information Database
    Kyung-Soo Kim, Bongseong Kim, Kyungdo Han
    Diabetes & Metabolism Journal.2025; 49(1): 13.     CrossRef
  • Effect of Glomerular Hyperfiltration on Incident Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus
    Seung Min Chung, Inha Jung, Da Young Lee, So Young Park, Ji Hee Yu, Jun Sung Moon, Ji A. Seo, Kyung-Do Han, Nan Hee Kim
    Clinical Journal of the American Society of Nephrology.2025; 20(3): 410.     CrossRef
  • Impact of Muscle Quality on Muscle Strength and Physical Performance Beyond Muscle Mass or Diabetes Status
    Jung A Kim, Chol Shin, Inha Jung, So Young Park, Da Young Lee, Ji Hee Yu, Hyunjoo Cho, Seung Ku Lee, Kyoung Jin Kim, Eyun Song, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Nan Hee Kim, Ji A Seo
    Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
  • A Machine Learning-Based Prediction Model for Diabetic Kidney Disease in Korean Patients with Type 2 Diabetes Mellitus
    Kyung Ae Lee, Jong Seung Kim, Yu Ji Kim, In Sun Goak, Heung Yong Jin, Seungyong Park, Hyejin Kang, Tae Sun Park
    Journal of Clinical Medicine.2025; 14(6): 2065.     CrossRef
  • Optimal Management of Diabetic Kidney Disease
    Jae-Han Jeon
    The Journal of Korean Diabetes.2025; 26(1): 1.     CrossRef
  • Association Between Healthy Dietary Patterns and Chronic Kidney Disease in Patients with Diabetes: Findings from Korean National Health and Nutrition Examination Survey 2019–2021
    Minsang Kim, Jung Koh, Jeong Cho, Semin Cho, Soojin Lee, Hyuk Huh, Seong Kim, Sehyun Jung, Eunjeong Kang, Sehoon Park, Jin Paek, Woo Park, Kyubok Jin, Seungyeup Han, Kwon Joo, Kyungdo Han, Dong Kim, Yaerim Kim
    Nutrients.2025; 17(9): 1600.     CrossRef
  • SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application
    Jae Hyun Bae
    Diabetes & Metabolism Journal.2025; 49(3): 386.     CrossRef
  • The Triglyceride-Glucose Index and Risk of End-Stage Renal Disease across Different Durations of Type 2 Diabetes Mellitus: A Longitudinal Cohort Study
    Mi-sook Kim, Kyu-Na Lee, Jeongmin Lee, Jeongeun Kwak, Seung-Hwan Lee, Hyuk-Sang Kwon, Jing Hughes, Kyung-Do Han, Eun Young Lee
    Endocrinology and Metabolism.2025; 40(5): 718.     CrossRef
  • Risk of End-Stage Kidney Disease in Individuals with Diabetes Living Alone: A Large-Scale Population-Based Study
    Kyunghun Sung, Jae-Seung Yun, Bongseong Kim, Hun-Sung Kim, Jae-Hyoung Cho, Yong-Moon Mark Park, Kyungdo Han, Seung-Hwan Lee
    Diabetes & Metabolism Journal.2025; 49(4): 862.     CrossRef
  • Physical activity intensity and amount are inversely correlated with the risk of tuberculosis in patients with diabetes
    Chiwook Chung, Kyu Na Lee, Kyungdo Han, Junhee Park, Dong Wook Shin, Sei Won Lee
    Scientific Reports.2025;[Epub]     CrossRef
  • 2024 Cardio-cerebrovascular disease fact sheet in Korea
    Kyungdo Han, Jin-Hyung Jung, Sang-Suk Choi, Seung-Hyun Ko
    Cardiovascular Prevention and Pharmacotherapy.2025; 7(3): 85.     CrossRef
  • Metabolomics and nutrient intake reveal metabolite–nutrient interactions in metabolic syndrome: insights from the Korean Genome and Epidemiology Study
    Minyeong Kim, Suyeon Lee, Junguk Hur, Dayeon Shin
    Nutrition Journal.2025;[Epub]     CrossRef
  • Dysregulation of miR‐21‐5p in diabetic nephropathy and its role in inflammatory response
    Yujiang Zhang, Qin Deng, Jianping Yi
    Journal of Diabetes Investigation.2025; 16(11): 2033.     CrossRef
  • Current Status of Continuous Glucose Monitoring Use in South Korean Type 1 Diabetes Mellitus Population–Pronounced Age-Related Disparities: Nationwide Cohort Study
    Ji Yoon Kim, Seohyun Kim, Jae Hyeon Kim
    Diabetes & Metabolism Journal.2025; 49(5): 1040.     CrossRef
  • Burden of End-Stage Kidney Disease by Type 2 Diabetes Mellitus Status in South Korea: A Nationwide Epidemiologic Study (Diabetes Metab J 2025;49:498-506)
    Ji Eun Jun
    Diabetes & Metabolism Journal.2025; 49(5): 1137.     CrossRef
  • Remnant Cholesterol as an Independent Cardiovascular Risk Factor in Young Adults
    Han Na Jung, Ji Hye Heo, Myung Jin Kim, Kyung-Do Han, Jun Goo Kang, Seong Jin Lee
    JACC.2025; 86(21): 2047.     CrossRef
  • Impact of Type 2 Diabetes Mellitus on Age at Death in the Hemodialysis Population: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
    Ji Hong You, Kang Ju Son, Kyoung Sook Park, Byung-Wan Lee, Sun Ok Song
    Diabetology.2025; 6(12): 145.     CrossRef
  • Endothelial NOX5 Obliterates the Reno-Protective Effect of Nox4 Deletion by Promoting Renal Fibrosis via Activation of EMT and ROS-Sensitive Pathways in Diabetes
    Karin A. M. Jandeleit-Dahm, Haritha R. Kankanamalage, Aozhi Dai, Jaroslawna Meister, Sara Lopez-Trevino, Mark E. Cooper, Rhian M. Touyz, Christopher R. J. Kennedy, Jay C. Jha
    Antioxidants.2024; 13(4): 396.     CrossRef
  • Management Strategies for Potassium Levels During Non-steroidal Mineralocorticoid Receptor Antagonist Therapy: A Comprehensive Review
    Hyung Eun Son
    Electrolytes & Blood Pressure.2024; 22(2): 29.     CrossRef
  • A New Era in Diabetic Kidney Disease Treatment: The Four Pillars and Strategies to Build Beyond
    Sangyub Han, Sejoong Kim
    Electrolytes & Blood Pressure.2024; 22(2): 21.     CrossRef
Cardiovascular risk/Epidemiology
Article image
Risk of Cardiovascular Disease according to Baseline Low-Density Lipoprotein Cholesterol Level in Different Age Groups in Korean Diabetes Population: A Cohort Study
Tae Kyung Yoo, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee
Diabetes Metab J. 2024;48(2):265-278.   Published online February 26, 2024
DOI: https://doi.org/10.4093/dmj.2022.0443
  • 6,313 View
  • 288 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The association between low-density lipoprotein (LDL-C) levels and cardiovascular disease (CVD) risk in different age groups within the diabetes mellitus (DM) population remains unclear. The cohort study was conducted to investigate this relationship.
Methods
We assessed the 2009 to 2012 Korean National Health Screening and National Health Insurance Service records, with follow-up to the primary outcome (myocardial infarction [MI] or stroke) or December 2018. After excluding the participants with a history of MI or stroke, 2,227,394 participants with DM were included and categorized according to baseline LDL-C levels and age. Cox proportional hazards modeling was conducted. The CVD risk of age <40 years and LDL-C <70 mg/dL was set as the reference. In each age group, LDL-C <70 mg/dL was used as a reference for the subgroup analysis.
Results
The cut-off LDL-C value for increased MI risk in each age group varied (<40 years old, LDL-C ≥160 mg/dL: hazard ratios [HR], 2.03; 95% confidence interval [CI], 1.644 to 2.506) (40–49-year-old, LDL-C <115 mg/dL: HR, 1.245; 95% CI, 1.04 to 1.489) (50–59-year-old, LDL-C <115 mg/dL: HR, 1.21; 95% CI, 1.014 to 1.445) (60-69-year-old, LDL-C <145 mg/dL: HR, 1.229; 95% CI, 1.022 to 1.479) (≥70 years old group, LDL-C <100 mg/dL: HR, 1.238; 95% CI, 1.018 to 1.504). The cut-off LDL-C values for increased stroke risk varied in each age subgroup (<40 years old, LDL-C ≥160 mg/dL: HR, 1.395; 95% CI, 1.094 to 1.779) (40–49-year-old, LDL-C <145 mg/dL: HR, 1.13; 95% CI, 1.019 to 1.253) (50–59-year-old, LDL-C <160 mg/dL: HR, 1.079; 95% CI, 1.008 to 1.154) (60–69-year-old, LDL-C <130 mg/dL: HR, 1.07; 95% CI, 1.022 to 1.119) (≥70 years old, LDL-C <115 mg/dL: HR, 1.064; 95% CI, 1.019 to 1.112).
Conclusion
The effect of LDL-C on the risk of CVD differs depending on the age of the population with DM.

Citations

Citations to this article as recorded by  
  • Innovative Lipid-Lowering Strategies: RNA-Based, Small Molecule, and Protein-Based Therapies
    Youngwoo Jang, Eun-Jung Rhee, Sung Hee Choi
    Endocrinology and Metabolism.2025; 40(5): 668.     CrossRef
Drug/Regimen
Article image
Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
Ji Hye Heo, Kyung Ah Han, Jun Hwa Hong, Hyun-Ae Seo, Eun-Gyoung Hong, Jae Myung Yu, Hye Seung Jung, Bong-Soo Cha
Diabetes Metab J. 2024;48(5):937-948.   Published online February 2, 2024
DOI: https://doi.org/10.4093/dmj.2023.0314
  • 20,838 View
  • 753 Download
  • 8 Web of Science
  • 11 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study assessed the efficacy and safety of triple therapy with pioglitazone 15 mg add-on versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and dapagliflozin.
Methods
In this multicenter, double-blind, randomized, phase 3 study, patients with T2DM with an inadequate response to treatment with metformin (≥1,000 mg/day) plus dapagliflozin (10 mg/day) were randomized to receive additional pioglitazone 15 mg/day (n=125) or placebo (n=125) for 24 weeks. The primary endpoint was the change in glycosylated hemoglobin (HbA1c) levels from baseline to week 24 (ClinicalTrials.gov identifier: NCT05101135).
Results
At week 24, the adjusted mean change from baseline in HbA1c level compared with placebo was significantly greater with pioglitazone treatment (–0.47%; 95% confidence interval, –0.61 to –0.33; P<0.0001). A greater proportion of patients achieved HbA1c <7% or <6.5% at week 24 with pioglitazone compared to placebo as add-on to 10 mg dapagliflozin and metformin (56.8% vs. 28% for HbA1c <7%, and 23.2% vs. 9.6% for HbA1c <6.5%; P<0.0001 for all). The addition of pioglitazone also significantly improved triglyceride, highdensity lipoprotein cholesterol levels, and homeostatic model assessment of insulin resistance levels, while placebo did not. The incidence of treatment-emergent adverse events was similar between the groups, and the incidence of fluid retention-related side effects by pioglitazone was low (1.5%).
Conclusion
Triple therapy with the addition of 15 mg/day of pioglitazone to dapagliflozin plus metformin was well tolerated and produced significant improvements in HbA1c in patients with T2DM inadequately controlled with dapagliflozin plus metformin.

Citations

Citations to this article as recorded by  
  • Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial
    Da Hea Seo, Kyung Wan Min, Ho Sang Sohn, Sang Yong Kim, In‐Kyung Jeong, Cheol‐Young Park, Kun‐Ho Yoon, So Hun Kim, Bong‐Soo Cha
    Diabetes, Obesity and Metabolism.2026; 28(1): 728.     CrossRef
  • Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
    Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
    Diabetes, Obesity and Metabolism.2026; 28(3): 1764.     CrossRef
  • Efficacy and safety of fixed-dose dapagliflozin–pioglitazone in Indian adults with type 2 diabetes: results from the randomized phase 3 PRO-1 trial
    Awadhesh Kumar Singh, Krishna G Seshadri, A G Unnikrishnan, Jothydev Kesavadev, Sanjay Kalra, Shashank R Joshi, Kaushik Pandit, Rakesh K Sahay, Vijay K Panikar, Ambrish Mithal, Smriti Gadia, Thamburaj Anthuvan
    Diabetology & Metabolic Syndrome.2026;[Epub]     CrossRef
  • Efficacy and Safety of Pioglitazone Add‐On in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
    Ubaid Khan, Zuhair Majeed, Muhammad Haris Khan, Ahmed Bostamy Elsnhory, Ahmed Mazen Amin, Anum Nawaz, Ahmed Raza, Hafiz Muhammad Waqas Siddque, Mustafa Turkmani, Mohamed Abuelazm
    Endocrinology, Diabetes & Metabolism.2025;[Epub]     CrossRef
  • Pioglitazone as Add-On to Metformin and Dapagliflozin Yields Significant Enhancements in Glycemic Control in Poorly Controlled Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Sara Sabbagh, Ahmed Hegazy, Ahmed Adel, Abdullah Ali, Mohamed Alquddosy, Sara Khalid, Abdallah M Ibrahim, Ahmed Mohamed, Abdelrahman Mostafa, Ahmed Hassan, Ola Mohamed, Rawan Mesbah, Osama Osman, Mohamed Hamouda Elkasaby
    Cureus.2025;[Epub]     CrossRef
  • Triple oral therapy with metformin, DPP‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)
    Miao Yu, Tong Wang, Chun Xu, Yan Bi, Ling Gao, Guang Wang, Guangda Xiang, Yaoming Xue, Tao Yang, Deying Kang, Zhiguang Zhou, Lixin Guo, Xinhua Xiao
    Diabetes, Obesity and Metabolism.2025; 27(S9): 3.     CrossRef
  • Thiazolidinediones for people with chronic kidney disease and diabetes
    Patrizia Natale, Suetonia C Green, David J Tunnicliffe, Giovanni Pellegrino, Tadashi Toyama, Pantelis Sarafidis, Giovanni FM Strippoli
    Cochrane Database of Systematic Reviews.2025;[Epub]     CrossRef
  • Targeting adipose remodeling: Synergistic mechanisms of drugs and adipose-derived stem cells in obese type 2 diabetes mellitus
    Cheng Luo, Xian-Mei Yu, Liang-Yan Hua, Mei-Qi Zeng, Hui Xu, Cheng-Zheng Duan, Shi-Yu Xu, Da Sun, Li-Ya Ye, Dong-Juan He
    World Journal of Stem Cells.2025;[Epub]     CrossRef
  • Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study
    Kyuho Kim, Seung-Hyun Ko, Jae-Seung Yun, Kwan-Woo Lee, Eun Sook Kim, In-Kyung Jeong, Jae Hyeon Kim, Sang Yong Kim, Kyu Chang Won, Mikyung Kim, Bong-Soo Cha, Sungrae Kim, Sung Hee Choi, Eun-Jung Rhee, Sin Gon Kim, Bo Hyun Kim, Kang Seo Park, Young-Cheol Ju
    Scientific Reports.2025;[Epub]     CrossRef
  • Identification and validation of biomarkers related to mitochondria-associated endoplasmic reticulum membranes in type 2 diabetes mellitus using peripheral blood transcriptomics
    Sufen Li, Yanqiong Yan, Qianjun Luo, Ruifei Tian, Jiahe Yan
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • Ideal Combination of Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus
    Hye Soon Kim
    Diabetes & Metabolism Journal.2024; 48(5): 882.     CrossRef
Metabolic Risk/Epidemiology
Article image
Harnessing Metabolic Indices as a Predictive Tool for Cardiovascular Disease in a Korean Population without Known Major Cardiovascular Event
Hyun-Jin Kim, Byung Sik Kim, Yonggu Lee, Sang Bong Ahn, Dong Wook Kim, Jeong-Hun Shin
Diabetes Metab J. 2024;48(3):449-462.   Published online February 1, 2024
DOI: https://doi.org/10.4093/dmj.2023.0197
  • 6,161 View
  • 256 Download
  • 6 Web of Science
  • 7 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study evaluated the usefulness of indices for metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and insulin resistance (IR), as predictive tools for cardiovascular disease in middle-aged Korean adults.
Methods
The prospective data obtained from the Ansan-Ansung cohort database, excluding patients with major adverse cardiac and cerebrovascular events (MACCE). The primary outcome was the incidence of MACCE during the follow-up period.
Results
A total of 9,337 patients were included in the analysis, of whom 1,130 (12.1%) experienced MACCE during a median follow-up period of 15.5 years. The metabolic syndrome severity Z-score, metabolic syndrome severity score, hepatic steatosis index, and NAFLD liver fat score were found to significantly predict MACCE at values above the cut-off point and in the second and third tertiles. Among these indices, the hazard ratios of the metabolic syndrome severity score and metabolic syndrome severity Z-score were the highest after adjusting for confounding factors. The area under the receiver operating characteristic curve (AUC) of the 10-year atherosclerotic cardiovascular disease (ASCVD) score for predicting MACCE was 0.716, and the metabolic syndrome severity Z-score had an AUC of 0.619.
Conclusion
The metabolic syndrome severity score is a highly reliable indicator and was closely associated with the 10-year ASCVD risk score in predicting MACCE in the general population. Given the specific characteristics and limitations of metabolic syndrome severity scores as well as the indices of NAFLD and IR, a more practical scoring system that considers these factors is essential to achieve greater accuracy in forecasting cardiovascular outcomes.

Citations

Citations to this article as recorded by  
  • Risk-associated and clinically informative biomarkers for cardiovascular risk stratification in metabolic dysfunction–Associated steatotic liver disease
    Jiaxin Zhong, Yiwei Zhao, Huifen He, Yi Lan, Zixin Cai
    American Journal of Preventive Cardiology.2026; 26: 101415.     CrossRef
  • Comparing non-alcoholic fatty liver disease indices in predicting the prevalence and incidence of metabolic syndrome in middle-aged adults
    Byung Sik Kim, Hyun-Jin Kim, Seong Won Jeon, Kyung Hwan Kim, Dong Wook Kim, Jeong-Hun Shin
    Heliyon.2025; 11(7): e43073.     CrossRef
  • Long-term clinical outcome and risk stratification across stages of cardiovascular-kidney-metabolic syndrome in a nationwide cohort
    Hyun-Jin Kim, Byung Sik Kim, Hasung Kim, Jungkuk Lee, Ha Hye Jo, Dong Wook Kim, Jeong-Hun Shin, Ki-Chul Sung
    The Korean Journal of Internal Medicine.2025; 40(6): 975.     CrossRef
  • Association of the triglyceride-glucose index with cardiovascular outcomes across cardiovascular-kidney-metabolic syndrome stages
    Byung Sik Kim, Hyun-Jin Kim, Shinje Moon, Hasung Kim, Jungkuk Lee, Jeong-Hun Shin
    The Korean Journal of Internal Medicine.2025; 40(6): 961.     CrossRef
  • Cardiovascular risk across stages of cardiovascular-kidney-metabolic syndrome in South Korea, 2002–2022: A population-based cohort study
    Jaehyeong Cho, Tae Hyeon Kim, Yejun Son, Yesol Yim, Jeongseon Oh, Hyunjee Kim, Jinyoung Jeong, Jiyeon Oh, Sooji Lee, Louis Jacob, Hanseul Cho, Yerin Hwang, Dong Keon Yon
    Medicine.2025; 104(51): e45960.     CrossRef
  • Association between mixed exposure to per- and polyfluoroalkyl substances and metabolic syndrome in Korean adults: Data from the Korean National environmental health survey cycle 4
    Seung Min Chung, Kyun Hoo Kim, Jun Sung Moon, Kyu Chang Won
    International Journal of Hygiene and Environmental Health.2024; 261: 114427.     CrossRef
  • Estimated pulse wave velocity as a forefront indicator of developing metabolic syndrome in Korean adults
    Hyun-Jin Kim, Byung Sik Kim, Dong Wook Kim, Jeong-Hun Shin
    The Korean Journal of Internal Medicine.2024; 39(4): 612.     CrossRef
Cardiovascular risk/Epidemiology
Article image
Real-World Treatment Patterns according to Clinical Practice Guidelines in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Korea: Multicenter, Retrospective, Observational Study
Ye Seul Yang, Nam Hoon Kim, Jong Ha Baek, Seung-Hyun Ko, Jang Won Son, Seung-Hwan Lee, Sang Youl Rhee, Soo-Kyung Kim, Tae Seo Sohn, Ji Eun Jun, In-Kyung Jeong, Chong Hwa Kim, Keeho Song, Eun-Jung Rhee, Junghyun Noh, Kyu Yeon Hur, Committee of Clinical Practice Guidelines, Korean Diabetes Association
Diabetes Metab J. 2024;48(2):279-289.   Published online January 26, 2024
DOI: https://doi.org/10.4093/dmj.2023.0225
  • 7,123 View
  • 406 Download
  • 8 Web of Science
  • 8 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Recent diabetes management guidelines recommend that sodium-glucose cotransporter 2 inhibitors (SGLT2is) or glucagon-like peptide 1 receptor agonists (GLP-1RAs) with proven cardiovascular benefits should be prioritized for combination therapy in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD). This study was aimed at evaluating SGLT2i or GLP-1RA usage rates and various related factors in patients with T2DM and established CVD.
Methods
We enrolled adults with T2DM aged ≥30 years who were hospitalized due to established CVD from January 2019 to May 2020 at 13 secondary and tertiary hospitals in Korea in this retrospective observational study.
Results
Overall, 2,050 patients were eligible for analysis among 2,107 enrolled patients. The mean patient age, diabetes duration, and glycosylated hemoglobin level were 70.0 years, 12.0 years, and 7.5%, respectively. During the mean follow-up duration of 9.7 months, 25.7% of the patients were prescribed SGLT2is after CVD events. However, only 1.8% were prescribed GLP-1RAs. Compared with SGLT2i non-users, SGLT2i users were more frequently male and obese. Furthermore, they had a shorter diabetes duration but showed worse glycemic control and better renal function at the time of the event. GLP-1RA users had a longer duration of diabetes and worse glycemic control at the time of the event than GLP-1RA non-users.
Conclusion
The SGLT2i or GLP-1RA prescription rates were suboptimal in patients with T2DM and established CVD. Sex, body mass index, diabetes duration, glycemic control, and renal function were associated with the use of these agents.

Citations

Citations to this article as recorded by  
  • 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
    Latha P. Palaniappan, Norrina B. Allen, Zaid I. Almarzooq, Cheryl A.M. Anderson, Pankaj Arora, Christy L. Avery, Carissa M. Baker-Smith, Nisha Bansal, Maria E. Currie, Rebecca S. Earlie, Wenjun Fan, Jessica L. Fetterman, Bethany Barone Gibbs, Debra G. Hea
    Circulation.2026;[Epub]     CrossRef
  • Use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with ischaemic heart disease and type 2 diabetes in Swedish primary care: a cross-sectional analysis of regional primary care registry data (QregPV)
    Tobias Andersson, Johan-Emil Bager, Margareta Hellgren, Maria Åberg, Georgios Mourtzinis
    BMJ Open.2026; 16(2): e110395.     CrossRef
  • Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
    Kyoung Hwa Ha, Soyoung Shin, EunJi Na, Dae Jung Kim
    Journal of Diabetes Investigation.2025; 16(2): 215.     CrossRef
  • A National Registry to Improve the Quality of Care for Patients With Acute Coronary Syndrome and Diabetes: Protocol for the China Diabetes Cardiovascular (CDCV) Project
    Na Yang, Jing Liu, Changsheng Ma, Dalong Zhu, Sidney C. Smith, Robert Eckel, Louise Morgan, Yongchen Hao, Jun Liu, Yan Zhou, Yaling Han, Dong Zhao
    Cardiology Discovery.2025;[Epub]     CrossRef
  • Sodium-glucose cotransporter-2 inhibitors and risk of autoimmune rheumatic diseases: population based cohort study
    Bin Hong, Hyesung Lee, Kyungyeon Jung, Sang Youl Rhee, Dong Keon Yon, Ju-Young Shin
    BMJ.2025; 391: e085196.     CrossRef
  • Comparative effectiveness of metformin and alogliptin combination therapy versus metformin monotherapy in patients with type 2 diabetes: an emulated target trial
    Jaehyeong Cho, Yerin Hwang, Selin Woo, Tae Hyeon Kim, Kyeongmin Lee, Yejun Son, Seoyoung Park, Hyunjee Kim, Ju-Young Shin, YongHyun Cho, Dahye Shin, Dosang Cho, Kyung-Jae Lee, Chang Hyun Kim, Sang Youl Rhee, Dong Keon Yon
    BMC Endocrine Disorders.2025;[Epub]     CrossRef
  • Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD
    Gwanpyo Koh
    Diabetes & Metabolism Journal.2024; 48(2): 208.     CrossRef
  • Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
    Jin Hwa Kim, Junyeop Lee, Kyungdo Han, Jae-Taek Kim, Hyuk-Sang Kwon
    Diabetes & Metabolism Journal.2024; 48(6): 1084.     CrossRef
Drug Regimen
Article image
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
Jun Sung Moon, Il Rae Park, Sang Soo Kim, Hye Soon Kim, Nam Hoon Kim, Sin Gon Kim, Seung Hyun Ko, Ji Hyun Lee, Inkyu Lee, Bo Kyeong Lee, Kyu Chang Won
Diabetes Metab J. 2023;47(6):818-825.   Published online November 24, 2023
DOI: https://doi.org/10.4093/dmj.2023.0171
  • 13,140 View
  • 616 Download
  • 12 Web of Science
  • 13 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
To investigate the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe combination compared to highintensity rosuvastatin in high atherosclerotic cardiovascular disease (ASCVD) risk patients with type 2 diabetes mellitus (T2DM).
Methods
This study was a randomized, multicenter, open, parallel phase 4 study, and enrolled T2DM subjects with an estimated 10-year ASCVD risk ≥7.5%. The primary endpoint was the low-density lipoprotein cholesterol (LDL-C) change rate after 24-week rosuvastatin 10 mg/ezetimibe 10 mg treatment was non-inferior to that of rosuvastatin 20 mg. The achievement proportion of 10-year ASCVD risk <7.5% or comprehensive lipid target (LDL-C <70 mg/dL, non-high-density lipoprotein cholesterol <100 mg/dL, and apolipoprotein B <80 mg/dL) without discontinuation, and several metabolic parameters were explored as secondary endpoints.
Results
A hundred and six participants were assigned to each group. Both groups showed significant reduction in % change of LDL-C from baseline at week 24 (–63.90±6.89 vs. –55.44±6.85, combination vs. monotherapy, p=0.0378; respectively), but the combination treatment was superior to high-intensity monotherapy in LDL-C change (%) from baseline (least square [LS] mean difference, –8.47; 95% confidence interval, –16.44 to –0.49; p=0.0378). The combination treatment showed a higher proportion of achieved comprehensive lipid targets rather than monotherapy (85.36% vs. 62.22% in monotherapy, p=0.015). The ezetimibe combination significantly improved homeostasis model assessment of β-cell function even without A1c changes (LS mean difference, 17.13; p=0.0185).
Conclusion
In high ASCVD risk patients with T2DM, the combination of moderate-intensity rosuvastatin and ezetimibe was not only non-inferior but also superior to improving dyslipidemia with additional benefits compared to high-intensity rosuvastatin monotherapy.

Citations

Citations to this article as recorded by  
  • Comparative outcomes of moderate-intensity statin with ezetimibe vs high-intensity statin therapy: A retrospective observational cohort study
    Junpil Yun, Seokhun Yang, Doyeon Hwang, Jeehoon Kang, Han-Mo Yang, Kyung Woo Park, Hyun-Jae Kang, Bon-Kwon Koo, Jung-Kyu Han
    Journal of Clinical Lipidology.2026; 20(1): 87.     CrossRef
  • Cardiovascular outcomes and adverse drug reactions associated with the use of ezetimibe in combination with a statin in diabetes mellitus patients with higher risk for myocardial infarction: a meta-analysis
    Yan Zhou, Ji Jin
    BMC Cardiovascular Disorders.2026;[Epub]     CrossRef
  • Clinical study on the effect of jejunoileal side-to-side anastomosis on metabolic parameters in patients with type 2 diabetes
    Ji-Kui Wang, Di Zhang, Jin-Feng Wang, Wan-Lin Lu, Jing-Yuan Wang, Shi-Feng Liang, Ran Liu, Jing-Xin Jiang, Hong-Tao Li, Xuan Yang
    World Journal of Diabetes.2025;[Epub]     CrossRef
  • Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant System
    Il Rae Park, Yong Geun Chung, Kyu Chang Won
    Diabetes & Metabolism Journal.2025; 49(1): 1.     CrossRef
  • Neuroprotective Effect of Rosuvastatin Calcium Combined with Hyperbaric Oxygen Mediated p38MAPK Pathway in Rats with Leukoaraiosis
    Yafeng Shi, Gemin Zhu, Jun Yan, Linxin Zhang, Yongku Du, Zhuoqiong Bian, Jing Fan
    Cell Biochemistry and Biophysics.2025; 83(3): 3205.     CrossRef
  • Ezetimibe plus statin combination versus double-dose statin in patients with dyslipidemia and atherosclerotic cardiovascular disease risk: a comprehensive systematic review and meta-analysis of 47 randomized controlled trials
    Abdelrahman Mahmoud, Hazem Mohamed Salamah, Hazem Rezq, Yazan Al-Mohtasib, Ali Ashraf Salah Ahmed, Mohamed R. Abdelraouf, Ahmed Mazen Amin, Ahmed A. Ibrahim, Yasmine Adel Mohammed, Omar Ahmed Abdelwahab, Majd M. AlBarakat, Salem Elshenawy, Husam Abu Suili
    Baylor University Medical Center Proceedings.2025; 38(4): 474.     CrossRef
  • Efficacy and safety of statins, ezetimibe, and fibrates monotherapy or combination therapy for hyperlipidemia: a systematic review and network meta-analysis
    Shujie Zhang, Tingting Sun, Lina Song, Xiaodong Jin, Bo Li
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • Effect of folic acid and vitamin B12 plus rosuvastatin in the treatment of coronary heart disease combined with hyperlipidemia
    Hao Wang, Tiezheng Wang
    Frontiers in Cardiovascular Medicine.2025;[Epub]     CrossRef
  • Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus
    Heinz Drexel, Andreas Festa, Thomas A Schmidt, Bianca Rocca, Dobromir Dobrev, Stefan Agewall, Juan Tamargo, Susanne Kaser
    European Heart Journal - Cardiovascular Pharmacotherapy.2025; 11(8): 698.     CrossRef
  • Pharmacokinetics of a single-pill combination of rosuvastatin and ezetimibe (2.5 mg/10 mg) in healthy Chinese subjects: an open-label, two-period, phase I study
    Ying Wang, Jiaxiang Ding, Dongmei Cheng, Yuzhou Ding, Tonghao Zhang, Wang Hu, Xiaoni Wang, Xu Zhu, Yunqiu Xie, Huan Zhou
    Naunyn-Schmiedeberg's Archives of Pharmacology.2025;[Epub]     CrossRef
  • Does Rosuvastatin/Ezetimibe Combination Therapy Offer Potential Benefits for Glucose Metabolism beyond Lipid-Lowering Efficacy in T2DM?
    Il Rae Park, Jun Sung Moon
    Diabetes & Metabolism Journal.2024; 48(3): 387.     CrossRef
  • Efficacy and safety of double-dose statin monotherapy versus moderate-intensity statin combined with ezetimibe dual therapy in diabetic patients: a systematic review and meta-analysis of randomized controlled trials
    Aman Goyal, Muhammad Daoud Tariq, Hritvik Jain, Abhigan Babu Shrestha, Laveeza Fatima, Romana Riyaz, Hritik Raj Yadav, Darsh Safi, Abdul Qahar K. Yasinzai, Rozi Khan, Amir Humza Sohail, Mohamed Daoud, Abu Baker Sheikh
    Cardiovascular Endocrinology & Metabolism.2024;[Epub]     CrossRef
  • Efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin monotherapy in the treatment of composite cardiovascular events with hypercholesterolemia: A meta-analysis
    Lingyan Liu, Yongkun Deng, Lei Li, Xingbiao Yang, Zhaoheng Yin, Yong Lai, Jaspinder Kaur
    PLOS ONE.2024; 19(11): e0310696.     CrossRef
Cardiovascular Risk/Epidemiology
Article image
Glycemic Control and Adverse Clinical Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus: Results from KNOW-CKD
Ga Young Heo, Hee Byung Koh, Hyung Woo Kim, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, Jayoun Kim, Soo Wan Kim, Yeong Hoon Kim, Su Ah Sung, Kook-Hwan Oh, Seung Hyeok Han
Diabetes Metab J. 2023;47(4):535-546.   Published online April 25, 2023
DOI: https://doi.org/10.4093/dmj.2022.0112
  • 9,376 View
  • 276 Download
  • 8 Web of Science
  • 11 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The optimal level of glycosylated hemoglobin (HbA1c) to prevent adverse clinical outcomes is unknown in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM).
Methods
We analyzed 707 patients with CKD G1-G5 without kidney replacement therapy and T2DM from the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD), a nationwide prospective cohort study. The main predictor was time-varying HbA1c level at each visit. The primary outcome was a composite of development of major adverse cardiovascular events (MACEs) or all-cause mortality. Secondary outcomes included the individual endpoint of MACEs, all-cause mortality, and CKD progression. CKD progression was defined as a ≥50% decline in the estimated glomerular filtration rate from baseline or the onset of end-stage kidney disease.
Results
During a median follow-up of 4.8 years, the primary outcome occurred in 129 (18.2%) patients. In time-varying Cox model, the adjusted hazard ratios (aHRs) for the primary outcome were 1.59 (95% confidence interval [CI], 1.01 to 2.49) and 1.99 (95% CI, 1.24 to 3.19) for HbA1c levels of 7.0%–7.9% and ≥8.0%, respectively, compared with <7.0%. Additional analysis of baseline HbA1c levels yielded a similar graded association. In secondary outcome analyses, the aHRs for the corresponding HbA1c categories were 2.17 (95% CI, 1.20 to 3.95) and 2.26 (95% CI, 1.17 to 4.37) for MACE, and 1.36 (95% CI, 0.68 to 2.72) and 2.08 (95% CI, 1.06 to 4.05) for all-cause mortality. However, the risk of CKD progression did not differ between the three groups.
Conclusion
This study showed that higher HbA1c levels were associated with an increased risk of MACE and mortality in patients with CKD and T2DM.

Citations

Citations to this article as recorded by  
  • Frequency of Diabetic Nephropathy among Patients of Type 2 Diabetes Mellitus
    Muhammad Irfan Jamil, Yasir Hussain, Muhammad Shahid Nawaz Khan, Anjum Shahzad, Azhar Iqbal, Adeel Ahmed, Iqra Naeem
    Pakistan Journal of Health Sciences.2025; : 18.     CrossRef
  • Type 2 diabetes mellitus modifies the relationship between coronary artery calcification and adverse kidney outcome in patients with chronic kidney disease: the findings from KNOW-CKD
    Hae-Ryong Yun, Young Su Joo, Hyung Woo Kim, Jung Tak Park, Nak-Hoon Son, Tae-Hyun Yoo, Shin-Wook Kang, Yaeni Kim, Soo Wan Kim, Yeong Hoon Kim, Kook-Hwan Oh, Seung Hyeok Han
    Journal of Nephrology.2025; 38(9): 2755.     CrossRef
  • Intervention effects of optimised carbohydrate diet in patients with type 2 diabetes: study protocol for a randomised controlled crossover trial
    Yuwei LU, Ruiqi Zhang, Jingyi Yang, Dan Liu, Qian Wu, Xiaoxue Long, Di Cheng, Jingyi Guo, Qian Li, Ying Zhang, Piao Kang, Qinyi Wang, Xiaojing Gao, Rong Zeng, Mingliang Zhang, Qichen Fang, Weiping Jia, Yueqiong Ni, Huating Li
    BMJ Open.2025; 15(10): e106756.     CrossRef
  • Interrelationship Between Dyslipidemia and Hyperuricemia in Patients with Uncontrolled Type 2 Diabetes: Clinical Implications and a Risk Identification Algorithm
    Lorena Paduraru, Cosmin Mihai Vesa, Mihaela Simona Popoviciu, Timea Claudia Ghitea, Dana Carmen Zaha
    Healthcare.2025; 13(20): 2605.     CrossRef
  • Baseline predictors of in-hospital mortality among patients with chronic kidney disease admitted to the emergency department
    Arun Prabhahar, Niranjan A Vijaykumar, Harpreet Kaur, Navneet Sharma, Ashok K Pannu
    World Journal of Nephrology.2025;[Epub]     CrossRef
  • Dietary management of patients with type 2 diabetes and chronic kidney disease: A comprehensive literature review
    Asmaa AlShammari, Ali AlSahow
    World Journal of Nephrology.2025;[Epub]     CrossRef
  • Unveiling the utility of artificial intelligence for prediction, diagnosis, and progression of diabetic kidney disease: an evidence-based systematic review and meta-analysis
    Sagar Dholariya, Siddhartha Dutta, Amit Sonagra, Mehul Kaliya, Ragini Singh, Deepak Parchwani, Anita Motiani
    Current Medical Research and Opinion.2024; 40(12): 2025.     CrossRef
  • Non-Alcoholic Fatty Liver Disease and Its Association with Kidney and Cardiovascular Outcomes in Moderate to Advanced Chronic Kidney Disease
    Cheol Ho Park, Hyunsun Lim, Youn Nam Kim, Jae Young Kim, Hyung Woo Kim, Tae Ik Chang, Seung Hyeok Han
    American Journal of Nephrology.2024; : 1.     CrossRef
  • The Beneficial Effect of Glycemic Control against Adverse Outcomes in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
    Dong-Hwa Lee
    Diabetes & Metabolism Journal.2023; 47(4): 484.     CrossRef
  • Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis
    Eneyew Talie Fenta, Habitu Birhan Eshetu, Natnael Kebede, Eyob Ketema Bogale, Amare Zewdie, Tadele Derbew Kassie, Tadele Fentabil Anagaw, Elyas Melaku Mazengia, Sintayehu Shiferaw Gelaw
    Diabetology & Metabolic Syndrome.2023;[Epub]     CrossRef
  • Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis
    Miao Zhu, Ruifang Guan, Guo Ma
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
Review
Metabolic Risk/Epidemiology
Article image
Gestational Diabetes Mellitus and Its Implications across the Life Span
Brandy Wicklow, Ravi Retnakaran
Diabetes Metab J. 2023;47(3):333-344.   Published online February 8, 2023
DOI: https://doi.org/10.4093/dmj.2022.0348
  • 37,218 View
  • 1,722 Download
  • 61 Web of Science
  • 70 Crossref
AbstractAbstract PDFPubReader   ePub   
Gestational diabetes mellitus (GDM) has historically been perceived as a medical complication of pregnancy that also serves as a harbinger of maternal risk of developing type 2 diabetes mellitus (T2DM) in the future. In recent decades, a growing body of evidence has detailed additional lifelong implications that extend beyond T2DM, including an elevated risk of ultimately developing cardiovascular disease. Furthermore, the risk factors that mediate this lifetime cardiovascular risk are evident not only after delivery but are present even before the pregnancy in which GDM is first diagnosed. The concept thus emerging from these data is that the diagnosis of GDM enables the identification of women who are already on an enhanced track of cardiometabolic risk that starts early in life. Studies of the offspring of pregnancies complicated by diabetes now suggest that the earliest underpinnings of this cardiometabolic risk profile may be determined in utero and may first manifest clinically in childhood. Accordingly, from this perspective, GDM is now seen as a chronic metabolic disorder that holds implications across the life span of both mother and child.

Citations

Citations to this article as recorded by  
  • Increased TGF-β/Activin-Smad2 signaling is associated with pancreatic β-cell dysfunction and glucose intolerance in gestational diabetes mellitus
    Talía Boronat-Belda, Hilda Ferrero, Sergi Soriano, Elena Ribes-García, Rubén Betoret-Gustems, Daniel Martínez-Bañón, Mónica Serrano-Selva, Juan Martínez-Pinna, Ángel Nadal, Iván Quesada, Paloma Alonso-Magdalena
    Molecular Metabolism.2026; 103: 102274.     CrossRef
  • Gestational Diabetes in the US From 2016 to 2024
    Emily L. Lam, James M. Walker, Michael C. Wang, Kartik K. Venkatesh, Sadiya S. Khan, Nilay S. Shah
    JAMA Internal Medicine.2026; 186(2): 269.     CrossRef
  • Metabolic biomarkers in early detection of gestational diabetes mellitus: a prospective diagnostic accuracy study
    Alihan Tigli, Yakup Baykus, Rulin Deniz, Kevser Tari Selcuk, Nazli Sener, Yasemin Ercan Degirmenci, Guzide Ece Akinci, İlknur Zeynep Acarturk, Nurseda Sertdemir, Suleyman Aydin
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Advances in Selenium Research on Perinatal Disorders
    学然 冯
    Advances in Clinical Medicine.2026; 16(01): 406.     CrossRef
  • Multiomics elucidation of triclosan-induced gestational diabetes mellitus: Identification of key targets and molecular mechanisms
    Kaiyan Yang, Pengyan Zhai, Ming Zhang, Wenbo Zhou
    Ecotoxicology and Environmental Safety.2026; 309: 119635.     CrossRef
  • Nursing-led tele-coaching for enhancing self-efficacy and lifestyle adherence among gestational diabetic women: tele-nursing versus traditional nursing intervention program
    Soheir Mahmoud Abd El-Hamid, Faiza Mohamed EL-Said, Hend Reda Ali El-kest, Ayman Muhammad Kamel Senosy, Amina Abdelrazek Aldeeb, Manar Gamal Mohamed
    BMC Nursing.2026;[Epub]     CrossRef
  • Implementing a Community-Centered Approach to Gestational Diabetes Screening in Rural Guatemala: A Process Report
    Victoria Rabello Kras, Sasha Hernandez, Concepción Damián Chicajau, Josefa Damián Coquix, Rachel Siretskiy, Jessica Oliveira
    Healthcare.2026; 14(3): 350.     CrossRef
  • circVEGFC strengthens high glucose-induced trophoblast cell inflammation and apoptosis
    Fang Miao, Chunli Wang
    Journal of Reproductive Immunology.2026; : 104851.     CrossRef
  • Diabetes: A comprehensive review of the Indian landscape in contrast with global trends
    Nidhi Singh Rana, Naveen Kumar Vishvakarma, Subash Chandra Sonkar, Mirza Masroor Ali Beg
    World Journal of Diabetes.2026;[Epub]     CrossRef
  • Elevated Systemic Immune-Inflammation Index is Associated with Gestational Diabetes Mellitus: A Multicenter Retrospective Studies
    Jingyang Li, Qiong Li, Yixuan Zhang, Xiaohu Chen, Chunyi Zhang, Yu Chen, Ying Gu, Chaoyan Yue
    Journal of Inflammation Research.2026; Volume 19: 1.     CrossRef
  • The Value of lncRNAs as a Biomarker for the Diagnosis of Gestational Diabetes: A Meta-Analysis
    Yang Fan, Xin Chen, Song Yang, Hongxia Tu, Youyi Zhang, Mingyi Wang, Jingying Jiang
    Hormone and Metabolic Research.2025; 57(01): 67.     CrossRef
  • Usefulness of glycated albumin levels in predicting the maternal or neonatal complications of gestational diabetes mellitus during ;ate pregnancy in South Korea: a retrospective study
    Jihan Kim, Sami Lee, Jong Sung Kim
    Korean Journal of Family Medicine.2025; 46(6): 401.     CrossRef
  • Evidence-Based Care Practices for Children Exposed to a Diabetes-Complicated Pregnancy
    Valerie C. Martinez, Jacqueline B. LaManna, Susan B. Quelly, Suzanne Hyer, Jean W. Davis, Carmen Giurgescu
    The Journal for Nurse Practitioners.2025; 21(1): 105254.     CrossRef
  • Genetic and epigenetic alterations associated with gestational diabetes mellitus and adverse neonatal outcomes
    Amreen Shamsad, Tanu Gautam, Renu Singh, Monisha Banerjee
    World Journal of Clinical Pediatrics.2025;[Epub]     CrossRef
  • Untreated women with first trimester fasting glycaemia 92−125 mg/dL and risk of gestational diabetes mellitus in the 24−28th week OGTT: prevalence and predictors
    Catarina Cidade-Rodrigues, Bruna Silva, Vânia Benido Silva, Catarina Chaves, Maria Luís Mazeda, Alexandra Araújo, Cláudia Machado, Catarina A. Pereira, Vânia Gomes, Odete Figueiredo, Anabela Melo, Anabela Ferreira, Mariana Martinho, Ana Morgado, Ana Saave
    Acta Diabetologica.2025; 62(8): 1291.     CrossRef
  • A Review of the Impact of Gestational Diabetes on Fetal Brain Development: An Update on Neurosonographic Markers During the Last Decade
    Efthymios Oikonomou, Christos Chatzakis, Sofoklis Stavros, Anastasios Potiris, Konstantinos Nikolettos, Sotirios Sotiriou, Ekaterini Domali, Nikolaos Nikolettos, Alexandros Sotiriadis, Angeliki Gerede
    Life.2025; 15(2): 210.     CrossRef
  • Gestational Diabetes Mellitus: Mechanisms Underlying Maternal and Fetal Complications
    Jooyeop Lee, Na Keum Lee, Joon Ho Moon
    Endocrinology and Metabolism.2025; 40(1): 10.     CrossRef
  • Unveiling Gestational Diabetes: An Overview of Pathophysiology and Management
    Rahul Mittal, Karan Prasad, Joana R. N. Lemos, Giuliana Arevalo, Khemraj Hirani
    International Journal of Molecular Sciences.2025; 26(5): 2320.     CrossRef
  • In-patient expenditure between 2011 and 2021 for patients with type 2 diabetes mellitus: a hospital-based multicenter retrospective study in southwest China
    Yuxin He, Juntao Tan, Qingzhu Tan, Xiao Zhang, Yunyu Liu, Yang Tang
    Frontiers in Public Health.2025;[Epub]     CrossRef
  • Knockdown of Aurora kinase B alleviates high glucose-triggered trophoblast cells damage and inflammation during gestational diabetes
    Yuzhuo Ma, Yongyun Shi, Yujie Liu
    Open Life Sciences.2025;[Epub]     CrossRef
  • Prediction of Gestational Diabetes Mellitus (GDM) risk in early pregnancy based on clinical data and ultrasound information: a nomogram
    Tong Zhu, Lin Tang, Man Qin, Wen-Wen Wang, Ling Chen
    BMC Medical Informatics and Decision Making.2025;[Epub]     CrossRef
  • Metabolomic profiling reveals early biomarkers of gestational diabetes mellitus and associated hepatic steatosis
    Youngae Jung, Seung Mi Lee, Jinhaeng Lee, Yeonjin Kim, Woojoo Lee, Ja Nam Koo, Ig Hwan Oh, Kue Hyun Kang, Byoung Jae Kim, Sun Min Kim, Jeesun Lee, Ji Hoi Kim, Yejin Bae, Sang Youn Kim, Gyoung Min Kim, Sae Kyung Joo, Dong Hyeon Lee, Joon Ho Moon, Bo Kyung
    Cardiovascular Diabetology.2025;[Epub]     CrossRef
  • Genetics and epigenetics in gestational diabetes contributing to type 2 diabetes
    Dewei Kong, Oliwia Kowalik, Emma Garratt, Keith M. Godfrey, Shiao-Yng Chan, Adrian Kee Keong Teo
    Trends in Endocrinology & Metabolism.2025; 36(10): 929.     CrossRef
  • Mechanisms of Fetal Overgrowth in Gestational Diabetes: The Potential Role of SOCS2
    Luisa Hernández-Baraza, Yeray Brito-Casillas, Carmen Valverde-Tercedor, Carlota Recio, Leandro Fernández-Pérez, Borja Guerra, Ana M. Wägner
    Nutrients.2025; 17(9): 1519.     CrossRef
  • Mediating effect of osteocalcin underlying the link between insulin-like growth factor-I and gestational diabetes mellitus
    Lingling Cui, Yuting Gao, Ruijie Sun, Zhiqian Li, Zhengya Zhang, Linpu Ji, Yibo Wang, Hua Ye, Luying Qin
    BMC Pregnancy and Childbirth.2025;[Epub]     CrossRef
  • Extracellular Vesicle-Mediated Network in the Pathogenesis of Obesity, Diabetes, Steatotic Liver Disease, and Cardiovascular Disease
    Joonyub Lee, Won Gun Choi, Marie Rhee, Seung-Hwan Lee
    Diabetes & Metabolism Journal.2025; 49(3): 348.     CrossRef
  • Co-Designing a postpartum diabetes prevention program after gestational diabetes mellitus: A MoSCoW prioritization workshop exercise
    Megan Racey, Paige Alliston, Diana Sherifali, Apishanthi Sriskandarajah, Katelyn Sushko, Lorraine Lipscombe
    Diabetes Research and Clinical Practice.2025; 225: 112269.     CrossRef
  • Circulating miR-4454 as a potential biomarker for the diagnosis of T2DM and the prediction value of comorbidity and complications in T2DM
    Song Yang, Mei Wang, Qin Deng
    BMC Endocrine Disorders.2025;[Epub]     CrossRef
  • Comparative analysis of adiposity indices for predicting 2-year hypertension incidence in children and adolescents: a retrospective study
    Bowen Zhu, Shumin Zhan, Hui Shi, Xingyun Wang, Jingwen Yue, Jianfang Gao, Tongshuai Wang, Rui Wang, Xirong Guo, Junfen Fu
    Pediatric Research.2025;[Epub]     CrossRef
  • Education on Prevention and Management of Gestational Diabetes of Pregnant Women at the Obstetrics and Gynecology Clinic of Rumah Sakit Kabupaten Kediri (RSKK)
    Prima Dewi Kusumawati, Siti Komariyah, Binti Ratna Khomsiyatin
    Journal of Community Service for Health.2025; 6(1): 017.     CrossRef
  • The effect of postpartum dietary interventions after gestational diabetes
    Wei Zhao, Zhangping Chen, Yan Jia, Huiren Zhuang
    Asian Journal of Surgery.2025; 48(12): 7683.     CrossRef
  • Omentin-1 protects against endothelial dysfunction through the AMPK/KLF2/eNOS pathway in adult rat offspring exposed to maternal diabetes
    ChunXiang Wang, QingHua Wang, HaoShan Mai
    Nutrition & Diabetes.2025;[Epub]     CrossRef
  • Gestational Diabetes and Cardiovascular Risk in Women: A Comprehensive Review of Thrombosis, Hemostasis, and Emerging Insights Into Coagulation and Fibrinolysis
    Shahid Shehzad, Nosheena A Shabbir, Marium Mumtaz, Ume-A-Aiman ., Maryam Ali Shaheen, Muhammad Rizwan Umer, Amna Sahar
    Cureus.2025;[Epub]     CrossRef
  • Association between statin therapy and incident diabetes mellitus in patients with nephrotic syndrome: a retrospective cohort study
    Yongsheng Qian, Wenyuan Gan, Yan Dong, Wenli Chen, Fan Zhu
    BMC Nephrology.2025;[Epub]     CrossRef
  • Life-course management of gestational diabetes mellitus: A narrative review
    Qing-Jing Luo, Qiang Ni
    World Journal of Clinical Cases.2025;[Epub]     CrossRef
  • Intrauterine hyperglycemia impairs mouse primordial germ cell development and fertility by sex-specific epigenetic reprogramming interference
    Jiangshan Cong, Qing Li, Yangyang Li, Minghao Li, Yan Shi, Peiran Hu, Xidi Yin, Qianyun Zhang, Jianzhong Sheng, Jinsong Li, Guolian Ding, Yu Zhang, Hefeng Huang
    Cell Discovery.2025;[Epub]     CrossRef
  • Pasteurized Akkermansia muciniphila ameliorates insulin resistance by reducing placental inflammation in GDM mouse model
    Yi Wang, Yuting Zhu, Yan Cui, Jiali Fang, Hong Zhong, Yujie Shi, Lan Liu, Xianwei Cui
    Reproductive Biology.2025; 25(4): 101073.     CrossRef
  • From Molecular Insights to Clinical Management of Gestational Diabetes Mellitus—A Narrative Review
    Mohamed-Zakaria Assani, Lidia Boldeanu, Maria-Magdalena Manolea, Mihail Virgil Boldeanu, Isabela Siloși, Alexandru-Dan Assani, Constantin-Cristian Văduva, Anda Lorena Dijmărescu
    International Journal of Molecular Sciences.2025; 26(17): 8719.     CrossRef
  • Association between essential metal elements in the blood of pregnant women in the first trimester and gestational diabetes mellitus and the mediating role of inflammatory indicators
    Guozhen Chen, Cunwei Ji, Li Wu, Yuanzhu Ma, Jianhong Xia, Youjie Wang, Guocheng liu
    International Journal of Hygiene and Environmental Health.2025; 270: 114668.     CrossRef
  • Gestational Diabetes and Obesity: Immediate and Late Sequelae for Offspring
    Maria Kaza, George Paltoglou, Kalliopi Rodolaki, Konstantinos Kakleas, Spyridon Karanasios, Kyriaki Karavanaki
    Children.2025; 12(9): 1263.     CrossRef
  • Relationship between TYG mediated pregnancy diabetes history and SII in American women: a retrospective cohort study of NHANES 2011-2018
    Yanan Duan, Ru Zhang, Yan Zhang, Yuanxuan Ma, Miaomiao Li, Wenke Zhang, Shiguo Liu
    BMC Endocrine Disorders.2025;[Epub]     CrossRef
  • Gestational age and models for predicting gestational diabetes mellitus
    Aisling Murphy, Jeffrey Gornbein, Ophelia Yin, Brian Koos
    Metabolomics.2025;[Epub]     CrossRef
  • Assessment of Maternal–Fetal Redox Balance in Gestational Diabetes Mellitus: A Cross-Sectional Study
    Sorina Cristina Chelu, Veronica Daniela Chiriac, Diana Andrei, Emil Robert Stoicescu, Claudia Borza
    Journal of Clinical Medicine.2025; 14(19): 7003.     CrossRef
  • New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov
    Fahad S. Alshehri
    Medicine.2025; 104(40): e44917.     CrossRef
  • Maternal and neonatal outcomes according to the timing of diagnosis of gestational diabetes: A critical appraisal
    John Punnose
    World Journal of Diabetes.2025;[Epub]     CrossRef
  • A bibliometric and visual analysis of global gestational diabetes mellitus over the past 24 years
    Ying Sun, Li-Meng Zhu, Chen-xi Wei, Yi-Jia Ren
    Journal of Diabetes & Metabolic Disorders.2025;[Epub]     CrossRef
  • Reference range of fetal gastric parameters using three-dimensional ultrasound VOCAL technique and significance in hyperglycemia in pregnancy: a prospective cross-sectional study
    Xihua Lian, Xiaoying Wang, Zhixing Zhu, Piaopiao Liu, Jing Bai, Huohu Zhong, Guorong Lyu, Shaozheng He, Zhenhong Xu, Shunlan Liu
    BMC Pregnancy and Childbirth.2025;[Epub]     CrossRef
  • miR-196a-5p suppresses the MAPK/ERK pathway by targeting HOXA7 to regulate the proliferation and apoptosis of placental trophoblasts in gestational diabetes
    Jianhua Li, Xinping Xie, Lin Lu, Bei Gan, Jianying Yan
    Placenta.2025; 172: 167.     CrossRef
  • Liver as a metabolic sensor in gestational diabetes: Implications for offspring’s liver and diabetes risk
    Mona Mohamed Ibrahim Abdalla, Mohammed Ismail-Khan
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • The impact of early pregnancy uric acid on gestational diabetes risk: a prospective cohort study in Northwest China
    Doudou Zhao, Nan Li, Yanfang Song, Jie Chen, Xiayang Li, Yishuai Huang, Danmeng Liu, Li Shan, Yang Mi, Pengfei Qu, Lei Shang
    BMC Pregnancy and Childbirth.2025;[Epub]     CrossRef
  • THE IMPACT OF SPORTS AND PHYSICAL ACTIVITY ON THE DEVELOPMENT OF PREGNANCY AND THE POSTPARTUM PERIOD CONSIDERING THE IMPACT OF PHYSICAL AND MENTAL HEALTH IN TERMS OF POSTPARTUM DEPRESSION
    Dominika Pietrzyk, Gabriela Furtak, Maria Łagódka, Katarzyna Zając, Bartosz Oder, Michał Pogoda, Wiktor Daniszewski, Wiktoria Knobelsdorf, Wojciech Karchut, Maciej Ćmil
    International Journal of Innovative Technologies in Social Science.2025;[Epub]     CrossRef
  • ATP5me alleviates high glucose-induced myocardial cell injury
    Qingsha Hou, Fang Yan, Xiuling Li, Huanling Liu, Xiang Yang, Xudong Dong
    International Immunopharmacology.2024; 129: 111626.     CrossRef
  • Prevalence and Predictors of Gestational Diabetes Mellitus and Overt Diabetes in Pregnancy: A Secondary Analysis of Nationwide Data from India
    Saurav Basu, Vansh Maheshwari, Rutul Gokalani, Chandrakant Lahariya
    Preventive Medicine: Research & Reviews.2024; 1(1): 52.     CrossRef
  • Serum betaine and dimethylglycine in mid-pregnancy and the risk of gestational diabetes mellitus: a case-control study
    Ziqing Zhou, Yao Yao, Yanan Sun, Xin Wang, Shang Huang, Jianli Hou, Lijun Wang, Fengxiang Wei
    Endocrine.2024; 85(2): 649.     CrossRef
  • Quality assessment of videos on social media platforms related to gestational diabetes mellitus in China: A cross-section study
    Qin-Yu Cai, Jing Tang, Si-Zhe Meng, Yi Sun, Xia Lan, Tai-Hang Liu
    Heliyon.2024; 10(7): e29020.     CrossRef
  • Association of VDR gene variant rs2228570-FokI with gestational diabetes mellitus susceptibility in Arab women
    Maysa Alzaim, Mohammed G.A. Ansari, Abeer A. Al-Masri, Malak N.K. Khattak, Abir Alamro, Amani Alghamdi, Amal Alenad, Majed Alokail, Omar S. Al-Attas, Ahmad G. Al-Zahrani, Nasser M. Al-Daghri
    Heliyon.2024; 10(11): e32048.     CrossRef
  • Variations in the LINGO2 and GLIS3 Genes and Gene–Environment Interactions Increase Gestational Diabetes Mellitus Risk in Chinese Women
    Xiao Huang, Weiwei Liang, Runqiu Yang, Lei Jin, Kai Zhao, Juan Chen, Xuejun Shang, Yuanzhong Zhou, Xin Wang, Hongsong Yu
    Environmental Science & Technology.2024; 58(26): 11596.     CrossRef
  • Pre-gestational diabetes mellitus, gestational diabetes mellitus, and its association with the MTHFR C677T polymorphism
    Nga Thi Ngoc Pham, Chau Thi Ngoc Huynh, Ai Thuy Thuy Nguyen, Chuong Quoc Ho, Linh My Duong, Dung The Bui, Ha Hong Nguyen
    Medicine.2024; 103(28): e38648.     CrossRef
  • Amelioration of Insulin Resistance after Delivery Is Associated with Reduced Risk of Postpartum Diabetes in Women with Gestational Diabetes Mellitus
    Heejun Son, Joon Ho Moon, Sung Hee Choi, Nam H. Cho, Soo Heon Kwak, Hak Chul Jang
    Endocrinology and Metabolism.2024; 39(5): 701.     CrossRef
  • Oral Wound Healing in Aging Population
    Claudia Florina Bogdan-Andreescu, Andreea-Mariana Bănățeanu, Oana Botoacă, Carmen Liliana Defta, Cristian-Viorel Poalelungi, Anca Daniela Brăila, Constantin Marian Damian, Matei Georgian Brăila, Laurențiu Mihai Dȋră
    Surgeries.2024; 5(4): 956.     CrossRef
  • Relationship between life’s essential 8 and the risk of gestational diabetes among us adults
    Lu Qin, Zhixing Fan, Qian Shi, Hao Hu, Fang Ma, Yanlin Huang, Fengzhi Tan
    The Journal of Maternal-Fetal & Neonatal Medicine.2024;[Epub]     CrossRef
  • The role of quercetin in NLRP3-associated inflammation
    Jiaqi Wu, Tongtong Lv, Yu Liu, Yifan Liu, Yukun Han, Xin Liu, Xiaochun Peng, Fengru Tang, Jun Cai
    Inflammopharmacology.2024; 32(6): 3585.     CrossRef
  • A Systematic Patent Review (2008-2023) for Treatment in Pregnancy
    Kélle Velasques Pereira, Camila Oliveira Pacheco, Izabel Almeida Alves, Sandra Elisa Haas
    Current Medicinal Chemistry.2024; 31(38): 6288.     CrossRef
  • Clinical Significance of miR-339-5p in Early Diagnosis and Predicting Pregnancy Outcome of Chinese Patients with Liver Injury in Pregnancy
    Ying Wang, Lichao Yuan, Falong Hu, Huilan Yu, Qiaofang Yang, Xiujuan Zheng
    Clinical and Experimental Obstetrics & Gynecology.2024;[Epub]     CrossRef
  • Single and Joint Associations Between Blood Cell‐Based Inflammatory Indicator in Early Pregnancy and Risk of Gestational Diabetes Mellitus (GDM): A Prospective Cohort Study
    Yanling Xiao, Haonan Zhang, Songlin An, Rui Yu, Jing Yang, Xingting Zheng, Nian Wu, Lin Tao, Dengqing Liao, Mingyu Deng, Zhongmei Hu, Yijun Liu, Qing Chen, Yuanzhong Zhou
    American Journal of Reproductive Immunology.2024;[Epub]     CrossRef
  • Gestational diabetes-combined excess weight gain exacerbates gut microbiota dysbiosis in newborns, associated with reduced abundance of Clostridium, Coriobacteriaceae, and Collinsella
    Yunshan Xiao, Yuan Shi, Yan Ni, Meilan Ni, Yuxin Yang, Xueqin Zhang
    Frontiers in Cellular and Infection Microbiology.2024;[Epub]     CrossRef
  • Untargeted metabolomics profiling of gestational diabetes mellitus: insights into early diagnosis and metabolic pathway alterations
    Shereen M. Aleidi, Hiba Al Fahmawi, Reem H. AlMalki, Maha Al Mogren, Mohammad Alwahsh, Muhammad Mujammami, Michele Costanzo, Anas Abdel Rahman
    Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
  • Inflammation and decreased cardiovagal modulation are linked to stress and depression at 36th week of pregnancy in gestational diabetes mellitus
    Manoharan Renugasundari, Gopal Krushna Pal, Latha Chaturvedula, Nivedita Nanda, K. T. Harichandrakumar, Thiyagarajan Durgadevi
    Scientific Reports.2023;[Epub]     CrossRef
  • Women with gestational diabetes mellitus, controlled for plasma glucose level, exhibit maternal and fetal dyslipidaemia that may warrant treatment
    Barbara J. Meyer, Colin Cortie, Marloes Dekker-Nitert, Helen L. Barrett, Dilys J. Freeman
    Diabetes Research and Clinical Practice.2023; 204: 110929.     CrossRef
  • Pregnancy diet to prevent gestational diabetes: study design and dietary assessments
    Sylvia H. Ley
    The American Journal of Clinical Nutrition.2023; 118(5): 847.     CrossRef
Original Articles
Cardiovascular Risk/Epidemiology
Article image
Cardiovascular Outcomes according to Comorbidities and Low-Density Lipoprotein Cholesterol in Korean People with Type 2 Diabetes Mellitus
Min Kyong Moon, Junghyun Noh, Eun-Jung Rhee, Sang Hyun Park, Hyeon Chang Kim, Byung Jin Kim, Hae Jin Kim, Seonghoon Choi, Jin Oh Na, Young Youl Hyun, Bum Joon Kim, Kyung-Do Han, In-Kyung Jeong, on Behalf of the Committee of Practice Guideline of Korean Lipid and Atheroscelerosis
Diabetes Metab J. 2023;47(1):45-58.   Published online January 26, 2023
DOI: https://doi.org/10.4093/dmj.2021.0344
  • 10,317 View
  • 370 Download
  • 8 Web of Science
  • 13 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
There are no clear data to support the cardiovascular (CV) risk categories and low-density lipoprotein cholesterol (LDL-C) treatment goals in Korean people with type 2 diabetes mellitus (T2DM). We evaluated the incidence of cardiovascular disease (CVD) according to comorbidities and suggested LDL-C treatment goals in Korean people with T2DM in nationwide cohort data.
Methods
Using the Korean National Health Insurance Service database, 248,002 people aged 30 to 90 years with T2DM who underwent routine health check-ups during 2009 were included. Subjects with previous CVD were excluded from the study. The primary outcome was incident CVD, defined as a composite of myocardial infarction and ischemic stroke during the follow-up period from 2009 to 2018.
Results
The mean age of the study participants was 59.6±10.9 years, and median follow-up period was 9.3 years. CVD incidence increased in the order of DM duration of 5 years or more (12.04/1,000 person-years), hypertension (HT) (12.27/1,000 personyears), three or more CV risk factors (14.10/1,000 person-years), and chronic kidney disease (18.28/1,000 person-years). The risk of incident CVD increased linearly from an LDL-C level of ≥70 mg/dL in most patients with T2DM. In T2DM patients without HT or with a DM duration of less than 5 years, the CVD incidence increased from LDL-C level of ≥100 mg/dL.
Conclusion
For primary prevention of CVD in Korean adults with T2DM, it can be helpful to lower LDL-C targets when there are chronic kidney disease, HT, a long duration of diabetes mellitus, or three or more CV risk factors.

Citations

Citations to this article as recorded by  
  • Clinical value of serum miR-214-3p expression in the diagnosis of type 2 diabetes mellitus and prediction of its chronic complications
    Meng Ding, Siyu Yang, Junli Li, Lie Ma, Cunyou Xiong, Jie Zhang
    BMC Endocrine Disorders.2025;[Epub]     CrossRef
  • Cholesterol and Cardiovascular Risk in Type 2 Diabetes: The Role of Kidney Function
    Ji-Hyun Kim, Seung-Hwan Lee, Kyu Na Lee, Kyungdo Han, Mee Kyoung Kim
    Journal of Lipid and Atherosclerosis.2025; 14(2): 190.     CrossRef
  • 2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association
    Shinae Kang, Seon Mee Kang, Jong Han Choi, Seung-Hyun Ko, Bo Kyung Koo, Hyuk-Sang Kwon, Mi Kyung Kim, Sang Yong Kim, Soo-Kyung Kim, Young-eun Kim, Eun Sook Kim, Jae Hyeon Kim, Chong Hwa Kim, Ji Min Kim, Hae Jin Kim, Min Kyong Moon, Sun Joon Moon, Jun Sung
    Diabetes & Metabolism Journal.2025; 49(4): 582.     CrossRef
  • Heterogeneity in the development of diabetes-related complications: narrative review of the roles of ancestry and geographical determinants
    Andrea O. Y. Luk, Yingnan Fan, Baoqi Fan, Edith W. K. Chow, Tony C. K. O
    Diabetologia.2025; 68(11): 2386.     CrossRef
  • Adherence-based experiences with a personalized self-care program for type 2 diabetes in South Korea: a mixed-methods study
    Haejung Lee, DaeEun Lee, Mihwan Kim
    Journal of Korean Biological Nursing Science.2025; 27(4): 706.     CrossRef
  • 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
    Jun Sung Moon, Shinae Kang, Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, Yoon Ju Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang
    Diabetes & Metabolism Journal.2024; 48(4): 546.     CrossRef
  • Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
    Diabetes & Metabolism Journal.2023; 47(1): 1.     CrossRef
  • Optimal Low-Density Lipoprotein Cholesterol Level for Primary Prevention in Koreans with Type 2 Diabetes Mellitus
    Ji Yoon Kim, Nam Hoon Kim
    Diabetes & Metabolism Journal.2023; 47(1): 42.     CrossRef
  • Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
    Journal of Lipid and Atherosclerosis.2023; 12(1): 12.     CrossRef
  • 2023 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Factors
    Ye Seul Yang
    The Journal of Korean Diabetes.2023; 24(3): 135.     CrossRef
  • 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
    Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, YoonJu Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae J
    Diabetes & Metabolism Journal.2023; 47(5): 575.     CrossRef
  • Management of Dyslipidemia in Patients with Diabetes Mellitus
    Kyung Ae Lee
    The Journal of Korean Diabetes.2023; 24(3): 111.     CrossRef
  • Significant Gap Between Guidelines and Practice in the Management of LDL Cholesterol: Insight From the Survey of the Korean Society of Myocardial Infarction
    Sang Yeub Lee, Kyung Hoon Cho, Jang Hoon Lee, Young Joon Hong, Jin yong Hwang, Myung Ho Jeong, Weon Kim
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
Cardiovascular Risk/Epidemiology
Article image
Association between Low-Density Lipoprotein Cholesterol Level and Cardiovascular Outcomes in Korean Adults: A Nationwide Cohort Study
Junghyun Noh, Min Kyong Moon, Eun-Jung Rhee, Sang Hyun Park, Hyeon Chang Kim, Byung Jin Kim, Hae Jin Kim, Seonghoon Choi, Jin Oh Na, Young Youl Hyun, Bum Joon Kim, Kyung-Do Han, In-Kyung Jeong, on Behalf of the Committee of Practice Guideline of Korean Lipid and Atheroscelerosis
Diabetes Metab J. 2023;47(1):59-71.   Published online January 26, 2023
DOI: https://doi.org/10.4093/dmj.2021.0320
  • 9,823 View
  • 332 Download
  • 3 Web of Science
  • 4 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
To validate the treatment target of low-density lipoprotein cholesterol (LDL-C) level according to the cardiovascular disease (CVD) risk which was recommended by Korean dyslipidemia guideline.
Methods
We used the Korean National Health Insurance Service database which included 3,958,048 people aged 20 to 89 years who underwent regular health screening. The primary outcome was incident CVD, defined as a composite of myocardial infarction and stroke during the follow-up period from 2009 to 2018.
Results
The risk of CVD increased from LDL-C level of 70 mg/dL in very high-risk and high-risk groups and from 130 mg/dL in moderate-risk and low-risk groups. Adjusted hazard ratios (HRs) of LDL-C ranges 70–99, 100–129, 130–159, 160–189, and ≥190 mg/dL were 1.20 (95% confidence interval [CI], 1.08–1.33), 1.27 (1.15–1.42), 1.39 (1.23–1.56), 1.69 (1.45–1.96), and 1.84 (1.49– 2.27) in very high-risk group, and 1.07 (1.02–1.13), 1.16 (1.10–1.21), 1.29 (1.22–1.36), 1.45 (1.36–1.55), and 1.73 (1.58–1.90) in high-risk group. Adjusted HRs (95% CI) of LDL-C ranges 130–159, 160–189, and ≥190 mg/dL were 1.15 (1.11–1.20), 1.28 (1.22– 1.34), and 1.45 (1.36–1.54) in moderate-risk group and 1.07 (1.02–1.13), 1.20 (1.13–1.26), and 1.47 (1.37–1.57) in low-risk group.
Conclusion
We confirmed the incidence of CVD was increased in higher LDL-C range. The risk of CVD increased from ≥70 mg/dL of LDL-C in very high-risk and high-risk groups, and from ≥130 mg/dL of LDL-C in moderate-risk and low-risk groups in Korean adults.

Citations

Citations to this article as recorded by  
  • A dual-signal electrochemical aptasensor based on rGO@MoS2-Fc nanozyme for sensitive detection of low-density lipoprotein
    Zhide Zhou, Haimei Li, Xiaohua Deng, Yuxuan Shi, Jiahang Huang, Yu Zhou, Xiaohong Tan, Jintao Liang, Guiyin Li
    Bioelectrochemistry.2026; 169: 109206.     CrossRef
  • Colorimetric aptasensors for sensitive low-density lipoprotein detection based on reduced oxide graphene@molybdenum disulfide-ferrocene nanosheets with peroxidase-like activity
    Guiyin Li, Tingting Yu, Haimei Li, Bingbing Wan, Xiaohong Tan, Xueqing Zhou, Jintao Liang, Zhide Zhou
    Analytical Methods.2025; 17(1): 136.     CrossRef
  • Cholesterol and Cardiovascular Risk in Type 2 Diabetes: The Role of Kidney Function
    Ji-Hyun Kim, Seung-Hwan Lee, Kyu Na Lee, Kyungdo Han, Mee Kyoung Kim
    Journal of Lipid and Atherosclerosis.2025; 14(2): 190.     CrossRef
  • Efficacy and Safety of a Single-Pill Triple Combination of Olmesartan, Amlodipine, and Rosuvastatin in Hypertensive Patients with Low-to-Moderate Cardiovascular Risk: A Multicenter, Randomized, Open-Label, Active-Control, Phase IV Clinical Trial
    Byung Jin Kim, Kwang Soo Cha, Wook Hyun Cho, Eung Ju Kim, Seung-Hyuk Choi, Moo Hyun Kim, Sang-Hyun Kim, Jun-Bean Park, Seong-Mi Park, Il Suk Sohn, Kyu Hyung Ryu, In-Ho Chae
    Journal of Cardiovascular Pharmacology and Therapeutics.2023;[Epub]     CrossRef
Reviews
Pathophysiology
Article image
Blood Pressure Target in Type 2 Diabetes Mellitus
Hyun-Jin Kim, Kwang-il Kim, on Behalf of the Policy Committee of Korean Society of Hypertension
Diabetes Metab J. 2022;46(5):667-674.   Published online September 19, 2022
DOI: https://doi.org/10.4093/dmj.2022.0215
  • 20,503 View
  • 814 Download
  • 26 Web of Science
  • 32 Crossref
AbstractAbstract PDFPubReader   ePub   
The prevalence of diabetes mellitus continues to increase worldwide, and it is a well-established cardiovascular risk factor. Hypertension is also an important cardiovascular risk factor to be controlled and is common among patients with diabetes mellitus. Optimal blood pressure (BP) goals have been the subject of great debate in the management of hypertension among patients with diabetes mellitus. This review provides detailed results from randomized controlled trials and meta-analyses of clinical outcomes according to the target BP in patients with type 2 diabetes mellitus. In addition, the target BP in patients with diabetes mellitus recommended by different guidelines was summarized and presented. A target BP of <140/90 mm Hg is recommended for patients with hypertension and diabetes mellitus, and BP should be controlled to <130/80 mm Hg in patients with diabetes mellitus who have high-risk clinical features. We hope that this review will be helpful to clinicians and patients by promoting the understanding and appropriate application of BP control in the comprehensive management of patients with diabetes mellitus.

Citations

Citations to this article as recorded by  
  • Diabetic Retinopathy Screening in Primary Care Real Practice: Study Procedures and Baseline Characteristics from the RETINAvalid Project
    Víctor-Miguel López-Lifante, Maria Palau-Antoja, Noemí Lamonja-Vicente, Cecilia Herrero-Alonso, Josefina Sala-Leal, Rosa García-Sierra, Adrià Prior-Rovira, Marina Alventosa-Zaidin, Meritxell Carmona-Cervelló, Erik Isusquiza Garcia, Idoia Besada, Pere Torá
    Healthcare.2026; 14(3): 334.     CrossRef
  • Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care – The countrywide cross‐sectional AUSTRO‐PROFIT study
    Harald Sourij, Kehkishan Azhar, Faisal Aziz, Harald Kojzar, Caren Sourij, Peter Fasching, Martin Clodi, Bernhard Ludvik, Julia K. Mader, Michael Resl, Gersina Rega‐Kaun, Claudia Ress, Lars Stechemesser, Harald Stingl, Norbert J. Tripolt, Thomas Wascher, S
    Diabetes, Obesity and Metabolism.2025; 27(1): 111.     CrossRef
  • Effect of systolic blood pressure status on coronary inflammation and high-risk plaque characteristics
    Cui-Ping Jiang, Yuan-Kang Liu, Pan-Pan Cheng, Yue Dong, Xiang Wang, Fan-Yu Wu, Yu-Xuan Xia, Peng-Yun Wang, Xiang-Yang Xu
    World Journal of Diabetes.2025;[Epub]     CrossRef
  • Baseline clinical and biochemical profiles of type 2 diabetes patients enrolled in a lifestyle management program in India, a cross-sectional study
    Pramod Tripathi, Nidhi Kadam, Thejas Kathrikolly, Diptika Tiwari, Anagha Vyawahare, Baby Sharma, Malhar Ganla, Banshi Saboo
    Scientific Reports.2025;[Epub]     CrossRef
  • Analysis of Factors Influencing Clinical Inertia in the Treatment of Type 2 Diabetes Mellitus Patients With Metformin
    Xuan Lu, Fubi Jin
    British Journal of Hospital Medicine.2025; 86(4): 1.     CrossRef
  • Significant Impacts of the Body-Mass Index, Blood Pressure, Blood Glucose, and Ankle-Brachial Index on Peripheral Neuropathy Risk in Indonesian With Type 2 Diabetes: A Cross-Sectional Study
    Siti Fadlilah, Vivi Leona Amelia, Cyruz P. Tuppal, Hui-Chen (Rita) Chang, Ching Wen Chang, Chia Ling Lin, Hsiu Ting Tsai
    Biological Research For Nursing.2025; 27(4): 558.     CrossRef
  • Sodium propionate improves cardiac function in Type 2 diabetic rats
    Folasade Omobolanle Ajao, Samad Abiola, Noheem Olaoluwa Kalejaiye, Sodik Olasunkami Mukaila, Marcus Olaoye Iyedupe, Olalekan Samson Agboola
    Medical Science and Discovery.2025; 12(5): 163.     CrossRef
  • Diabetes in resuscitated comatose out-of-hospital cardiac arrest patients: a substudy of the randomized BOX trial
    Jakob Josiassen, Jacob E Møller, Henrik Schmidt, Rasmus P Beske, Johannes Grand, Jesper Kjaergaard, Christian Hassager
    European Heart Journal: Acute Cardiovascular Care.2025; 14(9): 531.     CrossRef
  • Predictors of incident diabetic peripheral neuropathy: a systematic review of longitudinal studies in patients with diabetes mellitus
    Sher Mein Chew, Sanchi Dua Avinashi, Kavita Venkataraman
    Reviews in Endocrine and Metabolic Disorders.2025; 26(4): 659.     CrossRef
  • Identification of comorbid genes between type 2 diabetes and migraine through peripheral blood single-cell and Mendelian randomization analysis
    Bobo Yuan, Jianrui Li, Qing Shu, Xiaoye Wang, Guogang Luo, Ranran Ma
    The Journal of Headache and Pain.2025;[Epub]     CrossRef
  • In situ formation of fluorescent non-conjugated polymer dots for α-glucosidase activity assay and inhibitor screening
    Feifei Wang, Xinling Wang, Yu Wang, Yin Zhang, Tianxiang Liu, Jian Sun
    Microchimica Acta.2025;[Epub]     CrossRef
  • Age and sex differences of cardiovascular and mortality risks in Korean type 2 diabetes and prediabetes: An 8 million Korean nationwide population-based cohort study
    Jae-Seung Yun, Jin-Hyung Jung, Bongseong Kim, Kyuho Kim, Yu-Bae Ahn, Seung Yeon Kim, Sooha Jung, Kyungdo Han, Seung-Hyun Ko
    Diabetes Research and Clinical Practice.2025; 227: 112401.     CrossRef
  • Predicting HbA1c Target Achievement in Type 2 Diabetes: A Retrospective Single-Centre Nomogram Derived From National MMC-Standardised Management
    Ming Lu, Hua Zhou, Yanxing Liu, Juanjuan Song, Xiaolin Lu, Yan Liu
    Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 3589.     CrossRef
  • Sex-specific protective role of lower-body fat in type 2 diabetes: mediation through insulin resistance in a BMI-matched population
    Qiong Wang, Pei-Pei Chen, Wei Wei, Jia-Yu Guo, Yuan-Yuan Bao, Jing Zhang, Kang Yu
    BMJ Open Diabetes Research & Care.2025; 13(6): e005397.     CrossRef
  • Chronic complications among patients with type 2 diabetes in Southern Ethiopia
    Biniyam Demisse Andarge, Desta Haftu Hayelom, Sayih Mehari Degualem, Habtamu Esubalew Bezie, Habtamu Wondmagegn, Yohannes Habtegiorgis, Muluken Bekele Sorrie, Yilma Chisha, Mirna Alejandra Gonzalez-Gonzalez
    PLOS One.2025; 20(11): e0336666.     CrossRef
  • Diretriz Brasileira de Hipertensão Arterial – 2025
    Andréa Araujo Brandão, Cibele Isaac Saad Rodrigues, Luiz Aparecido Bortolotto, Anderson da Costa Armstrong, Rogério Andrade Mulinari, Audes Diógenes de Magalhães Feitosa, Marco Antonio Mota-Gomes, Eduardo Costa Duarte Barbosa, José Andrade Moura, Mario Fr
    Arquivos Brasileiros de Cardiologia.2025;[Epub]     CrossRef
  • Recent evidence on target blood pressure in patients with hypertension
    Hack-Lyoung Kim
    Cardiovascular Prevention and Pharmacotherapy.2024; 6(1): 17.     CrossRef
  • Using Generative AI to Improve the Performance and Interpretability of Rule-Based Diagnosis of Type 2 Diabetes Mellitus
    Leon Kopitar, Iztok Fister, Gregor Stiglic
    Information.2024; 15(3): 162.     CrossRef
  • Additive interaction of family medical history of diabetes with hypertension on the diagnosis of diabetes among older adults in India: longitudinal ageing study in India
    Waquar Ahmed
    BMC Public Health.2024;[Epub]     CrossRef
  • Risk factors of undiagnosed and uncontrolled hypertension in primary care patients with hypertension: a cross-sectional study
    Emmanuel Adediran, Robert Owens, Elena Gardner, Andrew Curtin, John Stuligross, Danielle Forbes, Jing Wang, Dominik Ose
    BMC Primary Care.2024;[Epub]     CrossRef
  • Interplay of Adiponectin With Glycemic and Metabolic Risk Metrics in Patients With Diabetes
    Ritu Tiwari, Nishtha Singh, Shraddha Singh, Manish Bajpai, Shivam Verma
    Cureus.2024;[Epub]     CrossRef
  • Clinical and Sociodemographic Profile, Self-Care, Adherence and Motivation for Treatment, and Satisfaction with Social Support in Portuguese Patients with Type 2 Diabetes
    Virginia M. G. Regufe, Manuel A. Lobão, Natália Cruz-Martins, Carla Luís, Pedro von Hafe, Cristina B. Pinto
    Journal of Clinical Medicine.2024; 13(21): 6423.     CrossRef
  • Effectiveness of King’s Theory of Goal Attainment in Blood Glucose Management for Newly Diagnosed Patients With Type 2 Diabetes: Randomized Controlled Trial
    Man Yan, Yingchun Yu, Shuping Li, Peiling Zhang, Jiaxiang Yu
    Journal of Medical Internet Research.2024; 26: e59142.     CrossRef
  • Natural polysaccharides: The potential biomacromolecules for treating diabetes and its complications via AGEs-RAGE-oxidative stress axis
    Jie Sun, Na Wei, Chenxi Yu, Chao Li, Wei Li, Xiuyan Sun, Yanqing Zhang, Yaxin Li, Junbo Xie
    International Immunopharmacology.2024; 143: 113426.     CrossRef
  • Management of arterial hypertension in patients with peripheral arterial disease
    Pavel POREDOŠ, Dimitri P. MIKHAILIDIS, Kosmas I. PARASKEVAS, Aleš BLINC, Pier L. ANTIGNANI, Agata STANEK, Armando MANSILHA, Matija CEVC
    International Angiology.2024;[Epub]     CrossRef
  • Assessment of Prescribing Practice of Anti-Hypertensive Medications in a Sample of Iraqi Patients with Diabetes
    Amina Jabri, Zaid Fakhrulddin, Evan Hameed
    Wiadomości Lekarskie.2024; 77(12): 2419.     CrossRef
  • Emerging roles of interferon-stimulated gene-15 in age-related telomere attrition, the DNA damage response, and cardiovascular disease
    María González-Amor, Beatriz Dorado, Vicente Andrés
    Frontiers in Cell and Developmental Biology.2023;[Epub]     CrossRef
  • Effects of Diabetes and Voluntary Exercise on IgA Concentration and Polymeric Immunoglobulin Receptor Expression in the Submandibular Gland of Rats
    Jaebum Park, Yuko Yamamoto, Kouki Hidaka, Satoko Wada-Takahashi, Shun-suke Takahashi, Toshiya Morozumi, Nobuhisa Kubota, Makiko Saita, Juri Saruta, Wakako Sakaguchi, Masahiro To, Tomoko Shimizu, Yuko Mikuni-Takagaki, Keiichi Tsukinoki
    Medicina.2023; 59(4): 789.     CrossRef
  • A diabetes update
    Zachary Bloomgarden
    Journal of Diabetes.2023; 15(7): 542.     CrossRef
  • CARDIOPROTECTIVE AND METABOLIC EFFECTS OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH SUCH COMORBIDITIES AS ARTERIAL HYPERTENSION, TYPE 2 DIABETES MELLITUS, AND OBESITY
    I. P. Dunaieva, N. O. Kravchun, І. A. Ilchenko
    Bulletin of Problems Biology and Medicine.2023; 1(2): 211.     CrossRef
  • Hypertensive Heart Failure
    Filippos Triposkiadis, Pantelis Sarafidis, Alexandros Briasoulis, Dimitrios E. Magouliotis, Thanos Athanasiou, John Skoularigis, Andrew Xanthopoulos
    Journal of Clinical Medicine.2023; 12(15): 5090.     CrossRef
  • 2023 Clinical Practice Guidelines for Diabetes
    Min Kyong Moon
    The Journal of Korean Diabetes.2023; 24(3): 120.     CrossRef
Drug/Regimen
Article image
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
Diabetes Metab J. 2022;46(4):517-532.   Published online July 27, 2022
DOI: https://doi.org/10.4093/dmj.2022.0198
Correction in: Diabetes Metab J 2022;46(5):817
  • 26,947 View
  • 1,230 Download
  • 58 Web of Science
  • 62 Crossref
AbstractAbstract PDFPubReader   ePub   
Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, even under optimal statin therapy, a significant residual ASCVD risk remains. Therefore, there has been an unmet clinical need for novel lipid-lowering agents that can target low-density lipoprotein cholesterol (LDL-C) and other atherogenic particles. During the past decade, several drugs have been developed for the treatment of dyslipidemia. Inclisiran, a small interfering RNA that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), shows comparable effects to that of PCSK9 monoclonal antibodies. Bempedoic acid, an ATP citrate lyase inhibitor, is a valuable treatment option for the patients with statin intolerance. Pemafibrate, the first selective peroxisome proliferator-activated receptor alpha modulator, showed a favorable benefit-risk balance in phase 2 trial, but the large clinical phase 3 trial (PROMINENT) was recently stopped for futility based on a late interim analysis. High dose icosapent ethyl, a modified eicosapentaenoic acid preparation, shows cardiovascular benefits. Evinacumab, an angiopoietin-like 3 (ANGPTL3) monoclonal antibody, reduces plasma LDL-C levels in patients with refractory hypercholesterolemia. Novel antisense oligonucleotides targeting apolipoprotein C3 (apoC3), ANGPTL3, and lipoprotein(a) have significantly attenuated the levels of their target molecules with beneficial effects on associated dyslipidemias. Apolipoprotein A1 (apoA1) is considered as a potential treatment to exploit the athero-protective effects of high-density lipoprotein cholesterol (HDL-C), but solid clinical evidence is necessary. In this review, we discuss the mode of action and clinical outcomes of these novel lipid-lowering agents beyond statins.

Citations

Citations to this article as recorded by  
  • CURRENT ADVANCES IN LIPOPROTEIN(A) MANAGEMENT: CLINICAL SIGNIFICANCE AND EMERGING THERAPIES
    Szymon Zysiak, Rafał Bednarczyk, Natalia Bednarczyk, Agnieszka Kurek, Natalia Krajewska, Aleksandra Lejman, Aleksandra Mazurkiewicz, Hubert Sidor, Monika Wołosik, Radosław Krzysztof Binkowski
    International Journal of Innovative Technologies in Social Science.2026;[Epub]     CrossRef
  • Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk in Populations With Different Low‐Density Lipoprotein Cholesterol Elevations: A Prospective Cohort Study
    Hong Zheng, Guanlin Chen, Zhenyu Huo, Yulong Lan, Yuxian Wang, Peng Fu, Weiqiang Wu, Haixiang Zheng, Kuangyi Wu, Zegui Huang, Dan Wu, Shouling Wu, Youren Chen
    Journal of the American Heart Association.2026;[Epub]     CrossRef
  • The mechanism of perilla oil in regulating lipid metabolism
    Jiawei Xia, Yi Wang, Xin Li, Li Liu, Pin Zhang, Wendong Dai, Peng Luo, Guoze Wang, Yanhong Li
    Food Chemistry.2025; 476: 143318.     CrossRef
  • The effect of vitamin E supplementation on serum low-density lipoprotein oxidization: A systematic review and meta-analysis of clinical trials
    Sepide Amini, Fatemeh Navab, Mohammad Hossein Rouhani, Tannaz Jamialahmadi, Mohammad Bagherniya, Prashant Kesharwani, Amirhossein Sahebkar
    European Journal of Pharmacology.2025; 997: 177491.     CrossRef
  • Acromegaly and the risk of cancer: a nationwide population-based cohort study in Korea
    Yeo Song Kim, Jae-Seung Yun, Hyunho Kim, Sin Soo Jeun, Bongseong Kim, Sea-Won Lee, Jung Eun Lee, Kyuho Kim, Seung-Hyun Ko, Yu-Bae Ahn, Kyungdo Han, Seung Ho Yang
    European Journal of Endocrinology.2025; 192(3): 220.     CrossRef
  • Cholesterol-modifying strategies for Alzheimer disease: promise or fallacy?
    Katia Azarfar, Boris Decourt, Brandon Sanchez Camacho, John Joshua Lawrence, Tania R. Omondi, Marwan N. Sabbagh
    Expert Review of Neurotherapeutics.2025; 25(5): 521.     CrossRef
  • Recent Advances in the Management of Dyslipidemia: A Systematic Review
    Huang Jacky Xiao Feng, Yousaf Adil, Moon Julie, Ahmed Ramiz, Uppal Krishma, Sudhakar Pemminati
    Cureus.2025;[Epub]     CrossRef
  • Atherosclerosis: from lipid-lowering and anti-inflammatory therapies to targeting arterial retention of ApoB-containing lipoproteins
    Gala Araujo, Leidy Marian Valencia, Agata Martin-Ozimek, Yosdel Soto, Spencer D. Proctor
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Statins and adhesion molecules: a review of a novel pleiotropic property of statins
    Mahvash Sadeghi, Sajad Dehnavi, Sanaz Keshavarz Shahbaz, Khadijeh Koushki, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar
    Immunologic Research.2025;[Epub]     CrossRef
  • Discordance of Small Dense LDL Cholesterol Beyond LDL Cholesterol or Non–HDL Cholesterol and Carotid Plaque
    Jinqi Wang, Xiaoyu Zhao, Yanchen Zhao, Rui Jin, Yunfei Li, Jiahe Wang, Yueruijing Liu, Zhiyuan Wu, Xiuhua Guo, Lixin Tao
    JACC: Asia.2025; 5(8): 1012.     CrossRef
  • Hyperlipidemia and atherosclerosis: experimental models
    K. I. Davletova, E. L. Chernolovskaya
    Bulletin of Siberian Medicine.2025; 24(2): 141.     CrossRef
  • CORRECTION OF DYSLIPIDEMIA: HISTORICAL ASPECT AND CURRENT VIEW OF THE PROBLEM (REVIEW, PART IІ)
    Dmytro D. Diachuk, Galina Z. Moroz, Oleksandr M. Tkalenko
    Clinical and Preventive Medicine.2025; (4): 134.     CrossRef
  • Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial
    Daniel Gaudet, Malgorzata Gonciarz, Xi Shen, Jennifer K. Leohr, Thomas P. Beyer, Jonathan W. Day, Garrett R. Mullins, Eugene Y. Zhen, Maryalice Hartley, Miriam Larouche, Robert J. Konrad, Olivier Benichou, Giacomo Ruotolo
    Nature Medicine.2025; 31(8): 2632.     CrossRef
  • Post-transcriptional targeting of PCSK9 by microRNAs: From mechanisms to therapeutic potential
    Maryam Mahjoubin-Tehran, Samaneh Rezaei, Tannaz Jamialahmadi, Prashant Kesharwani, Amirhossein Sahebkar
    Human Gene.2025; 45: 201456.     CrossRef
  • Assessing Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Patients at a Tertiary Hospital, Addis Ababa, Ethiopia
    Edomias Adyamseged Berhe, Rediet Ambachew Sema, Yididya Mehari Tesfaye, Abel Andargie Berhane, Mikale Dawit, Ephrem Mamo Gebrehiwot, Subah Abderehim Yesuf, Balamurugan Ramatchandirin
    Journal of Diabetes Research.2025;[Epub]     CrossRef
  • Dendrobium huoshanense C. Z. Tang & S. J. Cheng alleviates atherosclerosis by reducing lipid and improving vascular endothelial dysfunction
    Xiang-Cheng Fan, Wei-You Cao, Min-Yang He, Hui-Kai Wang, Qing Hao, Wen-Jing Liu, Zhao-Ying Ren, Li-Jun Wang, Jing-Yu Wang, Fei-Xue Wang, Lin Jiang, Qiu-Sheng Zheng, Jun Ma, Feng Zhang, Ji-Chun Han, Lei Zheng
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Two Sides of Triglycerides in Atherogenesis: An Essential Contributor
    Anastasia V Poznyak, Sergey Kozlov, Gulalek A Babayeva, Vasily N Sukhorukov, Alexander N Orekhov
    Clinical Medicine Insights: Cardiology.2025;[Epub]     CrossRef
  • Time-Restricted Eating, ANGPTL4, and Reduction in Residual Cardiovascular Risk
    Alejandro Gugliucci
    Journal of Clinical Medicine.2025; 14(19): 7026.     CrossRef
  • Genetic insights into lipid traits and atherosclerosis risk: a Mendelian randomization and polygenic risk score analysis
    Hongliang Zhang, Xiaoyu Long, Guannan Niu, Wence Shi, Zhenyan Zhao, Dejing Feng, Hui Sun, Yongjian Wu
    International Journal of Surgery.2025; 111(10): 6802.     CrossRef
  • Statins as Modulators of Epithelial to Mesenchymal Transition in Cardiovascular-Kidney-Metabolic Syndrome: a Comprehensive Review of Mechanisms and Therapeutic Implications
    Fatemeh Askarizadeh, Wael Almahmeed, Kasim Sakran Abass, Salim Virani, Amirhossein Sahebkar
    Current Atherosclerosis Reports.2025;[Epub]     CrossRef
  • Gut microbiota–cholesterol crosstalk in cardiovascular diseases: mechanisms, metabolites, and therapeutic modulation
    Mohammad Abavisani, Seyed Mohammad Sajjadi, Negar Ebadpour, Sercan Karav, Amirhossein Sahebkar
    Nutrition & Metabolism.2025;[Epub]     CrossRef
  • Innovations in Diagnosis and Treatment of Coronary Artery Disease
    Salaheldin Agamy, Sheref Zaghloul, Zahid Khan, Ahmed Shahin, Ramy Kishk, Ahmed Smman, Luciano Candilio
    Diagnostics.2025; 16(1): 98.     CrossRef
  • Clinical Determinants and Prognostic Significance of Circulating Angiopoietin-Like Protein 3 Levels in Patients With Chronic Coronary Syndrome
    Hiroki Tanaka, Yunosuke Matsuura, Kinuko Yamamoto, Soichi Komaki, Masashi Yamaguchi, Kohei Moribayashi, Takeshi Ideguchi, Michikazu Nakai, Toshihiro Tsuruda, Koichi Kaikita
    Circulation Reports.2025;[Epub]     CrossRef
  • The role of adherence in patients with chronic diseases
    Michel Burnier
    European Journal of Internal Medicine.2024; 119: 1.     CrossRef
  • Bempedoic acid: new evidence and recommendations on use
    Kristina Paponja, Ivan Pećin, Željko Reiner, Maciej Banach
    Current Opinion in Lipidology.2024; 35(1): 41.     CrossRef
  • Genetic insights into repurposing statins for hyperthyroidism prevention: a drug-target Mendelian randomization study
    Anqi Huang, Xinyi Wu, Jiaqi Lin, Chiju Wei, Wencan Xu
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
    Monika I. Konaklieva, Balbina J. Plotkin
    Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
  • Neutrophil Extracellular Traps (NETs) and Atherosclerosis: Does Hypolipidemic Treatment Have an Effect?
    Petros Adamidis, Despoina Pantazi, Iraklis Moschonas, Evangelos Liberopoulos, Alexandros Tselepis
    Journal of Cardiovascular Development and Disease.2024; 11(3): 72.     CrossRef
  • Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits
    Habib Yaribeygi, Mina Maleki, Farin Rashid-Farrokhi, Payman Raise Abdullahi, Mohammad Amin Hemmati, Tannaz Jamialahmadi, Amirhossein Sahebkar
    Heliyon.2024; 10(7): e28837.     CrossRef
  • Assessing the Benefits of Lifestyle Influences on Cardiovascu-lar Health After Acute Coronary Syndrome
    Marius Rus, Claudia Elena Stanis, Paula Marian, Lilliana Oana Pobirci, Loredana Ioana Banszki, Veronica Huplea, Gheorghe Adrian Osiceanu, Bianca-Maria Pop, Gabriela Dogaru, Felicia Liana Andronie-Cioara
    Balneo and PRM Research Journal.2024; 15(Vol.15, no): 660.     CrossRef
  • ​Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction
    Ziyi Sun, Zhangjun Yun, Jianguo Lin, Xiaoning Sun, Qingqing Wang, Jinlong Duan, Cheng Li, Xiaoxiao Zhang, Siyu Xu, Zeqi Wang, Xingjiang Xiong, Kuiwu Yao
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies
    Zaheer Qureshi, Mikail Khanzada, Adnan Safi, Eeshal Fatima, Faryal Altaf, Timothy J. Vittorio
    Annals of Medicine & Surgery.2024; 86(5): 2818.     CrossRef
  • Therapeutic approach in the treatment of dyslipidemia: Novelties and challenges
    Katarina Lalić, Nataša Rajković, Ljiljana Popović, Sandra Singh-Lukač, Iva Rasulić, Ana Petakov, Milica Krstić, Marija Mitrović
    Galenika Medical Journal.2024; 3(9): 31.     CrossRef
  • Lipid Variability Induces Endothelial Dysfunction by Increasing Inflammation and Oxidative Stress
    Marie Rhee, Joonyub Lee, Eun Young Lee, Kun-Ho Yoon, Seung-Hwan Lee
    Endocrinology and Metabolism.2024; 39(3): 511.     CrossRef
  • Exploring the Perceptions and Behaviours of UK Prescribers Concerning Novel Lipid-Lowering Agent Prescriptions: A Qualitative Study
    Sarah Baig, Shahrauz Mughal, Yousuf Murad, Mandeep Virdee, Zahraa Jalal
    Pharmacy.2024; 12(4): 104.     CrossRef
  • Need of education and training of healthcare professionals on the PCSK9 inhibitors in cardiovascular disease
    Jan Schjøtt, Kristine Heitmann
    European Journal of Cardiovascular Nursing.2024; 23(8): e191.     CrossRef
  • CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis
    Xize Wu, Changbin Yuan, Jiaxiang Pan, Yi Zhou, Xue Pan, Jian Kang, Lihong Ren, Lihong Gong, Yue Li
    Scientific Reports.2024;[Epub]     CrossRef
  • Lessons from PROMINENT and prospects for pemafibrate
    Jean-Charles Fruchart, Jamila Fruchart-Najib, Shizuya Yamashita, Peter Libby, Koutaro Yokote, Tatsuhiko Kodama, Yohei Tomita, Paul M. Ridker, Michel P. Hermans, Alberto Zambon
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • A novel lncRNA GM47544 modulates triglyceride metabolism by inducing ubiquitination-dependent protein degradation of APOC3
    Qianqian Xiao, Luyun Wang, Jing Wang, Man Wang, Dao Wen Wang, Hu Ding
    Molecular Metabolism.2024; 88: 102011.     CrossRef
  • Advances in pharmacotherapy of dyslipidemia
    Harshitha Chinta
    National Journal of Pharmacology and Therapeutics.2024; 2(2): 68.     CrossRef
  • ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients
    Jingfei Chen, Qin Luo, Yanfeng Yi, Jiangang Wang, Pengfei Chen, Fei Luo, Zhenfei Fang
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Assessing the effects of HMGCR, LPL, and PCSK9 inhibition on sleep apnea: Mendelian randomization analysis of drug targets
    Wei Tan, Xiujuan Deng, Xiaoning Tan, Guangbo Tan
    Medicine.2024; 103(43): e40194.     CrossRef
  • Causal association between remnant cholesterol level and risk of cardiovascular diseases: a bidirectional two sample mendelian randomization study
    Lei Zhong, Bo Xie, Hai-Li Wang, Xiao-Wei Ji
    Scientific Reports.2024;[Epub]     CrossRef
  • A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction
    Jing-Hui Wang, Guan-Rui Pan, Long Jiang
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Liver cancer cells as the model for developing liver-targeted RNAi therapeutics
    Beibei Hou, Linhui Qin, Linfeng Huang
    Biochemical and Biophysical Research Communications.2023; 644: 85.     CrossRef
  • Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization
    C. M. Schooling, J. V. Zhao
    Current Cardiology Reports.2023; 25(2): 67.     CrossRef
  • Secoisolariciresinol diglucoside and anethole ameliorate lipid abnormalities, oxidative injury, hypercholesterolemia, heart, and liver conditions
    Sana Noreen, Habib‐ur Rehman, Tabussam Tufail, Huma Badar Ul Ain, Chinaza Godswill Awuchi
    Food Science & Nutrition.2023; 11(6): 2620.     CrossRef
  • Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis
    Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán, Agustín Blanco, Mariano Blasco, José Luís Díaz Díaz, Ángel Díaz Rodríguez, Alipio Mangas, Vicente Pascual, Juan Pedro Botet, Pablo Pérez Martínez
    Clínica e Investigación en Arteriosclerosis.2023; 35(4): 206.     CrossRef
  • Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
    Michael J. Wilkinson, Norman E. Lepor, Erin D. Michos
    Journal of the American Heart Association.2023;[Epub]     CrossRef
  • The cell origins of foam cell and lipid metabolism regulated by mechanical stress in atherosclerosis
    Zhi Ouyang, Jian Zhong, Junyi Shen, Ye Zeng
    Frontiers in Physiology.2023;[Epub]     CrossRef
  • Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
    Alejandro Gugliucci
    Journal of Clinical Medicine.2023; 12(13): 4399.     CrossRef
  • Remnant cholesterol, vascular risk, and prevention of atherosclerosis
    Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán
    Clínica e Investigación en Arteriosclerosis (English Edition).2023; 35(4): 206.     CrossRef
  • Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications
    Marios Spanakis, Danny Alon-Ellenbogen, Petros Ioannou, Nikolaos Spernovasilis
    Pharmacy.2023; 11(4): 130.     CrossRef
  • Advances in Treatment of Dyslipidemia
    Jill Dybiec, Wiktoria Baran, Bartłomiej Dąbek, Piotr Fularski, Ewelina Młynarska, Ewa Radzioch, Jacek Rysz, Beata Franczyk
    International Journal of Molecular Sciences.2023; 24(17): 13288.     CrossRef
  • Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
    Elena Valeria Fuior, Evangelia Zvintzou, Theodosios Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E. Kypreos
    Biomedicines.2023; 11(10): 2696.     CrossRef
  • Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles
    Lixin Du, Huiling Lu, Yifei Xiao, Zhihua Guo, Ya Li
    Scientific Reports.2023;[Epub]     CrossRef
  • Dysregulation of Cholesterol Homeostasis in Ovarian Cancer
    Zahraa Qusairy, Anne Gangloff, Shuk On Annie Leung
    Current Oncology.2023; 30(9): 8386.     CrossRef
  • Riesgo residual. Conclusiones
    Ángel Cequier, José Luis Zamorano
    Revista Española de Cardiología Suplementos.2023; 23: 25.     CrossRef
  • Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study
    Zilong Tan, Jing Hong, Aochuan Sun, Mengdi Ding, Jianwu Shen
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Bibliometric analysis of residual cardiovascular risk: trends and frontiers
    Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li
    Journal of Health, Population and Nutrition.2023;[Epub]     CrossRef
  • Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review
    Kenneth Francis Rodrigues, Wilson Thau Lym Yong, Md. Safiul Alam Bhuiyan, Shafiquzzaman Siddiquee, Muhammad Dawood Shah, Balu Alagar Venmathi Maran
    Biology.2022; 11(9): 1308.     CrossRef
  • Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
    Joon Ho Moon, Kyuho Kim, Sung Hee Choi
    Endocrinology and Metabolism.2022; 37(4): 575.     CrossRef
Original Articles
Drug/Regimen
Article image
Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease
Jong Ha Baek, Ye Seul Yang, Seung-Hyun Ko, Kyung Do Han, Jae Hyeon Kim, Min Kyong Moon, Jong Suk Park, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Jong Han Choi, Kyu Yeon Hur, Committee of Clinical Practice Guidelines, Korean Diabetes Association
Diabetes Metab J. 2022;46(5):701-712.   Published online June 3, 2022
DOI: https://doi.org/10.4093/dmj.2022.0002
  • 9,012 View
  • 384 Download
  • 20 Web of Science
  • 23 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
To evaluate prescription trends and clinical factors of the sodium-glucose cotransporter 2 inhibitors (SGLT2i) use according to the presence of atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) in Korean patients with type 2 diabetes mellitus (T2DM).
Methods
Prescription patterns of SGLT2i use between 2015 and 2019 were determined using the Korean National Health Insurance Service database of claims.
Results
Of all patients with T2DM (n=4,736,493), the annual prescription rate of SGLT2i increased every year in patients with ASCVD (from 2.2% to 10.7%) or HF (from 2.0% to 11.1%). After the first hospitalization for ASCVD (n=518,572), 13.7% (n=71,259) of patients initiated SGLT2i with a median of 10.6 months. After hospitalization for HF (n=372,853), 11.2% (n=41,717) of patients initiated SGLT2i after a median of 8.8 months. In multivariate regression for hospitalization, older age (per 10 years, odds ratio [OR], 0.57; 95% confidence interval [CI], 0.56 to 0.57), lower household income (OR, 0.93; 95% CI, 0.92 to 0.95), rural residents (OR, 0.95; 95% CI, 0.93 to 0.97), and dipeptidyl peptidase-4 inhibitor (DPP-4i) users (OR, 0.82; 95% CI, 0.81 to 0.84) were associated with lesser initiation of SGLT2i in ASCVD. Additionally, female gender (OR, 0.97; 95% CI, 0.95 to 0.99) was associated with lesser initiation of SGLT2i in HF.
Conclusion
The prescription rate of SGLT2i increased gradually up to 2019 but was suboptimal in patients with ASCVD or HF. After the first hospitalization for ASCVD or HF, older age, female gender, low household income, rural residents, and DPP-4i users were less likely to initiate SGLT2i.

Citations

Citations to this article as recorded by  
  • Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database
    Kazuki Aoyama, Akira Okada, Hidehiro Kaneko, Tatsuhiko Azegami, Yuta Suzuki, Shu Meguro, Katsuhito Fujiu, Norifumi Takeda, Hiroyuki Morita, Koichi Node, Toshimasa Yamauchi, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi
    Diabetes, Obesity and Metabolism.2026; 28(1): 701.     CrossRef
  • Prescription Patterns and Associated Factors of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Use Among Patients Worldwide: A Systematic Review and Meta-Analysis of Real-World Studies
    Man Xu, Quanzhi Li, Ning Chen, Xi Zhang, Wei Zhang
    Journal of the American Medical Directors Association.2026; 27(2): 106036.     CrossRef
  • Sex Differences in Antiarrhythmic Effects of Empagliflozin
    Miyo Nakano, Yusuke Kondo, Shinya Fujiki, Yuki Shiko, Yohei Kawasaki, Yoshihisa Nakagawa, Kazuyoshi Takahashi, Masaaki Okabe, Kengo Kusano, Shingen Owada, Kenichi Tsujita, Yoshiaki Kubota, Hirofumi Tomita, Toshihisa Anzai, Kenichi Iijima, Takahiro Tanaka,
    JACC: Asia.2026;[Epub]     CrossRef
  • Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes
    Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Jin Komuro, Toshiyuki Ko, Katsuhito Fujiu, Norifumi Takeda, Hiroyuki Morita, Akira Nishiyama, Masaki Ieda, Koichi Node, Hideo Yasunaga, Masaomi Nangaku, Issei Komuro
    Nephrology Dialysis Transplantation.2025; 40(3): 495.     CrossRef
  • Evaluating the appropriateness and the factors associated with sodium-glucose co-transporter 2 inhibitors prescribing in a Middle Eastern country: a cross-sectional study
    Nancy Zaghloul, Ahmed Awaisu, Ahmed Mahfouz, Zainab Ali, Sumaya Alyafei, Hazem Elewa
    International Journal of Clinical Pharmacy.2025; 47(2): 314.     CrossRef
  • Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
    Kyoung Hwa Ha, Soyoung Shin, EunJi Na, Dae Jung Kim
    Journal of Diabetes Investigation.2025; 16(2): 215.     CrossRef
  • Prescribing patterns of SGLT-2 inhibitors and their association with heart failure readmissions: a single-center cross-sectional study from a low- and middle-income country
    Abrar Ali Chhachhar, Saadia Sattar, Farhala Baloch, Umair Javed, Maria Wajid, Salva Shariq, Muhammad Qamar Masood
    Hospital Practice.2025;[Epub]     CrossRef
  • Assessing the application of American Heart Association (AHA) guidelines in the management of heart failure with reduced ejection fraction
    Sima Sobhani Shahri, Zahra Pirayesh, Azar Zare Noughabi, Marzieh Heshmati, Saeede Khosravi Bizhaem, Shima Jafari, Toba Kazemi
    The Egyptian Heart Journal.2025;[Epub]     CrossRef
  • Optimisation of care among patients with diabetes mellitus and acute coronary syndrome through a specialised cardiodiabetes service—A registry study
    Muhammad Usman Shah, Alun Roebuck, Bala Srinivasan, Paul Edward Squires, Claire Elizabeth Hills, Maxime Inghels, Kelvin Lee
    Diabetic Medicine.2025;[Epub]     CrossRef
  • A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy: the OVOID Trial
    Sangyong Jo, Kyungil Park, Jae Hyuk Choi, Chang‐Bae Sohn, Jeonghwan Kim, Yong‐Seop Kwon, Su Hong Kim, Tae‐ho Park
    Journal of the American Heart Association.2025;[Epub]     CrossRef
  • Prescribing Patterns of SGLT2 Inhibitors and GLP‐1 Receptor Agonists in Patients With T2DM and ASCVD in South Korea
    Yeong Rok Eom, Hajung Joo, Seung Eun Chae, Nam Kyung Je
    Pharmacoepidemiology and Drug Safety.2025;[Epub]     CrossRef
  • Effectiveness and safety of sodium–glucose cotransporter 2 inhibitors in Asian populations
    Kyoung Hwa Ha, Dae Jung Kim
    Journal of Diabetes Investigation.2024; 15(3): 285.     CrossRef
  • Real-World Treatment Patterns according to Clinical Practice Guidelines in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Korea: Multicenter, Retrospective, Observational Study
    Ye Seul Yang, Nam Hoon Kim, Jong Ha Baek, Seung-Hyun Ko, Jang Won Son, Seung-Hwan Lee, Sang Youl Rhee, Soo-Kyung Kim, Tae Seo Sohn, Ji Eun Jun, In-Kyung Jeong, Chong Hwa Kim, Keeho Song, Eun-Jung Rhee, Junghyun Noh, Kyu Yeon Hur
    Diabetes & Metabolism Journal.2024; 48(2): 279.     CrossRef
  • Hospital Readmissions for Fluid Overload among Individuals with Diabetes and Diabetic Kidney Disease: Risk Factors and Multivariable Prediction Models
    Jiashen Cai, Dorothy Huang, Hanis Binte Abdul Kadir, Zhihua Huang, Li Choo Ng, Andrew Ang, Ngiap Chuan Tan, Yong Mong Bee, Wei Yi Tay, Chieh Suai Tan, Cynthia C. Lim
    Nephron.2024; 148(8): 523.     CrossRef
  • Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
    Ja Young Jeon, Dae Jung Kim
    Diabetes & Metabolism Journal.2024; 48(5): 837.     CrossRef
  • Impact of Chronic Kidney Disease and Gout on End-Stage Renal Disease in Type 2 Diabetes: Population-Based Cohort Study
    Inha Jung, Da Young Lee, Seung Min Chung, So Young Park, Ji Hee Yu, Jun Sung Moon, Ji A Seo, Kyungdo Han, Nan Hee Kim
    Endocrinology and Metabolism.2024; 39(5): 748.     CrossRef
  • Income-Related Disparities in Mortality Among Young Adults With Type 2 Diabetes
    Ji Yoon Kim, Sojeong Park, Minae Park, Nam Hoon Kim, Sin Gon Kim
    JAMA Network Open.2024; 7(11): e2443918.     CrossRef
  • Association of Succinate and Adenosine Nucleotide Metabolic Pathways with Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus
    Inha Jung, Seungyoon Nam, Da Young Lee, So Young Park, Ji Hee Yu, Ji A Seo, Dae Ho Lee, Nan Hee Kim
    Diabetes & Metabolism Journal.2024; 48(6): 1126.     CrossRef
  • Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis
    Teja Chakrala, Roshni O. Prakash, Justin Kim, Hanzhi Gao, Umar Ghaffar, Jaymin Patel, Alex Parker, Bhagwan Dass
    American Heart Journal Plus: Cardiology Research and Practice.2023; 28: 100286.     CrossRef
  • Risk of developing chronic kidney disease in young-onset Type 2 diabetes in Korea
    Joonyub Lee, Seung-Hwan Lee, Kun-Ho Yoon, Jae Hyoung Cho, Kyungdo Han, Yeoree Yang
    Scientific Reports.2023;[Epub]     CrossRef
  • Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
    Young Sang Lyu, Seok Oh, Jin Hwa Kim, Sang Yong Kim, Myung Ho Jeong
    Cardiovascular Diabetology.2023;[Epub]     CrossRef
  • Severe hypoglycemia as a risk factor for cardiovascular outcomes in patients with type 2 diabetes: is it preventable?
    Seung-Hyun Ko
    Cardiovascular Prevention and Pharmacotherapy.2022; 4(3): 106.     CrossRef
  • Association between the Diabetes Drug Cost and Cardiovascular Events and Death in Korea: A National Health Insurance Service Database Analysis
    Seung Min Chung, Ji-In Lee, Eugene Han, Hyun-Ae Seo, Eonju Jeon, Hye Soon Kim, Ji Sung Yoon
    Endocrinology and Metabolism.2022; 37(5): 759.     CrossRef
Cardiovascular Risk/Epidemiology
Myocardial Infarction, Stroke, and All-Cause Mortality according to Low-Density Lipoprotein Cholesterol Level in the Elderly, a Nationwide Study
You-Bin Lee, Minji Koo, Eunjin Noh, Soon Young Hwang, Jung A Kim, Eun Roh, So-hyeon Hong, Kyung Mook Choi, Sei Hyun Baik, Geum Joon Cho, Hye Jin Yoo
Diabetes Metab J. 2022;46(5):722-732.   Published online March 8, 2022
DOI: https://doi.org/10.4093/dmj.2021.0225
  • 13,704 View
  • 400 Download
  • 9 Web of Science
  • 10 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We assessed the myocardial infarction (MI), stroke, and all-cause death risks during follow-up according to the low-density lipoprotein cholesterol (LDL-C) levels among older adults.
Methods
The Korean National Health Insurance Service datasets (2002 to 2020) were used for this population-based cohort study. The hazards of MI, stroke, and all-cause mortality during follow-up were analyzed according to LDL-C level in individuals aged ≥65 years without baseline cardiovascular diseases (n=1,391,616).
Results
During a mean 7.55 years, 52,753 MIs developed; 84,224 strokes occurred over a mean 7.47 years. After a mean 8.50 years, 233,963 died. A decrease in LDL-C was associated with lower hazards of MI and stroke. The decreased hazard of stroke in lower LDL-C was more pronounced in statin users, and individuals with diabetes or obesity. The hazard of all-cause death during follow-up showed an inverted J-shaped pattern according to the LDL-C levels. However, the paradoxically increased hazard of mortality during follow-up in lower LDL-C was attenuated in statin users and individuals with diabetes, hypertension, or obesity. In statin users, lower LDL-C was associated with a decreased hazard of mortality during follow-up.
Conclusion
Among the elderly, lower LDL-C was associated with decreased risks of MI and stroke. Lower LDL-C achieved by statins in the elderly was associated with a decreased risk of all-cause death during follow-up, suggesting that LDL-C paradox for the premature death risk in the elderly should not be applied to statin users. Intensive statin therapy should not be hesitated for older adults with cardiovascular risk factors including diabetes.

Citations

Citations to this article as recorded by  
  • Low-density lipoprotein cholesterol and clinical outcomes in patients with liver cirrhosis: a nationwide cohort study
    Byung Sik Kim, Jiyeong Kim, Nayeon Choi, Hyun-Jin Kim, Jeong-Hun Shin
    Annals of Medicine.2025;[Epub]     CrossRef
  • Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study
    Ji Eun Jun, In-Kyung Jeong, Kyu Jeong Ahn, Ho Yeon Chung, You-Cheol Hwang
    European Journal of Preventive Cardiology.2024; 31(10): 1205.     CrossRef
  • Associations of Low-density Lipoprotein Cholesterol With All-cause and Cause-specific Mortality in Older Adults in China
    Wenqing Ni, Yuebin Lv, Xueli Yuan, Yan Zhang, Hongmin Zhang, Yijing Zheng, Xiaoming Shi, Jian Xu
    The Journal of Clinical Endocrinology & Metabolism.2024; 110(1): e132.     CrossRef
  • Risk Factors of Acute Ischemic Stroke and Mortality Among Adults With Endocardial Fibroelastosis
    Talal Warsi, Kamleshun Ramphul, Mansimran Singh Dulay, Saddam Jeelani, Renuka Verma, Nomesh Kumar, Jasninder Singh Dhaliwal, Caleb Carver, Hemamalini Sakthivel, Syed Khurram Mushtaq Gardezi, Saurabh Deshpande, Akil A. Sherif, Alexander Liu, Raheel Ahmed
    The Neurologist.2024; 29(6): 317.     CrossRef
  • A Look at Primary and Secondary Prevention in the Elderly: The Two Sides of the Same Coin
    Maurizio Giuseppe Abrignani, Fabiana Lucà, Vincenzo Abrignani, Giuseppe Pelaggi, Alessandro Aiello, Furio Colivicchi, Francesco Fattirolli, Michele Massimo Gulizia, Federico Nardi, Paolo Giuseppe Pino, Iris Parrini, Carmelo Massimiliano Rao
    Journal of Clinical Medicine.2024; 13(15): 4350.     CrossRef
  • Contradictions in traditional ideas about atherosclerosis and the efficacy of lipid-lowering therapy. Promising directions
    A. P. Vasiliev, N. N. Streltsova
    Сибирский научный медицинский журнал.2024; 44(4): 38.     CrossRef
  • The relationship of low-density lipoprotein cholesterol and all-cause or cardiovascular mortality in patients with type 2 diabetes: a retrospective study
    Chin-Huan Chang, Shu-Tin Yeh, Seng-Wei Ooi, Chung-Yi Li, Hua-Fen Chen
    PeerJ.2023; 11: e14609.     CrossRef
  • ERCC1 polymorphism and its expression associated with ischemic stroke in Chinese population
    Xiao-Dong Deng, Jian-Lin Ke, Tai-Yu Chen, Qin Gao, Zhuo-Lin Zhao, Wei Zhang, Huan Liu, Ming-Liang Xiang, Li-Zhen Wang, Ying Ma, Yun Liu
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
    Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
    Diabetes & Metabolism Journal.2022; 46(4): 517.     CrossRef
  • Association between the Diabetes Drug Cost and Cardiovascular Events and Death in Korea: A National Health Insurance Service Database Analysis
    Seung Min Chung, Ji-In Lee, Eugene Han, Hyun-Ae Seo, Eonju Jeon, Hye Soon Kim, Ji Sung Yoon
    Endocrinology and Metabolism.2022; 37(5): 759.     CrossRef
Review
Cardiovascular Risk/Epidemiology
Article image
Management of Cardiovascular Risk in Perimenopausal Women with Diabetes
Catherine Kim
Diabetes Metab J. 2021;45(4):492-501.   Published online July 30, 2021
DOI: https://doi.org/10.4093/dmj.2020.0262
  • 11,642 View
  • 231 Download
  • 13 Web of Science
  • 15 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFPubReader   ePub   
Cardiovascular disease is the primary cause of mortality in women and men with diabetes. Due to age and worsening of risk factors over the menopausal transition, risk of coronary heart disease events increases in postmenopausal women with diabetes. Randomized studies have conflicted regarding the beneficial impact of estrogen therapy upon intermediate cardiovascular disease markers and events. Therefore, estrogen therapy is not currently recommended for indications other than symptom management. However, for women at low risk of adverse events, estrogen therapy can be used to minimize menopausal symptoms. The risk of adverse events can be estimated using risk engines for the calculation of cardiovascular risk and breast cancer risk in conjunction with screening tools such as mammography. Use of estrogen therapy, statins, and anti-platelet agents can be guided by such calculators particularly for younger women with diabetes. Risk management remains focused upon lifestyle behaviors and achieving optimal levels of cardiovascular risk factors, including lipids, glucose, and blood pressure. Use of pharmacologic therapies to address these risk factors, particularly specific hypoglycemic agents, may provide some additional benefit for risk prevention. The minimal benefit for women with limited life expectancy and risk of complications with intensive therapy should also be considered.

Citations

Citations to this article as recorded by  
  • Analysis of Exosomal miRNA and Hepatic mRNA Expression in the Dysregulation of Insulin Action in Perimenopausal Mice
    Yu Yang, Yu Chen, Changju Liu, Su Wang, Yijing Zhao, Wen Cao, Kun Wang, Syed Anees Ahmed
    Journal of Diabetes Research.2025;[Epub]     CrossRef
  • Sex hormones correlate with heart rate variability in healthy women and this correlation is conserved in women with well-controlled type 2 diabetes mellitus
    Adriana Robles-Cabrera, Claudia Lerma, Silvia Ruiz-Velasco Acosta, Iván Pérez-Díaz, Ruben Fossion, Nejka Potocnik
    PLOS ONE.2025; 20(4): e0320982.     CrossRef
  • Impact of sex and menopausal hormonal therapy on cardiovascular diseases in people with diabetes or prediabetes
    Do Kyeong Song, Yeon-Ah Sung, Young Sun Hong, Min-ho Kim, Hyejin Lee
    Scientific Reports.2025;[Epub]     CrossRef
  • Machine-Learning Insights from the Framingham Heart Study: Enhancing Cardiovascular Risk Prediction and Monitoring
    Emi Yuda, Itaru Kaneko, Daisuke Hirahara
    Applied Sciences.2025; 15(15): 8671.     CrossRef
  • Vitamin D alleviates obesity-related metabolic abnormalities by modulating the gut microbiota in older female mice on a high-fat diet
    Dandan Li, Dongmei Liu, Yali Wang, Qian Xu, Tao Wang, Pengsha Sun, Xinjun Yu
    Frontiers in Cellular and Infection Microbiology.2025;[Epub]     CrossRef
  • Consensus Statements on Dyslipidemia in Indian Women
    Shibba Takkar Chhabra, Sujatha Vipperla, Sarita Rao, Jyotsna Maddury
    Indian Journal of Cardiovascular Disease in Women.2025; 10: 252.     CrossRef
  • Nurse-led intervention in the management of patients with cardiovascular diseases: a brief literature review
    Xiaoqin Qiu
    BMC Nursing.2024;[Epub]     CrossRef
  • Sex differences in the correlation between lipids related to cardiovascular risk factors and small dense LDL particles in patients with type 2 diabetes
    Alena Viktorinova, Robert Brnka, Margita Pirosova, Peter Pontuch, Sona Kinova
    Archives of Endocrinology and Metabolism.2024;[Epub]     CrossRef
  • Determination of the Level of Cardiovascular Risk in 172,282 Spanish Working Women
    Ángel Arturo López-González, María Albaladejo Blanco, Cristina Vidal Ribas, Pilar Tomás-Gil, Pere Riutord Sbert, José Ignacio Ramírez-Manent
    Diagnostics.2023; 13(17): 2734.     CrossRef
  • Comparison of seven surrogate insulin resistance indexes for predicting the prevalence of carotid atherosclerosis in normal-weight individuals
    Zeyu Liu, Bi Deng, Qin Huang, Ruxin Tu, Fang Yu, Jian Xia, Jie Feng
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Gestational Diabetes Mellitus: Diagnostic Approaches and Maternal-Offspring Complications
    Joon Ho Moon, Hak Chul Jang
    Diabetes & Metabolism Journal.2022; 46(1): 3.     CrossRef
  • Reproductive Life Span and Severe Hypoglycemia Risk in Postmenopausal Women with Type 2 Diabetes Mellitus
    Soyeon Kang, Yong-Moon Park, Dong Jin Kwon, Youn-Jee Chung, Jeong Namkung, Kyungdo Han, Seung-Hyun Ko
    Diabetes & Metabolism Journal.2022; 46(4): 578.     CrossRef
  • Global hotspots and prospects of perimenopausal depression: A bibliometric analysis via CiteSpace
    Mingzhou Gao, Hao Zhang, Zhan Gao, Ya Sun, Jieqiong Wang, Fengqin Wei, Dongmei Gao
    Frontiers in Psychiatry.2022;[Epub]     CrossRef
  • Traditional and Emerging Sex-Specific Risk Factors for Cardiovascular Disease in Women
    Puja K. Mehta, Scott Gaignard, Arielle Schwartz, JoAnn E. Manson
    Reviews in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • State of metabolic processes and ways to improve them in premenopausal women due to the life extension strategy
    I.V. Lakhno
    REPRODUCTIVE ENDOCRINOLOGY.2021; (61): 51.     CrossRef
Original Articles
Cardiovascular Risk/Epidemiology
Article image
Metabolic Syndrome Severity Score for Predicting Cardiovascular Events: A Nationwide Population-Based Study from Korea
Yo Nam Jang, Jun Hyeok Lee, Jin Sil Moon, Dae Ryong Kang, Seong Yong Park, Jerim Cho, Jang-Young Kim, Ji Hye Huh
Diabetes Metab J. 2021;45(4):569-577.   Published online January 30, 2021
DOI: https://doi.org/10.4093/dmj.2020.0103
  • 12,133 View
  • 318 Download
  • 25 Web of Science
  • 26 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Recently, a metabolic syndrome severity score (MS score) using a dataset of the Korea National Health and Nutrition Examination Surveys has been developed. We aimed to determine whether the newly developed score is a significant predictor of cardiovascular (CV) events among the Korean population.
Methods
From the Korean National Health Insurance System, 2,541,364 (aged 40 to 59 years) subjects with no history of CV events (ischemic stroke or myocardial infarction [MI]), who underwent health examinations from 2009 to 2011 and were followed up until 2014 to 2017, were identified. Cox proportional hazard model was employed to investigate the association between MS score and CV events. Model performance of MS score for predicting CV events was compared to that of conventional metabolic syndrome diagnostic criteria (Adult Treatment Program III [ATP-III]) using the Akaike information criterion and the area under the receiver operating characteristic curve.
Results
Over a median follow-up of 6 years, 15,762 cases of CV events were reported. MS score at baseline showed a linear association with incident CV events. In the multivariable-adjusted model, the hazard ratios (95% confidence intervals) comparing the highest versus lowest quartiles of MS score were 1.48 (1.36 to 1.60) for MI and 1.89 (1.74 to 2.05) for stroke. Model fitness and performance of the MS score in predicting CV events were superior to those of ATP-III.
Conclusion
The newly developed age- and sex-specific continuous MS score for the Korean population is an independent predictor of ischemic stroke and MI in Korean middle-aged adults even after adjusting for confounding factors.

Citations

Citations to this article as recorded by  
  • Associations of Changes in Metabolic Syndrome Status and Risk Factor Count With Incident Cardiovascular Events Among Cancer Survivors
    Jaeyong Lee, Hyeok-Hee Lee, Eun-Jin Kim, Hyeon Chang Kim, Hokyou Lee
    Journal of Lipid and Atherosclerosis.2026; 15(1): 98.     CrossRef
  • Metabolic syndrome severity score and long-term cardiovascular outcomes in patients with myocardial infarction with nonobstructive coronary arteries
    Side Gao, Sizhuang Huang, Xinming Liu, Mengyue Yu, Lin Zhao
    Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(10): 104104.     CrossRef
  • Assessing the diagnostic value of the metabolic score for insulin resistance in gestational diabetes mellitus
    Sobhy M Yakout, Malak N.K. Khattak, Abdullah M. Alnaami, Amal Alenad, Nasser M. Al-Daghri
    Journal of King Saud University – Science.2025; 37: 4452024.     CrossRef
  • The physical activity paradox in the development of metabolic syndrome: Based on the Korea National Health and nutrition examination survey
    Hyung Doo Kim, Tae-Won Jang
    Preventive Medicine Reports.2025; 57: 103203.     CrossRef
  • Metabolic Syndrome Clusters and Arterial Stiffness: Unraveling Early Predictors of Cardiovascular Risk in a Follow-Up Study
    Agnė Jucevičienė, Ligita Ryliškytė, Jolita Badarienė, Aleksandras Laucevičius
    Journal of Cardiovascular Development and Disease.2025; 12(9): 332.     CrossRef
  • Omics biomarkers and an approach for their practical implementation to delineate health status for personalized nutrition strategies
    Jaap Keijer, Xavier Escoté, Sebastià Galmés, Andreu Palou-March, Francisca Serra, Mona Adnan Aldubayan, Kristina Pigsborg, Faidon Magkos, Ella J. Baker, Philip C. Calder, Joanna Góralska, Urszula Razny, Malgorzata Malczewska-Malec, David Suñol, Mar Galofr
    Critical Reviews in Food Science and Nutrition.2024; 64(23): 8279.     CrossRef
  • Metabolic syndrome awareness in the general Korean population: results from a nationwide survey
    Hyun-Jin Kim, Mi-Seung Shin, Kyung-Hee Kim, Mi-Hyang Jung, Dong-Hyuk Cho, Ju-Hee Lee, Kwang Kon Koh
    The Korean Journal of Internal Medicine.2024; 39(2): 272.     CrossRef
  • BMI-based metabolic syndrome severity score and arterial stiffness in a cohort Chinese study
    Miao Wang, Chi Wang, Maoxiang Zhao, Shouling Wu, Hao Xue, Hongbin Liu
    Nutrition, Metabolism and Cardiovascular Diseases.2024; 34(7): 1761.     CrossRef
  • Association between metabolic syndrome severity score and cardiovascular disease: results from a longitudinal cohort study on Chinese adults
    Jing-jing Lin, Pin-yuan Dai, Jie Zhang, Yun-qi Guan, Wei-wei Gong, Min Yu, Le Fang, Ru-ying Hu, Qing-fang He, Na Li, Li-xin Wang, Ming-bin Liang, Jie-ming Zhong
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • No role of the third-trimester inflammatory factors in the association of gestational diabetes mellitus with postpartum cardiometabolic indicators
    Xiayan Yu, Wenjing Qiang, Kexin Gong, Yidan Cao, Shuangqin Yan, Guopeng Gao, Fangbiao Tao, Beibei Zhu
    BMC Pregnancy and Childbirth.2024;[Epub]     CrossRef
  • Harnessing Metabolic Indices as a Predictive Tool for Cardiovascular Disease in a Korean Population without Known Major Cardiovascular Event
    Hyun-Jin Kim, Byung Sik Kim, Yonggu Lee, Sang Bong Ahn, Dong Wook Kim, Jeong-Hun Shin
    Diabetes & Metabolism Journal.2024; 48(3): 449.     CrossRef
  • Metabolic syndrome severity z-score in non-diabetic non-obese Egyptian patients with chronic hepatitis c virus infection
    Safaa R. Askar, Radwa S. Hagag, Moamen A. Ismail, Heba I. Aly
    Future Journal of Pharmaceutical Sciences.2024;[Epub]     CrossRef
  • Correlation between gestational diabetes mellitus and postpartum cardiovascular metabolic indicators and inflammatory factors: a cohort study of Chinese population
    Xin Zhao, Dan Zhao, Jianbin Sun, Ning Yuan, Xiaomei Zhang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Risk factors for metabolic syndrome in the premetabolic state assessed using hierarchical clustering study in a health screening group
    Se-Jun PARK, Yu Na Kim, Byeong Kil Oh, Jeonggyu Kang
    Scientific Reports.2024;[Epub]     CrossRef
  • Optimal Cut-off Points of the Standardized Continuous Metabolic Syndrome Severity Score (cMetS-S) for Predicting Cardiovascular Disease (CVD) and CVD Mortality in the Tehran Lipid and Glucose Study (TLGS)
    Maryam Adib, Ladan Mehran, Safdar Masoumi, Iman Vatanpoor, Fereidoun Azizi, Atieh Amouzegar
    International Journal of Endocrinology and Metabolism.2024;[Epub]     CrossRef
  • Development and validation of a continuous metabolic syndrome severity score in the Tehran Lipid and Glucose Study
    Mohammadjavad Honarvar, Safdar Masoumi, Ladan Mehran, Davood Khalili, Atieh Amouzegar, Fereidoun Azizi
    Scientific Reports.2023;[Epub]     CrossRef
  • Associations of metabolic syndrome, its severity with cognitive impairment among hemodialysis patients
    Yuqi Yang, Qian Li, Yanjun Long, Jing Yuan, Yan Zha
    Diabetology & Metabolic Syndrome.2023;[Epub]     CrossRef
  • Resistin serum levels and its association with clinical profile and carotid intima-media thickness in psoriasis: a cross-sectional study
    Sofia Makishi Schlenker, Sofia Inez Munhoz, André Rochinski Busanello, Matheus Guedes Sanches, Barbara Stadler Kahlow, Renato Nisihara, Thelma Larocca Skare
    Anais Brasileiros de Dermatologia.2023; 98(6): 799.     CrossRef
  • Cholecystectomy Increases the Risk of Type 2 Diabetes in the Korean Population
    Ji Hye Huh, Kyong Joo Lee, Yun Kyung Cho, Shinje Moon, Yoon Jung Kim, Eun Roh, Kyung-do Han, Dong Hee Koh, Jun Goo Kang, Seong Jin Lee, Sung-Hee Ihm
    Annals of Surgery.2023; 278(2): e264.     CrossRef
  • Cardiorespiratory Endurance is Associated with Metabolic Syndrome Severity in Men
    V. V. Sverchkov, E. V. Bykov
    Journal Biomed.2023; 19(2): 61.     CrossRef
  • Effect of a Wearable Device–Based Physical Activity Intervention in North Korean Refugees: Pilot Randomized Controlled Trial
    Ji Yoon Kim, Kyoung Jin Kim, Kyeong Jin Kim, Jimi Choi, Jinhee Seo, Jung-Been Lee, Jae Hyun Bae, Nam Hoon Kim, Hee Young Kim, Soo-Kyung Lee, Sin Gon Kim
    Journal of Medical Internet Research.2023; 25: e45975.     CrossRef
  • Independent association between age- and sex-specific metabolic syndrome severity score and cardiovascular disease and mortality
    Mohammadjavad Honarvar, Ladan Mehran, Safdar Masoumi, Sadaf Agahi, Shayesteh Khalili, Fereidoun Azizi, Atieh Amouzegar
    Scientific Reports.2023;[Epub]     CrossRef
  • Optimal Low-Density Lipoprotein Cholesterol Levels in Adults Without Diabetes Mellitus: A Nationwide Population-Based Study Including More Than 4 Million Individuals From South Korea
    Ji Hye Huh, Sang Wook Park, Tae-Hwa Go, Dae Ryong Kang, Sang-Hak Lee, Jang-Young Kim
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Triglyceride-Glucose Index for the Diagnosis of Metabolic Syndrome: A Cross-Sectional Study of 298,652 Individuals Receiving a Health Check-Up in China
    Mingfei Jiang, Xiaoran Li, Huan Wu, Fan Su, Lei Cao, Xia Ren, Jian Hu, Grace Tatenda, Mingjia Cheng, Yufeng Wen, Hou De Zhou
    International Journal of Endocrinology.2022; 2022: 1.     CrossRef
  • Changes in body composition, body balance, metabolic parameters and eating behavior among overweight and obese women due to adherence to the Pilates exercise program
    Hyun Ju Kim, Jihyun Park, Mi Ri Ha, Ye Jin Kim, Chaerin Kim, Oh Yoen Kim
    Journal of Nutrition and Health.2022; 55(6): 642.     CrossRef
  • Metabolic Syndrome Severity Score, Comparable to Serum Creatinine, Could Predict the Occurrence of End-Stage Kidney Disease in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Pil Gyu Park, Jung Yoon Pyo, Sung Soo Ahn, Jason Jungsik Song, Yong-Beom Park, Ji Hye Huh, Sang-Won Lee
    Journal of Clinical Medicine.2021; 10(24): 5744.     CrossRef
Cardiovascular risk/Epidemiology
Article image
Increased Risk of Cardiovascular Disease and Mortality in Patients with Diabetes and Coexisting Depression: A Nationwide Population-Based Cohort Study
Inha Jung, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Yong-Gyu Park, Yang-Hyun Kim, Eun-Jung Rhee, Won-Young Lee
Diabetes Metab J. 2021;45(3):379-389.   Published online December 11, 2020
DOI: https://doi.org/10.4093/dmj.2020.0008
  • 12,066 View
  • 285 Download
  • 37 Web of Science
  • 34 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Previous studies have suggested that depression in patients with diabetes is associated with worse health outcomes. The aim of this study was to evaluate the risk of cardiovascular disease (CVD) and mortality in patients with diabetes with comorbid depression.
Methods
We examined the general health check-up data and claim database of the Korean National Health Insurance Service (NHIS) of 2,668,615 participants with type 2 diabetes mellitus who had examinations between 2009 and 2012. As NHIS database has been established since 2002, those who had been diagnosed with depression or CVD since 2002 were excluded. The 2,228,443 participants were classified into three groups according to the claim history of depression; normal group (n=2,166,979), transient depression group (one episode of depression, n=42,124) and persistent depression group (at least two episodes of depression, n=19,340). The development of CVD and mortality were analyzed from 2009 to 2017.
Results
Those with depression showed a significantly increased risk for stroke (transient depression group: hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.15 to 1.26) (persistent depression group: HR, 1.54; 95% CI, 1.46 to 1.63). Those with depression had an increased risk for myocardial infarction (transient depression group: HR, 1.25; 95% CI, 1.18 to 1.31) (persistent depression group: HR, 1.38; 95% CI, 1.29 to 1.49). The persistent depression group had an increased risk for all-cause mortality (HR, 1.66; 95% CI, 1.60 to 1.72).
Conclusion
Coexisting depression in patients with diabetes has a deleterious effect on the development of CVD and mortality. We suggest that more attention should be given to patients with diabetes who present with depressive symptoms.

Citations

Citations to this article as recorded by  
  • Mental Disorders as a Risk Factor of Acute Coronary Syndrome
    Arnav Gupta, Tushar Tejpal, Chanhee Seo, Nicholas Fabiano, Selina Zhao, Stanley Wong, Yuan Qiu, Jenna MacNeil, Dain R. Kim, Natasha Aleksova, Sara Siddiqi, Marco Solmi, Jess G. Fiedorowicz
    JAMA Psychiatry.2026;[Epub]     CrossRef
  • Risk of mortality and complications in people with depressive disorder and diabetes mellitus: A 20-year population-based propensity score-matched cohort study
    Matthew Tsz Ho Ho, Joe Kwun Nam Chan, Heidi Ka Ying Lo, Catherine Zhiqian Fang, Corine Sau Man Wong, Krystal Chi Kei Lee, Francisco Tsz Tsun Lai, Amy Pui Pui Ng, Ken Qingqi Chen, William Chi Wai Wong, Wing Chung Chang
    European Neuropsychopharmacology.2025; 92: 10.     CrossRef
  • Epidemiological insights into chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID‐19 infection: A nationwide population‐based study
    Min Hee Kim
    The Journal of Dermatology.2025; 52(3): 499.     CrossRef
  • The association between C-reactive protein-albumin-lymphocyte index and depression in adults with type 2 diabetes mellitus: A cross-sectional study from NHANES
    Wei Hu, Qian Yuan, Jie Hu, Mingzi Li, Yue Xi, Ling Luo
    Psychoneuroendocrinology.2025; 176: 107442.     CrossRef
  • Type 2 diabetes mellitus, cerebral small vessel disease and depressive disorders
    V.A. Serhiyenkо, O.M. Chemerys, V.I. Pankiv, A.A. Serhiyenko
    INTERNATIONAL NEUROLOGICAL JOURNAL.2025; 21(3): 226.     CrossRef
  • The neutrophil percentage-to-albumin ratio mediates the association between depression and all-cause mortality in U.S. adults: Evidence from NHANES 2009–2018
    Kunxiu Wang, Gaofeng Liu, Yuchen Pan, Siyu Li, Xiaoling Zhu, Hui Qu, Xuesong Liang, Song Chen, Wenbin Fu
    Journal of Affective Disorders.2025; 389: 119736.     CrossRef
  • Healthcare resource utilization of people with depressive disorder and co-occurring incident diabetes mellitus: A 20-year population-based propensity score-matched cohort study
    Matthew Tsz Ho Ho, Joe Kwun Nam Chan, Heidi Ka Ying Lo, Catherine Zhiqian Fang, Corine Sau Man Wong, Krystal Chi Kei Lee, Wing Chung Chang
    General Hospital Psychiatry.2025; 96: 244.     CrossRef
  • Prevalence and risk factors of depression in middle-aged and elderly women with diabetes: a protocol of systematic review and meta-analysis
    Yiting Pan, Longhan Zhang, An Luo, Yaqing Liu, Hao Bai, Lingqiao Song, Zeyuan Long, Li Liao
    BMJ Open.2025; 15(10): e104902.     CrossRef
  • The Bidirectional Relationship Between Myocardial Infarction and Depression: Risk Factors, Mechanisms, and Interventions
    Zhuorui Cui, Qiaoning Yang, Furong Yang, Yankai Yang, Xuexin Yang, Yanqiao Yu, Yajie Cai, Xiaodi Fan, Ruina Bai
    Biomedicines.2025; 13(11): 2838.     CrossRef
  • Psychological resilience mediates the relationship between diabetes distress and depression among persons with diabetes in a multi-group analysis
    Ajele Kenni Wojujutari, Erhabor Sunday Idemudia, Lawrence Ejike Ugwu
    Scientific Reports.2024;[Epub]     CrossRef
  • CVD incidence and mortality among people with diabetes and/or hypertension: Results from the English longitudinal study of ageing
    Paola Zaninotto, Andrew Steptoe, Eun-Jung Shim, Attila Csaba Nagy
    PLOS ONE.2024; 19(5): e0303306.     CrossRef
  • Impact of mental disorders on the all-cause mortality and cardiovascular disease outcomes in adults with new-onset type 1 diabetes: A nationwide cohort study
    Seohyun Kim, Gyuri Kim, So Hyun Cho, Rosa Oh, Ji Yoon Kim, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim
    Psychiatry Research.2024; 342: 116228.     CrossRef
  • Individual and joint effects of diabetes and depression on incident cardiovascular diseases and all-cause mortality: Results from a population-based cohort study
    Qiang Tu, Karice Hyun, Shuanglan Lin, Nashid Hafiz, Deborah Manandi, Qian Zhang, Xinzheng Wang, Na Zhang, Haisheng Wu, Julie Redfern
    Journal of Diabetes and its Complications.2024; 38(11): 108878.     CrossRef
  • A Nationwide Population-Based Study for Audio-Vestibular Disorders following COVID-19 Infection
    Hye Yeon Ko, Min Hee Kim
    Audiology and Neurotology.2024; 30(3): 245.     CrossRef
  • The mediating effect of depression on new-onset stroke in diabetic population: Evidence from the China health and retirement longitudinal study
    Gege Jiang, Yaoling Wang, Liping Wang, Minfang Chen, Wei Li
    Journal of Affective Disorders.2023; 321: 208.     CrossRef
  • Frailty and outcomes in lacunar stroke
    Sima Vazquez, Zehavya Stadlan, Justin M Lapow, Eric Feldstein, Smit Shah, Ankita Das, Alexandria F Naftchi, Eris Spirollari, Akash Thaker, Syed Faraz Kazim, Jose F Dominguez, Neisha Patel, Christeena Kurian, Ji Chong, Stephan A Mayer, Gurmeen Kaur, Chirag
    Journal of Stroke and Cerebrovascular Diseases.2023; 32(2): 106942.     CrossRef
  • Comparison of Operational Definition of Type 2 Diabetes Mellitus Based on Data from Korean National Health Insurance Service and Korea National Health and Nutrition Examination Survey
    Jong Ha Baek, Yong-Moon Park, Kyung Do Han, Min Kyong Moon, Jong Han Choi, Seung-Hyun Ko
    Diabetes & Metabolism Journal.2023; 47(2): 201.     CrossRef
  • The Association between Dietary Carotenoid Intake and Risk of Depression among Patients with Cardiometabolic Disease
    Jie Liang, Yuhao Wang, Min Chen
    International Heart Journal.2023; 64(2): 223.     CrossRef
  • Associations of concomitant retinopathy and depression with mortality in a nationally representative population
    Zheng Lyu, Yilin Chen, Zhuoting Zhu, Xiaoyang Luo, Ying Cui, Jie Xie, Zhifan Chen, Junbin Liu, Xiyu Wu, Gabrella Bulloch, Qianli Meng
    Journal of Affective Disorders.2023; 336: 15.     CrossRef
  • Clinical insights into the cross-link between mood disorders and type 2 diabetes: A review of longitudinal studies and Mendelian randomisation analyses
    Chiara Possidente, Giuseppe Fanelli, Alessandro Serretti, Chiara Fabbri
    Neuroscience & Biobehavioral Reviews.2023; 152: 105298.     CrossRef
  • Prevalence of depression and association with all-cause and cardiovascular mortality among individuals with type 2 diabetes: a cohort study based on NHANES 2005–2018 data
    Zhen Feng, Wai Kei Tong, Xinyue Zhang, Zhijia Tang
    BMC Psychiatry.2023;[Epub]     CrossRef
  • Cholecystectomy Increases the Risk of Type 2 Diabetes in the Korean Population
    Ji Hye Huh, Kyong Joo Lee, Yun Kyung Cho, Shinje Moon, Yoon Jung Kim, Eun Roh, Kyung-do Han, Dong Hee Koh, Jun Goo Kang, Seong Jin Lee, Sung-Hee Ihm
    Annals of Surgery.2023; 278(2): e264.     CrossRef
  • Risk of depression in patients with acromegaly in Korea (2006-2016): a nationwide population-based study
    Shinje Moon, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    European Journal of Endocrinology.2023; 189(3): 363.     CrossRef
  • The association between cardiovascular drugs and depression/anxiety in patients with cardiovascular disease: A meta-analysis
    Lijun Zhang, Yanping Bao, Shuhui Tao, Yimiao Zhao, Meiyan Liu
    Pharmacological Research.2022; 175: 106024.     CrossRef
  • Association of mental health with the risk of coronary artery disease in patients with diabetes: A mendelian randomization study
    Teng Hu, Fangkun Yang, Kewan He, Jiajun Ying, Hanbin Cui
    Nutrition, Metabolism and Cardiovascular Diseases.2022; 32(3): 703.     CrossRef
  • Comorbidity of Type 2 Diabetes Mellitus and Depression: Clinical Evidence and Rationale for the Exacerbation of Cardiovascular Disease
    Mengmeng Zhu, Yiwen Li, Binyu Luo, Jing Cui, Yanfei Liu, Yue Liu
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Understanding and Utilizing Claim Data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) Database for Research
    Dae-Sung Kyoung, Hun-Sung Kim
    Journal of Lipid and Atherosclerosis.2022; 11(2): 103.     CrossRef
  • Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-Calculate Marker for All-Cause and Cardiovascular Mortality
    Kyung-Soo Kim, Sangmo Hong, You-Cheol Hwang, Hong-Yup Ahn, Cheol-Young Park
    Journal of General Internal Medicine.2022; 37(16): 4153.     CrossRef
  • Evaluation of rosmarinic acid against myocardial infarction in maternally separated rats
    Himanshu Verma, Anindita Bhattacharjee, Naveen Shivavedi, Prasanta Kumar Nayak
    Naunyn-Schmiedeberg's Archives of Pharmacology.2022; 395(10): 1189.     CrossRef
  • Lipid cutoffs for increased cardiovascular disease risk in non-diabetic young people
    Mee Kyoung Kim, Kyungdo Han, Hun-Sung Kim, Kun-Ho Yoon, Seung-Hwan Lee
    European Journal of Preventive Cardiology.2022; 29(14): 1866.     CrossRef
  • Risk factors associated with mortality among individuals with type 2 diabetes and depression across two cohorts
    Christopher Rohde, Jens Steen Nielsen, Jakob Schöllhammer Knudsen, Reimar Wernich Thomsen, Søren Dinesen Østergaard
    European Journal of Endocrinology.2022; 187(4): 567.     CrossRef
  • Increased Risk of Cardiovascular Disease and Mortality in Patients with Diabetes and Coexisting Depression: A Nationwide Population-Based Cohort Study (Diabetes Metab J 2021;45:379-89)
    Jin Hwa Kim
    Diabetes & Metabolism Journal.2021; 45(5): 789.     CrossRef
  • Increased Risk of Cardiovascular Disease and Mortality in Patients with Diabetes and Coexisting Depression: A Nationwide Population-Based Cohort Study (Diabetes Metab J 2021;45:379-89)
    Inha Jung, Eun-Jung Rhee, Won-Young Lee
    Diabetes & Metabolism Journal.2021; 45(5): 793.     CrossRef
  • Affective Temperament and Glycemic Control – The Psychological Aspect of Obesity and Diabetes Mellitus
    Natalia Lesiewska, Anna Kamińska, Roman Junik, Magdalena Michalewicz, Bartłomiej Myszkowski, Alina Borkowska, Maciej Bieliński
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 4981.     CrossRef
Brief Report
Complications
Article image
Trends in Cardiovascular Complications and Mortality among Patients with Diabetes in South Korea
Jung Hwan Park, Kyoung Hwa Ha, Bo Yeon Kim, Jae Hyuk Lee, Dae Jung Kim
Diabetes Metab J. 2021;45(1):120-124.   Published online December 9, 2020
DOI: https://doi.org/10.4093/dmj.2020.0175
Correction in: Diabetes Metab J 2021;45(2):283
  • 17,369 View
  • 418 Download
  • 40 Web of Science
  • 45 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
We investigated the cardiovascular complications and mortality rates of patients with diabetes in South Korea. The rates of hospitalization due to cardiovascular complications and mortality were analyzed using the Korean National Health Insurance Service-National Sample Cohort. From 2006 to 2015, the rates of hospitalization due to major cardiovascular complications decreased, while those due to heart failure (from 72 to 146 and 124 to 161 per 10,000 men and women, respectively) and peripheral artery disease (from 39 to 55 and 19 to 35 per 10,000 men and women, respectively) increased. In the period 2007 to 2015, the mortality rates for cancer, cerebrovascular disease, diabetes, heart disease, and hypertensive disease all decreased. However, the mortality rate for pneumonia increased. We observed a continuous reduction in cardiovascular complications and mortality in adults with diabetes. However, with the increase in some diabetes complications, more efforts are needed to prevent diabetes complications.

Citations

Citations to this article as recorded by  
  • Sodium-Glucose Cotransporter 2 Inhibitors as Emerging Anticancer Agents
    Yun Kyung Cho, Chang Hee Jung
    Diabetes & Metabolism Journal.2026; 50(1): 1.     CrossRef
  • Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
    Kyoung Hwa Ha, Soyoung Shin, EunJi Na, Dae Jung Kim
    Journal of Diabetes Investigation.2025; 16(2): 215.     CrossRef
  • Different Associations between Lipid Levels and Risk for Heart Failure according to Diabetes Progression
    Seung-Hwan Lee, Kyu Na Lee, Jong-Chan Youn, Hun Sung Kim, Kyungdo Han, Mee Kyoung Kim
    Diabetes & Metabolism Journal.2025; 49(1): 105.     CrossRef
  • The connection between diabetes mellitus and stroke: a brief review
    Junghyun Noh
    Cardiovascular Prevention and Pharmacotherapy.2025; 7(2): 55.     CrossRef
  • 2025 Clinical Practice Guidelines for Diabetes: Cardiovascular Risk Management
    Hae Jin Kim
    The Journal of Korean Diabetes.2025; 26(3): 164.     CrossRef
  • Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
    Do Kyeong Song, Young Sun Hong, Yeon-Ah Sung, Hyejin Lee, Hidetaka Hamasaki
    PLOS ONE.2024; 19(2): e0299035.     CrossRef
  • Remnant cholesterol is an independent risk factor for the incidence of chronic kidney disease in newly-diagnosed type 2 diabetes: A nationwide population-based study
    Soo Yeon Jang, Minwoong Kang, Eyun Song, Ahreum Jang, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
    Diabetes Research and Clinical Practice.2024; 210: 111639.     CrossRef
  • The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes
    Sushant Koirala, Michael Sunnaa, Thomas Bernier, Ahmet Afsin Oktay
    Current Cardiology Reports.2024; 26(11): 1309.     CrossRef
  • Baicalin attenuates vascular inflammation and endothelial dysfunction in diabetes
    Lingchao Miao, Yifan Yang, Jinming Dai, Mei Bai, Yuehan Wang, Haiying Cui, Lin Lin, Metab Alharbi, Wai San Cheang
    Food Frontiers.2024; 5(6): 2756.     CrossRef
  • Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
    Jin Hwa Kim, Junyeop Lee, Kyungdo Han, Jae-Taek Kim, Hyuk-Sang Kwon
    Diabetes & Metabolism Journal.2024; 48(6): 1084.     CrossRef
  • Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century
    Peter A. Lazzarini, Susanna M. Cramb, Jonathan Golledge, Jedidiah I. Morton, Dianna J. Magliano, Jaap J. Van Netten
    Diabetologia.2023; 66(2): 267.     CrossRef
  • Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England
    Suping Ling, Francesco Zaccardi, Eyad Issa, Melanie J. Davies, Kamlesh Khunti, Karen Brown
    Diabetologia.2023; 66(4): 657.     CrossRef
  • Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
    Journal of Lipid and Atherosclerosis.2023; 12(1): 12.     CrossRef
  • Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
    Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
    International Journal of Heart Failure.2023; 5(1): 1.     CrossRef
  • Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study
    Dae Jung Kim, Wayne H‐H Sheu, Wook‐Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Elise Chia‐Hui Tan, Koichi Node, Atsutaka Yasui, Weiyu Lei, Sunwoo Lee, Laura Saarelainen, Anouk Deruaz‐Luyet, Moe H Kyaw, Yutaka Seino
    Journal of Diabetes Investigation.2023; 14(3): 417.     CrossRef
  • Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
    Diabetes & Metabolism Journal.2023; 47(1): 1.     CrossRef
  • Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
    Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
    Diabetes & Metabolism Journal.2023; 47(1): 10.     CrossRef
  • The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of heart failure in type 2 diabetes: a retrospective cohort study
    Seung Eun Lee, Juhwan Yoo, Bong-Seong Kim, Han Seok Choi, Kyungdo Han, Kyoung-Ah Kim
    Diabetology & Metabolic Syndrome.2023;[Epub]     CrossRef
  • Comparison of Operational Definition of Type 2 Diabetes Mellitus Based on Data from Korean National Health Insurance Service and Korea National Health and Nutrition Examination Survey
    Jong Ha Baek, Yong-Moon Park, Kyung Do Han, Min Kyong Moon, Jong Han Choi, Seung-Hyun Ko
    Diabetes & Metabolism Journal.2023; 47(2): 201.     CrossRef
  • Chronic disease management program applied to type 2 diabetes patients and prevention of diabetic complications: a retrospective cohort study using nationwide data
    Min Kyung Hyun, Jang Won Lee, Seung-Hyun Ko
    BMC Public Health.2023;[Epub]     CrossRef
  • The Present and Future of Artificial Intelligence-Based Medical Image in Diabetes Mellitus: Focus on Analytical Methods and Limitations of Clinical Use
    Ji-Won Chun, Hun-Sung Kim
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • The Role of Echocardiography in Evaluating Cardiovascular Diseases in Patients with Diabetes Mellitus
    Sun Hwa Lee, Jae-Hyeong Park
    Diabetes & Metabolism Journal.2023; 47(4): 470.     CrossRef
  • Long-term Effectiveness of the National Diabetes Quality Assessment Program in South Korea
    Ji Hye Huh, Serim Kwon, Gui Ok Kim, Bo Yeon Kim, Kyoung Hwa Ha, Dae Jung Kim
    Diabetes Care.2023; 46(9): 1700.     CrossRef
  • Management of Dyslipidemia in Patients with Diabetes Mellitus
    Kyung Ae Lee
    The Journal of Korean Diabetes.2023; 24(3): 111.     CrossRef
  • 2023 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Factors
    Ye Seul Yang
    The Journal of Korean Diabetes.2023; 24(3): 135.     CrossRef
  • Interpreting global trends in type 2 diabetes complications and mortality
    Mohammed K. Ali, Jonathan Pearson-Stuttard, Elizabeth Selvin, Edward W. Gregg
    Diabetologia.2022; 65(1): 3.     CrossRef
  • Cardiovascular disease in patients with type 2 diabetes
    Ja Young Jeon, Dae Jung Kim
    Journal of Diabetes Investigation.2022; 13(4): 614.     CrossRef
  • Effects of physical activity on cardiovascular outcomes and mortality in Korean patients with diabetes: a nationwide population-based cohort study
    Inha Jung, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee
    Cardiovascular Prevention and Pharmacotherapy.2022; 4(1): 42.     CrossRef
  • Editorial: Management of Diabetes and its Complications: A Focus on Endothelial Dysfunction
    Shanhu Qiu, Jianhua Ma, Tongzhi Wu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Smoking, Metabolic Syndrome, and Cardiovascular Disease
    Seo Young Kang
    Korean Journal of Family Practice.2022; 12(2): 59.     CrossRef
  • Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
    Cheng-Xu Ma, Xiao-Ni Ma, Cong-Hui Guan, Ying-Dong Li, Dídac Mauricio, Song-Bo Fu
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Adherence to healthy lifestyle behaviors as a preventable risk factor for severe hypoglycemia in people with type 2 diabetes: A longitudinal nationwide cohort study
    Jae‐Seung Yun, Kyungdo Han, Yong‐Moon Park, Eugene Han, Yong‐ho Lee, Seung‐Hyun Ko
    Journal of Diabetes Investigation.2022; 13(9): 1533.     CrossRef
  • Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines
    Soo Jin Yun, In-Kyung Jeong, Jin-Hye Cha, Juneyoung Lee, Ho Chan Cho, Sung Hee Choi, SungWan Chun, Hyun Jeong Jeon, Ho-Cheol Kang, Sang Soo Kim, Seung-Hyun Ko, Gwanpyo Koh, Su Kyoung Kwon, Jae Hyuk Lee, Min Kyong Moon, Junghyun Noh, Cheol-Young Park, Sung
    Diabetes & Metabolism Journal.2022; 46(3): 464.     CrossRef
  • Diabetes Fact Sheet in Korea 2021
    Jae Hyun Bae, Kyung-Do Han, Seung-Hyun Ko, Ye Seul Yang, Jong Han Choi, Kyung Mook Choi, Hyuk-Sang Kwon, Kyu Chang Won
    Diabetes & Metabolism Journal.2022; 46(3): 417.     CrossRef
  • Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus
    Jeongmin Lee, Jae-Seung Yun, Seung-Hyun Ko
    Nutrients.2022; 14(15): 3086.     CrossRef
  • Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
    Nam Hoon Kim, Nan Hee Kim
    Diabetes & Metabolism Journal.2022; 46(4): 543.     CrossRef
  • Association between carotid atherosclerosis and presence of intracranial atherosclerosis using three-dimensional high-resolution vessel wall magnetic resonance imaging in asymptomatic patients with type 2 diabetes
    Ji Eun Jun, You-Cheol Hwang, Kyu Jeong Ahn, Ho Yeon Chung, Geon-Ho Jahng, Soonchan Park, In-Kyung Jeong, Chang-Woo Ryu
    Diabetes Research and Clinical Practice.2022; 191: 110067.     CrossRef
  • Blood Pressure Target in Type 2 Diabetes Mellitus
    Hyun-Jin Kim, Kwang-il Kim
    Diabetes & Metabolism Journal.2022; 46(5): 667.     CrossRef
  • Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    Metabolism.2022; 137: 155327.     CrossRef
  • Trends in diabetes-related complications in Singapore, 2013–2020: A registry-based study
    Joshua Kuan Tan, Nur Nasyitah Mohamed Salim, Gek Hsiang Lim, Sing Yi Chia, Julian Thumboo, Yong Mong Bee, Ferdinando Carlo Sasso
    PLOS ONE.2022; 17(10): e0275920.     CrossRef
  • Association between the Diabetes Drug Cost and Cardiovascular Events and Death in Korea: A National Health Insurance Service Database Analysis
    Seung Min Chung, Ji-In Lee, Eugene Han, Hyun-Ae Seo, Eonju Jeon, Hye Soon Kim, Ji Sung Yoon
    Endocrinology and Metabolism.2022; 37(5): 759.     CrossRef
  • Impact of hypoglycemia at the time of hospitalization for heart failure from emergency department on major adverse cardiovascular events in patients with and without type 2 diabetes
    Seon-Ah Cha, Jae-Seung Yun, Gee-Hee Kim, Yu-Bae Ahn
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Heart Failure and Diabetes Mellitus: Dangerous Liaisons
    Hae-Young Lee
    International Journal of Heart Failure.2022; 4(4): 163.     CrossRef
  • Diabetes and Stroke
    Junghyun Noh
    The Journal of Korean Diabetes.2021; 22(1): 26.     CrossRef
  • Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
    Jae-Seung Yun, Seung-Hyun Ko
    Metabolism.2021; 123: 154838.     CrossRef
Reviews
Guideline/Fact Sheet
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee, Korean Diabetes Association (KDA) Fatty Liver Research Group
Diabetes Metab J. 2020;44(3):382-401.   Published online May 11, 2020
DOI: https://doi.org/10.4093/dmj.2020.0010
  • 25,769 View
  • 521 Download
  • 61 Web of Science
  • 61 Crossref
AbstractAbstract PDFPubReader   ePub   

This clinical practice position statement, a product of the Fatty Liver Research Group of the Korean Diabetes Association, proposes recommendations for the diagnosis, progression and/or severity assessment, management, and follow-up of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Patients with both T2DM and NAFLD have an increased risk of non-alcoholic steatohepatitis (NASH) and fibrosis and a higher risk of cardiovascular diseases and diabetic complications compared to those without NAFLD. With regards to the evaluation of patients with T2DM and NAFLD, ultrasonography-based stepwise approaches using noninvasive biomarker models such as fibrosis-4 or the NAFLD fibrosis score as well as imaging studies such as vibration-controlled transient elastography with controlled attenuation parameter or magnetic resonance imaging-proton density fat fraction are recommended. After the diagnosis of NAFLD, the stage of fibrosis needs to be assessed appropriately. For management, weight reduction achieved by lifestyle modification has proven beneficial and is recommended in combination with antidiabetic agent(s). Evidence that some antidiabetic agents improve NAFLD/NASH with fibrosis in patients with T2DM is emerging. However, there are currently no definite pharmacologic treatments for NAFLD in patients with T2DM. For specific cases, bariatric surgery may be an option if indicated.

Citations

Citations to this article as recorded by  
  • Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD
    Xiao-Dong Zhou, Li-You Lian, Qin-Fen Chen, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Junping Shi, Wah-Kheong Chan, Jérôme Boursier, Elisabetta Bugianesi, Yusuf Yilmaz, Hannes Hagström, Manuel Romero-Gomez,
    Journal of Hepatology.2026; 84(2): 254.     CrossRef
  • Successful Example of Implementing Screening of Liver Fibrosis in Specialist Diabetes Care
    Muna Tajudin, Hannes Hagström, Sophia Rössner
    Gastro Hep Advances.2025; 4(3): 100577.     CrossRef
  • The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
    Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta, Aikaterini Kountouri, Ioannis S. Papanikolaou, Vaia Lambadiari,
    Journal of Clinical Medicine.2025; 14(2): 428.     CrossRef
  • Value of triglyceride glucose-body mass index in predicting nonalcoholic fatty liver disease in individuals with type 2 diabetes mellitus
    Xiaoyi Qian, Wenwen Wu, Boyang Chen, Simin Zhang, Chunmei Xiao, Long Chen, Jun Chen, Lingli Ke, Meian He, Xiulou Li
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community
    Yongsoo Park, Kyung Soo Ko, Byoung Doo Rhee
    International Journal of Molecular Sciences.2025; 26(6): 2758.     CrossRef
  • Update in non-alcoholic fatty liver disease management: role of sodium-glucose cotransporter 2 inhibitors
    Oscar R. Zambrano-Vásquez, Fernando Cortés-Camacho, Jorge I. Castañeda-Sánchez, Elena Aréchaga-Ocampo, Estefanía Valle-Velázquez, Juan C. Cabrera-Angeles, José L. Sánchez-Gloria, Fausto Sánchez-Muñoz, Abraham S. Arellano-Buendia, Laura G. Sánchez-Lozada,
    Life Sciences.2025; 372: 123638.     CrossRef
  • Association between vitamin A, E, and folate levels and risk of non-alcoholic fatty liver disease in adults with diabetes mellitus
    Choungwon Jung, Soyoung Park, Hyunah Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial
    Minyoung Lee, Sukchul Hong, Yongin Cho, Hyungjin Rhee, Min Heui Yu, Jaehyun Bae, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
    BMC Medicine.2025;[Epub]     CrossRef
  • Impact of type 2 diabetes on the risk of cardiovascular disease and cardiovascular mortality in patients with non-alcoholic fatty liver disease: a nationwide population-based study
    Eun Roh, Han Na Jung, Ji Hye Heo, Kyungdo Han, Jun Goo Kang, Seong Jin Lee, Sung-Hee Ihm
    BMJ Public Health.2025; 3(1): e002020.     CrossRef
  • 2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association
    Shinae Kang, Seon Mee Kang, Jong Han Choi, Seung-Hyun Ko, Bo Kyung Koo, Hyuk-Sang Kwon, Mi Kyung Kim, Sang Yong Kim, Soo-Kyung Kim, Young-eun Kim, Eun Sook Kim, Jae Hyeon Kim, Chong Hwa Kim, Ji Min Kim, Hae Jin Kim, Min Kyong Moon, Sun Joon Moon, Jun Sung
    Diabetes & Metabolism Journal.2025; 49(4): 582.     CrossRef
  • Clinical management strategies for type 2 diabetes mellitus with metabolic dysfunction-associated fatty liver disease: an umbrella review of systematic reviews and meta-analyses
    Huiling Huang, Shaomei Shi, Dongsheng Li
    Exploration of Endocrine and Metabolic Diseases.2025;[Epub]     CrossRef
  • Association between Fatty Liver Index and Incident Diabetes according to Alcohol Consumption Status in Young Adults
    Joonyub Lee, Kyungdo Han
    Diabetes & Metabolism Journal.2025; 49(6): 1342.     CrossRef
  • Multiple Therapeutic Applications of Metformin Moving Beyond Its Anti-Diabetic Role:
    Asif Jan, Aftab Ullah, Syed Shaukat Ali, Rani Akbar, Bushra Waheed
    Journal of the ASEAN Federation of Endocrine Societies.2025; 40(2): 148.     CrossRef
  • A combined extract containing Schisandra chinensis (SCE) reduced hepatic triglyceride accumulation in rats fed a high-sucrose diet
    Haneul Lee, Eun Young Kang, Joowon Lee, Yejin Kim, Sumin Kang, Hayoon Kim, Hyun Kyung Kim, Gyoungok Gang, Sang-gil Lee, Cao Lei, Gwang-woong Go
    Food Science and Biotechnology.2024; 33(6): 1449.     CrossRef
  • Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    BMJ.2024; 384: e076388.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Association between urinary polycyclic aromatic hydrocarbons and risk of metabolic associated fatty liver disease
    Minzhen Wang, Shaoyan Tang, Lulu Zhang, Yamin Zhao, Yindi Peng, Shan zheng, Zanchao Liu
    International Archives of Occupational and Environmental Health.2024; 97(7): 695.     CrossRef
  • A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
    Seung Joon Choi, Sungjin Yoon, Kyoung-Kon Kim, Doojin Kim, Hye Eun Lee, Kwang Gi Kim, Seung Kak Shin, Ie Byung Park, Seong Min Kim, Dae Ho Lee
    Diabetes & Metabolism Journal.2024; 48(4): 740.     CrossRef
  • Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
    Xi Lu, Qingxing Xie, Xiaohui Pan, Ruining Zhang, Xinyi Zhang, Ge Peng, Yuwei Zhang, Sumin Shen, Nanwei Tong
    Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
    Jaehyun Bae, Eugene Han, Hye Won Lee, Cheol-Young Park, Choon Hee Chung, Dae Ho Lee, Eun-Hee Cho, Eun-Jung Rhee, Ji Hee Yu, Ji Hyun Park, Ji-Cheol Bae, Jung Hwan Park, Kyung Mook Choi, Kyung-Soo Kim, Mi Hae Seo, Minyoung Lee, Nan-Hee Kim, So Hun Kim, Won-
    Diabetes & Metabolism Journal.2024; 48(6): 1015.     CrossRef
  • Predictive Value of TyG and TyG-BMI Indices for Non-Alcoholic Fatty Liver Disease in High-Altitude Regions of China: A Cross-Sectional Study
    Xuejie Wang, Ziqiu Wang, Wen Du, Xiaobo Ma, Jun Ma, Zijin Chen, Chenni Gao, Xiaonong Chen
    Journal of Clinical Medicine.2024; 13(23): 7423.     CrossRef
  • Risk Scores for Prediction of Major Cardiovascular Events in Non-Alcoholic Fatty Liver Disease: A No Man’s Land?
    Liliana Gheorghe, Roxana Nemteanu, Andreea Clim, Gina Eosefina Botnariu, Irina Iuliana Costache, Alina Plesa
    Life.2023; 13(4): 857.     CrossRef
  • Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
    Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
    Metabolism.2023; 145: 155612.     CrossRef
  • Association between fatty liver index and risk of end-stage renal disease stratified by kidney function in patients with type 2 diabetes: A nationwide population-based study
    Goh Eun Chung, Kyungdo Han, Kyu-Na Lee, Jung Ho Bae, Sun Young Yang, Su-Yeon Choi, Jeong Yoon Yim, Nam Ju Heo
    Diabetes & Metabolism.2023; 49(4): 101454.     CrossRef
  • Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
    Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim
    Clinical and Molecular Hepatology.2023; 29(3): 693.     CrossRef
  • Histological analysis of hypoglycemic agents on liver fibrosis in patients with non-alcoholic fatty liver disease: a systematic review
    Qingxing Xie, Xiaohui Pan, Xinyue Zhang, Jinfang Ma, Ge Peng, Nanwei Tong
    Chinese Medical Journal.2023; 136(16): 2014.     CrossRef
  • Hepatotropc effects of glucose-lowering drugs: non-alcoholic fatty liver disease in focus
    E. V. Uzhakova, Z. E. Zshanko, E. N. Smirnova
    Experimental and Clinical Gastroenterology.2023; (6): 121.     CrossRef
  • Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model
    Yun Kyung Lee, Tae Jung Oh, Ji In Lee, Bo Yoon Choi, Hyen Chung Cho, Hak Chul Jang, Sung Hee Choi
    European Journal of Pharmacology.2023; 957: 175946.     CrossRef
  • Hepatic T-cell senescence and exhaustion are implicated in the progression of fatty liver disease in patients with type 2 diabetes and mouse model with nonalcoholic steatohepatitis
    Byeong Chang Sim, Yea Eun Kang, Sun Kyoung You, Seong Eun Lee, Ha Thi Nga, Ho Yeop Lee, Thi Linh Nguyen, Ji Sun Moon, Jingwen Tian, Hyo Ju Jang, Jeong Eun Lee, Hyon-Seung Yi
    Cell Death & Disease.2023;[Epub]     CrossRef
  • 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
    Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, YoonJu Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae J
    Diabetes & Metabolism Journal.2023; 47(5): 575.     CrossRef
  • Circ_0004535/miR-1827/CASP8 network involved in type 2 diabetes mellitus with nonalcoholic fatty liver disease
    Min Li, Ai Zeng, Xinle Tang, Hui Xu, Wei Xiong, Yanying Guo
    Scientific Reports.2023;[Epub]     CrossRef
  • Stratification by obesity class, rather than age, can identify a higher percent of children at risk for non‐alcoholic fatty liver disease and metabolic dysfunction
    Aurelia Radulescu, Adam J. Dugan, Mary Killian, Suzanna L. Attia, Marialena Mouzaki, George J. Fuchs, Rohit Kohli, Henrietta Bada, Philip A. Kern, Samir Softic
    Pediatric Obesity.2022;[Epub]     CrossRef
  • Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus
    Hae Kyung Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
    Diabetes & Metabolism Journal.2022; 46(1): 104.     CrossRef
  • Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
    Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
    Endocrinology and Metabolism.2022; 37(1): 74.     CrossRef
  • State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
    Yongin Cho, Yong-ho Lee
    Endocrinology and Metabolism.2022; 37(1): 38.     CrossRef
  • Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)
    Yongin Cho, Hyungjin Rhee, Young-eun Kim, Minyoung Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Jin-Young Choi, Yong-ho Lee
    BMC Medicine.2022;[Epub]     CrossRef
  • Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
    Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
    Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241.     CrossRef
  • Anti-Obesity and Anti-Hyperglycemic Effects of Meretrix lusoria Protamex Hydrolysate in ob/ob Mice
    Min Ju Kim, Ramakrishna Chilakala, Hee Geun Jo, Seung-Jae Lee, Dong-Sung Lee, Sun Hee Cheong
    International Journal of Molecular Sciences.2022; 23(7): 4015.     CrossRef
  • The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
    Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Cumulative Exposure to High γ-Glutamyl Transferase Level and Risk of Diabetes: A Nationwide Population-Based Study
    Ji-Yeon Park, Kyungdo Han, Hun-Sung Kim, Jae-Hyoung Cho, Kun-Ho Yoon, Mee Kyoung Kim, Seung-Hwan Lee
    Endocrinology and Metabolism.2022; 37(2): 272.     CrossRef
  • SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
    Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, Ele Ferrannini, Michael A. Nauck, Soo Lim
    Trends in Endocrinology & Metabolism.2022; 33(6): 424.     CrossRef
  • Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis
    Aron Park, Seung Joon Choi, Sungjin Park, Seong Min Kim, Hye Eun Lee, Minjae Joo, Kyoung Kon Kim, Doojin Kim, Dong Hae Chung, Jae Been Im, Jaehun Jung, Seung Kak Shin, Byung-Chul Oh, Cheolsoo Choi, Seungyoon Nam, Dae Ho Lee
    International Journal of Molecular Sciences.2022; 23(9): 5035.     CrossRef
  • Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Sihan Peng, Lu Liu, Ziyan Xie, Xiyu Zhang, Chunguang Xie, Sha Ye, Xiangeng Zhang, Xiaoli Liang, Hongyan Wang, Ya Liu
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity
    Eugene Han, Mi Kyung Kim, Seung-Soon Im, Byoung Kuk Jang, Hye Soon Kim
    Journal of Diabetes and its Complications.2022; 36(8): 108253.     CrossRef
  • Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
    Eun-Jung Rhee
    Endocrinology and Metabolism.2022; 37(3): 415.     CrossRef
  • Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis
    Moongi Ji, Yunju Jo, Seung Joon Choi, Seong Min Kim, Kyoung Kon Kim, Byung-Chul Oh, Dongryeol Ryu, Man-Jeong Paik, Dae Ho Lee
    Biomedicines.2022; 10(7): 1669.     CrossRef
  • Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes
    Yewon Na, Soo Wan Kim, Ie Byung Park, Soo Jung Choi, Seungyoon Nam, Jaehun Jung, Dae Ho Lee
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3022.     CrossRef
  • Nonalcoholic fatty liver disease is associated with early left ventricular diastolic dysfunction in patients with type 2 diabeteS
    Walaa Sheba, Eman Morsy, Salah Altahan, Mona Ayaad, Sameh A. Lashen
    Alexandria Journal of Medicine.2022; 58(1): 117.     CrossRef
  • The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study
    Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
    Diabetes Research and Clinical Practice.2022; 194: 110191.     CrossRef
  • Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)
    Ji Hye Huh
    Diabetes & Metabolism Journal.2022; 46(6): 953.     CrossRef
  • The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study
    Goh Eun Chung, Su-Min Jeong, Eun Ju Cho, Ji Won Yoon, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD)
    Jaehyun Bae, Young Jun Won, Byung-Wan Lee
    Life.2021; 11(3): 224.     CrossRef
  • Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
    Sook Jung Lee, Byung-Wan Lee
    The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
  • Non-alcoholic fatty liver disease
    Elizabeth E Powell, Vincent Wai-Sun Wong, Mary Rinella
    The Lancet.2021; 397(10290): 2212.     CrossRef
  • Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway
    In-Jin Cho, Da-Hee Oh, Jin Yoo, You-Cheol Hwang, Kyu Jeung Ahn, Ho-Yeon Chung, Soung Won Jeong, Ju-Young Moon, Sang-Ho Lee, Sung-Jig Lim, In-Kyung Jeong
    Scientific Reports.2021;[Epub]     CrossRef
  • Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya
    Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14.     CrossRef
  • Liver Fibrosis Indices for the Prediction of Mortality in Korean Subjects: A 16-Year Prospective Cohort Study
    Tae Jung Oh, Kyuho Kim, Jae Hoon Moon, Sung Hee Choi, Nam H Cho, Hak Chul Jang
    Journal of the Endocrine Society.2021;[Epub]     CrossRef
  • Reduced Rank Regression-Derived Dietary Patterns Related to the Fatty Liver Index and Associations with Type 2 Diabetes Mellitus among Ghanaian Populations under Transition: The RODAM Study
    Tracy Bonsu Osei, Anne-Marieke van Dijk, Sjoerd Dingerink, Felix Patience Chilunga, Erik Beune, Karlijn Anna Catharina Meeks, Silver Bahendeka, Matthias Bernd Schulze, Charles Agyemang, Mary Nicolaou, Adriaan Georgius Holleboom, Ina Danquah
    Nutrients.2021; 13(11): 3679.     CrossRef
  • Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes
    Kyuho Kim, Tae Jung Oh, Hyen Chung Cho, Yun Kyung Lee, Chang Ho Ahn, Bo Kyung Koo, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang
    Scientific Reports.2021;[Epub]     CrossRef
  • Evaluation of Grapefruit Juice in terms of Interleukin 18 Gene Expression in Rats with Fatty Liver and Healthy Rats
    Simin Bahmanpoor, Noosha Zia-Jahromi
    journal of ilam university of medical sciences.2021; 29(4): 74.     CrossRef
Drug/Regimen
Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
Nam Hoon Kim, Sin Gon Kim
Diabetes Metab J. 2020;44(2):213-221.   Published online April 23, 2020
DOI: https://doi.org/10.4093/dmj.2020.0001
  • 17,643 View
  • 449 Download
  • 64 Web of Science
  • 70 Crossref
AbstractAbstract PDFPubReader   ePub   

Fibrates, peroxisome proliferator-activated receptor-α agonists, are potent lipid-modifying drugs. Their main effects are reduction of triglycerides and increase in high-density lipoprotein levels. Several randomized controlled trials have not demonstrated their benefits on cardiovascular risk reduction, especially as an “add on” to statin therapy. However, subsequent analyses by major clinical trials, meta-analyses, and real-world evidence have proposed their potential in specific patient populations with atherogenic dyslipidemia and metabolic syndrome. Here, we have reviewed and discussed the accumulated data on fibrates to understand their current status in cardiovascular risk management.

Citations

Citations to this article as recorded by  
  • Continuous Flow Technologies for the Synthesis of Pharmaceutically and Biologically Important Molecules: Update and Analysis
    Yu‐kun Zhang, Eman Fayad, Dalal Nasser Binjawhar, Bing Sun, Hua‐Li Qin
    ChemistrySelect.2026;[Epub]     CrossRef
  • Apolipoprotein B-containing lipoproteins in atherogenesis
    Jan Borén, Chris J. Packard, Christoph J. Binder
    Nature Reviews Cardiology.2025; 22(6): 399.     CrossRef
  • Effect of Fibrates on Lipoprotein-associated Phospholipase A2 Mass and Activity: A Systematic Review and Meta-analysis of Controlled Clinical Trials
    Luis E. Simental-Mendia, Mario Simental-Mendía, Claudia I. Gamboa-Gomez, Tannaz Jamialahmadi, Amirhossein Sahebkar
    Current Pharmaceutical Design.2025; 31(15): 1205.     CrossRef
  • Fatty acid binding proteins-mediated mitochondrial dysfunction in the development of age-related diseases: A review
    Xingxing Ren, Chaoyuan Jin, Qilin Li, Congyi Fu, Yu Fang, Zihang Xu, Zi Liang, Tianshi Wang
    International Journal of Biological Macromolecules.2025; 309: 142913.     CrossRef
  • An update on renal tubular injury as related to glycolipid metabolism in diabetic kidney disease
    Anqi Feng, Ruili Yin, Rong Xu, Baoyu Zhang, Longyan Yang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Novel carboxamide derivatives increase lipoprotein lipase gene expression in endothelial and adipose tissues of triton WR- 1339 induced hyperlipidemic rats
    Suhair Hikmat, Aya Hasan, Lama Hamadneh, Mohammad Alwahsh, Sameer Al-Kouz, Yusuf Al-Hiari, Basmah Al-Jammal, Tariq Al-Qirim, Buthaina Hussein
    Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(10): 14315.     CrossRef
  • The approach to triglyceride levels in patients with coronary heart disease
    Ilay Shani, Avishay Elis
    European Journal of Internal Medicine.2025; 139: 106375.     CrossRef
  • Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial
    Eman M. Nada, Nashwa M. El-Gharbawy, Haidy Abbas, Rehab H. Werida
    BMC Pharmacology and Toxicology.2025;[Epub]     CrossRef
  • Effects of fibrates on lipid profile: a meta-analysis of randomized controlled trials
    Elena Olmastroni, Federica Galimberti, Sining Xie, Manuela Casula, Alberico L Catapano
    European Atherosclerosis Journal.2025;[Epub]     CrossRef
  • Hypertriglyceridemia (triglyceride-rich lipoproteins and their remnants): role in the development of atherosclerotic cardiovascular diseases and control strategy. Opinion of the Expert Committee of the Russian Society of Cardiology, the National Atheroscl
    M. G. Bubnova, M. N. Ezhov, D. M. Aronov, A. S. Galyavich, V. S. Gurevich, D. V. Duplyakov, V. K. Zafiraki, N. S. Karamnova, V. V. Kashtalap, G. A. Konovalov, A. N Meshkov, A. G. Obrezan, A. A. Semenkin, I. V. Sergienko, A. E. Filippov
    Russian Journal of Cardiology.2025; 30(5): 6364.     CrossRef
  • Chemical Synthesis, Biological Evaluation, and Cheminformatics Analysis of a Group of Chlorinated Diaryl Sulfonamides: Promising Inhibitors of Cholesteryl Ester Transfer Protein
    Reema Abu Khalaf, Ala’a Lafi, Rima Hajjo, Mahmoud A. Al-Sha'er
    Current Computer-Aided Drug Design.2025; 21(5): 694.     CrossRef
  • Characterizing Fenofibrate-Related Renal and Urinary Adverse Events: A Comprehensive Analysis of FDA Adverse Event Reporting System Database
    Li Wang, Xiangyun Jin, YanChun Li
    Clinical Therapeutics.2025; 47(12): 1149.     CrossRef
  • Hypertriglyceridemia (triglyceride-rich lipoproteins and their remnants): role in development of atherosclerotic cardiovascular diseases and control strategy consensus statement of the expert Committee of the Russian Society of Cardiology (RSC), the Natio
    Marina G. Bubnova, Marat V. Ezhov, David M. Aronov, Albert S. Galyаvich, Viktor S. Gurevich, Dmitry V. Duplyakov, Vitaliy K. Zafiraki, Natalia S. Karamnova, Vasily V. Kashtalap, Gennady A. Konovalov, Alexey N. Meshkov, Andrey G. Obrezan, Alexander A. Seme
    CardioSomatics.2025; 16(3): 192.     CrossRef
  • 2025: The year in cardiovascular disease – the year of triglyceride lowering therapies. Can we effectively reduce triglyceride-related residual cardiovascular disease and pancreatitis risk?
    Peter P. Toth, Maciej Banach
    Archives of Medical Science.2025; 21(6): 2229.     CrossRef
  • Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study
    Nam Hoon Kim, Ji Yoon Kim, Jimi Choi, Sin Gon Kim
    European Heart Journal - Cardiovascular Pharmacotherapy.2024; 10(2): 118.     CrossRef
  • Role of PPARα in inflammatory response of C2C12 myotubes
    Yuki Shimizu, Keiko Hamada, Tingting Guo, Chie Hasegawa, Yusuke Kuga, Katsushi Takeda, Takashi Yagi, Hiroyuki Koyama, Hiroshi Takagi, Daisuke Aotani, Hiromi Kataoka, Tomohiro Tanaka
    Biochemical and Biophysical Research Communications.2024; 694: 149413.     CrossRef
  • Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
    John J. P. Kastelein, Andrew Hsieh, Mary R. Dicklin, Marc Ditmarsch, Michael H. Davidson
    Current Atherosclerosis Reports.2024; 26(2): 35.     CrossRef
  • Metabolic Flexibility of the Heart: The Role of Fatty Acid Metabolism in Health, Heart Failure, and Cardiometabolic Diseases
    Virginia Actis Dato, Stephan Lange, Yoshitake Cho
    International Journal of Molecular Sciences.2024; 25(2): 1211.     CrossRef
  • ApoB100 and Atherosclerosis: What’s New in the 21st Century?
    Dimitris Kounatidis, Natalia G. Vallianou, Aikaterini Poulaki, Angelos Evangelopoulos, Fotis Panagopoulos, Theodora Stratigou, Eleni Geladari, Irene Karampela, Maria Dalamaga
    Metabolites.2024; 14(2): 123.     CrossRef
  • Follistatin-like 1 (FSTL1) levels as potential early biomarker of cardiovascular disease in a Mexican population
    N. Ponce-Ruíz, J. F. Herrera-Moreno, A. E. Rojas-García, B. S. Barrón-Vivanco, C. A. González-Arias, Y. Y. Bernal-Hernández, L. Ortega-Cervantes, J. Ponce-Gallegos, J. A. Hernández-Nolasco, I. M. Medina-Díaz
    Heart and Vessels.2024; 39(6): 563.     CrossRef
  • Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
    Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang
    Diabetes & Metabolism Journal.2024; 48(2): 184.     CrossRef
  • Coenzyme Q10 in atherosclerosis
    Minjun Liao, Xueke He, Yangyang Zhou, Weiqiang Peng, Xiao-Mei Zhao, Miao Jiang
    European Journal of Pharmacology.2024; 970: 176481.     CrossRef
  • Onion Polyphenols as Multi-Target-Directed Ligands in MASLD: A Preliminary Molecular Docking Study
    Maria Paravati, Anna Procopio, Maja Milanović, Giuseppe Scarlata, Nataša Milošević, Maja Ružić, Nataša Milić, Ludovico Abenavoli
    Nutrients.2024; 16(8): 1226.     CrossRef
  • Therapeutic approach in the treatment of dyslipidemia: Novelties and challenges
    Katarina Lalić, Nataša Rajković, Ljiljana Popović, Sandra Singh-Lukač, Iva Rasulić, Ana Petakov, Milica Krstić, Marija Mitrović
    Galenika Medical Journal.2024; 3(9): 31.     CrossRef
  • Research trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis
    Quankai Cheng, Jingjing Sun, Haicheng Zhong, Ziming Wang, Chang Liu, Sheng Zhou, Jie Deng
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Expression of FAM159B in Humans, Rats, and Mice: A Cross-species Examination
    Anna-Sophia Liselott Beyer, Daniel Kaemmerer, Jörg Sänger, Amelie Lupp
    Journal of Histochemistry & Cytochemistry.2024; 72(7): 467.     CrossRef
  • The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies
    Dimitris Kounatidis, Nikolaos Tentolouris, Natalia G. Vallianou, Iordanis Mourouzis, Irene Karampela, Theodora Stratigou, Eleni Rebelos, Marina Kouveletsou, Vasileios Stamatopoulos, Eleni Tsaroucha, Maria Dalamaga
    Metabolites.2024; 14(7): 388.     CrossRef
  • Fenofibrate’s impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study
    Sangmo Hong, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • The role of DGAT1 and DGAT2 in tumor progression via fatty acid metabolism: A comprehensive review
    Leisheng Wang, Shiwei Xu, Mengzhen Zhou, Hao Hu, Jinyou Li
    International Journal of Biological Macromolecules.2024; 278: 134835.     CrossRef
  • Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factor
    Nam Hoon Kim, Juneyoung Lee, Suk Chon, Jae Myung Yu, In-Kyung Jeong, Soo Lim, Won Jun Kim, Keeho Song, Ho Chan Cho, Hea Min Yu, Kyoung-Ah Kim, Sang Soo Kim, Soon Hee Lee, Chong Hwa Kim, Soo Heon Kwak, Yong‐ho Lee, Choon Hee Chung, Sihoon Lee, Heung Yong J
    Endocrinology and Metabolism.2024; 39(5): 722.     CrossRef
  • Safety and Efficacy of the Novel RNA Interference Therapies for Hypertriglyceridemia and Mixed Hyperlipidemia Management: A Systematic Review and Meta-analysis
    A.B.M. Kamrul-Hasan, Deep Dutta, Lakshmi Nagendra, Sunetra Mondal, Saptarshi Bhattacharya, Sanjay Kalra
    Endocrine Practice.2024; 30(11): 1103.     CrossRef
  • Effects of Fatty Acid Metabolism on Heart Failure
    日娜 萨
    Advances in Clinical Medicine.2024; 14(09): 787.     CrossRef
  • Revisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis
    Yiran Chen, Kunyu Zheng, Gahu Da, Xu Wang, Yi Wei, Guochun Wang, Fengchun Zhang, Li Wang
    Expert Opinion on Pharmacotherapy.2024; 25(13): 1825.     CrossRef
  • Integrated review of cardiometabolic biomarkers and dietary nutrients
    Ravindra Verma, Prakash S Bisen, Mònica Bulló
    Journal of Food Bioactives.2024; : 44.     CrossRef
  • Cardiovascular Diseases and Metabolic Medications in the Lebanese Population: A Post Hoc Analysis from a Nationwide Cross-Sectional Study
    Rony M. Zeenny, Rachel Abdo, Chadia Haddad, Aline Hajj, Rouba Karen Zeidan, Pascale Salameh, Jean Ferrieres
    Pharmacy.2024; 12(6): 171.     CrossRef
  • From Adipose to Ailing Kidneys: The Role of Lipid Metabolism in Obesity-Related Chronic Kidney Disease
    Wenchao Xu, Yuting Zhu, Siyuan Wang, Jihong Liu, Hao Li
    Antioxidants.2024; 13(12): 1540.     CrossRef
  • Exploring the mechanism of fibrates regulating HIF-1A in the treatment of ischemic stroke based on network pharmacology and molecular docking
    Fengjiao Yang, Zixuan Yang, Ya Yan, Yun Gu, Pengyu Wang, Min Wang, Jianjie Chen, Xiaoshan Du, Guangming Wang
    BMC Research Notes.2024;[Epub]     CrossRef
  • Present and Future of Dyslipidaemia Treatment—A Review
    Iveta Merćep, Andro Vujević, Dominik Strikić, Ivana Radman, Ivan Pećin, Željko Reiner
    Journal of Clinical Medicine.2023; 12(18): 5839.     CrossRef
  • VLDL receptor gene therapy for reducing atherogenic lipoproteins
    Ronald M. Krauss, Jonathan T. Lu, Joseph J. Higgins, Cathryn M. Clary, Ray Tabibiazar
    Molecular Metabolism.2023; 69: 101685.     CrossRef
  • The emerging role of PPAR-alpha in breast cancer
    Zhiwen Qian, Lingyan Chen, Jiayu Liu, Ying Jiang, Yan Zhang
    Biomedicine & Pharmacotherapy.2023; 161: 114420.     CrossRef
  • Molecular mechanisms and therapeutic perspectives of peroxisome proliferator‐activated receptor α agonists in cardiovascular health and disease
    Yujie Pu, Chak Kwong Cheng, Hongsong Zhang, Jiang‐Yun Luo, Li Wang, Brian Tomlinson, Yu Huang
    Medicinal Research Reviews.2023; 43(6): 2086.     CrossRef
  • Macrophage angiotensin-converting enzyme reduces atherosclerosis by increasing peroxisome proliferator-activated receptor α and fundamentally changing lipid metabolism
    DuoYao Cao, Zakir Khan, Xiaomo Li, Suguru Saito, Ellen A Bernstein, Aaron R Victor, Faizan Ahmed, Aoi O Hoshi, Luciana C Veiras, Tomohiro Shibata, Mingtian Che, Lei Cai, Michifumi Yamashita, Ryan E Temel, Jorge F Giani, Daniel J Luthringer, Ajit S Divakar
    Cardiovascular Research.2023; 119(9): 1825.     CrossRef
  • Rapid flow synthesis of fenofibrate via scalable flash chemistry with in-line Li recovery
    Sanket A. Kawale, Dong-Chang Kang, Gwang-Noh Ahn, Amirreza Mottafegh, Ji-Ho Kang, Gi-Su Na, Dong-Pyo Kim
    Chemical Engineering Journal.2023; 477: 147033.     CrossRef
  • Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome
    Marat V. Ezhov, Gregory P. Arutyunov
    Diseases.2023; 11(4): 140.     CrossRef
  • Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
    Giulio Preta
    Cells.2023; 12(20): 2466.     CrossRef
  • Exploring the hypolipidemic effects of bergenin from Saxifraga melanocentra Franch: mechanistic insights and potential for hyperlipidemia treatment
    Li Zhang, Yingying Tong, Yan Fang, Jinjin Pei, Qilan Wang, Gang Li
    Lipids in Health and Disease.2023;[Epub]     CrossRef
  • Obesity and Dyslipidemia
    Barbora Nussbaumerova, Hana Rosolova
    Current Atherosclerosis Reports.2023; 25(12): 947.     CrossRef
  • Bibliometric analysis of residual cardiovascular risk: trends and frontiers
    Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li
    Journal of Health, Population and Nutrition.2023;[Epub]     CrossRef
  • Hypertriglyceridemia in Apoa5–/– mice results from reduced amounts of lipoprotein lipase in the capillary lumen
    Ye Yang, Anne P. Beigneux, Wenxin Song, Le Phuong Nguyen, Hyesoo Jung, Yiping Tu, Thomas A. Weston, Caitlyn M. Tran, Katherine Xie, Rachel G. Yu, Anh P. Tran, Kazuya Miyashita, Katsuyuki Nakajima, Masami Murakami, Yan Q. Chen, Eugene Y. Zhen, Joonyoung R.
    Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • Blood-Derived Lipid and Metabolite Biomarkers in Cardiovascular Research from Clinical Studies: A Recent Update
    Dipali Kale, Amol Fatangare, Prasad Phapale, Albert Sickmann
    Cells.2023; 12(24): 2796.     CrossRef
  • Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia
    Gary F Lewis, Robert A Hegele
    The Lancet Diabetes & Endocrinology.2022; 10(2): 142.     CrossRef
  • Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study
    Thomas Metzner, Deborah R. Leitner, Karin Mellitzer, Andrea Beck, Harald Sourij, Tatjana Stojakovic, Gernot Reishofer, Winfried März, Ulf Landmesser, Hubert Scharnagl, Hermann Toplak, Günther Silbernagel
    Biomedicines.2022; 10(1): 193.     CrossRef
  • Is there a role of lipid-lowering therapies in the management of fatty liver disease?
    Ismini Tzanaki, Aris P Agouridis, Michael S Kostapanos
    World Journal of Hepatology.2022; 14(1): 119.     CrossRef
  • Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?
    Ana Clara Aprotosoaie, Alexandru-Dan Costache, Irina-Iuliana Costache
    Pharmaceutics.2022; 14(4): 722.     CrossRef
  • The Overlooked Transformation Mechanisms of VLCFAs: Peroxisomal β-Oxidation
    Qinyue Lu, Weicheng Zong, Mingyixing Zhang, Zhi Chen, Zhangping Yang
    Agriculture.2022; 12(7): 947.     CrossRef
  • Current Trends of Big Data Research Using the Korean National Health Information Database
    Mee Kyoung Kim, Kyungdo Han, Seung-Hwan Lee
    Diabetes & Metabolism Journal.2022; 46(4): 552.     CrossRef
  • New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
    Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
    Diabetes & Metabolism Journal.2022; 46(4): 517.     CrossRef
  • Novel Targets for a Combination of Mechanical Unloading with Pharmacotherapy in Advanced Heart Failure
    Agata Jedrzejewska, Alicja Braczko, Ada Kawecka, Marcin Hellmann, Piotr Siondalski, Ewa Slominska, Barbara Kutryb-Zajac, Magdi H. Yacoub, Ryszard T. Smolenski
    International Journal of Molecular Sciences.2022; 23(17): 9886.     CrossRef
  • Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
    Joon Ho Moon, Kyuho Kim, Sung Hee Choi
    Endocrinology and Metabolism.2022; 37(4): 575.     CrossRef
  • Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    Metabolism.2022; 137: 155327.     CrossRef
  • Alterations of HDL’s to piHDL’s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies
    Veronika Vyletelová, Mária Nováková, Ľudmila Pašková
    Pharmaceuticals.2022; 15(10): 1278.     CrossRef
  • Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data
    Cristina Gavina, Daniel Seabra Carvalho, Marisa Pardal, Marta Afonso-Silva, Diana Grangeia, Ricardo Jorge Dinis-Oliveira, Francisco Araújo, Tiago Taveira-Gomes
    Journal of Clinical Medicine.2022; 11(22): 6825.     CrossRef
  • New and Emerging lipid-lowering Therapy
    James M Backes, Daniel E Hilleman
    Future Cardiology.2021; 17(8): 1407.     CrossRef
  • Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not?
    Styliani Fragki, Hubert Dirven, Tony Fletcher, Bettina Grasl-Kraupp, Kristine Bjerve Gützkow, Ron Hoogenboom, Sander Kersten, Birgitte Lindeman, Jochem Louisse, Ad Peijnenburg, Aldert H. Piersma, Hans M. G. Princen, Maria Uhl, Joost Westerhout, Marco J. Z
    Critical Reviews in Toxicology.2021; 51(2): 141.     CrossRef
  • A network pharmacology analysis on drug‐like compounds from Ganoderma lucidum for alleviation of atherosclerosis
    Ki Kwang Oh, Md. Adnan, Dong Ha Cho
    Journal of Food Biochemistry.2021;[Epub]     CrossRef
  • Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study
    Myung Soo Park, Jong-Chan Youn, Eung Ju Kim, Ki Hoon Han, Sang Hak Lee, Sung Hea Kim, Byung Jin Kim, Sung Uk Kwon, Kyu-Hyung Ryu
    Clinical Therapeutics.2021; 43(10): 1735.     CrossRef
  • Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany
    Louis Jacob, Roger-Axel Greiner, Mark Luedde, Karel Kostev
    Journal of Cardiovascular Pharmacology.2021; 78(6): 885.     CrossRef
  • Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature
    Leili Rahimi, Mojtaba Malek, Faramarz Ismail-Beigi, Mohammad E. Khamseh
    Advances in Therapy.2020; 37(8): 3450.     CrossRef
  • Treatment With Gemfibrozil Prevents the Progression of Chronic Kidney Disease in Obese Dahl Salt-Sensitive Rats
    Corbin A. Shields, Bibek Poudel, Kasi C. McPherson, Andrea K. Brown, Ubong S. Ekperikpe, Evan Browning, Lamari Sutton, Denise C. Cornelius, Jan M. Williams
    Frontiers in Physiology.2020;[Epub]     CrossRef
  • Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes
    Amelia Charlton, Jessica Garzarella, Karin A. M. Jandeleit-Dahm, Jay C. Jha
    Biology.2020; 10(1): 18.     CrossRef
Original Article
Metabolic Risk/Epidemiology
Article image
Sex-, Age-, and Metabolic Disorder-Dependent Distributions of Selected Inflammatory Biomarkers among Community-Dwelling Adults
So Mi Jemma Cho, Hokyou Lee, Jee-Seon Shim, Hyeon Chang Kim
Diabetes Metab J. 2020;44(5):711-725.   Published online April 16, 2020
DOI: https://doi.org/10.4093/dmj.2019.0119
  • 10,652 View
  • 91 Download
  • 6 Web of Science
  • 7 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Inflammatory cytokines are increasingly utilized to detect high-risk individuals for cardiometabolic diseases. However, with large population and assay methodological heterogeneity, no clear reference currently exists.

Methods

Among participants of the Cardiovascular and Metabolic Diseases Etiology Research Center cohort, of community-dwelling adults aged 30 to 64 without overt cardiovascular diseases, we presented distributions of tumor necrosis factor (TNF)-α and -β, interleukin (IL)-1α, -1β, and 6, monocyte chemoattractant protein (MCP)-1 and -3 and high sensitivity C-reactive protein (hsCRP) with and without non-detectable (ND) measurements using multiplex enzyme-linked immunosorbent assay. Then, we compared each markers by sex, age, and prevalence of type 2 diabetes mellitus, hypertension, and dyslipidemia, using the Wilcoxon Rank-Sum Test.

Results

In general, there were inconsistencies in direction and magnitude of differences in distributions by sex, age, and prevalence of cardiometabolic disorders. Overall, the median and the 99th percentiles were higher in men than in women. Older participants had higher TNF-α, high sensitivity IL-6 (hsIL-6), MCP-1, hsCRP, TNF-β, and MCP-3 median, after excluding the NDs. Participants with type 2 diabetes mellitus had higher median for all assayed biomarkers, except for TNF-β, IL-1α, and MCP-3, in which the medians for both groups were 0.00 due to predominant NDs. Compared to normotensive group, participants with hypertension had higher TNF-α, hsIL-6, MCP-1, and hsCRP median. When stratifying by dyslipidemia prevalence, the comparison varied significantly depending on the treatment of NDs.

Conclusion

Our findings provide sex-, age-, and disease-specific reference values to improve risk prediction and diagnostic performance for inflammatory diseases in both population- and clinic-based settings.

Citations

Citations to this article as recorded by  
  • Impact of Sex on Plasma Biomarkers in ob/ob Mice
    Yunha Suh, Kwang-eun Kim
    International Journal of Molecular Sciences.2026; 27(4): 1712.     CrossRef
  • Systemic counterregulatory response of angiopoietin-2 after intravitreal injections with faricimab for nAMD
    Anna Lena Huber, Angelika Bauer, Julius Beirer, Katharina Frede, Katharina Kirchmair, Reinhard Angermann, Matus Rehak, Claus Zehetner, Yvonne Nowosielski
    Graefe's Archive for Clinical and Experimental Ophthalmology.2025; 263(5): 1259.     CrossRef
  • Immune regulation mechanism of polysaccharide from Dendrobium officinale Kimura et Migo on intestinal lamina propria cells
    Jia Li, Xiaoli Yang, Ziying Zheng, Shuang Song, Yang Tian, Zhongbin Bai
    Food Bioscience.2025; 71: 107410.     CrossRef
  • Characterizing CD8+ TEMRA Cells in CP/CPPS Patients: Insights from Targeted Single-Cell Transcriptomic and Functional Investigations
    Fei Zhang, Qintao Ge, Jialin Meng, Jia Chen, Chaozhao Liang, Meng Zhang
    ImmunoTargets and Therapy.2024; Volume 13: 111.     CrossRef
  • Within-subject variation of C-reactive protein and high-sensitivity C-reactive protein: A systematic review and meta-analysis
    Alex Gough, Alice Sitch, Erica Ferris, Tom Marshall, Andreas Zirlik
    PLOS ONE.2024; 19(11): e0304961.     CrossRef
  • Association between physical activity and inflammatory markers in community-dwelling, middle-aged adults
    So Mi Jemma Cho, Hokyou Lee, Jee-Seon Shim, Justin Y. Jeon, Hyeon Chang Kim
    Applied Physiology, Nutrition, and Metabolism.2021; 46(7): 828.     CrossRef
  • The monocyte-to-lymphocyte ratio: Sex-specific differences in the tuberculosis disease spectrum, diagnostic indices and defining normal ranges
    Thomas S. Buttle, Claire Y. Hummerstone, Thippeswamy Billahalli, Richard J. B. Ward, Korina E. Barnes, Natalie J. Marshall, Viktoria C. Spong, Graham H. Bothamley, Selvakumar Subbian
    PLOS ONE.2021; 16(8): e0247745.     CrossRef
Review
Basic Research
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases
Siqi Hu, Eun-Hee Cho, Ji-Young Lee
Diabetes Metab J. 2020;44(2):234-244.   Published online March 24, 2020
DOI: https://doi.org/10.4093/dmj.2019.0243
  • 11,457 View
  • 189 Download
  • 28 Web of Science
  • 29 Crossref
AbstractAbstract PDFPubReader   ePub   

As a member of the class IIa histone deacetylases (HDACs), HDAC9 catalyzes the deacetylation of histones and transcription factors, commonly leading to the suppression of gene transcription. The activity of HDAC9 is regulated transcriptionally and post-translationally. HDAC9 is known to play an essential role in regulating myocyte and adipocyte differentiation and cardiac muscle development. Also, recent studies have suggested that HDAC9 is involved in the pathogenesis of chronic diseases, including cardiovascular diseases, osteoporosis, autoimmune disease, cancer, obesity, insulin resistance, and liver fibrosis. HDAC9 modulates the expression of genes related to the pathogenesis of chronic diseases by altering chromatin structure in their promotor region or reducing the transcriptional activity of their respective transcription factors. This review summarizes the current knowledge of the regulation of HDAC9 expression and activity. Also, the roles of HDAC9 in the pathogenesis of chronic diseases are discussed, along with potential underlying mechanisms.

Citations

Citations to this article as recorded by  
  • Palmitic acid alters enhancers/super-enhancers near inflammatory and efferocytosis-associated genes in human monocytes
    Vinay Singh Tanwar, Marpadga A Reddy, Suchismita Dey, Vajir Malek, Linda Lanting, Zhuo Chen, Rituparna Ganguly, Rama Natarajan
    Journal of Lipid Research.2025; 66(4): 100774.     CrossRef
  • Exploration of Fingerprints and Data Mining-based Prediction of Some Bioactive Compounds from Allium sativum as Histone Deacetylase 9 (HDAC9) Inhibitors
    Totan Das, Arijit Bhattacharya, Tarun Jha, Shovanlal Gayen
    Current Computer-Aided Drug Design.2025; 21(3): 270.     CrossRef
  • HDAC9 as a Sex‐Dependent Epigenetic Driver of Hepatic Steatosis and Adipose Inflammation
    Yu Ji Kim, Jong‐Won Kim
    Journal of Gastroenterology and Hepatology.2025; 40(10): 2632.     CrossRef
  • Downregulation of HDAC9 Alleviates Autophagy Dysfunction by Inducing Acetylation of ATG4B in Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Xiao‐Han Ma, Guang‐Peng Liu, Le Liu, Zi‐yue Dou, Xue He, Xi Chen
    The FASEB Journal.2025;[Epub]     CrossRef
  • Molecular mechanisms of bamboo-derived miRNA-mediated gene regulation and dietary adaptation in giant pandas
    Zheng Yan, Qin Xu, Xin He, Ying Yao, Dingzhen Liu, Hairui Wang
    BMC Genomics.2025;[Epub]     CrossRef
  • The multifactorial role of HDAC9 at the maternal–fetal interface in the pathogenesis of preeclampsia
    Megan A. Opichka, Jennifer J. McIntosh, Justin L. Grobe
    Clinical Science.2025; 139(24): 1769.     CrossRef
  • Impact of housing temperature on adipose tissue HDAC9 expression and adipogenic differentiation in high fat‐fed mice
    Samah Ahmadieh, Brandee Goo, Abdalrahman Zarzour, David Kim, Hong Shi, Praneet Veerapaneni, Ronnie Chouhaita, Nicole K. H. Yiew, Carla Dominguez Gonzalez, Akash Chakravartty, James Pennoyer, Nazeera Hassan, Tyler W. Benson, Mourad Ogbi, David J. Fulton, R
    Obesity.2024; 32(1): 107.     CrossRef
  • HDAC9 inhibition reduces skeletal muscle atrophy and enhances regeneration in mice with cigarette smoke-induced COPD
    Guixian Zheng, Chao Li, Xiaoli Chen, Zhaohui Deng, Ting Xie, Zengyu Huo, Xinyan Wei, Yanbing Huang, Xia Zeng, Yu Luo, Jing Bai
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2024; 1870(4): 167023.     CrossRef
  • Identification of HDAC9 and ARRDC4 as potential biomarkers and targets for treatment of type 2 diabetes
    Jing Liu, Lingzhen Meng, Zhihong Liu, Ming Lu, Ruiying Wang
    Scientific Reports.2024;[Epub]     CrossRef
  • HDAC9 as a Privileged Target: Reviewing its Role in Different Diseases and Structure-activity Relationships (SARs) of its Inhibitors
    Totan Das, Samima Khatun, Tarun Jha, Shovanlal Gayen
    Mini-Reviews in Medicinal Chemistry.2024; 24(7): 767.     CrossRef
  • The role of histone deacetylases in inflammatory respiratory diseases: an update
    Sicen Pan, Xiangdong Wang, Jian Jiao, Luo Zhang
    Expert Review of Clinical Immunology.2024; 20(10): 1193.     CrossRef
  • The Human Genetic Differences in the Outcomes of mRNA Vaccination against COVID-19: A Prospective Cohort Study
    Ha-Eun Ryu, Jihyun Yoon, Ja-Eun Choi, Seok-Jae Heo, Kyung-Won Hong, Dong-Hyuk Jung
    Vaccines.2024; 12(6): 626.     CrossRef
  • Targeting histone deacetylases for cancer therapy: Trends and challenges
    Tao Liang, Fengli Wang, Reham M. Elhassan, Yongmei Cheng, Xiaolei Tang, Wengang Chen, Hao Fang, Xuben Hou
    Acta Pharmaceutica Sinica B.2023; 13(6): 2425.     CrossRef
  • Therapeutic approach of natural products that treat osteoporosis by targeting epigenetic modulation
    Guokai Zhang, Zhenying Liu, Zihan Li, Bing Zhang, Pengyu Yao, Yun Qiao
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Research Progress on Histone Deacetylase Inhibitors
    玉姜 汤
    Hans Journal of Medicinal Chemistry.2023; 11(02): 116.     CrossRef
  • HDAC9 Inhibition as a Novel Treatment for Stroke
    Hugh S. Markus
    Stroke.2023; 54(12): 3182.     CrossRef
  • Histone deacetylase 9 exacerbates podocyte injury in hyperhomocysteinemia through epigenetic repression of Klotho
    Min Liu, Yang Zhang, Ping Zhan, Wenjuan Sun, Chuanqiao Dong, Xiaohan Liu, Yujie Yang, Xiaojie Wang, Yusheng Xie, Chengjiang Gao, Huili Hu, Benkang Shi, Ziying Wang, Chun Guo, Fan Yi
    Pharmacological Research.2023; 198: 107009.     CrossRef
  • Molecular mechanism and therapeutic potential of HDAC9 in intervertebral disc degeneration
    Ming Lei, Hui Lin, Deyao Shi, Pan Hong, Hui Song, Bomansaan Herman, Zhiwei Liao, Cao Yang
    Cellular & Molecular Biology Letters.2023;[Epub]     CrossRef
  • Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A
    Sylvia Fong, Bridget Yates, Choong-Ryoul Sihn, Aras N. Mattis, Nina Mitchell, Su Liu, Chris B. Russell, Benjamin Kim, Adebayo Lawal, Savita Rangarajan, Will Lester, Stuart Bunting, Glenn F. Pierce, K. John Pasi, Wing Yen Wong
    Nature Medicine.2022; 28(4): 789.     CrossRef
  • Active RhoA Exerts an Inhibitory Effect on the Homeostasis and Angiogenic Capacity of Human Endothelial Cells
    Michael Hauke, Robert Eckenstaler, Anne Ripperger, Anna Ender, Heike Braun, Ralf A. Benndorf
    Journal of the American Heart Association.2022;[Epub]     CrossRef
  • HDAC9 Contributes to Serous Ovarian Cancer Progression through Regulating Epithelial–Mesenchymal Transition
    Long Xu, Jian Wang, Buhan Liu, Jiaying Fu, Yuanxin Zhao, Sihang Yu, Luyan Shen, Xiaoyu Yan, Jing Su
    Biomedicines.2022; 10(2): 374.     CrossRef
  • Common protein-coding variants influence the racing phenotype in galloping racehorse breeds
    Haige Han, Beatrice A. McGivney, Lucy Allen, Dongyi Bai, Leanne R. Corduff, Gantulga Davaakhuu, Jargalsaikhan Davaasambuu, Dulguun Dorjgotov, Thomas J. Hall, Andrew J. Hemmings, Amy R. Holtby, Tuyatsetseg Jambal, Badarch Jargalsaikhan, Uyasakh Jargalsaikh
    Communications Biology.2022;[Epub]     CrossRef
  • Proposed minimal essential co-expression and physical interaction networks involved in the development of cognition impairment in human mid and late life
    Zahra Salehi, Masoud Arabfard, Omid Sadatpour, Mina Ohadi
    Neurological Sciences.2021; 42(3): 951.     CrossRef
  • Emerging roles of SIRT6 in human diseases and its modulators
    Gang Liu, Haiying Chen, Hua Liu, Wenbo Zhang, Jia Zhou
    Medicinal Research Reviews.2021; 41(2): 1089.     CrossRef
  • Quis Custodiet Ipsos Custodes (Who Controls the Controllers)? Two Decades of Studies on HDAC9
    Claudio Brancolini, Eros Di Giorgio, Luigi Formisano, Teresa Gagliano
    Life.2021; 11(2): 90.     CrossRef
  • circ_0003204 Regulates Cell Growth, Oxidative Stress, and Inflammation in ox-LDL-Induced Vascular Endothelial Cells via Regulating miR-942-5p/HDAC9 Axis
    Huan Wan, Ting You, Wei Luo
    Frontiers in Cardiovascular Medicine.2021;[Epub]     CrossRef
  • Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer
    Chun Yang, Stéphane Croteau, Pierre Hardy
    Cellular Oncology.2021; 44(5): 997.     CrossRef
  • Dual HDAC/BRD4 inhibitors against cancer
    Negar Omidkhah, Farzin Hadizadeh, Razieh Ghodsi
    Medicinal Chemistry Research.2021; 30(10): 1822.     CrossRef
  • miR‐211‐5p is down‐regulated and a prognostic marker in bladder cancer
    Weisheng Wang, Zhiming Liu, Xuegang Zhang, Junning Liu, Junqing Gui, Maorong Cui, Yong Li
    The Journal of Gene Medicine.2020;[Epub]     CrossRef
Original Articles
Cardiovascular Risk/Epidemiology
Validation of Risk Prediction Models for Atherosclerotic Cardiovascular Disease in a Prospective Korean Community-Based Cohort
Jae Hyun Bae, Min Kyong Moon, Sohee Oh, Bo Kyung Koo, Nam Han Cho, Moon-Kyu Lee
Diabetes Metab J. 2020;44(3):458-469.   Published online January 13, 2020
DOI: https://doi.org/10.4093/dmj.2019.0061
  • 12,146 View
  • 311 Download
  • 20 Web of Science
  • 22 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

To investigate the performance of the 2013 American College of Cardiology/American Heart Association Pooled Cohort Equations (PCE) in a large, prospective, community-based cohort in Korea and to compare it with that of the Framingham Global Cardiovascular Disease Risk Score (FRS-CVD) and the Korean Risk Prediction Model (KRPM).

Methods

In the Korean Genome and Epidemiology Study (KOGES)-Ansan and Ansung study, we evaluated calibration and discrimination of the PCE for non-Hispanic whites (PCE-WH) and for African Americans (PCE-AA) and compared their predictive abilities with the FRS-CVD and the KRPM.

Results

The present study included 7,932 individuals (3,778 men and 4,154 women). The PCE-WH and PCE-AA moderately overestimated the risk of atherosclerotic cardiovascular disease (ASCVD) for men (6% and 13%, respectively) but underestimated the risk for women (−49% and −25%, respectively). The FRS-CVD overestimated ASCVD risk for men (91%) but provided a good risk prediction for women (3%). The KRPM underestimated ASCVD risk for men (−31%) and women (−31%). All the risk prediction models showed good discrimination in both men (C-statistic 0.730 to 0.735) and women (C-statistic 0.726 to 0.732). Recalibration of the PCE using data from the KOGES-Ansan and Ansung study substantially improved the predictive accuracy in men.

Conclusion

In the KOGES-Ansan and Ansung study, the PCE overestimated ASCVD risk for men and underestimated the risk for women. The PCE-WH and the FRS-CVD provided an accurate prediction of ASCVD in men and women, respectively.

Citations

Citations to this article as recorded by  
  • Increased risk of colorectal cancer in young males with higher cardiovascular risk: A nationwide population-based cohort study
    Ji Hyun Song, Su-Yeon Choi, Young Sun Kim, Sun Young Yang, Kyung-Do Han
    World Journal of Gastrointestinal Oncology.2025;[Epub]     CrossRef
  • Association Between Cardiovascular Risk and Subclinical Atherosclerosis in Korean Female Patients with Systemic Lupus Erythematosus
    Ju-Yang Jung, Jaemi Kim, Ji-Hyun Park, Bumhee Park, Ji-Won Kim, Hyoun-Ah Kim, Chang-Hee Suh
    Journal of Clinical Medicine.2025; 14(20): 7162.     CrossRef
  • Clinical Utility of an AI-Based Retinal Imaging Model for Cardiovascular Risk Prediction in Hypertensive Retinopathy
    Dongjin Nam, Yong-Hwan Jang, Yongseok Lee, Jaewon Seo, Sahil Thakur, Simon Nusinovici, Moonsu Kim, Yong Un Shin, Hwan-Cheol Park, Sunjin Hwang
    Canadian Journal of Ophthalmology.2025;[Epub]     CrossRef
  • Risk Factors for Infertility in Korean Women
    Juyeon Lee, Chang-Woo Choo, Kyoung Yong Moon, Sang Woo Lyu, Hoon Kim, Joong Yeup Lee, Jung Ryeol Lee, Byung Chul Jee, Kyungjoo Hwang, Seok Hyun Kim, Sue K. Park
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Evaluating cardiovascular disease risk stratification using multiple-polygenic risk scores and pooled cohort equations: insights from a 17-year longitudinal Korean cohort study
    Yi Seul Park, Hye-Mi Jang, Ji Hye Park, Bong-Jo Kim, Hyun-Young Park, Young Jin Kim
    Frontiers in Genetics.2024;[Epub]     CrossRef
  • Predictability of Cardiovascular Risk Scores for Carotid Atherosclerosis in Community-Dwelling Middle-Aged and Elderly Adults
    Chao-Liang Chou, Chun-Chieh Liu, Tzu-Wei Wu, Chun-Fang Cheng, Shu-Xin Lu, Yih-Jer Wu, Li-Yu Wang
    Journal of Clinical Medicine.2024; 13(9): 2563.     CrossRef
  • Improving Cardiovascular Disease Primary Prevention Treatment Thresholds in a New England Health Care System
    So Mi Jemma Cho, Rachel Rivera, Satoshi Koyama, Min Seo Kim, Shriienidhie Ganesh, Romit Bhattacharya, Kaavya Paruchuri, Patricia Masson, Michael C. Honigberg, Norrina B. Allen, Whitney Hornsby, Pradeep Natarajan
    JACC: Advances.2024; 3(10): 101257.     CrossRef
  • The role of the triglyceride-glucose index as a biomarker of cardio-metabolic syndromes
    Verena Gounden, Sridevi Devaraj, Ishwarlal Jialal
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Moderation of Weight Misperception on the Associations Between Obesity Indices and Estimated Cardiovascular Disease Risk
    Kayoung Lee
    International Journal of Behavioral Medicine.2023; 30(1): 89.     CrossRef
  • Validation of the general Framingham Risk Score (FRS), SCORE2, revised PCE and WHO CVD risk scores in an Asian population
    Sazzli Shahlan Kasim, Nurulain Ibrahim, Sorayya Malek, Khairul Shafiq Ibrahim, Muhammad Firdaus Aziz, Cheen Song, Yook Chin Chia, Anis Safura Ramli, Kazuaki Negishi, Nafiza Mat Nasir
    The Lancet Regional Health - Western Pacific.2023; 35: 100742.     CrossRef
  • Principles of cardiovascular risk management in perimenopausal women with type 2 diabetes
    F. O. Ushanova, T. Yu. Demidova, T. N. Korotkova
    FOCUS. Endocrinology.2023; 4(2): 19.     CrossRef
  • Prediction of the 10-year risk of atherosclerotic cardiovascular disease in the Korean population
    Sangwoo Park, Yong-Giun Kim, Soe Hee Ann, Young-Rak Cho, Shin-Jae Kim, Seungbong Han, Gyung-Min Park
    Epidemiology and Health.2023; 45: e2023052.     CrossRef
  • Triglyceride-Glucose Index Predicts Future Atherosclerotic Cardiovascular Diseases: A 16-Year Follow-up in a Prospective, Community-Dwelling Cohort Study
    Joon Ho Moon, Yongkang Kim, Tae Jung Oh, Jae Hoon Moon, Soo Heon Kwak, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi, Nam H. Cho
    Endocrinology and Metabolism.2023; 38(4): 406.     CrossRef
  • Validity of the models predicting 10-year risk of cardiovascular diseases in Asia: A systematic review and prediction model meta-analysis
    Mahin Nomali, Davood Khalili, Mehdi Yaseri, Mohammad Ali Mansournia, Aryan Ayati, Hossein Navid, Saharnaz Nedjat, Hean Teik Ong
    PLOS ONE.2023; 18(11): e0292396.     CrossRef
  • Genetic Risk Score for Prediction of Coronary Heart Disease in the Korean Genome and Epidemiology Study
    Hyunok Yun, Ji Eun Lim, Eun Young Lee
    Reviews in Cardiovascular Medicine.2023;[Epub]     CrossRef
  • Assessing the Validity of the Criteria for the Extreme Risk Category of Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Study
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    Journal of Lipid and Atherosclerosis.2022; 11(1): 73.     CrossRef
  • Mediation of Grip Strength on the Association Between Self-Rated Health and Estimated Cardiovascular Disease Risk
    Kayoung Lee
    Metabolic Syndrome and Related Disorders.2022; 20(6): 344.     CrossRef
  • Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular disease
    Xiao-Ying Li, Li Li, Sang-Hoon Na, Francesca Santilli, Zhongwei Shi, Michael Blaha
    American Journal of Preventive Cardiology.2022; 11: 100363.     CrossRef
  • The Risk of Cardiovascular Disease According to Chewing Status Could Be Modulated by Healthy Diet in Middle-Aged Koreans
    Hyejin Chun, Jongchul Oh, Miae Doo
    Nutrients.2022; 14(18): 3849.     CrossRef
  • Management of Cardiovascular Risk in Perimenopausal Women with Diabetes
    Catherine Kim
    Diabetes & Metabolism Journal.2021; 45(4): 492.     CrossRef
  • Comparative performance of the two pooled cohort equations for predicting atherosclerotic cardiovascular disease
    Alessandra M. Campos-Staffico, David Cordwin, Venkatesh L. Murthy, Michael P. Dorsch, Jasmine A. Luzum
    Atherosclerosis.2021; 334: 23.     CrossRef
  • Usefulness of Relative Handgrip Strength as a Simple Indicator of Cardiovascular Risk in Middle-Aged Koreans
    Won Bin Kim, Jun-Bean Park, Yong-Jin Kim
    The American Journal of the Medical Sciences.2021; 362(5): 486.     CrossRef
Cardiovascular Risk/Epidemiology
Pre-existing Depression among Newly Diagnosed Dyslipidemia Patients and Cardiovascular Disease Risk
Jihoon Andrew Kim, Seulggie Choi, Daein Choi, Sang Min Park
Diabetes Metab J. 2020;44(2):307-315.   Published online November 1, 2019
DOI: https://doi.org/10.4093/dmj.2019.0002
  • 9,335 View
  • 110 Download
  • 14 Web of Science
  • 13 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Whether depression before diagnosis of dyslipidemia is associated with higher cardiovascular disease (CVD) risk among newly diagnosed dyslipidemia patients is yet unclear.

Methods

The study population consisted of 72,235 newly diagnosed dyslipidemia patients during 2003 to 2012 from the National Health Insurance Service–Health Screening Cohort of South Korea. Newly diagnosed dyslipidemia patients were then detected for pre-existing depression within 3 years before dyslipidemia diagnosis. Starting from 2 years after the diagnosis date, patients were followed up for CVD until 2015. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for CVD were calculated by Cox proportional hazards regression.

Results

Compared to dyslipidemia patients without depression, those with depression had higher risk for CVD (aHR, 1.24; 95% CI, 1.09 to 1.41). Similarly, pre-existing depression was associated with increased risk for stroke (aHR, 1.27; 95% CI, 1.06 to 1.53). The risk for CVD among depressed dyslipidemia patients for high (aHR, 1.42; 95% CI, 1.06 to 1.90), medium (aHR, 1.17; 95% CI, 0.91 to 1.52), and low (aHR, 1.25; 95% CI, 1.05 to 1.50) statin compliance patients tended to be increased compared to patients without pre-existing dyslipidemia. The risk-elevating effect of depression on CVD tended to be preserved regardless of subgroups of smoking, alcohol consumption, physical activity, and body mass index.

Conclusion

Dyslipidemia patients with pre-existing depression had increased risk for CVD. Future studies that determine CVD risk after management of depression among dyslipidemia patients are needed.

Citations

Citations to this article as recorded by  
  • Association of cholecystectomy with short-term and long-term risks of depression and suicide
    Jiwon Yu, Sangwoo Park, Seogsong Jeong, Ahryoung Ko, Jaewon Lee, Saemi Han, Sang min Park
    Scientific Reports.2025;[Epub]     CrossRef
  • CHARLS insights into the impact of dual interactions of chronic diseases on depression in middle-aged and elderly individuals
    Dian-yin Liang, Xue Chen, Ke-hua Li
    Scientific Reports.2025;[Epub]     CrossRef
  • An application of the Bayesian network model based on the EN-ESL-GA algorithm: Exploring the predictors of heart disease in middle-aged and elderly people in China
    Wenlong Gao, Zhimei Zeng, Xiaojie Ma, Yongsong Ke, Minqian Zhi
    Technology and Health Care.2024; 32(6): 3903.     CrossRef
  • Higher atherogenic index of plasma is associated with increased major depressive disorder: insights from a nationally representative study
    Shiyi Tao, Lintong Yu, Jun Li, Xuanchun Huang, Tiantian Xue, Deshuang Yang, Yuqing Tan
    Frontiers in Psychiatry.2024;[Epub]     CrossRef
  • Elevated remnant cholesterol and the risk of prevalent major depressive disorder: a nationwide population-based study
    Shiyi Tao, Lintong Yu, Jun Li, Ji Wu, Deshuang Yang, Xuanchun Huang, Tiantian Xue
    Frontiers in Psychiatry.2024;[Epub]     CrossRef
  • Mediating effect of depression on the association between cardiovascular disease and the risk of all‐cause mortality: NHANES in 2005−2018
    Xinxin Ma, Huan Zhang, Yuan Tian, Yaping Wang, Ling Liu, Lei Wang
    Clinical Cardiology.2023; 46(11): 1380.     CrossRef
  • Associations of sleep duration, daytime napping, and snoring with depression in rural China: a cross-sectional study
    Xueyao Zhang, Guangxiao Li, Chuning Shi, Yingxian Sun
    BMC Public Health.2023;[Epub]     CrossRef
  • Association between socioeconomic inequality and the global prevalence of anxiety and depressive disorders: an ecological study
    Fatemeh Shahbazi, Marjan Shahbazi, Jalal Poorolajal
    General Psychiatry.2022; 35(3): e100735.     CrossRef
  • Impact of Alexithymia on the Lipid Profile in Major Depressed Individuals
    Camille Point, Benjamin Wacquier, Marjorie Dosogne, Mohammed Al Faker, Hadrien Willame, Gwenolé Loas, Matthieu Hein, Philip W. Wertz
    Journal of Lipids.2022; 2022: 1.     CrossRef
  • Association of Depression With Cardiovascular Diseases
    Zain I Warriach, Sruti Patel, Fatima Khan, Gerardo F Ferrer
    Cureus.2022;[Epub]     CrossRef
  • Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    Metabolism.2022; 137: 155327.     CrossRef
  • Dyslipidemia prevalence and trends among adult mental disorder inpatients in Beijing, 2005–2018: A longitudinal observational study
    Fude Yang, Qiuyue Ma, Botao Ma, Wenzhan Jing, Jue Liu, Moning Guo, Juan Li, Zhiren Wang, Min Liu
    Asian Journal of Psychiatry.2021; 57: 102583.     CrossRef
  • Non-HDL cholesterol level and depression among Canadian elderly—a cross-sectional analysis of the baseline data from the CLSA
    Jian Liu, Surim Son, Mike Giancaterino, Chris P. Verschoor, Miya Narushima, David Moher
    FACETS.2020; 5(1): 1006.     CrossRef
Lifesytle
Changes in the Quality of Life in Patients with Type 2 Diabetes Mellitus According to Physician and Patient Behaviors
Young-Joo Kim, In-Kyung Jeong, Sin-Gon Kim, Dong Hyeok Cho, Chong-Hwa Kim, Chul-Sik Kim, Won-Young Lee, Kyu-Chang Won, Jin-Hye Cha, Juneyoung Lee, Doo-Man Kim
Diabetes Metab J. 2020;44(1):91-102.   Published online October 23, 2019
DOI: https://doi.org/10.4093/dmj.2018.0251
  • 9,249 View
  • 121 Download
  • 9 Web of Science
  • 10 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Diabetes mellitus (DM) is the most common chronic metabolic disorder with an increasing prevalence worldwide. According to a previous study, physicians' treatment patterns or patients' behaviors change when they become aware of the risk for cardiovascular (CV) disease in patients with DM. However, there exist controversial reports from previous studies in the impact of physicians' behaviors on the patients' quality of life (QoL) improvements. So we investigate the changes in QoL according to physicians and patients' behavioral changes after the awareness of CV risks in patients with type 2 DM.

Methods

Data were obtained from a prospective, observational study where 799 patients aged ≥40 years with type 2 DM were recruited at 24 tertiary hospitals in Korea. Changes in physicians' behaviors were defined as changes in the dose/type of antihypertensive, lipid-lowering, and anti-platelet therapies within 6-month after the awareness of CV risks in patients. Changes in patients' behaviors were based on lifestyle modifications. Audit of Diabetes Dependent Quality of Life comprising 19-life-domains was used.

Results

The weighted impact score change for local or long-distance journey (P=0.0049), holidays (P=0.0364), and physical health (P=0.0451) domains significantly differed between the two groups; patients whose physician's behaviors changed showed greater improvement than those whose physician's behaviors did not change.

Conclusion

This study demonstrates that changes in physicians' behaviors, as a result of perceiving CV risks, improve QoL in some domains of life in DM patients. Physicians should recognize the importance of understanding CV risks and implement appropriate management.

Citations

Citations to this article as recorded by  
  • Quality of Life in Women With Gestational Diabetes Mellitus and Treatment Satisfaction Upon Intermittently Scanned Continuous Glucose Monitoring
    Sookyung Won, Hyeon Ji Kim, Jee Yoon Park, Kyung Joon Oh, Sung Hee Choi, Hak Chul Jang, Joon Ho Moon
    Journal of Korean Medical Science.2025;[Epub]     CrossRef
  • Inhibition mechanism of starch digestion by luteolin, eriodictyol, and their complex in vitro: Multispectral, kinetic, and theoretical calculations analysis
    Xinyu Jiang, Yanli Li, Yongliang Ma, Feng Gao, Yali Yu
    International Journal of Biological Macromolecules.2025; 308: 142649.     CrossRef
  • Evaluation of Health-Related Quality of Life in Patients with Type 2 Diabetes Mellitus through EQ-5D-3L: in public sector hospitals of Quetta, Pakistan
    Hamad Haider Khan, Faiz Ullah Khan, Tawseef Ahmad, Hui Guo , Bingyin Shi
    Jordan Journal of Pharmaceutical Sciences.2025; 18(2): 410.     CrossRef
  • Impact of socio-economic factors and lifestyle behaviours on the quality of life of diabetes patients in Markurdi Benue state Nigeria
    Oluwafunke O. Akinbule, Faith Nguvan Tor-Anyiin, Sultan A. Adenusi
    Scientific Reports.2025;[Epub]     CrossRef
  • Prevalence, awareness, treatment and control of type 2 diabetes in southeast China: A population‐based study
    Xiangju Hu, Xin Fang, Minxia Wu
    Journal of Diabetes Investigation.2024; 15(8): 1034.     CrossRef
  • Spline Longitudinal Multi-response Model for the Detection of Lifestyle- Based Changes in Blood Glucose of Diabetic Patients
    Anna Islamiyati
    Current Diabetes Reviews.2022;[Epub]     CrossRef
  • Characteristics of Glycemic Control and Long-Term Complications in Patients with Young-Onset Type 2 Diabetes
    Han-sang Baek, Ji-Yeon Park, Jin Yu, Joonyub Lee, Yeoree Yang, Jeonghoon Ha, Seung Hwan Lee, Jae Hyoung Cho, Dong-Jun Lim, Hun-Sung Kim
    Endocrinology and Metabolism.2022; 37(4): 641.     CrossRef
  • Agriophyllum Oligosaccharides Ameliorate Diabetic Insulin Resistance Through INS-R/IRS/Glut4-Mediated Insulin Pathway in db/db Mice and MIN6 Cells
    Shuyin Bao, Xiuzhi Wang, Sung Bo Cho, Yan-Ling Wu, Chengxi Wei, Shuying Han, Liming Bao, Qiong Wu, Wuliji Ao, Ji-Xing Nan
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Glycolipid metabolism and liver transcriptomic analysis of the therapeutic effects of pressed degreased walnut meal extracts on type 2 diabetes mellitus rats
    Yulan Li, Dan Chen, Chengmei Xu, Qingyujing Zhao, Yage Ma, Shenglan Zhao, Chaoyin Chen
    Food & Function.2020; 11(6): 5538.     CrossRef
  • Cause-of-death statistics in 2018 in the Republic of Korea
    Hyun-Young Shin, Jin Kim, Seokmin Lee, Min Sim Park, Sanghee Park, Sun Huh
    Journal of the Korean Medical Association.2020; 63(5): 286.     CrossRef
Obesity and Metabolic Syndrome
The Association between Z-Score of Log-Transformed A Body Shape Index and Cardiovascular Disease in Korea
Wankyo Chung, Jung Hwan Park, Hye Soo Chung, Jae Myung Yu, Shinje Moon, Dong Sun Kim
Diabetes Metab J. 2019;43(5):675-682.   Published online April 26, 2019
DOI: https://doi.org/10.4093/dmj.2018.0169
  • 11,321 View
  • 68 Download
  • 7 Web of Science
  • 7 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

In order to overcome the limitations of body mass index (BMI) and waist circumference (WC), the z-score of the log-transformed A Body Shape Index (LBSIZ) has recently been introduced. In this study, we analyzed the relationship between the LBSIZ and cardiovascular disease (CVD) in a Korean representative sample.

Methods

Data were collected from the Korea National Health and Nutrition Examination VI to V. The association between CVD and obesity indices was analyzed using a receiver operating characteristic curve. The cut-off value for the LBSIZ was estimated using the Youden index, and the odds ratio (OR) for CVD was determined via multivariate logistic regression analysis. ORs according to the LBSIZ value were analyzed using restricted cubic spline regression plots.

Results

A total of 31,227 Korean healthy adults were analyzed. Area under the curve (AUC) of LBSIZ against CVD was 0.686 (95% confidence interval [CI], 0.671 to 0.702), which was significantly higher than the AUC of BMI (0.583; 95% CI, 0.567 to 0.599) or WC (0.646; 95% CI, 0.631 to 0.661) (P<0.001). Similar results were observed for stroke and coronary artery diseases. The cut-off value for the LBSIZ was 0.35 (sensitivity, 64.5%; specificity, 64%; OR, 1.29, 95% CI, 1.12 to 1.49). Under restricted cubic spline regression, LBSIZ demonstrated that OR started to increase past the median value.

Conclusion

The findings of this study suggest that the LBSIZ might be more strongly associated with CVD risks compared to BMI or WC. These outcomes would be helpful for CVD risk assessment in clinical settings, especially the cut-off value of the LBSIZ suggested in this study.

Citations

Citations to this article as recorded by  
  • Associations of four obesity indices with diabetes mellitus in Korean middle-aged and older adults using the Korean Genome and Epidemiology Study (KoGES)
    Yiseul Lee, Nam-Kyoo Lim, Hyun-Young Park
    BMC Public Health.2025;[Epub]     CrossRef
  • Evaluating the potential of waist-to-BMI ratio, a body shape index, and other anthropometric parameters in predicting cardiovascular disease mortality: evidence from NHANES III
    Thung-Lip Lee, Fang-Ju Lin, Chih-Fan Yeh, Yu-Chung Hsiao, Kai-Chien Yang, Chin-Feng Hsuan, Chau-Chung Wu
    BMC Public Health.2025;[Epub]     CrossRef
  • Associations of longitudinal trajectories of triglyceride-glucose index combined with classical and novel obesity indices and cardiovascular disease: evidence from a nationwide prospective cohort study in China
    Chao Wang, Shiming He, Guobo Xie, Shuhua Zhang, Zhiyu Xiong, Hengcheng Lu, Qun Wang, Lin Xie, Wei Wang, Yang Zou, Xue Li
    Cardiovascular Diabetology.2025;[Epub]     CrossRef
  • Comparison of the TyG index, TyG-traditional obesity indices, and TyG-novel obesity indices: does increased complexity help in predicting cardiometabolic multimorbidity?
    Fanzhi Zhang, Bin Zhang, Xinfang Huang, Zhenyu Wang, Juan Wang, Houhui Lan, Guobo Xie, Wei Wang, Yang Zou, Chao Wang
    Lipids in Health and Disease.2025;[Epub]     CrossRef
  • Body Shape Index and Cardiovascular Risk in Individuals With Obesity
    Nazlı Hacıağaoğlu, Can Öner, Hüseyin Çetin, Engin Ersin Şimşek
    Cureus.2022;[Epub]     CrossRef
  • Association between body shape index and risk of mortality in the United States
    Heysoo Lee, Hye Soo Chung, Yoon Jung Kim, Min Kyu Choi, Yong Kyun Roh, Wankyo Chung, Jae Myung Yu, Chang-Myung Oh, Shinje Moon
    Scientific Reports.2022;[Epub]     CrossRef
  • Utility of the Z-score of log-transformed A Body Shape Index (LBSIZ) in the assessment for sarcopenic obesity and cardiovascular disease risk in the United States
    Wankyo Chung, Jung Hwan Park, Hye Soo Chung, Jae Myung Yu, Dong Sun Kim, Shinje Moon
    Scientific Reports.2019;[Epub]     CrossRef
Epidemiology
Association of Visit-to-Visit Variability of Blood Pressure with Cardiovascular Disease among Type 2 Diabetes Mellitus Patients: A Cohort Study
Zhe-Bin Yu, Die Li, Xue-Yu Chen, Pei-Wen Zheng, Hong-Bo Lin, Meng-Ling Tang, Ming-Juan Jin, Jian-Bing Wang, Kun Chen
Diabetes Metab J. 2019;43(3):350-367.   Published online March 6, 2019
DOI: https://doi.org/10.4093/dmj.2018.0108
  • 9,056 View
  • 95 Download
  • 15 Web of Science
  • 15 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Increasing evidence has shown that visit-to-visit variability (VVV) of blood pressure (BP) is associated with an increased risk of cardiovascular disease (CVD). The objective of this study was to evaluate the impact of VVV of systolic blood pressure (SBP) and diastolic blood pressure (DBP) on the risk of CVD among patients with type 2 diabetes mellitus (T2DM) in China.

Methods

We conducted a retrospective cohort study of 10,163 T2DM patients who were not previously diagnosed with CVD from January 2008 to December 2012 in Ningbo, China. The VVV of BP was calculated using five metrics, including standard deviation (SD), coefficient of variation (CV), variation independent of mean, average real variability, and successive variability (SV) of measurements, obtained over a 24-month measurement period. Hazard ratios and 95% confidence intervals (CIs) were estimated by Cox proportional hazards regression models for the associations of variability in BP with risk of CVD.

Results

A total of 894 CVD events were observed during a median follow-up of 49.5 months. The hazard ratio in the highest quintile of SD of SBP was 1.24 (95% CI, 1.01 to 1.52) compared with patients in the lowest quintile. The association between higher VVV of DBP and risk of CVD was not consistent across different metrics and sensitivity analyses.

Conclusion

Higher VVV of SBP was associated with an increased risk of CVD, irrespective of the mean SBP level. Future studies are needed to confirm these findings.

Citations

Citations to this article as recorded by  
  • The role of blood pressure stability in diabetic retinopathy development
    Chin-Chih Shih, Ling-Na Shih, Hung-An Lin, Yi-Ting Hsieh
    Eye.2026; 40(2): 245.     CrossRef
  • Visit-to-visit blood pressure variability and clinical outcomes in peritoneal dialysis – based on machine learning algorithms
    Yan Lin, Chunyan Yi, Peiyi Cao, Jianxiong Lin, Wei Chen, Haiping Mao, Xiao Yang, Qunying Guo
    Hypertension Research.2025; 48(5): 1702.     CrossRef
  • Visit-to-visit blood pressure variability and cardiovascular outcomes: a systematic review and dose-response meta-analysis
    Mifetika Lukitasari, Jitendra Jonnagaddala, Siaw-Teng Liaw, Bin Jalaludin
    European Journal of Preventive Cardiology.2025;[Epub]     CrossRef
  • Efficacy of using telecare services for community-dwelling people with diabetes: A systematic review and meta-analysis
    Qian Liu, Huali Song, Sitao Zhang, Mingzhu Zhao, Xuechun Bai, Haoying Liu, Wenxi Duan, Wei Xu, Haitao Song, Li Chen, Huiru Yin
    Primary Care Diabetes.2024; 18(4): 393.     CrossRef
  • Association between Variability of Metabolic Risk Factors and Cardiometabolic Outcomes
    Min Jeong Park, Kyung Mook Choi
    Diabetes & Metabolism Journal.2022; 46(1): 49.     CrossRef
  • Joint effect of blood pressure and glycemic variation on the risk of cardiovascular morbidity and mortality in persons with type 2 diabetes
    Cheng-Chieh Lin, Chia-Ing Li, Ya-Ling Juan, Chiu-Shong Liu, Chih-Hsueh Lin, Shing-Yu Yang, Tsai-Chung Li
    Metabolism.2022; 136: 155308.     CrossRef
  • Visit‐to‐visit variability of blood pressure and risk of macrovascular and microvascular complications in patients with type 2 diabetes: A Chinese primary‐care cohort study
    Ying Deng, Yin Liu, Shengchao Zhang, Hanbing Yu, Xiaozhou Zeng, Rongrong An, Zhenyuan Chen, Na Sun, Xiaoxv Yin, Yue Dong
    Journal of Diabetes.2022; 14(11): 767.     CrossRef
  • Visit‑to‑visit blood pressure variability is associated with arterial stiffness in Chinese adults: A prospective analysis
    Yuwen Zhang, Lizhan Bie, Mian Li, Tiange Wang, Min Xu, Jieli Lu, Shuangyuan Wang, Jie Zhang, Yufang Bi, Weiqing Wang, Guang Ning, Yuhong Chen, Yu Xu
    The Journal of Clinical Hypertension.2021; 23(4): 802.     CrossRef
  • Variability of risk factors and diabetes complications
    Antonio Ceriello, Francesco Prattichizzo
    Cardiovascular Diabetology.2021;[Epub]     CrossRef
  • Effectiveness of statin intensive therapy in type 2 diabetes mellitus with high visit-to-visit blood pressure variability
    Shota Ikeda, Keisuke Shinohara, Nobuyuki Enzan, Shouji Matsushima, Takeshi Tohyama, Kouta Funakoshi, Junji Kishimoto, Hiroshi Itoh, Issei Komuro, Hiroyuki Tsutsui
    Journal of Hypertension.2021; 39(7): 1435.     CrossRef
  • Prognostic importance of visit-to-visit blood pressure variability for micro- and macrovascular outcomes in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study
    Claudia R. L. Cardoso, Nathalie C. Leite, Gil F. Salles
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Impact of visit-to-visit variability in blood pressure on coronary plaque as assessed by integrated backscatter intravascular ultrasound
    Yuta Kato, Atsushi Iwata, Makito Futami, Motoki Yamashita, Eiji Shigemoto, Takashi Kuwano, Makoto Sugihara, Shin-Ichiro Miura
    Clinical and Experimental Hypertension.2020; 42(7): 608.     CrossRef
  • VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY IN RURAL MALES WITH ARTERIAL HYPERTENSION: ASSOCIATION WITH NON-VALVULAR ATRIAL FIBRILLATION
    T.I. Nimtsovych, A.M. Kravchenko, O.Yu. Mishcheniuk, К.О. Mikhaliev, T.Ya. Chursina
    Клінічна та профілактична медицина.2020; (2): 90.     CrossRef
  • VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY AND TARGET ORGAN DAMAGE IN RURAL DWELLERS WITH UNCOMPLICATED ARTERIAL HYPERTENSION
    Tetiana I. Nimtsovych, Anatolii M. Kravchenko, Olha Yu. Mishcheniuk, Tamara Ya. Chursina, Кyrylo О. Mikhaliev, Viktor P. Polovyi
    Wiadomości Lekarskie.2020; 73(12): 2591.     CrossRef
  • HDL-Cholesterol, Its Variability, and the Risk of Diabetes: A Nationwide Population-Based Study
    Seung-Hwan Lee, Hun-Sung Kim, Yong-Moon Park, Hyuk-Sang Kwon, Kun-Ho Yoon, Kyungdo Han, Mee Kyoung Kim
    The Journal of Clinical Endocrinology & Metabolism.2019; 104(11): 5633.     CrossRef
Clinical Diabetes & Therapeutics
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials
Yu Mi Kang, Yun Kyung Cho, Jiwoo Lee, Seung Eun Lee, Woo Je Lee, Joong-Yeol Park, Ye-Jee Kim, Chang Hee Jung, Michael A. Nauck
Diabetes Metab J. 2019;43(4):410-421.   Published online December 27, 2018
DOI: https://doi.org/10.4093/dmj.2018.0070
  • 10,383 View
  • 175 Download
  • 26 Web of Science
  • 26 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Based on reported results of three large cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), we aimed to investigate the overall effect of GLP-1 RAs on major adverse cardiovascular events (MACEs) and to identify subpopulations exhibiting the greatest cardiovascular (CV) benefit.

Methods

Three CVOTs reporting effects of long-acting GLP-1 RAs were included: LEADER (liraglutide), SUSTAIN-6 (semaglutide), and EXSCEL (exenatide once weekly). In all studies, the primary endpoint was three-point MACE, comprising CV death, non-fatal myocardial infarction, and non-fatal stroke. Overall effect estimates were calculated as hazard ratios and 95% confidence intervals (CIs) using the random-effects model; subgroup analyses reported in the original studies were similarly analyzed.

Results

Overall, statistically significant risk reductions in MACE and CV death were observed. Subgroup analysis indicated a significant racial difference with respect to CV benefit (P for interaction <0.001), and more substantial risk reductions were observed in subjects of African origin (relative risk [RR], 0.78; 95% CI, 0.60 to 0.99) and in Asians (RR, 0.35; 95% CI, 0.09 to 1.32). However, post hoc analysis (Bonferroni method) revealed that only Asians exhibited a significantly greater CV benefit from treatment, compared with white subjects (P<0.0001).

Conclusion

Long-acting GLP-1 RAs reduced risks of MACE and CV deaths in high-risk patients with type 2 diabetes mellitus. Our findings of a particularly effective reduction in CV events with GLP-1 RA in Asian populations merits further exploration and dedicated trials in specific populations.

Citations

Citations to this article as recorded by  
  • Comparative Efficacy and Safety of Oral Semaglutide in Asians and Non-Asians Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
    Tianzuo Wang, Yuying Cui, Lin Liao
    Diabetes Therapy.2025;[Epub]     CrossRef
  • Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or O
    Matthew M.Y. Lee, Nazim Ghouri, Anoop Misra, Yu Mi Kang, Martin K. Rutter, Hertzel C. Gerstein, Darren K. McGuire, Naveed Sattar
    Diabetes Care.2025; 48(3): 489.     CrossRef
  • Expert Opinion on the Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes and Established or High‑risk Atherosclerotic Cardiovascular Disease in Thailand
    Wanwarang Wongcharoen, Rungroj Krittayaphong, Wacin Buddhari, Songsak Kiatchoosakun, Apiradee Sriwijitkamol, Taweesak Wannachalee, Arintaya Phrommintikul
    Journal of Asian Pacific Society of Cardiology.2025;[Epub]     CrossRef
  • Assessing the Safety of Semaglutide and Tirzepatide in Black and Asian Populations: A Narrative Review
    Pulwasha Iftikhar, Chander P Khatri, Sri Ratna Divya Nanduri, Minahil Ramzan, Krishna Sai Kiran Sakalabaktula
    Cureus.2025;[Epub]     CrossRef
  • Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment
    Yuzi Cao, Indah Widyahening, Xiaodong Sun, Sheyu Li
    Diabetes, Obesity and Metabolism.2025; 27(S10): 3.     CrossRef
  • Comparative efficacy and safety of Glucagon‐like pepetide‐1 receptor agonists with metformin in Asian versus non‐Asian patients with type 2 diabetes: A systematic review and meta‐analysis
    Wenxuan Li, Linyan Huang, Ruixue Wang, Peiyan Peng, Aowen Song, Yi Zeng, Zhen Zhang
    Diabetes, Obesity and Metabolism.2025; 27(11): 6727.     CrossRef
  • Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study
    Jeonghee Han, Woo Je Lee, Kyu Yeon Hur, Jae Hyoung Cho, Byung Wan Lee, Cheol-Young Park
    Diabetes & Metabolism Journal.2024; 48(3): 418.     CrossRef
  • Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials
    Frederick Berro Rivera, Nathan Ross B. Bantayan, John Paul Aparece, Linnaeus Louisse A. Cruz, John Vincent Magallong, Polyn Luz Pine, Anne Mira Nicca Idian-Javier, Grace Nooriza O. Lumbang, Edgar V. Lerma, Kyla M. Lara-Breitinger, Martha Gulati, Krishnasw
    Journal of Clinical Lipidology.2024; 18(4): e588.     CrossRef
  • A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD‐JPN)
    Tomoaki Morioka, Masakazu Takeuchi, Akichika Ozeki, Masanori Emoto
    Diabetes, Obesity and Metabolism.2024; 26(8): 3167.     CrossRef
  • Coronary Artery Disease in South Asian Patients: Cardiovascular Risk Factors, Pathogenesis and Treatments
    Vincenzo Sucato, Giuseppe Coppola, Girolamo Manno, Giuseppe Vadalà, Giuseppina Novo, Egle Corrado, Alfredo Ruggero Galassi
    Current Problems in Cardiology.2023; 48(8): 101228.     CrossRef
  • Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
    Hodaka Yamada, Masashi Yoshida, Shunsuke Funazaki, Jun Morimoto, Shiori Tonezawa, Asuka Takahashi, Shuichi Nagashima, Kimura Masahiko, Otsuka Kiyoshi, Kazuo Hara
    Journal of Cardiovascular Development and Disease.2023; 10(4): 176.     CrossRef
  • Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus
    L. Yu. Khamnueva, L. S. Andreeva
    Problems of Endocrinology.2023; 69(2): 38.     CrossRef
  • Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
    Sian A. Bradley, Kevin J. Spring, Roy G. Beran, Dimitrios Chatzis, Murray C. Killingsworth, Sonu M. M. Bhaskar
    Diabetes/Metabolism Research and Reviews.2022;[Epub]     CrossRef
  • Obesity Pillars Roundtable: Obesity and East Asians
    Harold Edward Bays, Jennifer Ng, Jeffrey Sicat, Michelle Look
    Obesity Pillars.2022; 2: 100011.     CrossRef
  • Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
    Calvin Ke, K. M. Venkat Narayan, Juliana C. N. Chan, Prabhat Jha, Baiju R. Shah
    Nature Reviews Endocrinology.2022; 18(7): 413.     CrossRef
  • Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Timothy M. E. Davis, Anna Giczewska, Yuliya Lokhnygina, Robert J. Mentz, Naveed Sattar, Rury R. Holman
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
    Xiaoling Cai, Linong Ji
    Diabetes Therapy.2021; 12(7): 1861.     CrossRef
  • Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
    Jae-Seung Yun, Seung-Hyun Ko
    Metabolism.2021; 123: 154838.     CrossRef
  • Sex and ethnic differences in the cardiovascular complications of type 2 diabetes
    Jian L. Yeo, Emer M. Brady, Gerry P. McCann, Gaurav S. Gulsin
    Therapeutic Advances in Endocrinology and Metabolism.2021;[Epub]     CrossRef
  • Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Efficacy and safety of dulaglutide in type 2 diabetes patients in endocrinology clinics of Islamabad, Pakistan
    Matiullah Kamin, SajjadAli Khan, UmarYousaf Raja, Osama Ishtiaq, Asmara Malik, Tejhmal Rehman, MuhammadUmar Wahab
    Indian Journal of Endocrinology and Metabolism.2021; 25(5): 456.     CrossRef
  • Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in South Asians: a Unique Population with a Growing Challenge
    Afreen I. Shariff, Nitya Kumar, William S. Yancy, Leonor Corsino
    Current Diabetes Reports.2020;[Epub]     CrossRef
  • Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
    Christopher S. Wilcox
    Hypertension.2020; 75(4): 894.     CrossRef
  • Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
    Liyun He, Na Yang, Lingling Xu, Fan Ping, Wei Li, Yuxiu Li, Huabing Zhang
    Diabetes Therapy.2020; 11(9): 2121.     CrossRef
  • 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
    Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu, Kuan-Cheng Chang, Kou-Gi Shyu, Jin-Long Huang, Cheng-Dao Tsai, Huei-Fong Hung, Ming-En Liu, Tze-Fan Chao,
    Journal of the Chinese Medical Association.2020; 83(7): 587.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
Obesity and Metabolic Syndrome
The Risk of Myocardial Infarction and Ischemic Stroke According to Waist Circumference in 21,749,261 Korean Adults: A Nationwide Population-Based Study
Jung-Hwan Cho, Eun-Jung Rhee, Se-Eun Park, Hyemi Kwon, Jin-Hyung Jung, Kyung-Do Han, Yong-Gyu Park, Hye Soon Park, Yang-Hyun Kim, Soon-Jib Yoo, Won-Young Lee
Diabetes Metab J. 2019;43(2):206-221.   Published online December 27, 2018
DOI: https://doi.org/10.4093/dmj.2018.0039
  • 9,790 View
  • 122 Download
  • 42 Web of Science
  • 46 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Waist circumference (WC) is a well-known obesity index that predicts cardiovascular disease (CVD). We studied the relationship between baseline WC and development of incident myocardial infarction (MI) and ischemic stroke (IS) using a nationwide population-based cohort, and evaluated if its predictability is better than body mass index (BMI).

Methods

Our study included 21,749,261 Koreans over 20 years of age who underwent the Korean National Health Screening between 2009 and 2012. The occurrence of MI or IS was investigated until the end of 2015 using National Health Insurance Service data.

Results

A total of 127,289 and 181,637 subjects were newly diagnosed with MI and IS. The incidence rate and hazard ratio of MI and IS increased linearly as the WC level increased, regardless of adjustment for BMI. When the analyses were performed according to 11 groups of WC, the lowest risk of MI was found in subjects with WC of 70 to 74.9 and 65 to 69.9 cm in male and female, and the lowest risk of IS in subjects with WC of 65 to 69.9 and 60 to 64.9 cm in male and female, respectively. WC showed a better ability to predict CVD than BMI with smaller Akaike information criterion. The optimal WC cutoffs were 84/78 cm for male/female for predicting MI, and 85/78 cm for male/female for predicting IS.

Conclusion

WC had a significant linear relationship with the risk of MI and IS and the risk began to increase from a WC that was lower than expected.

Citations

Citations to this article as recorded by  
  • Joint effects of waist circumference trajectories and aging with risk of heart disease
    Xiaodi Tang, Rong He, Ping Zhang
    BMC Cardiovascular Disorders.2026;[Epub]     CrossRef
  • Waist Circumference Trajectory and Its Association with Cardiovascular Disease in Patients with Hypertension: A Retrospective Primary-care Cohort Study
    Zhen Liu, Xinfeng Zhang, Hongbin Xu
    Nutrition, Metabolism and Cardiovascular Diseases.2026; : 104605.     CrossRef
  • Epidemiology and characteristics of obesity in Koreans based on the 2024 Obesity Fact Sheet
    Eun-Jung Rhee
    Journal of the Korean Medical Association.2026; 69(1): 4.     CrossRef
  • Positive correlation between n−6 : n−3 PUFA ratio intake with serum oxHDL/HDL-c ratio in patients with coronary artery disease
    Sissi Godinez-Mora, Wendy Campos-Perez, Mariana Perez-Robles, Cesar Robles-Jimarez, Alejandra Muñoz-Hernandez, Joel Torres-Vanegas, Erika Martinez-Lopez
    Coronary Artery Disease.2025; 36(3): 190.     CrossRef
  • General obesity, abdominal obesity, and the risk of cardiovascular disease including stroke in 5-year breast cancer survivors
    Ji Soo Kim, Jihun Song, Seulggie Choi, Sang Min Park
    The Breast.2025; 79: 103857.     CrossRef
  • Morbidity and Mortality Risk Among People With HIV and Central or Visceral Adiposity: A Targeted Literature Review
    Alison M Bjornson, Roger J Bedimo, Shelagh M Szabo, Hannah Rochon, Daniel Lee
    Clinical Infectious Diseases.2025; 80(6): 1306.     CrossRef
  • Associations of waist circumference and BMI with the trajectory of cardiometabolic multimorbidity in hypertensive patients: A multi-state model
    Lisha Xu, Jie Qiu, Peng Shen, Yixing Wang, Yonghao Wu, Jingjing Hu, Zongming Yang, Zhanghang Zhu, Hongbo Lin, Liming Shui, Zhiqin Jiang, Mengling Tang, Mingjuan Jin, Feng Tong, Kun Chen, Jianbing Wang
    Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(5): 103851.     CrossRef
  • Lifestyle risk factors and stroke: findings from the national health and nutrition examination survey (1999–2020) and a Mendelian randomization analysis
    Xiaomin Feng, Zhangping He, Zuoyu Qin, Jing Lu, Chao Qin, Yanyan Tang
    Neurological Research.2025; 47(7): 582.     CrossRef
  • Hypertension mediates the association between weight-adjusted waist index and new onset stroke risk in middle-aged and older Chinese adults: evidence from the CHARLS study
    Fei Xu, Hongwei Liu, Meng Li, Minheng Zhang, Xuan Chen, Miaomiao Hou
    Frontiers in Neurology.2025;[Epub]     CrossRef
  • Exploring the link between A Body Shape Index and abdominal aortic calcification in chronic kidney disease: a cross-sectional analysis from 2013–2014 National Health and Nutrition Examination Survey
    Yang Li, Kun Zou, Yixuan Wang, Yucheng Zhang, Jingtao Zhong, Wu Zhou, Fang Tang, Lu Peng, Xusheng Liu, Lili Deng
    Renal Failure.2025;[Epub]     CrossRef
  • Multimodal machine learning-based marker enables the link between obesity-related indices and future stroke: a prospective cohort study
    Beilei Hu, Xuan Chen, Tingyang Chen, Tong Xu, Yungang Cao, Jing Sun, Xuanyu Chen, Songfang Chen, Keyang Chen
    eClinicalMedicine.2025; 85: 103331.     CrossRef
  • Levelling the field? A cross-sectional study exploring potentially equigenic effects of green space on socioeconomic inequalities in adult body mass index
    Tanya Pritchard, Thomas Astell-Burt, Brenda Lin, Belinda Parmenter, Lennert Veerman, Xiaoqi Feng
    Urban Forestry & Urban Greening.2025; 112: 128984.     CrossRef
  • Association between delayed statin initiation after high LDL-cholesterol detection and cardiovascular risk in general health screening examinees
    Jinsun Lee, Min Woo Kang, Jae-ik Oh, Minsang Kim, Jung Hun Koh, Eunjeong Kang, Jeong Min Cho, Semin Cho, Seong Geun Kim, Soojin Lee, Yaerim Kim, Sehyun Jung, Hyeok Huh, Dong Ki Kim, Kyungdo Han, Sehoon Park
    European Heart Journal - Quality of Care and Clinical Outcomes.2025; 11(8): 1377.     CrossRef
  • Dynamic waist circumference change: A superior predictor of incident stroke compared to novel and traditional obesity indices
    Huizhen Liu, Ting Wang, Xiaoqin Zhou, Deying Kang
    Journal of Stroke and Cerebrovascular Diseases.2025; 34(12): 108496.     CrossRef
  • Cross sectional analysis of the association between extreme climate events and stroke incidence in middle aged and older Chinese adults
    Xia Jiang, Shixuan Chen, Wenci Chen, Pingping Ruan, Jing Ji
    Scientific Reports.2025;[Epub]     CrossRef
  • Association between the cumulative estimated glucose disposal rate and incident stroke in adults aged 50 and above without diabetes: a prospective nationwide cohort study in China
    Ran Yan, Yawen Yin, Yizhen Hu, Juxiang Yang, Jindong Chang, Yi Wang, Gang Song
    Cardiovascular Diabetology.2025;[Epub]     CrossRef
  • Usefulness of New Criteria for Metabolic Syndrome Optimized for Prediction of Cardiovascular Diseases in Japanese
    Yurie Yamazaki, Kazuya Fujihara, Takaaki Sato, Mayuko Harada Yamada, Yuta Yaguchi, Yasuhiro Matsubayashi, Takaho Yamada, Satoru Kodama, Kiminori Kato, Hitoshi Shimano, Hirohito Sone
    Journal of Atherosclerosis and Thrombosis.2024; 31(4): 382.     CrossRef
  • Association between body composition and subsequent cardiovascular diseases among 5-year breast cancer survivors
    Ji Soo Kim, Jihun Song, Seulggie Choi, Sung Min Kim, Young Jun Park, Sun Jae Park, Yoosun Cho, Yun Hwan Oh, Seogsong Jeong, Kyae Hyung Kim, Sang Min Park
    Nutrition, Metabolism and Cardiovascular Diseases.2024;[Epub]     CrossRef
  • Association between physical activity changes and incident myocardial infarction after ischemic stroke: a nationwide population-based study
    Dae Young Cheon, Kyung do Han, Yeon Jung Lee, Jeen Hwa Lee, Myung Soo Park, Do Young Kim, Jae Hyuk Choi, Sook Jin Lee, Kyung-Ho Yu, Seongwoo Han, Sunki Lee, Minwoo Lee
    BMC Public Health.2024;[Epub]     CrossRef
  • Conventional and genetic associations of BMI with major vascular and non-vascular disease incidence and mortality in a relatively lean Chinese population: U-shaped relationship revisited
    Andri Iona, Fiona Bragg, Zammy Fairhurst-Hunter, Iona Y Millwood, Neil Wright, Kuang Lin, Ling Yang, Huaidong Du, Yiping Chen, Pei Pei, Liang Cheng, Dan Schmidt, Daniel Avery, Canqing Yu, Jun Lv, Robert Clarke, Robin Walters, Liming Li, Sarah Parish, Zhen
    International Journal of Epidemiology.2024;[Epub]     CrossRef
  • Association Between Overweight/Obesity Metabolic Phenotypes Defined by Two Criteria of Metabolic Abnormality and Cardiovascular Diseases: A Cross‐Sectional Analysis in a Chinese Population
    Yue Qiu, Shujin Fan, Jing Liu, Xiaodan He, Tianxin Zhu, Li Yan, Meng Ren
    Clinical Cardiology.2024;[Epub]     CrossRef
  • Sex-differential effect of waist circumference on new-onset cerebral infarction: a nationwide cohort study
    Sang Min Lee, Minha Hong, Jae-Hong Ryoo
    Frontiers in Neurology.2024;[Epub]     CrossRef
  • Metabolic Syndrome in Non-diabetic Stroke Patients
    Ahmed Wahab, Jamil Muqtadir, Abdul R Ansari , Muhammad Tahseen, Kashif Ayoob, Syed Haris M Zaidi, Arhama S Muhammad, Aisha Khan, Sehar Ahmed
    Cureus.2024;[Epub]     CrossRef
  • Association between weight-adjusted waist circumference index and myocardial infarction: results from the national health and nutrition examination survey, 1999–2014
    Jian-hong Yu, Ming-gang Yin
    Frontiers in Cardiovascular Medicine.2024;[Epub]     CrossRef
  • 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association
    Cheryl Bushnell, Walter N. Kernan, Anjail Z. Sharrief, Seemant Chaturvedi, John W. Cole, William K. Cornwell, Christine Cosby-Gaither, Sarah Doyle, Larry B. Goldstein, Olive Lennon, Deborah A. Levine, Mary Love, Eliza Miller, Mai Nguyen-Huynh, Jennifer Ra
    Stroke.2024;[Epub]     CrossRef
  • Body mass index, waist circumference and cardiovascular diseases in transitional ages (40 and 66 years)
    Jung Eun Yoo, Kyungdo Han, Jin‐Hyung Jung, Yang‐Im Hur, Yang Hyun Kim, Eun Sook Kim, Jang Won Son, Eun‐Jung Rhee, Won‐Young Lee, Ga Eun Nam
    Journal of Cachexia, Sarcopenia and Muscle.2023; 14(1): 369.     CrossRef
  • Risk factors for stroke among anthropometric indices and lipid profiles in the Korean population: a large-scale cross-sectional study
    Mi Hong Yim, Young Ju Jeon, Bum Ju Lee
    Scientific Reports.2023;[Epub]     CrossRef
  • Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database
    Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee
    Endocrinology and Metabolism.2023; 38(1): 10.     CrossRef
  • Research on obesity using the National Health Information Database: recent trends
    Eun-Jung Rhee
    Cardiovascular Prevention and Pharmacotherapy.2023; 5(2): 35.     CrossRef
  • Association between the weight-adjusted waist index and stroke: a cross-sectional study
    Jiayi Ye, Yanjie Hu, Xinrong Chen, Zhe Yin, Xingzhu Yuan, Liping Huang, Ka Li
    BMC Public Health.2023;[Epub]     CrossRef
  • Increased risk of ischemic stroke associated with elevated gamma-glutamyl transferase level in adult cancer survivors: a population-based cohort study
    Kyuwoong Kim, Hyeyun Jung, Edvige Di Giovanna, Tae Joon Jun, Young-Hak Kim
    Scientific Reports.2023;[Epub]     CrossRef
  • Changes in body composition and subsequent cardiovascular disease risk among 5-year breast cancer survivors
    Ji Soo Kim, Jihun Song, Seulggie Choi, Sang Min Park
    Frontiers in Cardiovascular Medicine.2023;[Epub]     CrossRef
  • Association between Stroke and Abdominal Obesity in the Middle-Aged and Elderly Korean Population: KNHANES Data from 2011–2019
    Jong Yeon Kim, Sung Min Cho, Youngmin Yoo, Taesic Lee, Jong Koo Kim
    International Journal of Environmental Research and Public Health.2022; 19(10): 6140.     CrossRef
  • Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort
    Nathalia Garrido-Torres, Miguel Ruiz-Veguilla, Luis Alameda, Manuel Canal-Rivero, María Juncal Ruiz, Marcos Gómez-Revuelta, Rosa Ayesa-Arriola, Ana Rubio-García, Benedicto Crespo-Facorro, Javier Vázquez-Bourgon
    Schizophrenia Research.2022; 246: 277.     CrossRef
  • Development and validation of risk prediction models for stroke and mortality among patients with type 2 diabetes in northern China
    X. Shao, H. Liu, F. Hou, Y. Bai, Z. Cui, Y. Lin, X. Jiang, P. Bai, Y. Wang, Y. Zhang, C. Lu, H. Liu, S. Zhou, P. Yu
    Journal of Endocrinological Investigation.2022; 46(2): 271.     CrossRef
  • Neck circumference for predicting the occurrence of future cardiovascular events: A 7.6-year longitudinal study
    Tingting Hu, Yun Shen, Weijie Cao, Yiting Xu, Yufei Wang, Xiaojing Ma, Yuqian Bao
    Nutrition, Metabolism and Cardiovascular Diseases.2022; 32(12): 2830.     CrossRef
  • A prospective study of waist circumference trajectories and incident cardiovascular disease in China: the Kailuan Cohort Study
    Liang Wang, Yujin Lee, Yuntao Wu, Xinyuan Zhang, Cheng Jin, Zhe Huang, Yixin Wang, Zhiyi Wang, Penny Kris-Etherton, Shouling Wu, Xiang Gao
    The American Journal of Clinical Nutrition.2021; 113(2): 338.     CrossRef
  • The Repeatedly Elevated Fatty Liver Index Is Associated With Increased Mortality: A Population-Based Cohort Study
    Chang-Hoon Lee, Kyung-Do Han, Da Hye Kim, Min-Sun Kwak
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Obesity Degree and Glycemic Status: Factors That Should Be Considered in Heart Failure
    Hye Soon Kim
    Diabetes & Metabolism Journal.2020; 44(4): 529.     CrossRef
  • Exposure-weighted scoring for metabolic syndrome and the risk of myocardial infarction and stroke: a nationwide population-based study
    Eun Young Lee, Kyungdo Han, Da Hye Kim, Yong-Moon Park, Hyuk-Sang Kwon, Kun-Ho Yoon, Mee Kyoung Kim, Seung-Hwan Lee
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Predicting the Development of Myocardial Infarction in Middle-Aged Adults with Type 2 Diabetes: A Risk Model Generated from a Nationwide Population-Based Cohort Study in Korea
    Seung-Hwan Lee, Kyungdo Han, Hun-Sung Kim, Jae-Hyoung Cho, Kun-Ho Yoon, Mee Kyoung Kim
    Endocrinology and Metabolism.2020; 35(3): 636.     CrossRef
  • Obesity Fact Sheet in Korea, 2018: Data Focusing on Waist Circumference and Obesity-Related Comorbidities
    Ga Eun Nam, Yang-Hyun Kim, Kyungdo Han, Jin-Hyung Jung, Yong Gyu Park, Kwan-Woo Lee, Eun-Jung Rhee, Jang Won Son, Seong-Su Lee, Hyuk-Sang Kwon, Won-Young Lee, Soon Jib Yoo
    Journal of Obesity & Metabolic Syndrome.2019; 28(4): 236.     CrossRef
  • Simply the Best: Anthropometric Indices for Predicting Cardiovascular Disease
    Jie-Eun Lee
    Diabetes & Metabolism Journal.2019; 43(2): 156.     CrossRef
  • Association and Interaction Analysis of Lipid Accumulation Product with Impaired Fasting Glucose Risk: A Cross-Sectional Survey
    Jian Song, Xue Chen, Yuhong Jiang, Jing Mi, Yuyuan Zhang, Yingying Zhao, Xuesen Wu, Huaiquan Gao
    Journal of Diabetes Research.2019; 2019: 1.     CrossRef
  • Letter: Association of Z-Score of the Log-Transformed A Body Shape Index with Cardiovascular Disease in People Who Are Obese but Metabolically Healthy: The Korea National Health and Nutrition Examination Survey 2007-2010 (J Obes Metab Syndr 2018;27:158-65
    Eun-Jung Rhee
    Journal of Obesity & Metabolic Syndrome.2019; 28(2): 139.     CrossRef
  • Response: The Differential Association between Muscle Strength and Diabetes Mellitus According to the Presence or Absence of Obesity (J Obes Metab Syndr 2019;28:46-52)
    Bo Kyung Koo
    Journal of Obesity & Metabolic Syndrome.2019; 28(4): 297.     CrossRef
Clinical Diabetes and Therapeutics
Cardio-Ankle Vascular Index as a Surrogate Marker of Early Atherosclerotic Cardiovascular Disease in Koreans with Type 2 Diabetes Mellitus
So Young Park, Sang Ook Chin, Sang Youl Rhee, Seungjoon Oh, Jeong-Taek Woo, Sung Woon Kim, Suk Chon
Diabetes Metab J. 2018;42(4):285-295.   Published online July 27, 2018
DOI: https://doi.org/10.4093/dmj.2017.0080
  • 8,216 View
  • 65 Download
  • 22 Web of Science
  • 22 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Carotid artery intima medial thickness (IMT), brachial-ankle pulse wave velocity (baPWV), and ankle-brachial index (ABI) are commonly used surrogate markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2DM). The cardio-ankle vascular index (CAVI) is a complement to the baPWV, which is affected by blood pressure. However, it is unclear which marker is the most sensitive predictor of atherosclerotic cardiovascular disease (ASCVD).

Methods

This was a retrospective non-interventional study that enrolled 219 patients with T2DM. The correlations among IMT, ABI, and CAVI as well as the relationship of these tests to the 10-year ASCVD risk were also analyzed.

Results

Among the 219 patients, 39 (17.8%) had ASCVD. In the non-ASCVD group, CAVI correlated significantly with IMT after adjusting for confounding variables, but ABI was not associated with CAVI or IMT. The analyses after dividing the non-ASCVD group into three subgroups according to the CAVI score (<8, ≥8 and <9, and ≥9) demonstrated the significant increase in the mean IMT, 10-year ASCVD risk and number of metabolic syndrome risk factors, and decrease in the mean ABI in the high-CAVI group. A high CAVI was an independent risk factor in the non-ASCVD group for both a high 10-year ASCVD risk (≥7.5%; odds ratio [OR], 2.42; P<0.001) and atherosclerosis (mean IMT ≥1 mm; OR, 1.53; P=0.007).

Conclusion

In Korean patients with T2DM without ASCVD, CAVI was the most sensitive of several surrogate markers for the detection of subclinical atherosclerosis.

Citations

Citations to this article as recorded by  
  • Predictive factors and diagnostic value of vascular markers for carotid artery disease in type 2 diabetes mellitus patients
    Juan Qin, Rongli Sun, Yi Zhang
    Medicine.2025; 104(40): e44333.     CrossRef
  • The effects of severe periodontitis on arterial stiffness using cardio‐ankle vascular index in patients with type 2 diabetes
    Gizem Torumtay Cin, Semin Melahat Fenkci, Ismail Doğu Kiliç, Halil Serdar Aslan, Cihan İlyas Sevgican, Hande Şenol
    Journal of Periodontal Research.2024; 59(1): 74.     CrossRef
  • Predictive value of Systematic Coronary Risk Evaluation 2‐Diabetes risk model and arterial stiffness for cardiovascular events in the Asian population with type 2 diabetes mellitus
    Pannipa Suwannasom, Tasalak Thonghong, Krit Leemasawat, Teerapat Nantsupawat, Narawudt Prasertwitayakij, Chutamas Pairoj, Wanwarang Wongcharoen, Arintaya Phrommintikul
    Journal of Diabetes Investigation.2024; 15(9): 1266.     CrossRef
  • Prediction of cardiovascular disease using deep learning algorithms to prevent COVID 19
    Malathi S, Arockia Raj Y, Abhishek Kumar, V D Ashok Kumar, Ankit Kumar, Elangovan D, V D Ambeth Kumar, Chitra B, a Abirami
    Journal of Experimental & Theoretical Artificial Intelligence.2023; 35(6): 791.     CrossRef
  • Association of cardio-ankle vascular index and future major adverse cardiovascular events in older adults living with HIV
    Amaraporn Rerkasem, Arunrat Tangmunkongvorakul, Linda Aurpibul, Patumrat Sripan, Wason Parklak, Sothida Nantakool, Kriengkrai Srithanaviboonchai, Kittipan Rerkasem
    AIDS Care.2023; 35(4): 591.     CrossRef
  • Impact of Fasting Blood Glucose Levels on Blood Pressure Parameters among Older Adults with Prediabetes
    Thapanee Roengrit, Ruchada Sri-Amad, Nawiya Huipao, Suphawadee Phababpha, Piyapong Prasertsri, Francesco Giallauria
    The Scientific World Journal.2023; 2023: 1.     CrossRef
  • A framework of biomarkers for vascular aging: a consensus statement by the Aging Biomarker Consortium
    Le Zhang, Jun Guo, Yuehong Liu, Shimin Sun, Baohua Liu, Qi Yang, Jun Tao, Xiao-Li Tian, Jun Pu, Huashan Hong, Miao Wang, Hou-Zao Chen, Jie Ren, Xiaoming Wang, Zhen Liang, Yuan Wang, Kai Huang, Weiqi Zhang, Jing Qu, Zhenyu Ju, Guang-Hui Liu, Gang Pei, Jian
    Life Medicine.2023;[Epub]     CrossRef
  • Diastolic Pressure and ACR Are Modifiable Risk Factors of Arterial Stiffness in T2DM Without Cardiovascular Disease
    Gateano Leto, Lida Tartaglione, Silverio Rotondi, Marzia Pasquali, Ernesto Maddaloni, Carmen Mignogna, Luca D’Onofrio, Simona Zampetti, Angela Carlone, Maria Luisa Muci, Daniela Mastroluca, Valeria Fassino, Raffaella Buzzetti, Sandro Mazzaferro
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(9): e3857.     CrossRef
  • Risk assessment indicators and brachial-ankle pulse wave velocity to predict atherosclerotic cardiovascular disease
    Hung-Ju Ko, Chuan-Chuan Liu, Po-Jui Hsu, Kuang-Chun Hu, Chung-Lieh Hung, Lo-Yip Yu, Yun-Chieh Huang, Shou-Chuan Shih
    Medicine.2022; 101(32): e29609.     CrossRef
  • Prediction of Cardiovascular Disease Using Machine Learning Technique—A Modern Approach
    Jung-Hwa Kim, Jin-Woo Jeong
    Computers, Materials & Continua.2022; 71(1): 855.     CrossRef
  • Cardio-ankle vascular index represents the best surrogate for 10-year ASCVD risk estimation in patients with primary hypertension
    Mustafa Tarik Agac, Süret Ağaç, Muhammed Necati Murat Aksoy, Mehmet Bülent Vatan
    Clinical and Experimental Hypertension.2021; 43(4): 349.     CrossRef
  • Relation between fragmented QRS complex and cardio-ankle vascular index in asymptomatic subjects
    Ali Rıza Akyüz, Sinan Şahin, Ömer Faruk Çırakoğlu, Selim Kul, Turhan Turan, Hakan Erkan
    Clinical and Experimental Hypertension.2021; 43(4): 368.     CrossRef
  • Progress of clinical evaluation for vascular aging in humans
    Yumin Qiu, Yuanya Liu, Jun Tao
    Journal of Translational Internal Medicine.2021; 9(1): 17.     CrossRef
  • Effects of long-term air pollution exposure on ankle-brachial index and cardio-ankle vascular index: A longitudinal cohort study using data from the Electricity Generating Authority of Thailand study
    Kanawat Paoin, Kayo Ueda, Prin Vathesatogkit, Thammasin Ingviya, Suhaimee Buya, Arthit Phosri, Xerxes Tesoro Seposo, Nisakron Thongmung, Teerapat Yingchoncharoen, Akiko Honda, Hirohisa Takano, Piyamitr Sritara
    International Journal of Hygiene and Environmental Health.2021; 236: 113790.     CrossRef
  • The Relationship Between Glycemic Control and Concomitant Hypertension on Arterial Stiffness in Type II Diabetes


    Teonchit Nuamchit, Duangduan Siriwittayawan, Piyanuch Thitiwuthikiat
    Vascular Health and Risk Management.2020; Volume 16: 343.     CrossRef
  • Relationship between cardio-ankle vascular index and obstructive coronary artery disease
    Divya Birudaraju, Lavanya Cherukuri, April Kinninger, Bhanu T. Chaganti, Pishoy Haroun, Sivakrishna Pidikiti, Suvasini Lakshmanan, Sajad Hamal, Ferdinand Flores, Christopher Dailing, Kashif Shaikh, Sion K. Roy, Matthew J. Budoff
    Coronary Artery Disease.2020; 31(6): 550.     CrossRef
  • Association of Kidney Function Tests with a Cardio-Ankle Vascular Index in Community-Dwelling Individuals with a Normal or Mildly Decreased Estimated Glomerular Filtration Rate
    Javad Alizargar, Chyi-Huey Bai, Nan-Chen Hsieh, Shu-Fang Vivienne Wu, Shih-Yen Weng, Jia-Ping Wu
    Medicina.2019; 55(10): 657.     CrossRef
  • Cardiovascular remodeling in patients with diabetic сardiomyopathy
    A. S. Veklich, N. A. Koziolova, P. G. Karavaev
    Russian Journal of Cardiology.2019; (11): 42.     CrossRef
  • Short‑term impact of aged garlic extract on endothelial function in diabetes: A randomized, double‑blind, placebo‑controlled trial
    Sajad Hamal, Lavanya Cherukuri, Divya Birudaraju, Suguru Matsumoto, April Kinninger, Bhanu Chaganti, Ferdinand Flores, Kashif Shaikh, Sion Roy, Matthew Budoff
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • Association between Breakfast Frequency and Atherosclerotic Cardiovascular Disease Risk: A Cross-Sectional Study of KNHANES Data, 2014–2016
    Hyeon Ji Lee, Jieun Jang, Sang Ah Lee, Dong-Woo Choi, Eun-Cheol Park
    International Journal of Environmental Research and Public Health.2019; 16(10): 1853.     CrossRef
  • Response: Cardio-Ankle Vascular Index as a Surrogate Marker of Early Atherosclerotic Cardiovascular Disease in Koreans with Type 2 Diabetes Mellitus (Diabetes Metab J 2018;42:285-95)
    So Young Park, Suk Chon
    Diabetes & Metabolism Journal.2018; 42(5): 449.     CrossRef
  • Letter: Cardio-Ankle Vascular Index as a Surrogate Marker of Early Atherosclerotic Cardiovascular Disease in Koreans with Type 2 Diabetes Mellitus (Diabetes Metab J 2018;42:285-95)
    Dongwon Yi
    Diabetes & Metabolism Journal.2018; 42(5): 447.     CrossRef
Complications
Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome
Kwi-Hyun Bae, Sung Woo Kim, Yeon-Kyung Choi, Jung Beom Seo, Namkyun Kim, Chang-Yeon Kim, Won Kee Lee, Sungwoo Lee, Jung Guk Kim, In-Kyu Lee, Jang Hoon Lee, Keun-Gyu Park
Diabetes Metab J. 2018;42(3):207-214.   Published online May 2, 2018
DOI: https://doi.org/10.4093/dmj.2017.0081
  • 8,479 View
  • 83 Download
  • 30 Web of Science
  • 30 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that promotes degradation of the low density lipoprotein receptor. PCSK9 has emerged as a target for lipid-lowering therapy, but the predictive value of the serum level of PCSK9 for the severity of coronary disease is largely unknown.

Methods

From December 2009 to July 2012, 121 individuals who underwent coronary angiography (CAG) because of clinically suspected acute coronary syndrome were enrolled in this study. Serum levels of PCSK9 and metabolic parameters were measured. SYNTAX (SYNergy between percutaneous coronary intervention with [paclitaxel-eluting] TAXUS stent and cardiac surgery) and GRACE (Global Registry of Acute Coronary Events) scores were calculated.

Results

Individuals with CAG lesions (n=100) had significantly higher levels of PCSK9 than those without lesions (n=21). The study population was stratified into three groups according to serum levels of PCSK9. The odds radio for occurrence of one or more CAG lesions was significantly higher in the group with the highest level of PCSK9 (odds ratio, 7.468; P=0.011) than in the group with the lowest level of PCSK9. Serum PCSK9 was positively associated with the number of involved coronary arteries. Multivariable linear regression indicated that levels of PCSK9 were positively correlated with GRACE risk scores and SYNTAX scores.

Conclusion

Serum PCSK9 concentrations are higher in patients with coronary artery lesions, and are associated with SYNTAX and GRACE scores, suggesting that PCSK9 is a potential biomarker of the severity of coronary artery disease.

Citations

Citations to this article as recorded by  
  • A study of extended lipid profile in patients with acute coronary syndrome: Focus on Lipoprotein(a) and PCSK9
    Pradeep Kumar, Sudesh Prajapathi, Abhishek Singh, Akshyaya Pradhan, Ayush Shukla, Monika Bhandari, Akhil Sharma, Pravesh Vishwakarma, Gaurav Chaudhary, Sharad Chandra, Rishi Sethi, Sudhanshu Dwivedi, Raman Puri
    International Journal of Cardiology Cardiovascular Risk and Prevention.2026; 28: 200558.     CrossRef
  • PCSK9 in metabolism and diseases
    Amir Ajoolabady, Domenico Pratico, Mohsen Mazidi, Ian G. Davies, Gregory Y.H. Lip, Nabil Seidah, Peter Libby, Guido Kroemer, Jun Ren
    Metabolism.2025; 163: 156064.     CrossRef
  • The correlation between serum MHR and NLR and the severity of coronary lesions in NSTE-ACS patients of different genders
    Yanping Yang, Xiaobing Lv, Kai Tan, Kai Li, Shaohua Li, Xia Meng, Yunyun Chen, Fuqing Wang, Hui Xin
    Frontiers in Cardiovascular Medicine.2025;[Epub]     CrossRef
  • Clinical Significance of PCSK9 and Soluble P-selectin in Predicting Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome
    Yao Yao, Qining Qiu, Xiaoye Li, Zi Wang, Shikun Xu, Qianzhou Lv
    Cardiovascular Innovations and Applications.2024;[Epub]     CrossRef
  • The role of PCSK9 in heart failure and other cardiovascular diseases—mechanisms of action beyond its effect on LDL cholesterol
    Mieczysław Dutka, Karolina Zimmer, Michał Ćwiertnia, Tomasz Ilczak, Rafał Bobiński
    Heart Failure Reviews.2024; 29(5): 917.     CrossRef
  • Serum mature and furin-cleaved proprotein convertase subtilisin/kexin type 9 levels and their association with cardiovascular events in statin-treated patients with cardiovascular disease
    Kiyoshi Hibi, Masaomi Gohbara, Kohei Uemura, Noriaki Iwahashi, Kozo Okada, Hiroshi Iwata, Yoshihiro Fukumoto, Takafumi Hiro, Yukio Ozaki, Satoshi Iimuro, Ichiro Sakuma, Seiji Hokimoto, Katsumi Miyauchi, Yutaka Matsuyama, Yoshihisa Nakagawa, Hisao Ogawa, H
    Journal of Clinical Lipidology.2024; 18(5): e844.     CrossRef
  • Lipoprotein transport and metabolism markers in patients with myocardial infarction in the Biobank of Yugra blood sample collection
    A. S. Vorobyov, M. Yu. Donnikov, O. S. Glotov, L. V. Kovalenko, K. Yu. Nikolaev, I. A. Urvantseva, Yu. A. Drenina, A. V. Morozkina, G. N. Chernysheva
    Cardiovascular Therapy and Prevention.2024; 23(11): 4178.     CrossRef
  • Stratification in Heterozygous Familial Hypercholesterolemia: Imaging, Biomarkers, and Genetic Testing
    Pablo Corral, Carlos A. Aguilar Salinas, María Gabriela Matta, Valeria Zago, Laura Schreier
    Current Atherosclerosis Reports.2023; 25(12): 899.     CrossRef
  • Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9 in Patients with Acute Coronary Syndrome: An Observational Study
    Arshi Sanober, M Noorjahan, J Ashwini Kumari, Oruganti Sai Satish, N N Sreedevi, M Vijaya Bhaskar, Sai Baba S S Kompella, Siraj Ahmed Khan
    Journal of Clinical and Preventive Cardiology.2023; 12(1): 3.     CrossRef
  • Relationship of sortilin and proprotein convertase subtilisin/kexin type 9 in blood serum with the severity of carotid and coronary atherosclerosis in hypertensive patients
    Yu. Yu. Vukolova, I. V. Gubareva
    Russian Journal of Cardiology.2022; 27(2S): 4903.     CrossRef
  • PCSK9 Inhibition could be Effective for Acute Myocardial Infarction
    Baris Gencer, François Mach
    Current Medicinal Chemistry.2022; 29(6): 1016.     CrossRef
  • Peri-event plasma PCSK9 and hsCRP after an acute myocardial infarction correlate with early deterioration of left ventricular ejection fraction: a cohort study
    Lina S. Silva-Bermúdez, Andrea Vargas-Villanueva, Carlos A. Sánchez-Vallejo, Ana C. Palacio, Andrés F. Buitrago, Carlos O. Mendivil
    Lipids in Health and Disease.2022;[Epub]     CrossRef
  • Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Inversely Associated with N-Terminal Pro B-Type Natriuretic Peptide in Older Men and Women
    Francesco Spannella, Federico Giulietti, Roberta Galeazzi, Anna Passarelli, Serena Re, Chiara Di Pentima, Massimiliano Allevi, Paolo Magni, Riccardo Sarzani
    Biomedicines.2022; 10(8): 1961.     CrossRef
  • Sex difference in circulating PCSK9 and its clinical implications
    Fang Jia, Si-Fan Fei, De-Bing Tong, Cong Xue, Jian-Jun Li
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall
    Yanan Guo, Binjie Yan, Yu Gui, Zhihan Tang, Shi Tai, Shenghua Zhou, Xi‐Long Zheng
    Journal of Cellular Physiology.2021; 236(4): 2333.     CrossRef
  • PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction
    Marianne Zeller, Gilles Lambert, Michel Farnier, Maud Maza, Brice Nativel, Luc Rochette, Catherine Vergely, Yves Cottin
    Nutrition, Metabolism and Cardiovascular Diseases.2021; 31(3): 880.     CrossRef
  • Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction
    Jing Gao, Ya-Nan Yang, Zhuang Cui, Si-Yuan Feng, Jing Ma, Chang-Ping Li, Yin Liu
    Lipids in Health and Disease.2021;[Epub]     CrossRef
  • Circulating Biomarkers for Cardiovascular Disease Risk Prediction in Patients With Cardiovascular Disease
    Yuen-Kwun Wong, Hung-Fat Tse
    Frontiers in Cardiovascular Medicine.2021;[Epub]     CrossRef
  • Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations and Cardiovascular Events in Cardiovascular Disease: A Systemic Review and Meta-Analysis
    Jiahui Liu, Fangfang Fan, Xingyu Luo, Wenjun Ji, Yaokun Liu, Yan Zhang, Bo Zheng
    Frontiers in Cardiovascular Medicine.2021;[Epub]     CrossRef
  • PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics
    Yu. A. Drenina, K. Yu. Nikolaev
    Cardiovascular Therapy and Prevention.2020; 19(4): 2484.     CrossRef
  • Relation of Proprotein Convertase Subtilisin/Kexin Type 9 to Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention
    Ik Jun Choi, Sungmin Lim, Dongjae Lee, Won Jik Lee, Kwan Yong Lee, Mi-Jeong Kim, Doo Soo Jeon
    The American Journal of Cardiology.2020; 133: 54.     CrossRef
  • A Narrative Review and Expert Panel Recommendations on Dyslipidaemia Management After Acute Coronary Syndrome in Countries Outside Western Europe and North America
    Ashraf Reda, Wael Almahmeed, Idit Dobrecky-Mery, Po-Hsun Huang, Ursulo Juarez-Herrera, Naresh Ranjith, Tobias Sayre, Miguel Urina-Triana
    Advances in Therapy.2020; 37(5): 1754.     CrossRef
  • PCSK9 concentrations in different stages of subclinical atherosclerosis and their relationship with inflammation
    Štefan Tóth, Peter Olexa, Zdenka Hertelyová, Peter Štefanič, Ivan Kopolovets, Peter Berek, Vladimir Filip, Ryan Chakravarty, Monika Široká, Daniel Pella
    Open Chemistry.2020; 18(1): 1011.     CrossRef
  • Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus
    Wen Guo, Yingyun Gong, Jie Li, Pei Qin, Jing Lu, Xiaona Li, Wenfang Zhu, Nianzhen Xu, Hongwen Zhou, Qun Zhang
    Nutrition, Metabolism and Cardiovascular Diseases.2019; 29(8): 815.     CrossRef
  • PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography
    Yunes Panahi, Mohsen Sadeghi Ghahrodi, Mohsen Jamshir, Mohammad Amin Safarpour, Vanessa Bianconi, Matteo Pirro, Maryam Moshkani Farahani, Amirhossein Sahebkar
    Clinical Biochemistry.2019; 74: 12.     CrossRef
  • Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina
    Chiara Caselli, Serena Del Turco, Rosetta Ragusa, Valentina Lorenzoni, Michiel De Graaf, Giuseppina Basta, Arthur Scholte, Raffaele De Caterina, Danilo Neglia
    Cardiovascular Diabetology.2019;[Epub]     CrossRef
  • PCSK9 inhibition and inflammation: A narrative review
    Massimiliano Ruscica, Lale Tokgözoğlu, Alberto Corsini, Cesare R. Sirtori
    Atherosclerosis.2019; 288: 146.     CrossRef
  • Letter: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14)
    Jin Hwa Kim
    Diabetes & Metabolism Journal.2018; 42(4): 348.     CrossRef
  • Response: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14)
    Sung Woo Kim, Keun-Gyu Park
    Diabetes & Metabolism Journal.2018; 42(4): 350.     CrossRef
  • Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
    Gaojun Cai, Lei Yu, Zhiying Huang, Li Li, Xingli Fu
    Lipids in Health and Disease.2018;[Epub]     CrossRef
Epidemiology
Ten-Year Mortality Trends for Adults with and without Diabetes Mellitus in South Korea, 2003 to 2013
Kyeong Jin Kim, Tae Yeon Kwon, Sungwook Yu, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Sin Gon Kim, Yousung Park, Nam Hoon Kim
Diabetes Metab J. 2018;42(5):394-401.   Published online April 26, 2018
DOI: https://doi.org/10.4093/dmj.2017.0088
  • 8,519 View
  • 70 Download
  • 27 Web of Science
  • 30 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

To estimate and compare the trends of all-cause and cause-specific mortality rates for subjects with and without diabetes in South Korea, from 2003 to 2013.

Methods

Using a population-based cohort (2003 to 2013), we evaluated annual mortality rates in adults (≥30 years) with and without diabetes. The number of subjects in this analysis ranged from 585,795 in 2003 to 670,020 in 2013.

Results

Age- and sex-adjusted all-cause mortality rates decreased consistently in both groups from 2003 to 2013 (from 14.4 to 9.3/1,000 persons in subjects with diabetes and from 7.9 to 4.4/1,000 persons in those without diabetes). The difference in mortality rates between groups also decreased (6.61 per 1,000 persons in 2003 to 4.98 per 1,000 persons in 2013). The slope associated with the mortality rate exhibited a steeper decrease in subjects with diabetes than those without diabetes (regression coefficients of time: −0.50 and −0.33, respectively; P=0.004). In subjects with diabetes, the mortality rate from cardiovascular disease decreased by 53.5% (from 2.73 to 1.27 per 1,000 persons, P for trend <0.001). Notably, the decrease in mortality from ischemic stroke (79.2%, from 1.20 to 0.25 per 1,000 persowns) was more profound than that from ischemic heart disease (28.3%, from 0.60 to 0.43 per 1,000 persons).

Conclusion

All-cause and cardiovascular mortality rates decreased substantially from 2003 to 2013, and the decline in ischemic stroke mortality mainly contributed to the decreased cardiovascular mortality in Korean people with diabetes.

Citations

Citations to this article as recorded by  
  • Green tea consumption and incidence of cardiovascular disease in type 2 diabetic patients with overweight/obesity: a community-based cohort study
    Bingyue Liu, Shujun Gu, Jin Zhang, Hui Zhou, Jian Su, Sudan Wang, Qian Sun, Zhengyuan Zhou, Jinyi Zhou, Chen Dong
    Archives of Public Health.2024;[Epub]     CrossRef
  • Trends in all-cause and cause-specific mortality in older adults with and without diabetes: A territory-wide analysis in one million older adults in Hong Kong
    Aimin Yang, Tingting Chen, Mai Shi, Eric Lau, Raymond SM Wong, Jones Chan, Juliana CN Chan, Elaine Chow
    Diabetes Research and Clinical Practice.2024; 210: 111618.     CrossRef
  • Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
    Journal of Lipid and Atherosclerosis.2023; 12(1): 12.     CrossRef
  • Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
    Diabetes & Metabolism Journal.2023; 47(1): 1.     CrossRef
  • Letter: Triglyceride-Glucose Index Predicts Cardiovascular Outcome in Metabolically Unhealthy Obese Population: A Nationwide Population-Based Cohort Study (J Obes Metab Syndr 2022;31:178-86)
    Gwanpyo Koh
    Journal of Obesity & Metabolic Syndrome.2023; 32(2): 179.     CrossRef
  • Management of Dyslipidemia in Patients with Diabetes Mellitus
    Kyung Ae Lee
    The Journal of Korean Diabetes.2023; 24(3): 111.     CrossRef
  • 2023 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Factors
    Ye Seul Yang
    The Journal of Korean Diabetes.2023; 24(3): 135.     CrossRef
  • The Characteristics and Risk of Mortality in the Elderly Korean Population
    Sunghwan Suh
    Endocrinology and Metabolism.2023; 38(5): 522.     CrossRef
  • Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines
    Soo Jin Yun, In-Kyung Jeong, Jin-Hye Cha, Juneyoung Lee, Ho Chan Cho, Sung Hee Choi, SungWan Chun, Hyun Jeong Jeon, Ho-Cheol Kang, Sang Soo Kim, Seung-Hyun Ko, Gwanpyo Koh, Su Kyoung Kwon, Jae Hyuk Lee, Min Kyong Moon, Junghyun Noh, Cheol-Young Park, Sung
    Diabetes & Metabolism Journal.2022; 46(3): 464.     CrossRef
  • Health-related Quality of Life Instrument With 8 Items for Use in Patients With Type 2 Diabetes Mellitus: A Validation Study in Korea
    Juyoung Kim, Hyeon-Jeong Lee, Min-Woo Jo
    Journal of Preventive Medicine and Public Health.2022; 55(3): 234.     CrossRef
  • Improvement in Age at Mortality and Changes in Causes of Death in the Population with Diabetes: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
    Eugene Han, Sun Ok Song, Hye Soon Kim, Kang Ju Son, Sun Ha Jee, Bong-Soo Cha, Byung-Wan Lee
    Endocrinology and Metabolism.2022; 37(3): 466.     CrossRef
  • Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
    Nam Hoon Kim, Nan Hee Kim
    Diabetes & Metabolism Journal.2022; 46(4): 543.     CrossRef
  • Diabetic Ketoacidosis and COVID-19: A Retrospective Observational Study
    Govind Nagdev, Gajanan Chavan, Charuta Gadkari, Gaurav Sahu
    Cureus.2022;[Epub]     CrossRef
  • Trends in the effects of pre‐transplant diabetes on mortality and cardiovascular events after kidney transplantation
    Ja Young Jeon, Soo Jung Kim, Kyoung Hwa Ha, Ji Hyun Park, Bumhee Park, Chang‐Kwon Oh, Seung Jin Han
    Journal of Diabetes Investigation.2021; 12(5): 811.     CrossRef
  • Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports
    Na-young Kim, Eunyeong Ha, Jun Sung Moon, Yong-Hoon Lee, Eun Young Choi
    Diabetes & Metabolism Journal.2020; 44(2): 349.     CrossRef
  • Polysomnographic phenotyping of obstructive sleep apnea and its implications in mortality in Korea
    Jeong-Whun Kim, Tae-Bin Won, Chae-Seo Rhee, Young Mi Park, In-Young Yoon, Sung-Woo Cho
    Scientific Reports.2020;[Epub]     CrossRef
  • Peripheral arterial endothelial dysfunction predicts future cardiovascular events in diabetic patients with albuminuria: a prospective cohort study
    Bo Kyung Koo, Woo-Young Chung, Min Kyong Moon
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Metformin treatment for patients with diabetes and chronic kidney disease: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
    Kyu Yeon Hur, Mee Kyoung Kim, Seung Hyun Ko, Miyeun Han, Dong Won Lee, Hyuk-Sang Kwon
    Kidney Research and Clinical Practice.2020; 39(1): 32.     CrossRef
  • Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study
    Sangmo Hong, Kyungdo Han, Cheol-Young Park
    Mayo Clinic Proceedings.2020; 95(1): 101.     CrossRef
  • Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
    Kyu Yeon Hur, Mee Kyoung Kim, Seung Hyun Ko, Miyeun Han, Dong Won Lee, Hyuk-Sang Kwon
    Diabetes & Metabolism Journal.2020; 44(1): 3.     CrossRef
  • A systematic review of trends in all-cause mortality among people with diabetes
    Lei Chen, Rakibul M. Islam, Joanna Wang, Thomas R. Hird, Meda E. Pavkov, Edward W. Gregg, Agus Salim, Maryam Tabesh, Digsu N. Koye, Jessica L. Harding, Julian W. Sacre, Elizabeth L. M. Barr, Dianna J. Magliano, Jonathan E. Shaw
    Diabetologia.2020; 63(9): 1718.     CrossRef
  • Diabetic ketoacidosis precipitated by COVID-19: A report of two cases and review of literature
    Pavan Kumar Reddy, Mohammad Shafi Kuchay, Yatin Mehta, Sunil Kumar Mishra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(5): 1459.     CrossRef
  • Prognostic value of long-term gamma-glutamyl transferase variability in individuals with diabetes: a nationwide population-based study
    Da Young Lee, Kyungdo Han, Ji Hee Yu, Sanghyun Park, Ji A Seo, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Seon Mee Kim, Kyung Mook Choi, Sei Hyun Baik, Yong Gyu Park, Nan Hee Kim
    Scientific Reports.2020;[Epub]     CrossRef
  • Arterial stiffness is an independent predictor for risk of mortality in patients with type 2 diabetes mellitus: the REBOUND study
    Jeong Mi Kim, Sang Soo Kim, In Joo Kim, Jong Ho Kim, Bo Hyun Kim, Mi Kyung Kim, Soon Hee Lee, Chang Won Lee, Min Chul Kim, Jun Hyeob Ahn, Jinmi Kim
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease: a population-based study
    Sangmo Hong, Kyungdo Han, Cheol-Young Park
    BMC Medicine.2020;[Epub]     CrossRef
  • Increased Age of Death and Change in Causes of Death Among Persons With Diabetes Mellitus From the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
    Eugene Han, Sun Ok Song, Hye Soon Kim, Kang Ju Son, Sun Ha Jee, Bong-Soo Cha, Byung-Wan Lee
    SSRN Electronic Journal .2020;[Epub]     CrossRef
  • Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2019;43:582–9)
    Tae Seo Sohn
    Diabetes & Metabolism Journal.2019; 43(6): 909.     CrossRef
  • Diabetes Mellitus, Still Major Threat to Mortality from Various Causes
    Nam Hoon Kim
    Diabetes & Metabolism Journal.2019; 43(3): 273.     CrossRef
  • Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
    Sunghwan Suh, Kwang-Won Kim
    Diabetes & Metabolism Journal.2019; 43(6): 733.     CrossRef
  • Trends of Diabetes Epidemic in Korea
    Ji Cheol Bae
    Diabetes & Metabolism Journal.2018; 42(5): 377.     CrossRef
Reviews
Clinical Diabetes & Therapeutics
Article image
Past and Current Status of Adult Type 2 Diabetes Mellitus Management in Korea: A National Health Insurance Service Database Analysis
Seung-Hyun Ko, Kyungdo Han, Yong-ho Lee, Junghyun Noh, Cheol-Young Park, Dae-Jung Kim, Chang Hee Jung, Ki-Up Lee, Kyung-Soo Ko
Diabetes Metab J. 2018;42(2):93-100.   Published online April 19, 2018
DOI: https://doi.org/10.4093/dmj.2018.42.2.93
  • 12,931 View
  • 190 Download
  • 98 Web of Science
  • 100 Crossref
AbstractAbstract PDFPubReader   ePub   

Korea's National Healthcare Program, the National Health Insurance Service (NHIS), a government-affiliated agency under the Korean Ministry of Health and Welfare, covers the entire Korean population. The NHIS supervises all medical services in Korea and establishes a systematic National Health Information database (DB). A health information DB system including all of the claims, medications, death information, and health check-ups, both in the general population and in patients with various diseases, is not common worldwide. On June 9, 2014, the NHIS signed a memorandum of understanding with the Korean Diabetes Association (KDA) to provide limited open access to its DB. By October 31, 2017, seven papers had been published through this collaborative research project. These studies were conducted to investigate the past and current status of type 2 diabetes mellitus and its complications and management in Korea. This review is a brief summary of the collaborative projects between the KDA and the NHIS over the last 3 years. According to the analysis, the national health check-up DB or claim DB were used, and the age category or study period were differentially applied.

Citations

Citations to this article as recorded by  
  • Pancreatic Cystic Neoplasm Risk Among Individuals With Diabetes
    In Rae Cho, Sung Hoon Chang, Sang Hyub Lee, Kyung-Do Han, Kwang Hyun Chung, Min Woo Lee, Jin Ho Choi, Woo Hyun Paik, Ji Kon Ryu
    JAMA Network Open.2026; 9(2): e2556951.     CrossRef
  • The effect of sarpogrelate compared to aspirin in high- or very-high-risk diabetes for primary prevention
    Soo Hyun Kang, Kilyoon Pack, Jung Ho Kim, Youngwoo Jang
    Scientific Reports.2025;[Epub]     CrossRef
  • The influence of uterine leiomyomatosis on the onset of psoriasis: a nationwide population-based study of 2.5 million Korean females
    Yeong Ho Kim, Hyun Jee Kim, Jee Yun Doh, Kyung Do Han, Ji Hyun Lee
    BMC Women's Health.2025;[Epub]     CrossRef
  • Longitudinal Income Dynamics and Risk of End-Stage Kidney Disease in Type 2 Diabetes: A South Korean Population–Based Cohort Study
    Min Woo Kang, Jae-ik Oh, Jinsun Lee, Minsang Kim, Jung Hun Koh, Jeong Min Cho, Seong Geun Kim, Semin Cho, Soojin Lee, Yaerim Kim, Dong Ki Kim, Kyungdo Han, Sehoon Park
    American Journal of Kidney Diseases.2025; 86(2): 166.     CrossRef
  • Diabetes status, duration and risk of dementia in patients with myocardial infarction
    Dae Young Cheon, Kyungdo Han, Ye Seul Yang, Minwoo Lee, Mi Sun Oh
    Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
  • Sex-Specific Associations of Glycemic Status and Smoking with Bladder Cancer Risk: A Nationwide Cohort Study
    Joo-Hyun Park, Jung Yong Hong, Kyungdo Han, Jay J. Shen
    Cancers.2025; 17(13): 2262.     CrossRef
  • Pregravid Weight Gain Is Associated with an Increased Risk of Gestational Diabetes
    Sunmie Kim, Kyungdo Han, Su-Yeon Choi, Min Joo Kim, Sun Young Yang, Seung Ho Choi, Jeong Yoon Yim, Jin Ju Kim, Min-Jeong Kim
    Diabetes & Metabolism Journal.2025; 49(4): 826.     CrossRef
  • Exercise intensity and the risk of end-stage renal disease in diabetes: A nationwide population-based study
    Eun Hui Bae, Sang Yup Lim, Bong-Seong Kim, Kyung-Do Han, Sang Heon Suh, Hong Sang Choi, Chang Seong Kim, Seong Kwon Ma, Soo Wan Kim
    World Journal of Diabetes.2025;[Epub]     CrossRef
  • Impact of Health Insurance Status on HbA1c Control Among United States Adults With Type 2 Diabetes: A Cross-Sectional Analysis of Nationally Representative Data
    Basit O Bolarinwa, Chiamaka J Ohiri, Rasheedat A Sadiq-Onilenla, Sunday P Iziogo, Okelue E Okobi
    Cureus.2025;[Epub]     CrossRef
  • Impact of Prepregnancy Maternal Fasting Glucose Levels on Pregnancy and Neonatal Morbidity in Women With Pregestational Diabetes Mellitus
    Young Mi Jung, Joon Ho Moon, Won Young Wi, Kyu-Dong Cho, Su Jung Hong, Han Sung Hwang, Se Jin Lee, Seung Mi Lee, Soo-Jeong Lee, Min-Jeong Oh, Hyun Sun Ko, Geum Joon Cho
    Journal of Korean Medical Science.2025;[Epub]     CrossRef
  • Fetal malformations in women with pregestational diabetes mellitus based on pre-pregnancy fasting plasma glucose levels
    Subeen Hong, Kyung A. Lee, Young Mi Jung, Heechul Jeong, Ji-Hee Sung, Hyun-Joo Seol, Won Joon Seong, Soo Ran Choi, Joon Ho Lee, Seung Chul Kim, Sae-Kyoung Choi, Ji Young Kwon, Hyun Soo Park, Hyun Sun Ko, Geum Joon Cho
    Scientific Reports.2025;[Epub]     CrossRef
  • Various Antihypertensive Drug Compliance Models and Cardiovascular Prognosis of People With Incidentally Detected High Blood Pressure During Health Check‐Up in Korea
    Jong-Kwan Park, Sungyoun Chun, Joongmin Kim, Hancheol Lee, Ji-Yong Jang, Kyeong-Hyeon Chun, Hyeongsoo Kim, Seung-Jin Oh, Geunhee Park, Se-Jung Yoon, Peng Geng
    International Journal of Hypertension.2025;[Epub]     CrossRef
  • Associations Between Physical Activity and the Risk of Hip Fracture Depending on Glycemic Status: A Nationwide Cohort Study
    Kyoung Min Kim, Kyoung Jin Kim, Kyungdo Han, Yumie Rhee
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1194.     CrossRef
  • Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study
    Eun-Gyoung Hong, Kyung-Wan Min, Jung Soo Lim, Kyu-Jeung Ahn, Chul Woo Ahn, Jae-Myung Yu, Hye Soon Kim, Hyun Jin Kim, Won Kim, Dong Han Kim, Hak Chul Jang
    Advances in Therapy.2024; 41(5): 1967.     CrossRef
  • Gamma‐glutamyl transferase and the risk of all‐cause and disease‐specific mortality in patients with diabetes: A nationwide cohort study
    Goh Eun Chung, Su‐Min Jeong, Su Jong Yu, Jeong‐Ju Yoo, Yuri Cho, Kyu‐na Lee, Dong Wook Shin, Yoon Jun Kim, Jung‐Hwan Yoon, Kyungdo Han, Eun Ju Cho
    Journal of Diabetes.2024;[Epub]     CrossRef
  • 2023 Diabetic Kidney Disease Fact Sheet in Korea
    Nam Hoon Kim, Mi-Hae Seo, Jin Hyung Jung, Kyung Do Han, Mi Kyung Kim, Nan Hee Kim
    Diabetes & Metabolism Journal.2024; 48(3): 463.     CrossRef
  • Effect of smoking on the risk of gastrointestinal cancer after cholecystectomy: A national population-based cohort study
    Minseob Kim, Kyung-Do Han, Seung-Hyun Ko, Yoonkyung Woo, Jae Hyun Han
    World Journal of Gastrointestinal Surgery.2024; 16(9): 2796.     CrossRef
  • Association of Succinate and Adenosine Nucleotide Metabolic Pathways with Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus
    Inha Jung, Seungyoon Nam, Da Young Lee, So Young Park, Ji Hee Yu, Ji A Seo, Dae Ho Lee, Nan Hee Kim
    Diabetes & Metabolism Journal.2024; 48(6): 1126.     CrossRef
  • Association between waist circumference or weight change after smoking cessation and incidence of cardiovascular disease or all-cause death in Korean adults with type 2 diabetes
    Heajung Lee, Jaeyong Shin, Jae Woo Choi
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Association Between Glycemic Status and the Risk of Kidney Cancer in Men and Women: A Nationwide Cohort Study
    Joo-Hyun Park, Jung Yong Hong, Kyungdo Han, Jay J. Shen
    Diabetes Care.2023; 46(1): 38.     CrossRef
  • Remnant Cholesterol Is an Independent Predictor of Type 2 Diabetes: A Nationwide Population-Based Cohort Study
    Ji Hye Huh, Eun Roh, Seong Jin Lee, Sung-Hee Ihm, Kyung-Do Han, Jun Goo Kang
    Diabetes Care.2023; 46(2): 305.     CrossRef
  • Efficacy of acupuncture on cardiovascular complications in patients with diabetes mellitus in Korea: A nationwide retrospective cohort
    Hyejin Jung, Tiana Won, Ga-Yeon Kim, Jowon Jang, Sujung Yeo, Sabina Lim
    Journal of Integrative Medicine.2023; 21(2): 176.     CrossRef
  • Comparison of Operational Definition of Type 2 Diabetes Mellitus Based on Data from Korean National Health Insurance Service and Korea National Health and Nutrition Examination Survey
    Jong Ha Baek, Yong-Moon Park, Kyung Do Han, Min Kyong Moon, Jong Han Choi, Seung-Hyun Ko
    Diabetes & Metabolism Journal.2023; 47(2): 201.     CrossRef
  • Epidemiology of PAH in Korea: An Analysis of the National Health Insurance Data, 2002–2018
    Albert Youngwoo Jang, Hyeok-Hee Lee, Hokyou Lee, Hyeon Chang Kim, Wook-Jin Chung
    Korean Circulation Journal.2023; 53(5): 313.     CrossRef
  • Increased Risks of Open-Angle Glaucoma in Untreated Hypertension
    Jihei Sara Lee, Yong Joon Kim, Sunyeup Kim, Hyoung Won Bae, Sung Soo Kim, Seung Won Lee, Chan Yun Kim
    American Journal of Ophthalmology.2023; 252: 111.     CrossRef
  • Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
    Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
    Cardiovascular Diabetology.2023;[Epub]     CrossRef
  • Association between glycemic status and the risk of acute pancreatitis: a nationwide population-based study
    In Rae Cho, Kyung-Do Han, Sang Hyub Lee, Young Hoon Choi, Kwang Hyun Chung, Jin Ho Choi, Namyoung Park, Min Woo Lee, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim
    Diabetology & Metabolic Syndrome.2023;[Epub]     CrossRef
  • Type 2 Diabetes and Its Association With Psychiatric Disorders in Young Adults in South Korea
    Min-Kyung Lee, Su-Young Lee, Seo-Young Sohn, Jiyeon Ahn, Kyungdo Han, Jae-Hyuk Lee
    JAMA Network Open.2023; 6(6): e2319132.     CrossRef
  • Cholecystectomy Increases the Risk of Type 2 Diabetes in the Korean Population
    Ji Hye Huh, Kyong Joo Lee, Yun Kyung Cho, Shinje Moon, Yoon Jung Kim, Eun Roh, Kyung-do Han, Dong Hee Koh, Jun Goo Kang, Seong Jin Lee, Sung-Hee Ihm
    Annals of Surgery.2023; 278(2): e264.     CrossRef
  • The Risk of Type 2 Diabetes Mellitus according to Changes in Obesity Status in Late Middle-Aged Adults: A Nationwide Cohort Study of Korea
    Joon Ho Moon, Yeonhoon Jang, Tae Jung Oh, Se Young Jung
    Diabetes & Metabolism Journal.2023; 47(4): 514.     CrossRef
  • Scalable Infrastructure Supporting Reproducible Nationwide Healthcare Data Analysis toward FAIR Stewardship
    Ji-Woo Kim, Chungsoo Kim, Kyoung-Hoon Kim, Yujin Lee, Dong Han Yu, Jeongwon Yun, Hyeran Baek, Rae Woong Park, Seng Chan You
    Scientific Data.2023;[Epub]     CrossRef
  • Association between Smoking Status and the Risk of Hip Fracture in Patients with Type 2 Diabetes: A Nationwide Population-Based Study
    Se-Won Lee, Jun-Young Heu, Ju-Yeong Kim, Jinyoung Kim, Kyungdo Han, Hyuk-Sang Kwon
    Endocrinology and Metabolism.2023; 38(6): 679.     CrossRef
  • Urgensi Kepesertaan BPJS Kesehatan Sebagai Syarat Peralihan Hak Atas Tanah Berdasarkan Instruksi Presiden Nomor 1 Tahun 2022 Tentang Optimalisasi Pelaksanaan Program Jaminan Kesehatan Nasional
    Nur Dwi Safitri, Fauziyah Fauziyah
    Indonesian Journal of Law and Justice.2023; 1(2): 10.     CrossRef
  • Risk of Incident Dementia According to Glycemic Status and Comorbidities of Hyperglycemia: A Nationwide Population-Based Cohort Study
    Woo Jung Kim, Seo Jung Lee, Eun Lee, Eun Y. Lee, Kyungdo Han
    Diabetes Care.2022; 45(1): 134.     CrossRef
  • Effects of physical activity on cardiovascular outcomes and mortality in Korean patients with diabetes: a nationwide population-based cohort study
    Inha Jung, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee
    Cardiovascular Prevention and Pharmacotherapy.2022; 4(1): 42.     CrossRef
  • Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
    Sangmo Hong, Chang Hee Jung, Song Han, Cheol-Young Park
    Diabetes & Metabolism Journal.2022; 46(1): 63.     CrossRef
  • Changes in Patterns of Physical Activity and Risk of Heart Failure in Newly Diagnosed Diabetes Mellitus Patients
    Inha Jung, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Yong-Gyu Park, Eun-Jung Rhee, Won-Young Lee
    Diabetes & Metabolism Journal.2022; 46(2): 327.     CrossRef
  • Synergistic association between underweight and type 2 diabetes on the development of laryngeal cancer: a national population-based retrospective cohort study
    Oh. Hyeong Lee, Yong-Moon Park, Seung-Hyun Ko, Kyuna Lee, Yeonji Kim, Kyungdo Han, Jung-Hae Cho
    BMC Cancer.2022;[Epub]     CrossRef
  • Cardiovascular Implications of the 2021 KDIGO Blood Pressure Guideline for Adults With Chronic Kidney Disease
    Hyeok-Hee Lee, Hokyou Lee, Raymond R. Townsend, Dong-Wook Kim, Sungha Park, Hyeon Chang Kim
    Journal of the American College of Cardiology.2022; 79(17): 1675.     CrossRef
  • Cumulative Exposure to High γ-Glutamyl Transferase Level and Risk of Diabetes: A Nationwide Population-Based Study
    Ji-Yeon Park, Kyungdo Han, Hun-Sung Kim, Jae-Hyoung Cho, Kun-Ho Yoon, Mee Kyoung Kim, Seung-Hwan Lee
    Endocrinology and Metabolism.2022; 37(2): 272.     CrossRef
  • Skin accumulation of advanced glycation end products and cardiovascular risk in Korean patients with type 2 diabetes mellitus
    Lee-Seoul Choi, Kainat Ahmed, Young-Seol Kim, Jung-Eun Yim
    Heliyon.2022; 8(6): e09571.     CrossRef
  • Risk for Behçet’s disease gauged via high-density lipoprotein cholesterol: a nationwide population-based study in Korea
    Yeong Ho Kim, Hyun Jee Kim, Jin Woo Park, Kyung Do Han, Yong Gyu Park, Young Bok Lee, Ji Hyun Lee
    Scientific Reports.2022;[Epub]     CrossRef
  • Association between the Diabetes Drug Cost and Cardiovascular Events and Death in Korea: A National Health Insurance Service Database Analysis
    Seung Min Chung, Ji-In Lee, Eugene Han, Hyun-Ae Seo, Eonju Jeon, Hye Soon Kim, Ji Sung Yoon
    Endocrinology and Metabolism.2022; 37(5): 759.     CrossRef
  • Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study
    Ji Hye Huh, Kyung-do Han, Yun Kyung Cho, Eun Roh, Jun Goo Kang, Seong Jin Lee, Sung-Hee Ihm
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Associations between migraine and major cardiovascular events in type 2 diabetes mellitus
    Dae Young Cheon, Kyungdo Han, Ye Seul Yang, Yerim Kim, Sang-Hwa Lee, Chulho Kim, Jong-Hee Sohn, Mi Sun Oh, Byung-Chul Lee, Minwoo Lee, Kyung-Ho Yu
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study
    Jun Sung Moon, Sunghwan Suh, Sang Soo Kim, Heung Yong Jin, Jeong Mi Kim, Min Hee Jang, Kyung Ae Lee, Ju Hyung Lee, Seung Min Chung, Young Sang Lyu, Jin Hwa Kim, Sang Yong Kim, Jung Eun Jang, Tae Nyun Kim, Sung Woo Kim, Eonju Jeon, Nan Hee Cho, Mi-Kyung Ki
    Diabetes & Metabolism Journal.2021; 45(5): 675.     CrossRef
  • Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
    Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
    Diabetes & Metabolism Journal.2021; 45(2): 260.     CrossRef
  • Associations of general obesity and central obesity with the risk of hepatocellular carcinoma in a Korean population: A national population‐based cohort study
    Seawon Hwang, Yong‐Moon Park, Kyung‐Do Han, Jae‐Seung Yun, Seung‐Hyun Ko, Yu‐Bae Ahn, Jae Hyun Han
    International Journal of Cancer.2021; 148(5): 1144.     CrossRef
  • Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24‐week, randomized controlled trial
    Jaehyun Bae, Ji Hye Huh, Minyoung Lee, Yong‐Ho Lee, Byung‐Wan Lee
    Diabetes, Obesity and Metabolism.2021; 23(2): 609.     CrossRef
  • Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study
    Hokyou Lee, Yong-ho Lee, Seung Up Kim, Hyeon Chang Kim
    Clinical Gastroenterology and Hepatology.2021; 19(10): 2138.     CrossRef
  • Severe hypoglycemia as a preventable risk factor for cardiovascular disease in patients with type 2 diabetes mellitus
    Soo-Yeon Choi, Seung-Hyun Ko
    The Korean Journal of Internal Medicine.2021; 36(2): 263.     CrossRef
  • Changes in metabolic syndrome status affect the incidence of end-stage renal disease in the general population: a nationwide cohort study
    Eun Sil Koh, Kyung Do Han, Mee Kyoung Kim, Eun Sook Kim, Min-Kyung Lee, Ga Eun Nam, Oak-Kee Hong, Hyuk-Sang Kwon
    Scientific Reports.2021;[Epub]     CrossRef
  • Status of Diabetic Neuropathy in Korea: A National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015)
    Seong-Su Moon, Chong Hwa Kim, Seon Mee Kang, Eun Sook Kim, Tae Jung Oh, Jae-Seung Yun, Ho Chan Cho, Dae Jung Kim, Tae Sun Park
    Diabetes & Metabolism Journal.2021; 45(1): 115.     CrossRef
  • Thirty-six Year Trends in Mortality from Diseases of Circulatory System in Korea
    Jongmin Baek, Hokyou Lee, Hyeok-Hee Lee, Ji Eun Heo, So Mi Jemma Cho, Hyeon Chang Kim
    Korean Circulation Journal.2021; 51(4): 320.     CrossRef
  • Severe hypoglycemia and the risk of end stage renal disease in type 2 diabetes
    Jae-Seung Yun, Yong-Moon Park, Kyungdo Han, Hyung-Wook Kim, Seon-Ah Cha, Yu-Bae Ahn, Seung-Hyun Ko
    Scientific Reports.2021;[Epub]     CrossRef
  • Adherence to Antihypertensive Medication and Incident Cardiovascular Events in Young Adults With Hypertension
    Hokyou Lee, Yuichiro Yano, So Mi Jemma Cho, Ji Eun Heo, Dong-Wook Kim, Sungha Park, Donald M. Lloyd-Jones, Hyeon Chang Kim
    Hypertension.2021; 77(4): 1341.     CrossRef
  • Cumulative exposure to impaired fasting glucose and future risk of type 2 diabetes mellitus
    Mee Kyoung Kim, Kyungdo Han, Eun Sil Koh, Oak-Kee Hong, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon
    Diabetes Research and Clinical Practice.2021; 175: 108799.     CrossRef
  • Association between toothbrushing and non-alcoholic fatty liver disease
    Ji-Youn Kim, Yong-Moon Park, Gyu-Na Lee, Hyun Chul Song, Yu-Bae Ahn, Kyungdo Han, Seung-Hyun Ko, Houkai Li
    PLOS ONE.2021; 16(5): e0243686.     CrossRef
  • Weight change and microvascular outcomes in patients with new-onset diabetes: a nationwide cohort study
    Eun Sil Koh, Kyung Do Han, Mee Kyoung Kim, Eun Sook Kim, Min-Kyung Lee, Ga Eun Nam, Hyuk-Sang Kwon
    The Korean Journal of Internal Medicine.2021; 36(4): 932.     CrossRef
  • Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future
    Brian Godman, Mainul Haque, Santosh Kumar, Salequl Islam, Jaykaran Charan, Farhana Akter, Amanj Kurdi, Eleonora Allocati, Muhammed Abu Bakar, Sagir Abdur Rahim, Nusrat Sultana, Farzana Deeba, M. A. Halim Khan, A. B. M Muksudul Alam, Iffat Jahan, Zubair Ma
    Current Medical Research and Opinion.2021; 37(9): 1529.     CrossRef
  • Development and Validation of a Deep Learning Based Diabetes Prediction System Using a Nationwide Population-Based Cohort
    Sang Youl Rhee, Ji Min Sung, Sunhee Kim, In-Jeong Cho, Sang-Eun Lee, Hyuk-Jae Chang
    Diabetes & Metabolism Journal.2021; 45(4): 515.     CrossRef
  • Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
    Ja Young Jeon, Kyoung Hwa Ha, Dae Jung Kim
    Diabetes & Metabolism Journal.2021; 45(4): 505.     CrossRef
  • Nonalcoholic fatty liver disease and the risk of insulin-requiring gestational diabetes
    Sang Youn You, Kyungdo Han, Seung-Hawn Lee, Mee Kyoung Kim
    Diabetology & Metabolic Syndrome.2021;[Epub]     CrossRef
  • On-Treatment Blood Pressure and Cardiovascular Outcomes in Adults With Hypertension and Left Ventricular Hypertrophy
    Hyeok-Hee Lee, Hokyou Lee, So Mi Jemma Cho, Dong-Wook Kim, Sungha Park, Hyeon Chang Kim
    Journal of the American College of Cardiology.2021; 78(15): 1485.     CrossRef
  • The Effects of Glucose Lowering Agents on the Secondary Prevention of Coronary Artery Disease in Patients with Type 2 Diabetes
    Inha Jung, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Yong-Gyu Park, Eun-Jung Rhee, Won-Young Lee
    Endocrinology and Metabolism.2021; 36(5): 977.     CrossRef
  • Changes in metabolic syndrome and its components and the risk of type 2 diabetes: a nationwide cohort study
    Min-Kyung Lee, Kyungdo Han, Mee Kyoung Kim, Eun Sil Koh, Eun Sook Kim, Ga Eun Nam, Hyuk-Sang Kwon
    Scientific Reports.2020;[Epub]     CrossRef
  • Obesity and metabolic health status are determinants for the clinical expression of hypertrophic cardiomyopathy
    Jun-Bean Park, Da Hye Kim, Heesun Lee, In-Chang Hwang, Yeonyee E Yoon, Hyo Eun Park, Su-Yeon Choi, Yong-Jin Kim, Goo-Yeong Cho, Kyungdo Han, Steve R Ommen, Hyung-Kwan Kim
    European Journal of Preventive Cardiology.2020; 27(17): 1849.     CrossRef
  • Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes
    Sang Ouk Chin, In Gyoon Ha, Sang Youl Rhee, Su Jin Jeong, Suk Chon, Sung Hoon Kim, Kyu Jeung Ahn, Sei Hyun Baik, Yongsoo Park, Moon Suk Nam, Kwan Woo Lee, Jeong Taek Woo
    International Journal of Endocrinology.2020; 2020: 1.     CrossRef
  • Impact of Mean and Variability of High‐Density Lipoprotein‐Cholesterol on the Risk of Myocardial Infarction, Stroke, and Mortality in the General Population
    Byung‐Hun Han, Kyungdo Han, Kun‐Ho Yoon, Mee Kyoung Kim, Seung‐Hwan Lee
    Journal of the American Heart Association.2020;[Epub]     CrossRef
  • The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study
    Jung-Min Lee, Yong-Moon Park, Jae-Seung Yun, Yu-Bae Ahn, Kang-Moon Lee, Dae Bum Kim, Ji Min Lee, Kyungdo Han, Seung-Hyun Ko, Ming-Lung Yu
    PLOS ONE.2020; 15(1): e0226351.     CrossRef
  • Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study
    Sangmo Hong, Kyungdo Han, Cheol-Young Park
    Mayo Clinic Proceedings.2020; 95(1): 101.     CrossRef
  • Association Between Glycemic Status and the Risk of Parkinson Disease: A Nationwide Population-Based Study
    Sang Youl Rhee, Kyung-Do Han, Hyemi Kwon, Se-Eun Park, Yong-Gyu Park, Yang-Hyun Kim, Soon-Jip Yoo, Eun-Jung Rhee, Won-Young Lee
    Diabetes Care.2020; 43(9): 2169.     CrossRef
  • A model to predict risk of stroke in middle-aged adults with type 2 diabetes generated from a nationwide population-based cohort study in Korea
    Mee-Kyoung Kim, Kyungdo Han, Jae-Hyoung Cho, Hyuk-Sang Kwon, Kun-Ho Yoon, Seung-Hwan Lee
    Diabetes Research and Clinical Practice.2020; 163: 108157.     CrossRef
  • Diabetic Retinopathy and Related Clinical Practice for People with Diabetes in Korea: A 10-Year Trend Analysis
    Yoo-Ri Chung, Kyoung Hwa Ha, Kihwang Lee, Dae Jung Kim
    Diabetes & Metabolism Journal.2020; 44(6): 928.     CrossRef
  • Prepregnancy smoking and the risk of gestational diabetes requiring insulin therapy
    Mee Kyoung Kim, Kyungdo Han, Sang Youn You, Hyuk-Sang Kwon, Kun-Ho Yoon, Seung-Hwan Lee
    Scientific Reports.2020;[Epub]     CrossRef
  • Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults
    Hokyou Lee, Yuichiro Yano, So Mi Jemma Cho, Jong Heon Park, Sungha Park, Donald M. Lloyd-Jones, Hyeon Chang Kim
    Circulation.2020; 141(22): 1778.     CrossRef
  • Middle-aged men with type 2 diabetes as potential candidates for pancreatic cancer screening: a 10-year nationwide population-based cohort study
    Dong-Hoe Koo, Kyung-Do Han, Hong Joo Kim, Cheol-Young Park
    Acta Diabetologica.2020; 57(2): 197.     CrossRef
  • Predicting the Development of Myocardial Infarction in Middle-Aged Adults with Type 2 Diabetes: A Risk Model Generated from a Nationwide Population-Based Cohort Study in Korea
    Seung-Hwan Lee, Kyungdo Han, Hun-Sung Kim, Jae-Hyoung Cho, Kun-Ho Yoon, Mee Kyoung Kim
    Endocrinology and Metabolism.2020; 35(3): 636.     CrossRef
  • Fasting plasma glucose level and the risk of open angle glaucoma: Nationwide population-based cohort study in Korea
    Jin A. Choi, Yong-Moon Park, Kyungdo Han, Jiyoung Lee, Jae-Seung Yun, Seung-Hyun Ko, Bang V Bui
    PLOS ONE.2020; 15(9): e0239529.     CrossRef
  • Effect of Variability in Blood Pressure, Glucose and Cholesterol Concentrations, and Body Weight on Emergency Hospitalization and 30‐Day Mortality in the General Population
    Seung‐Hwan Lee, Kyungdo Han, Hyuk‐Sang Kwon, Kun‐Ho Yoon, Mee Kyoung Kim
    Journal of the American Heart Association.2020;[Epub]     CrossRef
  • Does Diabetes Increase the Risk of Contracting COVID-19? A Population-Based Study in Korea
    Sung-Youn Chun, Dong Wook Kim, Sang Ah Lee, Su Jung Lee, Jung Hyun Chang, Yoon Jung Choi, Seong Woo Kim, Sun Ok Song
    Diabetes & Metabolism Journal.2020; 44(6): 897.     CrossRef
  • Appropriate Medical Technology in the Era of the 4th Industrial Revolution
    Sang Youl Rhee
    The Korean Journal of Medicine.2019; 94(5): 387.     CrossRef
  • Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study
    Su Jin Lee, Kyoung Hwa Ha, Jung Hyun Lee, Hokyou Lee, Dae Jung Kim, Hyeon Chang Kim, Tatsuo Shimosawa
    PLOS ONE.2019; 14(2): e0211959.     CrossRef
  • 2017 ACC/AHA Blood Pressure Classification and Cardiovascular Disease in 15 Million Adults of Age 20–94 Years
    Hokyou Lee, So Mi Jemma Cho, Jong Heon Park, Sungha Park, Hyeon Chang Kim
    Journal of Clinical Medicine.2019; 8(11): 1832.     CrossRef
  • Management of Cardiovascular Risk Factors in Elderly Diabetes Mellitus Patients
    Sung Hoon Yu
    The Journal of Korean Diabetes.2019; 20(4): 233.     CrossRef
  • Cholesterol levels and development of cardiovascular disease in Koreans with type 2 diabetes mellitus and without pre-existing cardiovascular disease
    Mee Kyoung Kim, Kyungdo Han, Han Na Joung, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon
    Cardiovascular Diabetology.2019;[Epub]     CrossRef
  • Comprehensive Efforts Are Needed to Improve the Quality of Primary Diabetes Care in Korea
    Chan-Hee Jung
    Endocrinology and Metabolism.2019; 34(3): 265.     CrossRef
  • Blood Pressure and Development of Cardiovascular Disease in Koreans With Type 2 Diabetes Mellitus
    Mee Kyoung Kim, Kyungdo Han, Eun Sil Koh, Eun Sook Kim, Min-Kyung Lee, Ga Eun Nam, Hyuk-Sang Kwon
    Hypertension.2019; 73(2): 319.     CrossRef
  • Weight change and mortality and cardiovascular outcomes in patients with new-onset diabetes mellitus: a nationwide cohort study
    Mee Kyoung Kim, Kyungdo Han, Eun Sil Koh, Eun Sook Kim, Min-Kyung Lee, Ga Eun Nam, Hyuk-Sang Kwon
    Cardiovascular Diabetology.2019;[Epub]     CrossRef
  • Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2019;43:582–9)
    Tae Seo Sohn
    Diabetes & Metabolism Journal.2019; 43(6): 909.     CrossRef
  • Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study
    Yoo-Ri Chung, Kyoung Hwa Ha, Hyeon Chang Kim, Sang Jun Park, Kihwang Lee, Dae Jung Kim
    Diabetes & Metabolism Journal.2019; 43(5): 640.     CrossRef
  • The Need to Improve the Quality of Diabetes Care in Korea
    Seung Jin Han, Dae Jung Kim
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • Chasms in Achievement of Recommended Diabetes Care among Geographic Regions in Korea
    Sanghyun Cho, Ji-Yeon Shin, Hyun Joo Kim, Sang Jun Eun, Sungchan Kang, Won Mo Jang, Hyemin Jung, Yoon Kim, Jin Yong Lee
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
    Ji A Seo
    Diabetes & Metabolism Journal.2019; 43(5): 578.     CrossRef
  • National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus
    Jisu Kim, Susin Park, Hyunsoo Kim, Nam Kyung Je
    European Journal of Clinical Pharmacology.2019; 75(12): 1723.     CrossRef
  • HDL-Cholesterol, Its Variability, and the Risk of Diabetes: A Nationwide Population-Based Study
    Seung-Hwan Lee, Hun-Sung Kim, Yong-Moon Park, Hyuk-Sang Kwon, Kun-Ho Yoon, Kyungdo Han, Mee Kyoung Kim
    The Journal of Clinical Endocrinology & Metabolism.2019; 104(11): 5633.     CrossRef
  • Current Management of Type 2 Diabetes Mellitus in Primary Care Clinics in Korea
    Da Hea Seo, Shinae Kang, Yong-ho Lee, Jung Yoon Ha, Jong Suk Park, Byoung-Wan Lee, Eun Seok Kang, Chul Woo Ahn, Bong-Soo Cha
    Endocrinology and Metabolism.2019; 34(3): 282.     CrossRef
  • Heritability estimation of dichotomous phenotypes using a liability threshold model on ascertained family‐based samples
    Wonji Kim, Soo Heon Kwak, Sungho Won
    Genetic Epidemiology.2019; 43(7): 761.     CrossRef
  • Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
    Jun Sung Moon
    Diabetes & Metabolism Journal.2019; 43(6): 911.     CrossRef
  • Association of Obstructive Sleep Apnea With the Risk of Ménière’s Disease and Sudden Sensorineural Hearing Loss: A Study Using Data From the Korean National Health Insurance Service
    Jong-Yeup Kim, Inseok Ko, Bum-Joo Cho, Dong-Kyu Kim
    Journal of Clinical Sleep Medicine.2019; 15(9): 1293.     CrossRef
Obesity and Metabolic Syndrome
Being Metabolically Healthy, the Most Responsible Factor for Vascular Health
Eun-Jung Rhee
Diabetes Metab J. 2018;42(1):19-25.   Published online January 26, 2018
DOI: https://doi.org/10.4093/dmj.2018.42.1.19
  • 7,627 View
  • 57 Download
  • 9 Web of Science
  • 12 Crossref
AbstractAbstract PDFPubReader   ePub   

The prevalence of obesity is rapidly increasing worldwide. One-thirds of world population is suffering from the deleterious effects of excessive fat and adipose tissue in their body. At the same time, the average life expectancy is becoming higher and higher every decade. Therefore, living healthy and longer is the dream for everyone. Simply being obese is not the primary cause for the consequence of obesity; rather, the depot where the fat is accumulated, is the primary key for the deleterious effects of obesity. Results from historical research suggest that visceral fat increases the risk for cardiovascular and metabolic diseases, such as diabetes, myocardial infarction and ischemic stroke, not subcutaneous fat. Therefore, body mass index (BMI), which reflects body weight relative to height might not reflect the appropriate size of metabolic burden of fat in our body. In contrast, waist circumference, which reflects abdominal obesity, would mirror the metabolic burden of fat better than BMI. Visceral fat is the marker of ectopic fat accumulation. In this review, I will introduce my researches mainly involved in uncovering the clues to the link between metabolic health and cardiovascular disease.

Citations

Citations to this article as recorded by  
  • Interaction Between Maternal Obesity and Metabolic Dysfunction in Gestational Hypertension and Preeclampsia: A Prospective Birth Cohort Study
    Jiayi Chen, Yibing Zhu, Junwei Liu, Qingxiu Li, Huimin Shi, Wenjuan Liu, Haiyan Gao, Wei Li, Zhengqin Wu, Bin Sun, Qian Zhang, Haibo Li
    The Journal of Clinical Hypertension.2026;[Epub]     CrossRef
  • Association between Cumulative Exposure to Metabolic Score for Visceral Fat and the risk of stroke in a population with cardiovascular-kidney-metabolic syndrome stages 0–3: a nationwide prospective cohort study
    Le Zhao, Qisheng Gao
    Nutrition, Metabolism and Cardiovascular Diseases.2026; : 104610.     CrossRef
  • The association between visceral fat metabolic score and stroke: mediation by declining kidney function
    Yue Cao, Weixing Wen, Hao Zhang, Weiwen Li, Guolin Huang, Yuli Huang
    Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
  • Triglyceride-glucose indices predict all-cause mortality after stroke in NHANES 1999–2018
    Jiaqian Zheng, Weiwen Mao, Mengqian Sang, Xinyu Pan, Yiluo Xie, Yichi Xie
    Frontiers in Aging Neuroscience.2025;[Epub]     CrossRef
  • Maternal obesity phenotype, metabolic dysfunction, and preterm birth: a prospective birth cohort study
    Jiayi Chen, Yecheng Miao, Qingxiu Li, Qian Zhang, Bin Sun, Zhengqin Wu, Wenjuan Liu, Junwei Liu, Huimin Shi, Haiyan Gao, Wei Li, Yibing Zhu, Haibo Li
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Correlations between modest weight loss and leptin to adiponectin ratio, insulin and leptin resensitization in a small cohort of Norwegian individuals with obesity
    Victoria T. Isaksen, Maria A. Larsen, Rasmus Goll, Eyvind J. Paulssen, Jon R. Florholmen
    Endocrine and Metabolic Science.2023; 12: 100134.     CrossRef
  • Allostatic load in patients with breast cancer
    K. F. Makkonen, N. M. Agarkov, U. S. Stanoevich, A. A. Titov, M. S. Mitikhina, E. A. Moskaleva
    Siberian journal of oncology.2022; 21(4): 40.     CrossRef
  • Effect of glucocorticoids on glyceroneogenesis in adipose tissue: A systematic review
    Mariana Lima-de-Freitas Marcondes-de-Mello, Maria Cristina Serafim-Costa, Mariela Mesquita Alves-e-Silva, Natália Rodrigues Oliveira, Nicola Vasconcellos Bertolucci-Caldo, Ruan Krubniki Ferraz, Valéria Ernestânia Chaves
    Biochimie.2020; 168: 210.     CrossRef
  • Risk of type 2 diabetes according to the cumulative exposure to metabolic syndrome or obesity: A nationwide population‐based study
    You‐Bin Lee, Da Hye Kim, Seon Mee Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Yong Gyu Park, Kyungdo Han, Hye Jin Yoo
    Journal of Diabetes Investigation.2020; 11(6): 1583.     CrossRef
  • Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status: a nationwide population-based study
    You-Bin Lee, Da Hye Kim, Seon Mee Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Yong Gyu Park, Kyungdo Han, Hye Jin Yoo
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk
    Elizabeth T. Cirulli, Lining Guo, Christine Leon Swisher, Naisha Shah, Lei Huang, Lori A. Napier, Ewen F. Kirkness, Tim D. Spector, C. Thomas Caskey, Bernard Thorens, J. Craig Venter, Amalio Telenti
    Cell Metabolism.2019; 29(2): 488.     CrossRef
  • Impact of the Dynamic Change of Metabolic Health Status on the Incident Type 2 Diabetes: A Nationwide Population-Based Cohort Study
    Jung A Kim, Da Hye Kim, Seon Mee Kim, Yong Gyu Park, Nan Hee Kim, Sei Hyun Baik, Kyung Mook Choi, Kyungdo Han, Hye Jin Yoo
    Endocrinology and Metabolism.2019; 34(4): 406.     CrossRef
Original Articles
Epidemiology
Application of the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline to the Korean National Health and Nutrition Examination Surveys from 1998 to 2012
Young Shin Song, Tae Jung Oh, Kyoung Min Kim, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang, Kyong Soo Park, Soo Lim
Diabetes Metab J. 2017;41(1):38-50.   Published online December 16, 2016
DOI: https://doi.org/10.4093/dmj.2017.41.1.38
  • 8,636 View
  • 41 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline for the treatment of blood cholesterol recommends statin therapy for individuals at high risk of atherosclerotic cardiovascular disease (ASCVD). The aim of this study was to investigate serial trends in the percentages of Korean adults considered eligible for statin therapy according to the new ACC/AHA cholesterol guideline.

Methods

Data from the Korean National Health and Nutrition Examination Survey (KNHANES) I (1998, n=7,698), II (2001, n=5,654), III (2005, n=5,269), IV (2007 to 2009, n=15,727), and V (2010 to 2012, n=16,304), which used a stratified, multistage, probability sampling design, were used as representative of the entire Korean population.

Results

The percentage of adults eligible for statin therapy according to the ACC/AHA cholesterol guideline increased with time: 17.0%, 19.0%, 20.8%, 20.2%, and 22.0% in KNHANES I, II, III, IV, and V, respectively (P=0.022). The prevalence of ASCVD was 1.4% in KNHANES I and increased to 3.3% in KNHANES V. The percentage of diabetic patients aged 40 to 75 years with a low density lipoprotein cholesterol levels of 70 to 189 mg/dL increased from 4.8% in KNHANES I to 6.1% in KNHANES V. People with an estimated 10-year ASCVD risk ≥7.5% and aged 40 to 75 years accounted for the largest percentage among the four statin benefit groups: 9.1% in KNHANES I and 11.0% in KNHANES V.

Conclusion

Application of the 2013 ACC/AHA guideline has found that the percentage of Korean adults in the statin benefit groups has increased over the past 15 years.

Citations

Citations to this article as recorded by  
  • Sex differences in risk factors for subclinical hypothyroidism
    Jeonghoon Ha, Jeongmin Lee, Kwanhoon Jo, Dong-Jun Lim, Moo Il Kang, Bong Yun Cha, Min-Hee Kim
    Endocrine Connections.2018; 7(4): 511.     CrossRef
Epidemiology
Dietary Sodium Intake in People with Diabetes in Korea: The Korean National Health and Nutrition Examination Survey for 2008 to 2010
Myung Shin Kang, Chong Hwa Kim, Su Jin Jeong, Tae Sun Park
Diabetes Metab J. 2016;40(4):290-296.   Published online June 23, 2016
DOI: https://doi.org/10.4093/dmj.2016.40.4.290
  • 6,234 View
  • 47 Download
  • 17 Web of Science
  • 20 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Diabetics are likely to receive advice from their physicians concerning lifestyle changes. To understand how much sodium is consumed by diabetics in Korea, we compared the average daily sodium intake between diabetics and non-diabetics after controlling for confounding factors.

Methods

We obtained the sodium intake data for 13,957 individuals who participated in the Korean National Health and Nutrition Examination Survey (KNHANES), 2008 to 2010, which consisted of a health interview and behavioral and nutritional surveys. The KNHANES uses a stratified, multistage, probability-sampling design, and weighting adjustments were conducted to represent the entire population.

Results

Our analysis revealed that, overall, diabetics tended to have lower sodium intake (4,910.2 mg) than healthy individuals (5,188.2 mg). However, both diabetic and healthy individuals reported higher sodium intake than is recommended by the World Health Organization (WHO). Stratified subgroup analyses revealed that the sodium intake (4,314.2 mg) among newly diagnosed diabetics was higher among women when compared to patients with known diabetes (3,812.5 mg, P=0.035). Female diabetics with cardiovascular disease had lower average sodium intake compared to those without cardiovascular disease after adjusting for sex, age, body mass index, and total energy intake (P=0.058). Sodium intake among male diabetics with hypercholesterolemia (P=0.011) and female diabetics with hypertriglyceridemia (P=0.067) tended to be higher than that among those who without dyslipidemia.

Conclusion

The average sodium intake of diabetics in Korea was higher than the WHO recommends. Sodium intake in newly diagnosed diabetics was significantly higher than that in non-diabetics and previously diagnosed diabetics among females. Prospective studies are needed to identify the exact sodium intake.

Citations

Citations to this article as recorded by  
  • Salt Intake in Adults with Diabetes and Hypertension: The Longitudinal Study of Adult Health-Brasil Study
    Natália Gonçalves Ribeiro, Deborah F. Lelis, Rosane H. Griep, Sandhi M. Barreto, Maria del Carmen B Molina, Maria I. Schmidt, Bruce B. Duncan, Isabela Bensenor, Paulo A. Lotufo, José G. Mill, Marcelo Perim Baldo
    Metabolic Syndrome and Related Disorders.2024; 22(5): 356.     CrossRef
  • Dietary patterns and the risk of diabetes in Korean adults: A cross-sectional and prospective cohort study
    Jiyoung Hwang, Hyesook Kim, Oran Kwon
    Nutrition.2024; 125: 112491.     CrossRef
  • Higher Consumption of Dietary Sodium than RDA among the Patients of Diabetes Mellitus and Hypertension in the City of Aligarh: A Hospital-Based Study
    Roshina Bano, Anisa M. Durrani, Ajmal M.R.
    The Indian Journal of Nutrition and Dietetics.2024; : 121.     CrossRef
  • Effects of different diets on glycemic control among patients with type 2 diabetes: A literature review
    Maryam E Al-Adwi, Zinab M Al-Haswsa, Karmen M Alhmmadi, Yasmin A Eissa, Aya Hamdan, Hiba Bawadi, Reema F Tayyem
    Nutrition and Health.2023; 29(2): 215.     CrossRef
  • Dietary salt intake predicts future development of metabolic syndrome in the general population
    Hiroyuki Takase, Kazusa Hayashi, Fumihiko Kin, Suguru Nakano, Masashi Machii, Shin Takayama, Tomonori Sugiura, Yasuaki Dohi
    Hypertension Research.2023; 46(1): 236.     CrossRef
  • High Sodium Intake, as Assessed by Urinary Sodium Excretion, Is Associated with Nonalcoholic Fatty Liver Disease or Sarcopenia
    Eugene Han, Mi Kyung Kim, Seung-Soon Im, Hye Soon Kim, Taeg Kyu Kwon, Byoung Kuk Jang
    Gut and Liver.2023; 17(3): 456.     CrossRef
  • Trends of Dietary Intakes and Metabolic Diseases in Japanese Adults: Assessment of National Health Promotion Policy and National Health and Nutrition Survey 1995–2019
    Muhammad Fauzi, Indri Kartiko-Sari, Hemant Poudyal
    Journal of Clinical Medicine.2022; 11(9): 2350.     CrossRef
  • Determinants of Type 2 Diabetes Mellitus Among Adults in Dill-Chora Referral Hospital, Dire Dawa, East Ethiopia
    Tewodros Getnet Amera, Yibekal Manaye Tefera, Tameru Menberu, Aminu Mohammed Yassin
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 3565.     CrossRef
  • Dietary sodium and cardiovascular morbidity/mortality: a brief commentary on the ‘J-shape hypothesis’
    Christiana Tsirimiagkou, Kalliopi Karatzi, Antonios Argyris, Eirini D. Basdeki, Panagiota Kaloudi, Mary Yannakoulia, Athanase D. Protogerou
    Journal of Hypertension.2021; 39(12): 2335.     CrossRef
  • Associations of Dietary Salt and Its Sources with Hemoglobin A1c in Patients with Type 2 Diabetes Not Taking Anti-Diabetic Medications: Analysis Based on 6-Month Intervention with a Moderate Low-Carbohydrate Diet
    Hajime Haimoto, Takashi Murase, Shiho Watanabe, Keiko Maeda, Kenji Wakai
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 4569.     CrossRef
  • Association of rheumatoid arthritis and high sodium intake with major adverse cardiovascular events: a cross-sectional study from the seventh Korean National Health and Nutrition Examination Survey
    Jeong-Hyeon Bae, Min-Young Shin, Eun Ha Kang, Yun Jong Lee, You-Jung Ha
    BMJ Open.2021; 11(12): e056255.     CrossRef
  • Nineteen-year trends in fermented food consumption and sodium intake from fermented foods for Korean adults from 1998 to 2016
    Sang Young Kim, Jeanne H Freeland-Graves, Hyun Ja Kim
    Public Health Nutrition.2020; 23(3): 515.     CrossRef
  • Dietary Sodium Intake and Health Indicators: A Systematic Review of Published Literature between January 2015 and December 2019
    Katherine J Overwyk, Zerleen S Quader, Joyce Maalouf, Marlana Bates, Jacqui Webster, Mary G George, Robert K Merritt, Mary E Cogswell
    Advances in Nutrition.2020; 11(5): 1174.     CrossRef
  • Lower Leg Fat Depots Are Associated with Albuminuria Independently of Obesity, Insulin Resistance, and Metabolic Syndrome (Korea National Health and Nutrition Examination Surveys 2008 to 2011)
    Eugene Han, Nan Hee Cho, Mi Kyung Kim, Hye Soon Kim
    Diabetes & Metabolism Journal.2019; 43(4): 461.     CrossRef
  • Factors Predicting Sodium Intake of Korean Americans with Type 2 Diabetes
    Jisook Ko, Kim B. Kim, Gayle M. Timmerman, Angela P. Clark, Miyong Kim
    Journal of Immigrant and Minority Health.2018; 20(3): 641.     CrossRef
  • Evaluation of the association between the number of natural teeth and anemia among Korean adults using nationally representative data
    Kyungdo Han, Jun‐Beom Park
    Journal of Periodontology.2018; 89(10): 1184.     CrossRef
  • Clinical implications of age and sex in the prevalence of periodontitis in Korean adults with diabetes
    Kyungdo Han, Jun‑Beom Park
    Experimental and Therapeutic Medicine.2018;[Epub]     CrossRef
  • Association between underweight and tooth loss among Korean adults
    In-Seok Song, Kyungdo Han, Jae-Jun Ryu, Jun-Beom Park
    Scientific Reports.2017;[Epub]     CrossRef
  • The Science of Salt: A regularly updated systematic review of the implementation of salt reduction interventions (March–August 2016)
    Joseph Alvin Santos, Kathy Trieu, Thout Sudhir Raj, JoAnne Arcand, Claire Johnson, Jacqui Webster, Rachael McLean
    The Journal of Clinical Hypertension.2017; 19(4): 439.     CrossRef
  • Salt-sensitive genes and their relation to obesity
    Yong-Pil Cheon, Myoungsook Lee
    Journal of Nutrition and Health.2017; 50(3): 217.     CrossRef
Complications
Severe Hypoglycemia and Cardiovascular or All-Cause Mortality in Patients with Type 2 Diabetes
Seon-Ah Cha, Jae-Seung Yun, Tae-Seok Lim, Seawon Hwang, Eun-Jung Yim, Ki-Ho Song, Ki-Dong Yoo, Yong-Moon Park, Yu-Bae Ahn, Seung-Hyun Ko
Diabetes Metab J. 2016;40(3):202-210.   Published online April 5, 2016
DOI: https://doi.org/10.4093/dmj.2016.40.3.202
  • 9,118 View
  • 78 Download
  • 51 Web of Science
  • 59 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

We investigated the association between severe hypoglycemia (SH) and the risk of cardiovascular (CV) or all-cause mortality in patients with type 2 diabetes.

Methods

The study included 1,260 patients aged 25 to 75 years with type 2 diabetes from the Vincent Type 2 Diabetes Resgistry (VDR), who consecutively enrolled (n=1,260) from January 2000 to December 2010 and were followed up until May 2015 with a median follow-up time of 10.4 years. Primary outcomes were death from any cause or CV death. We investigated the association between the CV or all-cause mortality and various covariates using Cox proportional hazards regression analysis.

Results

Among the 906 participants (71.9%) who completed follow-up, 85 patients (9.4%) had at least one episode of SH, and 86 patients (9.5%) died (9.1 per 1,000 patient-years). Patients who had died were older, had a longer duration of diabetes and hypertension, received more insulin, and had more diabetic microvascular complications at baseline, as compared with surviving patients. The experience of SH was significantly associated with an increased risk of all-cause mortality (hazard ratio [HR], 2.64; 95% confidence interval [CI], 1.39 to 5.02; P=0.003) and CV mortality (HR, 6.34; 95% CI, 2.02 to 19.87; P=0.002) after adjusting for sex, age, diabetic duration, hypertension, mean glycosylated hemoglobin levels, diabetic nephropathy, lipid profiles, and insulin use.

Conclusion

We found a strong association between SH and increased risk of all-cause and CV mortality in patients with type 2 diabetes.

Citations

Citations to this article as recorded by  
  • The association between stress-induced hyperglycemia ratio and cardiovascular events as well as all-cause mortality in patients with chronic kidney disease and diabetic nephropathy
    Boning Cao, Zhendong Guo, Dan-Ting Li, Le-Ying Zhao, Zhen Wang, Ya-Bin Gao, Yao-Xian Wang
    Cardiovascular Diabetology.2025;[Epub]     CrossRef
  • Impaired Awareness of Hypoglycemia and its Risk Factors among Diabetic Patients in Jazan, Saudi Arabia: A Cross-Sectional Study
    Omar Oraibi, Abdulelah Alameer, Mohammed Dalak, Sawsan Alsharif, Shatha A. Hakami, Mohammed Sumayli, Ayman Shami, Mostafa Mohrag, Mohammed A. Madkhali, Mohammed Ali Madkhali, Luai Alhazmi, Majid Darraj
    Current Diabetes Reviews.2024;[Epub]     CrossRef
  • The prognostic value of the stress hyperglycemia ratio for all-cause and cardiovascular mortality in patients with diabetes or prediabetes: insights from NHANES 2005–2018
    Lei Ding, Hongda Zhang, Cong Dai, Aikai Zhang, Fengyuan Yu, Lijie Mi, Yingjie Qi, Min Tang
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Navigating the future of diabetes: innovative nomogram models for predicting all-cause mortality risk in diabetic nephropathy
    Sensen Wu, Hui Wang, Dikang Pan, Julong Guo, Fan Zhang, Yachan Ning, Yongquan Gu, Lianrui Guo
    BMC Nephrology.2024;[Epub]     CrossRef
  • Association of hypoglycaemia with the risks of arrhythmia and mortality in individuals with diabetes - a systematic review and meta-analysis
    Gangfeng Li, Shuping Zhong, Xingmu Wang, Fuyuan Zhuge
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Diabetes mellitus und Straßenverkehr – ein Positionspapier der Österreichischen Diabetesgesellschaft (Update 2023)
    Heidemarie Abrahamian, Birgit Salamon, Angelika Lahnsteiner, Christian Schelkshorn, Alexander Bräuer, Lars Stechemesser, Gerd Köhler, Martin Clodi
    Wiener klinische Wochenschrift.2023; 135(S1): 319.     CrossRef
  • Validation of the hypoglycemia awareness questionnaire to assess hypoglycemia awareness in patients with type 2 diabetes treated with insulin
    Diana Cristina Henao-Carrillo, Fabio Alexander Sierra-Matamoros, Ana Julia Carrillo Algarra, Julieth Patricia García-Lugo, Sandra Milena Hernández-Zambrano
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(12): 102917.     CrossRef
  • Basal insulin analogues in people with diabetes and chronic kidney disease
    David León‐Jiménez, José Pablo Miramontes‐González, Laura Márquez‐López, Francisco Astudillo‐Martín, Luis M. Beltrán‐Romero, Fernando Moreno‐Obregón, Javier Escalada‐San Martín
    Diabetic Medicine.2022;[Epub]     CrossRef
  • Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study
    Eugene Han, Kyung-do Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Seung-Hyun Ko, Yong-ho Lee
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(5): e1976.     CrossRef
  • Validación transcultural del HypoA-Q para medir conciencia de hipoglucemia en pacientes diabéticos
    Ana Julia Carrillo-Algarra, Sandra Milena Hernandez-Zambrano, Fabio Alexander Sierra-Matamoros, Diana Cristina Henao-Carrillo, Ana María Gómez-Medina, Daniel Esteban Hurtado-Barrera
    Revista Ciencia y Cuidado.2022; 19(1): 42.     CrossRef
  • Validity of the diagnosis of diabetic microvascular complications in Korean national health insurance claim data
    Hyung Jun Kim, Moo-Seok Park, Jee-Eun Kim, Tae-Jin Song
    Annals of Clinical Neurophysiology.2022; 24(1): 7.     CrossRef
  • Severe hypoglycemia as a risk factor for cardiovascular outcomes in patients with type 2 diabetes: is it preventable?
    Seung-Hyun Ko
    Cardiovascular Prevention and Pharmacotherapy.2022; 4(3): 106.     CrossRef
  • Evaluation of a Clinical Platform to Promote Chronic Disease Management
    Laura Greene, Nila Sathe, John A. House, Laura L. Schott, Stella Safo
    Population Health Management.2021; 24(4): 470.     CrossRef
  • Severe hypoglycemia as a preventable risk factor for cardiovascular disease in patients with type 2 diabetes mellitus
    Soo-Yeon Choi, Seung-Hyun Ko
    The Korean Journal of Internal Medicine.2021; 36(2): 263.     CrossRef
  • Meta-Analysis: Association Between Hypoglycemia and Serious Adverse Events in Older Patients Treated With Glucose-Lowering Agents
    Katharina Mattishent, Yoon K. Loke
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Epidemiology and outcomes from severe hypoglycemia in Kuwait: a prospective cohort study
    Dalal Al Hasan, Ameen Yaseen, Mohammad Al Roudan, Lee Wallis
    BMC Emergency Medicine.2021;[Epub]     CrossRef
  • The incidence of hypoglycemia and its risk factors among diabetic patients in the Eastern Province of Saudi Arabia
    Ahmed Elshebiny, Hassan Alali, Zainab Alamer, Yasmin Alsultan, Hashim Alkhalaf, Abdullah Alkishi, Mohammed Alsuwaylih
    International Journal of Medicine in Developing Countries.2021; : 614.     CrossRef
  • Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
    Jae-Seung Yun, Seung-Hyun Ko
    Metabolism.2021; 123: 154838.     CrossRef
  • Real-world Evaluation of glycemic control and hypoglycemic Events among type 2 Diabetes mellitus study (REEDS): a multicentre, cross-sectional study in Thailand
    Bancha Satirapoj, Thongchai Pratipanawatr, Boonsong Ongphiphadhanakul, Sompongse Suwanwalaikorn, Yupin Benjasuratwong, Wannee Nitiyanant
    BMJ Open.2020; 10(2): e031612.     CrossRef
  • Predictors of Diabetes Self-Care Practice Among Patients with Type 2 Diabetes in Public Hospitals in Northeastern Ethiopia: A Facility-Based Cross-Sectional Study


    Tesfaye Molla Gulentie, Ebrahim Mohammed Yesuf, Taklo Simeneh Yazie, Belayneh Kefale
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 3137.     CrossRef
  • Hypoglycemia in Older Patients
    Byron J. Hoogwerf
    Clinics in Geriatric Medicine.2020; 36(3): 395.     CrossRef
  • Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study
    Francesco Zaccardi, Suping Ling, Claire Lawson, Melanie J. Davies, Kamlesh Khunti
    Diabetologia.2020; 63(10): 2129.     CrossRef
  • Insulin Glargine U100 Improved Glycemic Control and Reduced Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3 and 4
    Carolina C. Betônico, Silvia Maria O. Titan, Aécio Lira, Tatiana S. Pelaes, Maria Lúcia C. Correa-Giannella, Márcia Nery, Márcia Queiroz
    Clinical Therapeutics.2019; 41(10): 2008.     CrossRef
  • Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478)
    Athena Philis-Tsimikas, Irene Stratton, Lone Nørgård Troelsen, Britta Anker Bak, Lawrence A. Leiter
    Journal of Diabetes Science and Technology.2019; 13(3): 498.     CrossRef
  • Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes
    Yehuda Handelsman, Christina Chovanes, Terry Dex, Francesco Giorgino, Neil Skolnik, Elisabeth Souhami, William Stager, Elisabeth Niemoeller, Juan Pablo Frias
    Journal of Diabetes and its Complications.2019; 33(3): 236.     CrossRef
  • Urinary glucose excretion after dapagliflozin treatment: An exposure‐response modelling comparison between Japanese and non‐Japanese patients diagnosed with type 1 diabetes mellitus
    Victor Sokolov, Tatiana Yakovleva, Shinya Ueda, Joanna Parkinson, David W. Boulton, Robert C. Penland, Weifeng Tang
    Diabetes, Obesity and Metabolism.2019; 21(4): 829.     CrossRef
  • Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population‐based, propensity‐score‐matched cohort study
    Shihchen Kuo, Chun‐Ting Yang, Jin‐Shang Wu, Huang‐Tz Ou
    Diabetes, Obesity and Metabolism.2019; 21(2): 312.     CrossRef
  • Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
    Richard E. Pratley, Scott S. Emerson, Edward Franek, Matthew P. Gilbert, Steven P. Marso, Darren K. McGuire, Thomas R. Pieber, Bernard Zinman, Charlotte T. Hansen, Melissa V. Hansen, Thomas Mark, Alan C. Moses, John B. Buse
    Diabetes, Obesity and Metabolism.2019; 21(7): 1625.     CrossRef
  • Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial
    Marile Santamarina, Curt J. Carlson
    BMC Cardiovascular Disorders.2019;[Epub]     CrossRef
  • Effects of a 12-week moderate-intensity exercise training on blood glucose response in patients with type 2 diabetes
    Shang-Lin Chiang, Margaret McLean Heitkemper, Yi-Jen Hung, Wen-Chii Tzeng, Meei-Shyuan Lee, Chia-Huei Lin
    Medicine.2019; 98(36): e16860.     CrossRef
  • Impaired Awareness of Hypoglycaemia in Insulin-treated Type 2 Diabetes Mellitus
    Mohammad J. Alkhatatbeh, Nedaa A. Abdalqader , Mohammad A.Y. Alqudah
    Current Diabetes Reviews.2019; 15(5): 407.     CrossRef
  • Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management
    Stephanie A Amiel, Pablo Aschner, Belinda Childs, Philip E Cryer, Bastiaan E de Galan, Brian M Frier, Linda Gonder-Frederick, Simon R Heller, Timothy Jones, Kamlesh Khunti, Lawrence A Leiter, Yingying Luo, Rory J McCrimmon, Ulrik Pedersen-Bjergaard, Eliza
    The Lancet Diabetes & Endocrinology.2019; 7(5): 385.     CrossRef
  • Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population‐based cohort study
    Kristian B. Filion, Antonios Douros, Laurent Azoulay, Hui Yin, Oriana H. Yu, Samy Suissa
    British Journal of Clinical Pharmacology.2019; 85(10): 2378.     CrossRef
  • Selectivity of beta-blockers, cardiovascular and all-cause mortality in people with hypoglycaemia: An observational study
    F. Zaccardi, L.L. Nystrup Husemoen, B.L. Thorsted, D.R. Webb, S.K. Paul, M.J. Davies, K. Khunti
    Nutrition, Metabolism and Cardiovascular Diseases.2019; 29(5): 481.     CrossRef
  • Cost-effectiveness of a primary care multidisciplinary Risk Assessment and Management Program for patients with diabetes mellitus (RAMP-DM) over lifetime
    Fangfang Jiao, Eric Yuk Fai Wan, Colman Siu Cheung Fung, Anca Ka Chun Chan, Sarah Morag McGhee, Ruby Lai Ping Kwok, Cindy Lo Kuen Lam
    Endocrine.2019; 63(2): 259.     CrossRef
  • Efficacy and safety of sensor-augmented pump therapy (SAPT) with predictive low-glucose management in patients diagnosed with type 1 diabetes mellitus previously treated with SAPT and low glucose suspend
    Ana María Gómez, Diana Cristina Henao, Angelica Imitola, Oscar Mauricio Muñoz, Martín Alonso Rondón Sepúlveda, Laura Kattah, Juan Sebastian Guerrero, Elly Morros, Juan Pablo Llano, Maira García Jaramillo, Fabián León-Vargas
    Endocrinología, Diabetes y Nutrición.2018; 65(8): 451.     CrossRef
  • Recent diabetes-related mortality trends in Romania
    Sorin Ioacara, Elisabeta Sava, Olivia Georgescu, Anca Sirbu, Simona Fica
    Acta Diabetologica.2018; 55(8): 821.     CrossRef
  • Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia
    D. A. Lebedev, A. Yu. Babenko
    Medical Council.2018; (16): 100.     CrossRef
  • Severe hypoglycemia is a risk factor for atrial fibrillation in type 2 diabetes mellitus: Nationwide population-based cohort study
    Seung-Hyun Ko, Yong-Moon Park, Jae-Seung Yun, Seon-Ah Cha, Eue-Keun Choi, Kyungdo Han, Eugene Han, Yong-ho Lee, Yu-Bae Ahn
    Journal of Diabetes and its Complications.2018; 32(2): 157.     CrossRef
  • Antioxidant effects of epigallocatechin-3-gallate on the aTC1-6 pancreatic alpha cell line
    Ting Cao, Xiong Zhang, Dan Yang, Yue-Qian Wang, Zheng-Dong Qiao, Jian-Ming Huang, Peng Zhang
    Biochemical and Biophysical Research Communications.2018; 495(1): 693.     CrossRef
  • Hemoglobin glycation index predicts cardiovascular disease in people with type 2 diabetes mellitus: A 10-year longitudinal cohort study
    Mee Kyoung Kim, Jee Sun Jeong, Jae-Seung Yun, Hyuk-Sang Kwon, Ki Hyun Baek, Ki-Ho Song, Yu-Bae Ahn, Seung-Hyun Ko
    Journal of Diabetes and its Complications.2018; 32(10): 906.     CrossRef
  • Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
    Bernard Zinman, Steven P. Marso, Neil R. Poulter, Scott S. Emerson, Thomas R. Pieber, Richard E. Pratley, Martin Lange, Kirstine Brown-Frandsen, Alan Moses, Ann Marie Ocampo Francisco, Jesper Barner Lekdorf, Kajsa Kvist, John B. Buse
    Diabetologia.2018; 61(1): 48.     CrossRef
  • Efficacy and safety of sensor-augmented pump therapy (SAPT) with predictive low-glucose management in patients diagnosed with type 1 diabetes mellitus previously treated with SAPT and low glucose suspend
    Ana María Gómez, Diana Cristina Henao, Angelica Imitola, Oscar Mauricio Muñoz, Martín Alonso Rondón Sepúlveda, Laura Kattah, Juan Sebastian Guerrero, Elly Morros, Juan Pablo Llano, Maira García Jaramillo, Fabián León-Vargas
    Endocrinología, Diabetes y Nutrición (English ed.).2018; 65(8): 451.     CrossRef
  • Time- and frequency-domain measures of heart rate variability predict cardiovascular outcome in patients with type 2 diabetes
    Seon-Ah Cha, Yong-Moon Park, Jae-Seung Yun, Seung-Hwan Lee, Yu-Bae Ahn, Sung-Rae Kim, Seung-Hyun Ko
    Diabetes Research and Clinical Practice.2018; 143: 159.     CrossRef
  • Newly diagnosed type 2 diabetes in an ethnic minority population: clinical presentation and comparison to other populations
    Michael Morkos, Bettina Tahsin, Louis Fogg, Leon Fogelfeld
    BMJ Open Diabetes Research & Care.2018; 6(1): e000568.     CrossRef
  • DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
    Thomas R. Pieber, Steven P. Marso, Darren K. McGuire, Bernard Zinman, Neil R. Poulter, Scott S. Emerson, Richard E. Pratley, Vincent Woo, Simon Heller, Martin Lange, Kirstine Brown-Frandsen, Alan Moses, Jesper Barner Lekdorf, Lucine Lehmann, Kajsa Kvist,
    Diabetologia.2018; 61(1): 58.     CrossRef
  • Intervention effects of Compound Houttuyniae Herba to diabetic renal damage based on SOCS-JAK/STAT negative feedback regulation
    Yun Fang, Sai-cong Shao, Hai-ying Wang
    Chinese Herbal Medicines.2018; 10(4): 424.     CrossRef
  • Monotherapy in Patients with Type 2 Diabetes Mellitus
    Sang Youl Rhee, Hyun Jin Kim, Seung-Hyun Ko, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Kyung Mook Choi, Jin Hwa Kim
    Diabetes & Metabolism Journal.2017; 41(5): 349.     CrossRef
  • Monotherapy in patients with type 2 diabetes mellitus
    Sang Youl Rhee, Hyun Jin Kim, Seung-Hyun Ko, Kyu Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Kyung Mook Choi, Jin Hwa Kim
    The Korean Journal of Internal Medicine.2017; 32(6): 959.     CrossRef
  • Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
    Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
    The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef
  • Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review
    Shishi Xu, Xinyue Zhang, Lizhi Tang, Fang Zhang, Nanwei Tong
    Postgraduate Medicine.2017; 129(2): 205.     CrossRef
  • Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
    Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
    Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
  • Effects of propofol on myocardial ischemia-reperfusion injury in rats with type-2 diabetes mellitus
    Ying Wang, Xiuru Qi, Chunliang Wang, Danning Zhao, Hongjie Wang, Jianxin Zhang
    Biomedical Reports.2017; 6(1): 69.     CrossRef
  • Cardiovascular risk assessment in patients with diabetes
    Marcello Casaccia Bertoluci, Viviane Zorzanelli Rocha
    Diabetology & Metabolic Syndrome.2017;[Epub]     CrossRef
  • Pathogenetic features of the combined course of arterial hypertension and diabetes mellitus 2 type
    O.M. Bilovol, L.R. Bobronnikova, O.V. Al-Trawneh
    Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini.2017; 2017(1): 4.     CrossRef
  • Risk Factors and Adverse Outcomes of Severe Hypoglycemia in Type 2 Diabetes Mellitus
    Jae-Seung Yun, Seung-Hyun Ko
    Diabetes & Metabolism Journal.2016; 40(6): 423.     CrossRef
  • Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study
    Koutaro Yokote, Yasuo Terauchi, Ichiro Nakamura, Haruko Sugamori
    Expert Opinion on Pharmacotherapy.2016; 17(15): 1995.     CrossRef
  • Hypoglycemia: Culprit or Bystander?
    You-Cheol Hwang
    Diabetes & Metabolism Journal.2016; 40(3): 190.     CrossRef
  • Schwere Hypoglykämien erhöhen die Mortalität
    E. Fritschka
    MMW - Fortschritte der Medizin.2016; 158(S3): 46.     CrossRef
Review
Clinical Care/Education
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies
Jang Won Son, Sungrae Kim
Diabetes Metab J. 2015;39(5):373-383.   Published online October 22, 2015
DOI: https://doi.org/10.4093/dmj.2015.39.5.373
  • 10,136 View
  • 92 Download
  • 35 Web of Science
  • 32 Crossref
AbstractAbstract PDFPubReader   ePub   

Dipeptidyl peptidase 4 (DPP4) inhibitors have been touted as promising antihyperglycemic agents due to their beneficial effects on glycemia without inducing hypoglycemia or body weight gain and their good tolerability. Beyond their glucose-lowering effects, numerous clinical trials and experimental studies have suggested that DPP4 inhibitors may exert cardioprotective effects through their pleiotropic actions via glucagon-like peptide 1-dependent mechanisms or involving other substrates. Since 2008, regulatory agencies have required an assessment of cardiovascular disease (CVD) safety for the approval of all new anti-hyperglycemic agents, including incretin-based therapies. Three large prospective DPP4 inhibitor trials with cardiovascular (CV) outcomes have recently been published. According to the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR-TIMI 53) and EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE) trials, DPP4 inhibitors, including saxagliptin and alogliptin, did not appear to increase the risk of CV events in patients with type 2 diabetes and established CVD or high risk factors. Unexpectedly, saxagliptin significantly increased the risk of hospitalization for heart failure by 27%, a finding that has not been explained and that requires further exploration. More recently, the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) trial demonstrated the CV safety of sitagliptin, including assessments of the primary composite CV endpoint and hospitalization for heart failure in patients with type 2 diabetes and established CVD. The CV outcomes of an ongoing linagliptin trial are expected to provide new evidence about the CV effects of a DPP4-inhibitor in patients with type 2 diabetes.

Citations

Citations to this article as recorded by  
  • Comparative Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists to Dipeptidyl Peptidase 4 Inhibitors in Patients With Heart Failure and Type 2 Diabetes
    Takefumi Kishimori, Takao Kato, Atsuyuki Wada, Akira Tani, Ryosuke Yamaji, Jumpei Koike, Yoshihiro Iwasaki, Takehiro Matsumoto, Takafumi Yagi, Masaharu Okada
    Journal of the American Heart Association.2025;[Epub]     CrossRef
  • Effectiveness of semaglutide on survival outcomes in patients with type 2 diabetes and chronic kidney disease
    Takefumi Kishimori, Takao Kato, Atsuyuki Wada, Akira Tani, Ryosuke Yamaji, Jumpei Koike, Yoshihiro Iwasaki, Takehiro Matsumoto, Takafumi Yagi, Masaharu Okada
    Open Heart.2025; 12(2): e003382.     CrossRef
  • Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors
    Takefumi Kishimori, Takao Kato, Atsuyuki Wada, Akira Tani, Ryosuke Yamaji, Jumpei Koike, Yoshihiro Iwasaki, Takehiro Matsumoto, Takafumi Yagi, Masaharu Okada
    European Heart Journal - Quality of Care and Clinical Outcomes.2025; 11(8): 1319.     CrossRef
  • Dipeptidyl Peptidase IV Activated Near-Infrared Fluorescent Probe for Visually Evaluating Diabetes Models under Microplastic Exposure
    Xiao Sun, Yan Huang, Lili Fu, Xinlei Wang, Shuang Li, Xiaoyan Wang, Lingxin Chen, Yu-Qing Zhao
    Analytical Chemistry.2025; 97(48): 26677.     CrossRef
  • Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population
    Weijia Li, Adarsh Katamreddy, Rachna Kataria, Merle L. Myerson, Cynthia C. Taub
    Drugs - Real World Outcomes.2022; 9(1): 53.     CrossRef
  • Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials
    Yu Jiang, Pingping Yang, Linghua Fu, Lizhe Sun, Wen Shen, Qinghua Wu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
    Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine,
    Diabetes Care.2022; 45(4): 938.     CrossRef
  • Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus


    Eugene Han, Minyoung Lee, Yong-ho Lee, Hye Soon Kim, Byung-wan Lee, Bong-Soo Cha, Eun Seok Kang
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 4113.     CrossRef
  • Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL
    Miki Imazu, Atsushi Nakano, Shin Ito, Toshimitsu Hamasaki, Masafumi Kitakaze
    Cardiovascular Drugs and Therapy.2019; 33(3): 363.     CrossRef
  • Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study
    N.H. Kim, J. Choi, N.H. Kim, K.M. Choi, S.H. Baik, J. Lee, S.G. Kim
    Diabetes & Metabolism.2018; 44(4): 361.     CrossRef
  • Glucagon secretion determined by the RIA method is lower in patients with low left ventricular ejection fraction: The new glass study
    Makoto Murata, Hitoshi Adachi, Taishuke Nakade, Shigeru Oshima
    Diabetes Research and Clinical Practice.2018; 144: 260.     CrossRef
  • Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
    Yi-Hsuan Lin, Yu-Yao Huang, Yi-Ling Wu, Cheng-Wei Lin, Pei-Chun Chen, Chee Jen Chang, Sheng-Hwu Hsieh, Jui-Hung Sun, Szu-Tah Chen, Chia-Hung Lin
    Diabetology & Metabolic Syndrome.2018;[Epub]     CrossRef
  • Postmeal increment in intact glucagon-like peptide 1 level, but not intact glucose-dependent insulinotropic polypeptide levels, is inversely associated with metabolic syndrome in patients with type 2 diabetes
    Soyeon Yoo, Eun-Jin Yang, Sang Ah Lee, Gwanpyo Koh
    Endocrine Research.2018; 43(1): 47.     CrossRef
  • Dipeptidyl Peptidase‐4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study
    Michael R. Cobretti, Benjamin Bowman, Ted Grabarczyk, Emily Potter
    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2018; 38(3): 334.     CrossRef
  • Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
    Daisaku Masuda, Takuya Kobayashi, Masami Sairyou, Hiroyuki Hanada, Tohru Ohama, Masahiro Koseki, Makoto Nishida, Norikazu Maeda, Shinji Kihara, Tatsuya Minami, Koji Yanagi, Yasushi Sakata, Shizuya Yamashita
    Journal of Atherosclerosis and Thrombosis.2018; 25(6): 512.     CrossRef
  • Management of diabetes in older adults
    G. Sesti, R. Antonelli Incalzi, E. Bonora, A. Consoli, A. Giaccari, S. Maggi, G. Paolisso, F. Purrello, G. Vendemiale, N. Ferrara
    Nutrition, Metabolism and Cardiovascular Diseases.2018; 28(3): 206.     CrossRef
  • DPP4 inhibitors and cardiovascular outcomes: safety on heart failure
    Chang Xia, Aditya Goud, Jason D’Souza, CHanukya Dahagam, Xiaoquan Rao, Sanjay Rajagopalan, Jixin Zhong
    Heart Failure Reviews.2017; 22(3): 299.     CrossRef
  • Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
    Yuliya Lytvyn, Petter Bjornstad, Jacob A. Udell, Julie A. Lovshin, David Z.I. Cherney
    Circulation.2017; 136(17): 1643.     CrossRef
  • Antidiabetic medications use trends in an Andalusian region from 2001 to 2014
    Rocío López-Sepúlveda, María Ángeles García Lirola, Esther Espínola García, Jose María Jurado Martínez, Salvadora Martín Sances, Sonia Anaya Ordóñez, José Cabeza Barrera
    Primary Care Diabetes.2017; 11(3): 254.     CrossRef
  • The regulatory role of DPP4 in atherosclerotic disease
    Lihua Duan, Xiaoquan Rao, Chang Xia, Sanjay Rajagopalan, Jixin Zhong
    Cardiovascular Diabetology.2017;[Epub]     CrossRef
  • Guidelines on the management of arterial hypertension and related comorbidities in Latin America

    Journal of Hypertension.2017; 35(8): 1529.     CrossRef
  • Sodium Glucose Cotransporter 2 and Dipeptidyl Peptidase-4 Inhibition: Promise of a Dynamic Duo
    Ildiko Lingvay
    Endocrine Practice.2017; 23(7): 831.     CrossRef
  • Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio
    Masayuki Kaneko, Mamoru Narukawa
    Annals of Pharmacotherapy.2017; 51(7): 570.     CrossRef
  • Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
    Ming Zhao, Jiayi Chen, Yanyan Yuan, Zuquan Zou, Xiaolong Lai, Daud M Rahmani, Fuyan Wang, Yang Xi, Qin Huang, Shizhong Bu
    Scientific Reports.2017;[Epub]     CrossRef
  • High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: a case–control
    Shajith Anoop, Anoop Misra, Surya Prakash Bhatt, Seema Gulati, Ravindra Mohan Pandey, Harsh Mahajan
    BMJ Open Diabetes Research & Care.2017; 5(1): bmjdrc-2017-000393.     CrossRef
  • Vildagliptin reduces plasma stromal cell‐derived factor‐1α in patients with type 2 diabetes compared with glimepiride
    Kyeong Seon Park, SooHeon Kwak, Young Min Cho, Kyong Soo Park, Hak C Jang, Seong Yeon Kim, Hye Seung Jung
    Journal of Diabetes Investigation.2017; 8(2): 218.     CrossRef
  • New peroral antidiabetic drugs and heart failure
    Jana Jiráčková, Alena Šmahelová
    Interní medicína pro praxi.2016; 18(2): 78.     CrossRef
  • Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients
    Jing Wei Li, Yun Dai Chen, Wei Ren Chen, Jing Jing, Jie Liu, Yong Qiang Yang
    Scientific Reports.2016;[Epub]     CrossRef
  • Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study
    Yi-Chih Hung, Che-Chen Lin, Wei-Lun Huang, Man-Ping Chang, Ching-Chu Chen
    Scientific Reports.2016;[Epub]     CrossRef
  • Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up
    Takashi Nakamura, Yoshitaka Iwanaga, Yuki Miyaji, Ryuji Nohara, Takao Ishimura, Shunichi Miyazaki
    Cardiovascular Diabetology.2016;[Epub]     CrossRef
  • Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit
    Ersilia M. DeFilippis, Michael M. Givertz
    Current Heart Failure Reports.2016; 13(3): 111.     CrossRef
  • Transcriptomic alterations in the heart of non-obese type 2 diabetic Goto-Kakizaki rats
    Márta Sárközy, Gergő Szűcs, Veronika Fekete, Márton Pipicz, Katalin Éder, Renáta Gáspár, Andrea Sója, Judit Pipis, Péter Ferdinandy, Csaba Csonka, Tamás Csont
    Cardiovascular Diabetology.2016;[Epub]     CrossRef
Original Article
Complications
Cardiovascular Disease Predicts Severe Hypoglycemia in Patients with Type 2 Diabetes
Jae-Seung Yun, Seung-Hyun Ko, Sun-Hye Ko, Ki-Ho Song, Ki-Dong Yoo, Kun-Ho Yoon, Yong-Moon Park, Yu-Bae Ahn
Diabetes Metab J. 2015;39(6):498-506.   Published online July 8, 2015
DOI: https://doi.org/10.4093/dmj.2015.39.6.498
  • 6,307 View
  • 50 Download
  • 23 Web of Science
  • 23 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

To investigate whether a history of prior cardiovascular disease (CVD) is associated with severe hypoglycemia (SH) in patients with type 2 diabetes.

Methods

We conducted a prospective cohort study from January 2001 to December 2012 with a median follow-up time of 9.5 years (5,814 person-years). Patients aged 25 to 75 years with type 2 diabetes and without chronic kidney disease were enrolled (n=894), and 624 patients completed follow-up. SH was defined as hypoglycemic episodes requiring hospitalization or medical care in an emergency department. We used the Cox proportional hazards regression analysis to test associations between SH episodes and potential explanatory variables.

Results

Among the 624 participants who completed follow-up, 60 patients (9.6%) had previous CVD. Compared to patients without CVD, patients with previous CVD were older, had a longer duration of diabetes and hypertension, received more insulin, and had more diabetic microvascular complications at baseline. During follow-up, 62 patients (9.9%) experienced at least one SH episode (incidence of 1.33 per 100 patient-years). The development of SH was associated with a history of CVD (hazard ratio, 1.99; 95% confidence interval, 1.07 to 3.72; P=0.031) after adjusting for sex, age, diabetic duration, hypertension, hemoglobin A1c levels, diabetic complications, cardiovascular autonomic neuropathy, and insulin use.

Conclusion

A history of CVD was an independent risk factor for the development of SH in patients with type 2 diabetes mellitus. For patients with CVD, modulation of glycemic targets and diabetic education for the prevention of hypoglycemia should be implemented.

Citations

Citations to this article as recorded by  
  • Multiple long-term conditions as the next transition in the global diabetes epidemic
    Edward W. Gregg, Naomi Holman, Marisa Sophiea, Shivani Misra, Jonathan Pearson-Stuttard, Jonathan Valabhji, Kamlesh Khunti
    Communications Medicine.2025;[Epub]     CrossRef
  • Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetes
    Ninoschka C. D’Souza, Julian A. Aiken, Emily G. Hoffman, Sara C. Atherley, Sabrina Champsi, Nadia Aleali, Dorsa Shakeri, Maya El-Zahed, Nicky Akbarian, Mehran Nejad-Mansouri, Parinaz Z. Bavani, Richard L. Liggins, Owen Chan, Michael C. Riddell
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Relationship between autonomic and peripheral neuropathies and cardiovascular outcomes in diabetes
    Jae-Seung Yun
    Cardiovascular Prevention and Pharmacotherapy.2024; 6(4): 123.     CrossRef
  • Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study
    Jenny Dimakos, Ying Cui, Robert W. Platt, Christel Renoux, Kristian B. Filion, Antonios Douros
    Diabetes Care.2023; 46(2): 377.     CrossRef
  • Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
    Yangyang Zhang, Liang Zhang, Pengcheng Ge, Ruyi Xu, Zhen Ye
    European Journal of Medical Research.2023;[Epub]     CrossRef
  • Diabetic Neuropathy and Risk of Cardiovascular Disease
    Jae-Seung Yun
    The Journal of Korean Diabetes.2022; 23(4): 245.     CrossRef
  • Randomised controlled trial of pharmacist-led patient counselling in controlling hypoglycaemic attacks in older adults with type 2 diabetes mellitus (ROSE-ADAM): A study protocol of the SUGAR intervention
    Huda Y. Almomani, Carlos Rodriguez Pascual, Sayer I. Al-Azzam, Keivan Ahmadi
    Research in Social and Administrative Pharmacy.2021; 17(5): 885.     CrossRef
  • Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes
    W. David Strain, Su Down, Pam Brown, Amar Puttanna, Alan Sinclair
    Diabetes Therapy.2021; 12(5): 1227.     CrossRef
  • Management of hypoglycemia in older adults with type 2 diabetes
    Jeffrey Freeman
    Postgraduate Medicine.2019; 131(4): 241.     CrossRef
  • Use of stellate ganglion block for treatment of recurrent syncope followed by chest pain
    Young-ung Kim, Yong-joon Shin, Young Woo Cho
    Yeungnam University Journal of Medicine.2018; 35(1): 104.     CrossRef
  • Coronary artery disease severity modifies associations between glycemic control and both mortality and myocardial infarction
    Sridharan Raghavan, Wenhui G. Liu, P. Michael Ho, Mary E. Plomondon, Anna E. Barón, Liron Caplan, Karen E. Joynt Maddox, David Magid, David R. Saxon, Corrine I. Voils, Steven M. Bradley, Thomas M. Maddox
    Journal of Diabetes and its Complications.2018; 32(5): 480.     CrossRef
  • Depth and combined infection is important predictor of lower extremity amputations in hospitalized diabetic foot ulcer patients
    Eun-Gyo Jeong, Sung Shim Cho, Sang-Hoon Lee, Kang-Min Lee, Seo-Kyung Woo, Yoongoo Kang, Jae-Seung Yun, Seon-Ah Cha, Yoon-Jung Kim, Yu-Bae Ahn, Seung-Hyun Ko, Jung-Min Lee
    The Korean Journal of Internal Medicine.2018; 33(5): 952.     CrossRef
  • Time- and frequency-domain measures of heart rate variability predict cardiovascular outcome in patients with type 2 diabetes
    Seon-Ah Cha, Yong-Moon Park, Jae-Seung Yun, Seung-Hwan Lee, Yu-Bae Ahn, Sung-Rae Kim, Seung-Hyun Ko
    Diabetes Research and Clinical Practice.2018; 143: 159.     CrossRef
  • Risk Factors for Severe Hypoglycemia in Black and White Adults With Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study
    Alexandra K. Lee, Clare J. Lee, Elbert S. Huang, A. Richey Sharrett, Josef Coresh, Elizabeth Selvin
    Diabetes Care.2017; 40(12): 1661.     CrossRef
  • Early inner retinal thinning and cardiovascular autonomic dysfunction in type 2 diabetes
    Jin A. Choi, Hyo Won Kim, Jin-Woo Kwon, Yun-sub Shim, Dong Hyun Jee, Jae-Seung Yun, Yu-Bae Ahn, Chan Kee Park, Seung-Hyun Ko, Patrice E. Fort
    PLOS ONE.2017; 12(3): e0174377.     CrossRef
  • Cardiovascular Autonomic Dysfunction Predicts Diabetic Foot Ulcers in Patients With Type 2 Diabetes Without Diabetic Polyneuropathy
    Jae-Seung Yun, Seon-Ah Cha, Tae-Seok Lim, Eun-Young Lee, Ki-Ho Song, Yu-Bae Ahn, Ki-Dong Yoo, Joon-Sung Kim, Yong-Moon Park, Seung-Hyun Ko
    Medicine.2016; 95(12): e3128.     CrossRef
  • Clinical Course and Risk Factors of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus in Korea
    Jae-Seung Yun, Tae-Seok Lim, Seon-Ah Cha, Yu-Bae Ahn, Ki-Ho Song, Jin A Choi, Jinwoo Kwon, Donghyun Jee, Yang Kyung Cho, Yong-Moon Park, Seung-Hyun Ko
    Diabetes & Metabolism Journal.2016; 40(6): 482.     CrossRef
  • Diabetic Cardiovascular Autonomic Neuropathy Predicts Recurrent Cardiovascular Diseases in Patients with Type 2 Diabetes
    Seon-Ah Cha, Jae-Seung Yun, Tae-Seok Lim, Kyoungil Min, Ki-Ho Song, Ki-Dong Yoo, Yong-Moon Park, Yu-Bae Ahn, Seung-Hyun Ko, James M Wright
    PLOS ONE.2016; 11(10): e0164807.     CrossRef
  • Meta-analysis: Association between hypoglycaemia and serious adverse events in older patients
    Katharina Mattishent, Yoon Kong Loke
    Journal of Diabetes and its Complications.2016; 30(5): 811.     CrossRef
  • Letter: Cardiovascular Disease Predicts Severe Hypoglycemia in Patients with Type 2 Diabetes (Diabetes Metab J 2015;39:498-506)
    Mi-Kyung Kim
    Diabetes & Metabolism Journal.2016; 40(1): 83.     CrossRef
  • Response: Cardiovascular Disease Predicts Severe Hypoglycemia in Patients with Type 2 Diabetes (Diabetes Metab J 2015;39:498-506)
    Jae-Seung Yun, Yu-Bae Ahn
    Diabetes & Metabolism Journal.2016; 40(1): 85.     CrossRef
  • Lipoprotein(a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus
    J.‐S. Yun, Y.‐B. Ahn, K.‐H. Song, K.‐D. Yoo, Y.‐M. Park, H.‐W. Kim, S.‐H. Ko
    Diabetic Medicine.2016; 33(5): 639.     CrossRef
  • Severe Hypoglycemia and Cardiovascular Disease in Type 2 Diabetes
    Hyeong Kyu Park
    Diabetes & Metabolism Journal.2015; 39(6): 478.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP